METLIFE INC
10-Qs and 10-Ks
PROXIES
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________
Form 10-Q
(Mark One)
|
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
FOR THE QUARTERLY PERIOD ENDED MARCH 31,
2017
or
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
FOR THE TRANSITION PERIOD FROM TO
Commission file number: 001-15787
________________________________________
MetLife, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
13-4075851
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
200 Park Avenue, New York, N.Y.
|
|
10166-0188
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(212) 578-9500
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
þ
No
¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes
þ
No
¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer
|
þ
|
Accelerated filer
|
¨
|
|
Non-accelerated filer (Do not check if a smaller reporting company)
|
¨
|
||
|
Smaller reporting company
|
¨
|
||
|
Emerging growth company
|
¨
|
||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
¨
No
þ
At
April 28, 2017
,
1,075,933,159
shares of the registrant’s common stock, $0.01 par value per share, were outstanding.
Table of Contents
|
Page
|
||
|
Item 1.
|
Financial Statements (at March 31, 2017 (Unaudited) and December 31, 2016 and for the Three Months Ended March 31, 2017 and 2016 (Unaudited))
|
|
|
Item 2.
|
||
|
Item 3.
|
||
|
Item 4.
|
||
|
Item 1.
|
||
|
Item 1A.
|
||
|
Item 2.
|
||
|
Item 6.
|
||
As used in this Form 10
‑
Q, “MetLife,” the “Company,” “we,” “our” and “us” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates.
Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10‑Q, including Management’s Discussion and Analysis of Financial Condition and Results of Operations, may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning, or are tied to future periods, in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective services or products, future performance or results of current and anticipated services or products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, trends in operations and financial results.
Any or all forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining the actual future results of MetLife, Inc., its subsidiaries and affiliates. These statements are based on current expectations and the current economic environment. They involve a number of risks and uncertainties that are difficult to predict. These statements are not guarantees of future performance. Actual results could differ materially from those expressed or implied in the forward-looking statements. Risks, uncertainties, and other factors that might cause such differences include the risks, uncertainties and other factors identified in MetLife, Inc.’s filings with the U.S. Securities and Exchange Commission. These factors include: (1) difficult conditions in the global capital markets; (2) increased volatility and disruption of the global capital and credit markets, which may affect our ability to meet liquidity needs and access capital, including through our credit facilities, generate fee income and market-related revenue and finance statutory reserve requirements and may require us to pledge collateral or make payments related to declines in value of specified assets, including assets supporting risks ceded to certain of our captive reinsurers or hedging arrangements associated with those risks; (3) exposure to global financial and capital market risks, including as a result of the United Kingdom’s notice of withdrawal from the European Union, other disruption in Europe and possible withdrawal of one or more countries from the Euro zone; (4) impact on us of comprehensive financial services regulation reform, including potential regulation of MetLife, Inc. as a non-bank systemically important financial institution, or otherwise; (5) numerous rulemaking initiatives required or permitted by the Dodd-Frank Wall Street Reform and Consumer Protection Act which may impact how we conduct our business, including those compelling the liquidation of certain financial institutions; (6) regulatory, legislative or tax changes relating to our insurance, international, or other operations that may affect the cost of, or demand for, our products or services, or increase the cost or administrative burdens of providing benefits to employees; (7) adverse results or other consequences from litigation, arbitration or regulatory investigations; (8) unanticipated developments that could delay, prevent or otherwise adversely affect the separation of Brighthouse Financial; (9) our ability to address difficulties, unforeseen liabilities, asset impairments, or rating agency actions arising from (a) business acquisitions and integrating and managing the growth of such acquired businesses, (b) dispositions of businesses via sale, initial public offering, spin-off or otherwise, including failure to achieve projected operational benefit from such transactions and any restrictions, liabilities, losses or indemnification obligations arising from any transitional services or tax arrangements related to the separation of any business, or from the failure of such a separation to qualify for any intended tax-free treatment; (c) entry into joint ventures, or (d) legal entity reorganizations; (10) potential liquidity and other risks resulting from our participation in a securities lending program and other transactions; including any separated business’ incurrence of debt in connection with such a separation; (11) investment losses and defaults, and changes to investment valuations; (12) changes in assumptions related to investment valuations, deferred policy acquisition costs, deferred sales inducements, value of business acquired or goodwill; (13) impairments of goodwill and realized losses or market value impairments to illiquid assets; (14) defaults on our mortgage loans; (15) the defaults or deteriorating credit of other financial institutions that could adversely affect us; (16) economic, political, legal, currency and other risks relating to our international operations, including with respect to fluctuations of exchange rates; (17) downgrades in our claims paying ability, financial strength or credit ratings; (18) a deterioration in the experience of the closed block established in connection with the reorganization of Metropolitan Life Insurance Company; (19) availability and effectiveness of reinsurance, hedging or indemnification arrangements, as well as any default or failure of counterparties to perform; (20) differences between actual claims experience and underwriting and reserving assumptions; (21) ineffectiveness of risk management policies and procedures; (22) catastrophe losses; (23) increasing cost and limited market capacity for statutory life insurance reserve financings; (24) heightened competition, including with respect to pricing, entry of new competitors, consolidation of distributors, the development of new products by new and existing competitors, and for personnel; (25) exposure to losses related to variable annuity guarantee benefits, including from significant and sustained downturns or extreme volatility in equity markets, reduced interest rates, unanticipated policyholder behavior, mortality or longevity, and any adjustment for nonperformance risk; (26) legal, regulatory and other restrictions affecting MetLife, Inc.’s ability to pay dividends and repurchase common stock; (27) MetLife, Inc.’s and its subsidiary holding companies’ primary reliance, as holding companies, on dividends from its subsidiaries to meet its free cash flow targets and debt payment obligations and the applicable regulatory restrictions on the ability of the subsidiaries to pay such dividends; (28) the possibility that MetLife, Inc.’s Board of Directors may influence the outcome of stockholder votes through the voting provisions of the MetLife Policyholder Trust; (29) changes in accounting standards, practices and/or policies; (30) increased expenses relating to pension and postretirement benefit plans, as well as health care and other employee benefits; (31) inability to protect our intellectual property rights or claims of infringement of the intellectual property rights of others; (32) difficulties in marketing and distributing products through our distribution channels; (33) provisions of laws and our incorporation documents may delay, deter or prevent takeovers and corporate combinations involving MetLife; (34) the effects of business disruption or economic contraction due to disasters such as terrorist attacks, cyberattacks, other hostilities, or natural catastrophes, including any related impact on the value of our investment portfolio, our disaster recovery systems, cyber- or other information security systems and management continuity planning; (35) any failure to protect the confidentiality of client information; (36) the effectiveness of our programs and practices in avoiding giving our associates incentives to take excessive risks; and (37) other risks and uncertainties described from time to time in MetLife, Inc.’s filings with the U.S. Securities and Exchange Commission.
MetLife, Inc. does not undertake any obligation to publicly correct or update any forward-looking statement if MetLife, Inc. later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures MetLife, Inc. makes on related subjects in reports to the U.S. Securities and Exchange Commission.
Corporate Information
We announce financial and other information about MetLife to our investors through the MetLife Investor Relations web page at www.metlife.com, as well as U.S. Securities and Exchange Commission filings, news releases, public conference calls and webcasts. MetLife encourages investors to visit the Investor Relations web page from time to time, as information is updated and new information is posted. The information found on our website is not incorporated by reference into this Quarterly Report on Form 10-Q or in any other report or document we file with the U.S. Securities and Exchange Commission, and any references to our website are intended to be inactive textual references only.
Note Regarding Reliance on Statements in Our Contracts
See “Exhibit Index — Note Regarding Reliance on Statements in Our Contracts” for information regarding agreements included as exhibits to this Quarterly Report on Form 10-Q.
2
Part I — Financial Information
Item 1. Financial Statements
MetLife, Inc.
Interim Condensed Consolidated Balance Sheets
March 31, 2017 (Unaudited) and December 31, 2016
(In millions, except share and per share data)
|
March 31, 2017
|
December 31, 2016
|
|||||||
|
Assets
|
||||||||
|
Investments:
|
||||||||
|
Fixed maturity securities available-for-sale, at estimated fair value (amortized cost: $333,985 and $330,354, respectively; includes $0 and $3,422, respectively, relating to variable interest entities)
|
$
|
355,528
|
|
$
|
350,889
|
|
||
|
Equity securities available-for-sale, at estimated fair value (cost: $2,919 and $2,744, respectively)
|
3,377
|
|
3,194
|
|
||||
|
Fair value option securities, at estimated fair value (includes $7 and $8, respectively, relating to variable interest entities)
|
14,399
|
|
13,923
|
|
||||
|
Mortgage loans (net of valuation allowances of $353 and $344, respectively; includes $129 and $136, respectively, at estimated fair value, relating to variable interest entities; includes $639 and $566, respectively, under the fair value option)
|
76,541
|
|
74,545
|
|
||||
|
Policy loans
|
11,115
|
|
11,028
|
|
||||
|
Real estate and real estate joint ventures (includes $8 and $59, respectively, of real estate held-for-sale)
|
9,464
|
|
9,041
|
|
||||
|
Other limited partnership interests (includes $14 and $14, respectively, relating to variable interest entities)
|
6,762
|
|
6,778
|
|
||||
|
Short-term investments, principally at estimated fair value (includes $50 and $0, respectively, relating to variable interest entities)
|
9,968
|
|
7,810
|
|
||||
|
Other invested assets, principally at estimated fair value (includes $31 and $31, respectively, relating to variable interest entities)
|
19,724
|
|
23,185
|
|
||||
|
Total investments
|
506,878
|
|
500,393
|
|
||||
|
Cash and cash equivalents, principally at estimated fair value (includes $3,374 and $1, respectively, relating to variable interest entities)
|
17,411
|
|
17,877
|
|
||||
|
Accrued investment income (includes $1 and $1, respectively, relating to variable interest entities)
|
3,984
|
|
3,988
|
|
||||
|
Premiums, reinsurance and other receivables (includes $6 and $2, respectively, relating to variable interest entities)
|
25,916
|
|
26,081
|
|
||||
|
Deferred policy acquisition costs and value of business acquired
|
25,547
|
|
24,798
|
|
||||
|
Current income tax recoverable
|
25
|
|
20
|
|
||||
|
Goodwill
|
9,350
|
|
9,220
|
|
||||
|
Other assets (includes $3 and $3, respectively, relating to variable interest entities)
|
8,055
|
|
7,767
|
|
||||
|
Separate account assets
|
317,521
|
|
308,620
|
|
||||
|
Total assets
|
$
|
914,687
|
|
$
|
898,764
|
|
||
|
Liabilities and Equity
|
||||||||
|
Liabilities
|
||||||||
|
Future policy benefits
|
$
|
203,226
|
|
$
|
199,971
|
|
||
|
Policyholder account balances
|
214,757
|
|
210,235
|
|
||||
|
Other policy-related balances
|
14,713
|
|
14,386
|
|
||||
|
Policyholder dividends payable
|
699
|
|
708
|
|
||||
|
Policyholder dividend obligation
|
1,983
|
|
1,931
|
|
||||
|
Payables for collateral under securities loaned and other transactions
|
32,899
|
|
33,264
|
|
||||
|
Short-term debt
|
260
|
|
242
|
|
||||
|
Long-term debt (includes $32 and $35, respectively, at estimated fair value, relating to variable interest entities)
|
16,511
|
|
16,502
|
|
||||
|
Collateral financing arrangements
|
4,059
|
|
4,071
|
|
||||
|
Junior subordinated debt securities
|
3,169
|
|
3,169
|
|
||||
|
Deferred income tax liability
|
9,550
|
|
9,367
|
|
||||
|
Other liabilities
|
27,232
|
|
28,818
|
|
||||
|
Separate account liabilities
|
317,521
|
|
308,620
|
|
||||
|
Total liabilities
|
846,579
|
|
831,284
|
|
||||
|
Contingencies, Commitments and Guarantees (Note 13)
|
|
|
||||||
|
Equity
|
||||||||
|
MetLife, Inc.’s stockholders’ equity:
|
||||||||
|
Preferred stock, par value $0.01 per share; $2,100 aggregate liquidation preference
|
—
|
|
—
|
|
||||
|
Common stock, par value $0.01 per share; 3,000,000,000 shares authorized; 1,165,870,885 and 1,164,029,985 shares issued, respectively; 1,081,321,114 and 1,095,519,005 shares outstanding, respectively
|
12
|
|
12
|
|
||||
|
Additional paid-in capital
|
30,990
|
|
30,944
|
|
||||
|
Retained earnings
|
34,863
|
|
34,480
|
|
||||
|
Treasury stock, at cost; 84,549,771 and 68,510,980 shares, respectively
|
(4,332
|
)
|
(3,474
|
)
|
||||
|
Accumulated other comprehensive income (loss)
|
6,396
|
|
5,347
|
|
||||
|
Total MetLife, Inc.’s stockholders’ equity
|
67,929
|
|
67,309
|
|
||||
|
Noncontrolling interests
|
179
|
|
171
|
|
||||
|
Total equity
|
68,108
|
|
67,480
|
|
||||
|
Total liabilities and equity
|
$
|
914,687
|
|
$
|
898,764
|
|
||
3
MetLife, Inc.
Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
For the Three Months Ended March 31, 2017 and 2016 (Unaudited)
(In millions, except per share data)
|
Three Months
Ended March 31, |
||||||||
|
2017
|
2016
|
|||||||
|
Revenues
|
||||||||
|
Premiums
|
$
|
9,315
|
|
$
|
9,693
|
|
||
|
Universal life and investment-type product policy fees
|
2,302
|
|
2,344
|
|
||||
|
Net investment income
|
5,196
|
|
4,559
|
|
||||
|
Other revenues
|
374
|
|
487
|
|
||||
|
Net investment gains (losses):
|
||||||||
|
Other-than-temporary impairments on fixed maturity securities
|
—
|
|
(78
|
)
|
||||
|
Other net investment gains (losses)
|
8
|
|
93
|
|
||||
|
Total net investment gains (losses)
|
8
|
|
15
|
|
||||
|
Net derivative gains (losses)
|
(926
|
)
|
1,335
|
|
||||
|
Total revenues
|
16,269
|
|
18,433
|
|
||||
|
Expenses
|
||||||||
|
Policyholder benefits and claims
|
9,859
|
|
9,678
|
|
||||
|
Interest credited to policyholder account balances
|
1,712
|
|
1,326
|
|
||||
|
Policyholder dividends
|
317
|
|
315
|
|
||||
|
Other expenses
|
3,564
|
|
4,192
|
|
||||
|
Total expenses
|
15,452
|
|
15,511
|
|
||||
|
Income (loss) before provision for income tax
|
817
|
|
2,922
|
|
||||
|
Provision for income tax expense (benefit)
|
(12
|
)
|
719
|
|
||||
|
Net income (loss)
|
829
|
|
2,203
|
|
||||
|
Less: Net income (loss) attributable to noncontrolling interests
|
3
|
|
2
|
|
||||
|
Net income (loss) attributable to MetLife, Inc.
|
826
|
|
2,201
|
|
||||
|
Less: Preferred stock dividends
|
6
|
|
6
|
|
||||
|
Net income (loss) available to MetLife, Inc.’s common shareholders
|
$
|
820
|
|
$
|
2,195
|
|
||
|
Comprehensive income (loss)
|
$
|
1,879
|
|
$
|
8,388
|
|
||
|
Less: Comprehensive income (loss) attributable to noncontrolling interests, net of income tax
|
4
|
|
93
|
|
||||
|
Comprehensive income (loss) attributable to MetLife, Inc.
|
$
|
1,875
|
|
$
|
8,295
|
|
||
|
Net income (loss) available to MetLife, Inc.’s common shareholders per common share:
|
||||||||
|
Basic
|
$
|
0.75
|
|
$
|
1.99
|
|
||
|
Diluted
|
$
|
0.75
|
|
$
|
1.98
|
|
||
|
Cash dividends declared per common share
|
$
|
0.400
|
|
$
|
0.375
|
|
||
See accompanying notes to the interim condensed consolidated financial statements.
4
MetLife, Inc.
Interim Condensed Consolidated Statements of Equity
For the Three Months Ended March 31, 2017 and 2016 (Unaudited)
(In millions)
|
Preferred
Stock
|
Common
Stock
|
Additional
Paid-in
Capital
|
Retained
Earnings
|
Treasury
Stock
at Cost
|
Accumulated
Other
Comprehensive
Income (Loss)
|
Total
MetLife, Inc.’s
Stockholders’
Equity
|
Noncontrolling
Interests
|
Total
Equity
|
||||||||||||||||||||||||||||
|
Balance at December 31, 2016
|
$
|
—
|
|
$
|
12
|
|
$
|
30,944
|
|
$
|
34,480
|
|
$
|
(3,474
|
)
|
$
|
5,347
|
|
$
|
67,309
|
|
$
|
171
|
|
$
|
67,480
|
|
|||||||||
|
Treasury stock acquired in connection with share repurchases
|
|
|
|
(858
|
)
|
(858
|
)
|
(858
|
)
|
|||||||||||||||||||||||||||
|
Stock-based compensation
|
46
|
|
46
|
|
46
|
|
||||||||||||||||||||||||||||||
|
Dividends on preferred stock
|
(6
|
)
|
(6
|
)
|
(6
|
)
|
||||||||||||||||||||||||||||||
|
Dividends on common stock
|
(437
|
)
|
(437
|
)
|
(437
|
)
|
||||||||||||||||||||||||||||||
|
Change in equity of noncontrolling interests
|
—
|
|
4
|
|
4
|
|
||||||||||||||||||||||||||||||
|
Net income (loss)
|
826
|
|
826
|
|
3
|
|
829
|
|
||||||||||||||||||||||||||||
|
Other comprehensive income (loss), net of income tax
|
1,049
|
|
1,049
|
|
1
|
|
1,050
|
|
||||||||||||||||||||||||||||
|
Balance at March 31, 2017
|
$
|
—
|
|
$
|
12
|
|
$
|
30,990
|
|
$
|
34,863
|
|
$
|
(4,332
|
)
|
$
|
6,396
|
|
$
|
67,929
|
|
$
|
179
|
|
$
|
68,108
|
|
|||||||||
|
Preferred
Stock
|
Common
Stock
|
Additional
Paid-in
Capital
|
Retained
Earnings
|
Treasury
Stock
at Cost
|
Accumulated
Other
Comprehensive
Income (Loss)
|
Total
MetLife, Inc.’s
Stockholders’
Equity
|
Noncontrolling
Interests
|
Total
Equity
|
||||||||||||||||||||||||||||
|
Balance at December 31, 2015
|
$
|
—
|
|
$
|
12
|
|
$
|
30,749
|
|
$
|
35,519
|
|
$
|
(3,102
|
)
|
$
|
4,771
|
|
$
|
67,949
|
|
$
|
470
|
|
$
|
68,419
|
|
|||||||||
|
Treasury stock acquired in connection with share repurchases
|
(70
|
)
|
(70
|
)
|
(70
|
)
|
||||||||||||||||||||||||||||||
|
Stock-based compensation
|
20
|
|
20
|
|
20
|
|
||||||||||||||||||||||||||||||
|
Dividends on preferred stock
|
(6
|
)
|
(6
|
)
|
(6
|
)
|
||||||||||||||||||||||||||||||
|
Dividends on common stock
|
(413
|
)
|
(413
|
)
|
(413
|
)
|
||||||||||||||||||||||||||||||
|
Change in equity of noncontrolling interests
|
—
|
|
(373
|
)
|
(373
|
)
|
||||||||||||||||||||||||||||||
|
Net income (loss)
|
2,201
|
|
2,201
|
|
2
|
|
2,203
|
|
||||||||||||||||||||||||||||
|
Other comprehensive income (loss), net of income tax
|
6,094
|
|
6,094
|
|
91
|
|
6,185
|
|
||||||||||||||||||||||||||||
|
Balance at March 31, 2016
|
$
|
—
|
|
$
|
12
|
|
$
|
30,769
|
|
$
|
37,301
|
|
$
|
(3,172
|
)
|
$
|
10,865
|
|
$
|
75,775
|
|
$
|
190
|
|
$
|
75,965
|
|
|||||||||
See accompanying notes to the interim condensed consolidated financial statements.
5
MetLife, Inc.
Interim Condensed Consolidated Statements of Cash Flows
For the Three Months Ended March 31, 2017 and 2016 (Unaudited)
(In millions)
|
Three Months
Ended March 31, |
|||||||
|
2017
|
2016
|
||||||
|
Net cash provided by (used in) operating activities
|
$
|
2,098
|
|
$
|
1,913
|
|
|
|
Cash flows from investing activities
|
|||||||
|
Sales, maturities and repayments of:
|
|||||||
|
Fixed maturity securities
|
23,086
|
|
35,095
|
|
|||
|
Equity securities
|
188
|
|
631
|
|
|||
|
Mortgage loans
|
1,776
|
|
2,857
|
|
|||
|
Real estate and real estate joint ventures
|
39
|
|
56
|
|
|||
|
Other limited partnership interests
|
461
|
|
295
|
|
|||
|
Purchases of:
|
|||||||
|
Fixed maturity securities
|
(22,484
|
)
|
(37,247
|
)
|
|||
|
Equity securities
|
(299
|
)
|
(675
|
)
|
|||
|
Mortgage loans
|
(3,430
|
)
|
(4,413
|
)
|
|||
|
Real estate and real estate joint ventures
|
(341
|
)
|
(233
|
)
|
|||
|
Other limited partnership interests
|
(362
|
)
|
(281
|
)
|
|||
|
Cash received in connection with freestanding derivatives
|
2,515
|
|
1,337
|
|
|||
|
Cash paid in connection with freestanding derivatives
|
(3,372
|
)
|
(1,173
|
)
|
|||
|
Net change in policy loans
|
(20
|
)
|
85
|
|
|||
|
Net change in short-term investments
|
(1,892
|
)
|
(2,302
|
)
|
|||
|
Net change in other invested assets
|
(43
|
)
|
252
|
|
|||
|
Other, net
|
(98
|
)
|
(23
|
)
|
|||
|
Net cash provided by (used in) investing activities
|
(4,276
|
)
|
(5,739
|
)
|
|||
|
Cash flows from financing activities
|
|||||||
|
Policyholder account balances:
|
|||||||
|
Deposits
|
21,271
|
|
19,925
|
|
|||
|
Withdrawals
|
(19,100
|
)
|
(19,310
|
)
|
|||
|
Net change in payables for collateral under securities loaned and other transactions
|
391
|
|
4,161
|
|
|||
|
Net change in short-term debt
|
18
|
|
—
|
|
|||
|
Long-term debt repaid
|
(4
|
)
|
(5
|
)
|
|||
|
Collateral financing arrangements repaid
|
(12
|
)
|
(12
|
)
|
|||
|
Financing element on certain derivative instruments and other derivative related transactions, net
|
188
|
|
(13
|
)
|
|||
|
Treasury stock acquired in connection with share repurchases
|
(858
|
)
|
(70
|
)
|
|||
|
Dividends on preferred stock
|
(6
|
)
|
(6
|
)
|
|||
|
Dividends on common stock
|
(437
|
)
|
(413
|
)
|
|||
|
Other, net
|
48
|
|
34
|
|
|||
|
Net cash provided by (used in) financing activities
|
1,499
|
|
4,291
|
|
|||
|
Effect of change in foreign currency exchange rates on cash and cash equivalents balances
|
213
|
|
73
|
|
|||
|
Change in cash and cash equivalents
|
(466
|
)
|
538
|
|
|||
|
Cash and cash equivalents, beginning of period
|
17,877
|
|
12,752
|
|
|||
|
Cash and cash equivalents, end of period
|
$
|
17,411
|
|
$
|
13,290
|
|
|
|
Supplemental disclosures of cash flow information
|
|||||||
|
Net cash paid (received) for:
|
|||||||
|
Interest
|
$
|
255
|
|
$
|
249
|
|
|
|
Income tax
|
$
|
109
|
|
$
|
125
|
|
|
|
Non-cash transactions:
|
|||||||
|
Reduction of fixed maturity securities in connection with a reinsurance transaction
|
$
|
—
|
|
$
|
224
|
|
|
|
Deconsolidation of operating joint venture:
|
|||||||
|
Reduction of fixed maturity securities
|
$
|
—
|
|
$
|
917
|
|
|
|
Reduction of noncontrolling interests
|
$
|
—
|
|
$
|
373
|
|
|
See accompanying notes to the interim condensed consolidated financial statements.
6
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies
Business
“MetLife” and the “Company” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. MetLife is a global provider of life insurance, annuities, employee benefits and asset management. As previously announced, in the third quarter of 2016, MetLife reorganized its businesses into
six
segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa (“EMEA”); MetLife Holdings; and Brighthouse Financial, as a result of the Company’s plan to separate a substantial portion of its former Retail segment, as well as certain portions of its former Corporate Benefit Funding segment and Corporate & Other (the “Separation”). See
Note 2
for further information on the reorganization, which was applied retrospectively.
Basis of Presentation
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates.
Consolidation
The accompanying interim condensed consolidated financial statements include the accounts of MetLife, Inc. and its subsidiaries, as well as partnerships and joint ventures in which the Company has control, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions have been eliminated.
The Company uses the equity method of accounting for equity securities when it has significant influence or at least 20% interest and for real estate joint ventures and other limited partnership interests (“investees”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations. The Company generally recognizes its share of the investee’s earnings on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period. The Company uses the cost method of accounting for investments in which it has virtually no influence over the investee’s operations.
Reclassifications
Certain amounts in the prior year periods’ interim condensed consolidated financial statements and related footnotes thereto have been reclassified to conform to the 2017 presentation as discussed throughout the Notes to the Interim Condensed Consolidated Financial Statements.
The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. The
December 31, 2016
consolidated balance sheet data was derived from audited consolidated financial statements included in MetLife, Inc.’s Annual Report on Form 10‑K for the year ended
December 31, 2016
(the “2016 Annual Report”), which include all disclosures required by GAAP. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the
2016
Annual Report.
Adoption of New Accounting Pronouncements
Effective January 1, 2017, the Company early adopted guidance relating to business combinations. The new guidance clarifies the definition of a business and requires that an entity apply certain criteria in order to determine when a set of assets and activities qualifies as a business. The adoption of this standard will result in fewer acquisitions qualifying as businesses and, accordingly, acquisition costs for those acquisitions that do not qualify as businesses will be capitalized rather than expensed. The adoption did not have an impact on the Company’s consolidated financial statements.
Effective January 1, 2017, the Company retrospectively adopted guidance relating to consolidation. The new guidance does not change the characteristics of a primary beneficiary under current GAAP. It changes how a reporting entity evaluates whether it is the primary beneficiary of a VIE by changing how a reporting entity that is a single decisionmaker of a VIE handles indirect interests in the entity held through related parties that are under common control with the reporting entity. The adoption of this new guidance did not have a material impact on the Company’s consolidated financial statements.
7
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continue
d)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
Effective January 1, 2017, the Company adopted new guidance related to stock-based compensation. The new guidance changes several aspects of the accounting for share-based payment and award transactions, including (i) income tax consequences when awards vest or are settled; (ii) classification as either equity or liability due to statutory tax withholding requirements; and (iii) classification on the statement of cash flows. In addition, the new guidance provides an accounting policy election to account for forfeitures as they occur, rather than to account for them based on an estimate of expected forfeitures. The Company has elected to continue to account for forfeitures based on an estimate of expected forfeitures. In addition, the Company elected to apply the change in presentation in the statement of cash flows related to excess tax benefits prospectively and prior periods have not been adjusted. The change in presentation for cash paid to a taxing authority when directly withholding equivalent shares has been classified as a financing activity in the statement of cash flows. The change was applied retrospectively and thus the directly withheld share equivalent amount was reclassified from an operating activity to a financing activity in the consolidated statements of cash flows for the three months ended March 31, 2016. The adoption of this new guidance did not have a material impact on the Company’s consolidated financial statements.
Other
Effective January 3, 2017, the Chicago Mercantile Exchange (“CME”) amended its rulebook, resulting in the characterization of variation margin transfers as settlement payments, as opposed to adjustments to collateral. These amendments impacted the accounting treatment of the Company’s centrally cleared derivatives for which the CME serves as the central clearing party. As of the effective date, the application of the amended rulebook reduced gross derivative assets by
$1.8 billion
, gross derivative liabilities by
$2.0 billion
, accrued investment income by
$101 million
, accrued investment expense recorded within other liabilities by
$14 million
, collateral receivables recorded within premiums, reinsurance and other receivables of
$991 million
, and collateral payables recorded within payables for collateral under securities loaned and other transactions of
$816 million
.
Future Adoption of New Accounting Pronouncements
In March 2017, the Financial Accounting Standards Board (“FASB”) issued new guidance on purchased callable debt securities (Accounting Standards Update (“ASU”) 2017-08,
Receivables-Nonrefundable Fees and Other Costs (Subtopic 310-20), Premium Amortization on Purchased Callable Debt Securities
.) The new guidance is effective for fiscal years beginning after December 15, 2018 and interim periods within those years and should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings. Early adoption is permitted. The ASU shortens the amortization period for certain callable debt securities held at a premium and requires the premium to be amortized to the earliest call date. However, the new guidance does not require an accounting change for securities held at a discount whose discount continues to be amortized to maturity. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.
In March 2017, the FASB issued new guidance on the presentation of net periodic pension cost and net periodic postretirement benefit cost (ASU 2017-07,
Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost)
. The new guidance is effective for annual periods beginning after December 15, 2017 and interim periods within those annual periods. Early adoption is permitted as of the beginning of an annual period for which financial statements (interim or annual) have not been issued or made available for issuance. The guidance requires that an employer that offers to its employees defined benefit pension or other postretirement benefit plans report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations, if one is presented. The guidance should be applied retrospectively for the presentation of the service cost component in the income statement and allows a practical expedient for the estimation basis for applying the retrospective presentation requirements. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.
In February 2017, the FASB issued new guidance on derecognition of nonfinancial assets (ASU 2017-05,
Other Income-Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets
). The new guidance is effective for fiscal years beginning after December 15, 2017 and interim periods within those years. Early adoption is permitted for interim or annual reporting periods beginning after December 15, 2016. The guidance may be applied retrospectively for all periods presented or retrospectively with a cumulative-effect adjustment at the date of adoption. The new guidance clarifies the scope and accounting of a financial asset that meets the definition of an “in-substance nonfinancial asset” and defines the term, “in-substance nonfinancial asset.” The ASU also adds guidance for partial sales of nonfinancial assets. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.
8
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continue
d)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
In January 2017, the FASB issued new guidance on goodwill impairment (ASU 2017-04,
Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment
). The new guidance is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years, and should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The new guidance simplifies the current two-step goodwill impairment test by eliminating Step 2 of the test. The new guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, if any. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.
In November 2016, the FASB issued new guidance on restricted cash (ASU 2016-18,
Statement of Cash Flows (Topic 230): a consensus of the FASB Emerging Issues Task Force
). The new guidance is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and should be applied on a retrospective basis. Early adoption is permitted. The new guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. As a result, the new guidance requires that amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new guidance does not provide a definition of restricted cash or restricted cash equivalents. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.
In October 2016, the FASB issued new guidance on tax accounting for intra-entity transfers of assets (ASU 2016
-
16,
Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory
). The new guidance is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and should be applied on a modified retrospective basis. Early adoption is permitted in the first interim or annual reporting period. Current guidance prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to an outside party. The new guidance requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. Also, the guidance eliminates the exception for an intra-entity transfer of an asset other than inventory. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.
In August 2016, the FASB issued new guidance on cash flow statement presentation (ASU 2016-15,
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments
). The new guidance is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and should be applied retrospectively to all periods presented. Early adoption is permitted in any interim or annual period. This ASU addresses diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.
In June 2016, the FASB issued new guidance on measurement of credit losses on financial instruments (ASU 2016-13,
Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
)
. The new guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. This ASU replaces the incurred loss impairment methodology with one that reflects expected credit losses. The measurement of expected credit losses should be based on historical loss information, current conditions, and reasonable and supportable forecasts. The new guidance requires that an
other-than-temporary impairment (“OTTI”)
on a debt security will be recognized as an allowance going forward, such that improvements in expected future cash flows after an impairment will no longer be reflected as a prospective yield adjustment through net investment income, but rather a reversal of the previous impairment and recognized through realized investment gains and losses. The guidance also requires enhanced disclosures. The Company has assessed the asset classes impacted by the new guidance and is currently assessing the accounting and reporting system changes that will be required to comply with the new guidance. The Company believes that the most significant impact upon adoption will be to its mortgage loan investments. The Company is continuing to evaluate the overall impact of the new guidance on its consolidated financial statements.
9
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continue
d)
1. Business, Basis of Presentation and Summary of Significant Accounting Policies (continued)
In February 2016, the FASB issued new guidance on leasing transactions (ASU 2016-02,
Leases - Topic 842
). The new guidance is effective for the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and requires a modified retrospective transition approach. Early adoption is permitted. The new guidance requires a lessee to recognize assets and liabilities for leases with lease terms of more than 12 months. Leases would be classified as finance or operating leases and both types of leases will be recognized on the balance sheet. Lessor accounting will remain largely unchanged from current guidance except for certain targeted changes. The new guidance will also require new qualitative and quantitative disclosures. The Company’s implementation efforts are primarily focused on the review of its existing lease contracts as well as identification of other contracts that may fall under the scope of the new guidance. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.
In January 2016, the FASB issued new guidance (ASU 2016-01,
Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities
) on the recognition and measurement of financial instruments. The new guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted for the instrument-specific credit risk provision. The new guidance changes the current accounting guidance related to (i) the classification and measurement of certain equity investments, (ii) the presentation of changes in the fair value of financial liabilities measured under the
fair value option (“FVO”)
that are due to instrument-specific credit risk, and (iii) certain disclosures associated with the fair value of financial instruments. Additionally, there will no longer be a requirement to assess equity securities for impairment since such securities will be measured at fair value through net income. The Company has assessed the population of financial instruments that are subject to the new guidance and has determined that the most significant impact will be the requirement to report changes in fair value in net income each reporting period for all equity securities currently classified as
available-for-sale (“AFS”)
and to a lesser extent, other limited partnership interests and real estate joint ventures that are currently accounted for under the cost method. The population of these investments accounted for under the cost method is not material. The Company is continuing to evaluate the overall impact of this guidance on its consolidated financial statements.
In May 2014, the FASB issued a comprehensive new revenue recognition standard (ASU 2014-09,
Revenue from Contracts with Customers (Topic 606)
), effective for fiscal years beginning after December 15, 2017 and interim periods within those years. The guidance may be applied retrospectively for all periods presented or retrospectively with a cumulative-effect adjustment at the date of adoption. The new guidance will supersede nearly all existing revenue recognition guidance under U.S. GAAP; however, it will not impact the accounting for insurance and investment contracts within the scope of Financial Services insurance (Topic 944), leases, financial instruments and guarantees. For those contracts that are impacted, the guidance will require an entity to recognize revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled, in exchange for those goods or services. Given the scope of the new revenue recognition guidance, the Company does not expect the adoption to have a material impact on its consolidated revenues or statements of operations, with the Company’s implementation efforts primarily focused on other revenues on the consolidated statements of operations, which represents less than
3%
of consolidated total revenues in 2016.
10
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
2. Segment Information
As previously announced, in the third quarter of 2016, MetLife reorganized its businesses into
six
segments: U.S.; Asia; Latin America; EMEA; MetLife Holdings; and Brighthouse Financial, in anticipation of the proposed Separation. In addition
, the Company reports certain of its results of operations in Corporate & Other. Prior period results have been revised in connection with the reorganization and did not have an impact on total consolidated net income (loss) or operating earnings.
On January 12, 2016, MetLife, Inc. announced its plan to pursue the Separation. MetLife, Inc. subsequently re-segmented the business to be separated and rebranded it as “Brighthouse Financial.”
On October 5, 2016, Brighthouse Financial, Inc., a subsidiary of MetLife, Inc. (“Brighthouse”), filed a registration statement on Form 10 (the “Form 10”) with the U.S. Securities and Exchange Commission (“SEC”). On December 6, 2016 and on April 18, 2017, Brighthouse filed amendments to its registration statement on Form 10 with the SEC. The information statement filed as an exhibit to the Form 10 disclosed that the Company intends to include Brighthouse Life Insurance Company (formerly, MetLife Insurance Company USA (“MetLife USA”)) (“Brighthouse Insurance”), New England Life Insurance Company (“NELICO”), Brighthouse Life Insurance Company of NY (formerly, First MetLife Investors Insurance Company (“FMLI”)), Brighthouse Investment Advisers, LLC (formerly, MetLife Advisers, LLC) and certain captive reinsurance companies in the proposed separated business and distribute at least 80.1% of the shares of Brighthouse’s common stock on a pro rata basis to the holders of MetLife, Inc. common stock.
Effective April 28, 2017, following receipt of applicable regulatory approvals, MetLife contributed certain captive reinsurance companies to Brighthouse Insurance, which were then merged into a newly-formed captive reinsurance company that is wholly-owned by Brighthouse Insurance. See Note 14 for information on related financing arrangements.
The ultimate form and timing of the Separation will be influenced by a number of factors, including regulatory considerations and economic conditions. MetLife continues to evaluate and pursue structural alternatives for the proposed Separation. The Separation remains subject to certain conditions, including among others, obtaining final approval from the MetLife, Inc. Board of Directors, receipt of a favorable ruling from the Internal Revenue Service and an opinion from MetLife’s tax advisor regarding certain U.S. federal income tax matters, insurance and other regulatory approvals, and an SEC declaration of the effectiveness of the Form 10.
U.S.
The U.S. segment offers a broad range of protection products and services aimed at serving the financial needs of customers throughout their lives. These products are sold to corporations and their respective employees, other institutions and their respective members, as well as individuals. The U.S. segment is organized into three businesses: Group Benefits, Retirement and Income Solutions and Property & Casualty.
|
•
|
The Group Benefits business offers insurance products and services which include life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, critical illness, vision and accident & health coverages, as well as prepaid legal plans. This business also sells administrative services-only arrangements to some employers.
|
|
•
|
The Retirement and Income Solutions business offers a broad range of annuity and investment products, including guaranteed interest contracts and other stable value products, institutional income annuities and separate account contracts for the investment management of defined benefit and defined contribution plan assets. This business also includes structured settlements and certain products to fund postretirement benefits and company-, bank- or trust-owned life insurance used to finance nonqualified benefit programs for executives.
|
|
•
|
The Property & Casualty business offers personal and commercial lines of property and casualty insurance, including private passenger automobile, homeowners’ and personal excess liability insurance. In addition, Property & Casualty offers small business owners property, liability and business interruption insurance.
|
Asia
The Asia segment offers a broad range of products to both individuals and corporations, as well as other institutions and their respective employees, which include whole life, term life, variable life, universal life, accident & health insurance, fixed and variable annuities, credit insurance and endowment products.
11
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
2. Segment Information (continued)
Latin America
The Latin America segment offers a broad range of products to both individuals and corporations, as well as other institutions and their respective employees, which include life insurance, accident & health insurance, group medical, dental, credit insurance, endowment and retirement and savings products.
EMEA
The EMEA segment offers a broad range of products to both individuals and corporations, as well as other institutions and their respective employees, which include life insurance, accident & health insurance, credit insurance, annuities, endowment and retirement and savings products.
MetLife Holdings
The MetLife Holdings segment consists of operations relating to products and businesses no longer actively marketed by the Company in the United States. These products and businesses include variable, universal, term and whole life, as well as variable, fixed and index-linked annuities. The MetLife Holdings segment also includes the Company’s discontinued long-term care business and the assumed reinsurance of certain variable annuity products from the Company’s former operating joint venture in Japan.
Brighthouse Financial
The Brighthouse Financial segment offers a broad range of products and services which include variable, fixed, index-linked and income annuities, as well as variable, universal, term and whole life products. These products and services are actively marketed through various third party retail distribution channels in the United States. In addition, the Brighthouse Financial segment includes certain run-off businesses which are not actively marketed.
Corporate & Other
Corporate & Other contains the excess capital, as well as certain charges and activities, not allocated to the segments, including external integration and disposition costs, internal resource costs for associates committed to acquisitions and dispositions, enterprise-wide strategic initiative restructuring charges and various start-up businesses (including expatriate benefits insurance and the investment management business through which the Company offers fee-based investment management services to institutional clients, as well as the direct to consumer portion of the U.S. Direct business). Corporate & Other also includes interest expense related to the majority of the Company’s outstanding debt, as well as expenses associated with certain legal proceedings and income tax audit issues. In addition, Corporate & Other includes the elimination of intersegment amounts, which generally relate to affiliated reinsurance and intersegment loans, which bear interest rates commensurate with related borrowings.
Financial Measures and Segment Accounting Policies
Operating earnings is used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, operating earnings is also the Company’s GAAP measure of segment performance and is reported below. Operating earnings should not be viewed as a substitute for net income (loss).The Company believes the presentation of operating earnings as the Company measures it for management purposes enhances the understanding of its performance by highlighting the results of operations and the underlying profitability drivers of the business. Operating earnings allows analysis of the Company’s performance relative to the Company’s business plan and facilitates comparisons to industry results.
Operating earnings is defined as operating revenues less operating expenses, both net of income tax.
The financial measures of operating revenues and operating expenses focus on the Company’s primary businesses principally by excluding the impact of market volatility, which could distort trends, and revenues and costs related to non-core products and divested businesses and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations and other businesses that have been or will be sold or exited by MetLife and are referred to as divested businesses. In addition, for the three months ended March 31, 2016, operating revenues and operating expenses exclude the financial impact of converting the Company’s Japan operations to calendar year-end reporting without retrospective application of this change to prior periods and is referred to as lag elimination. Operating revenues also excludes net investment gains (losses) and net derivative gains (losses). Operating expenses also excludes goodwill impairments.
12
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
2. Segment Information (continued)
The following additional adjustments are made to revenues, in the line items indicated, in calculating operating revenues:
|
•
|
Universal life and investment-type product policy fees excludes the amortization of unearned revenue related to net investment gains (losses) and net derivative gains (losses) and certain variable annuity
guaranteed minimum income benefits (“GMIBs”) fees (“GMIB Fees”); and
|
|
•
|
Net investment income: (i) includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment,(ii) excludes post-tax operating earnings adjustments relating to insurance joint ventures accounted for under the equity method, (iii) excludes certain amounts related to contractholder-directed unit-linked investments and (iv) excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and
|
|
•
|
Other revenues are adjusted for settlements of foreign currency earnings hedges.
|
The following additional adjustments are made to expenses, in the line items indicated, in calculating operating expenses:
|
•
|
Policyholder benefits and claims and policyholder dividends excludes: (i) changes in the policyholder dividend obligation related to net investment gains (losses) and net derivative gains (losses), (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments and amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass through adjustments, (iii) benefits and hedging costs related to GMIBs (“GMIB Costs”) and (iv) market value adjustments associated with surrenders or terminations of contracts (“Market Value Adjustments”);
|
|
•
|
Interest credited to policyholder account balances includes adjustments for earned income on derivatives and amortization of premium on derivatives that are hedges of policyholder account balances but do not qualify for hedge accounting treatment and excludes amounts related to net investment income earned on contractholder-directed unit-linked investments;
|
|
•
|
Amortization of deferred policy acquisition costs (“DAC”) and
value of business acquired (“VOBA”)
excludes amounts related to: (i) net investment gains (losses) and net derivative gains (losses), (ii) GMIB Fees and GMIB Costs and (iii) Market Value Adjustments;
|
|
•
|
Amortization of negative VOBA excludes amounts related to Market Value Adjustments;
|
|
•
|
Interest expense on debt excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and
|
|
•
|
Other expenses excludes costs related to: (i) noncontrolling interests, (ii) implementation of new insurance regulatory requirements, and (iii) acquisition, integration and other costs.
|
Operating earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.
The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from the Company’s effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.
Set forth in the tables below is certain financial information with respect to the Company’s segments, as well as Corporate & Other, for the
three months ended
March 31, 2017
and
2016
. The segment accounting policies are the same as those used to prepare the Company’s consolidated financial statements, except for operating earnings adjustments as defined above. In addition, segment accounting policies include the method of capital allocation described below, with the exception of the Brighthouse Financial segment,
for which equity is reflective of the historical equity of the legal entities which comprise Brighthouse and related companies, which will be eliminated upon Separation. The Brighthouse Financial segment equity is not indicative of Brighthouse and related companies’ equity on a combined standalone basis.
Economic capital is an internally developed risk capital model, the purpose of which is to measure the risk in the business and to provide a basis upon which capital is deployed. The economic capital model accounts for the unique and specific nature of the risks inherent in the Company’s business.
13
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
2. Segment Information (continued)
The Company’s economic capital model, coupled with considerations of local capital requirements, aligns segment allocated equity with emerging standards and consistent risk principles. The model applies statistics-based risk evaluation principles to the material risks to which the Company is exposed. These consistent risk principles include calibrating required economic capital shock factors to a specific confidence level and time horizon while applying an industry standard method for the inclusion of diversification benefits among risk types.
The Company’s management is responsible for the ongoing production and enhancement of the economic capital model and reviews its approach periodically to ensure that it remains consistent with emerging industry practice standards.
Segment net investment income, with the exception of the Brighthouse Financial segment, is credited or charged based on the level of allocated equity; however, changes in allocated equity do not impact the Company’s consolidated net investment income, net income (loss) or operating earnings. As noted above, the Brighthouse Financial segment’s net investment income represents that of the legal entities which comprise Brighthouse and related companies on a historical basis, however, Brighthouse Financial segment’s net investment income may not be indicative of that on a combined standalone basis.
Net investment income is based upon the actual results of each segment’s specifically identifiable investment portfolios adjusted for allocated equity. Other costs are allocated to each of the segments based upon: (i) a review of the nature of such costs; (ii) time studies analyzing the amount of employee compensation costs incurred by each segment; and (iii) cost estimates included in the Company’s product pricing.
14
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
2. Segment Information (continued)
|
|
|
Operating Results
|
|
|
|
|
||||||||||||||||||||||||||||||||||
|
Three Months Ended March 31, 2017
|
|
U.S.
|
Asia
|
Latin
America |
EMEA
|
MetLife
Holdings
|
Brighthouse
Financial
|
Corporate &
Other
|
Total
|
Adjustments
|
Total
Consolidated |
|||||||||||||||||||||||||||||
|
|
|
(In millions)
|
||||||||||||||||||||||||||||||||||||||
|
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
|
Premiums
|
|
$
|
5,185
|
|
|
$
|
1,708
|
|
|
$
|
647
|
|
|
$
|
502
|
|
|
$
|
1,059
|
|
|
$
|
177
|
|
|
$
|
37
|
|
|
$
|
9,315
|
|
|
$
|
—
|
|
|
$
|
9,315
|
|
|
Universal life and investment-type product policy fees
|
|
265
|
|
|
366
|
|
|
260
|
|
|
95
|
|
|
362
|
|
|
884
|
|
|
(31
|
)
|
|
2,201
|
|
|
101
|
|
|
2,302
|
|
||||||||||
|
Net investment income
|
|
1,612
|
|
|
702
|
|
|
303
|
|
|
74
|
|
|
1,441
|
|
|
858
|
|
|
5
|
|
|
4,995
|
|
|
201
|
|
|
5,196
|
|
||||||||||
|
Other revenues
|
|
204
|
|
|
10
|
|
|
9
|
|
|
17
|
|
|
96
|
|
|
74
|
|
|
(42
|
)
|
|
368
|
|
|
6
|
|
|
374
|
|
||||||||||
|
Net investment gains (losses)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
8
|
|
|
8
|
|
||||||||||
|
Net derivative gains (losses)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(926
|
)
|
|
(926
|
)
|
||||||||||
|
Total revenues
|
|
7,266
|
|
2,786
|
|
1,219
|
|
688
|
|
2,958
|
|
1,993
|
|
(31
|
)
|
16,879
|
|
(610
|
)
|
16,269
|
|
|||||||||||||||||||
|
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
|
Policyholder benefits and claims and policyholder dividends
|
|
5,235
|
|
|
1,315
|
|
|
633
|
|
|
269
|
|
|
1,736
|
|
|
631
|
|
|
9
|
|
|
9,828
|
|
|
348
|
|
|
10,176
|
|
||||||||||
|
Interest credited to policyholder account balances
|
|
351
|
|
|
321
|
|
|
82
|
|
|
24
|
|
|
257
|
|
|
275
|
|
|
—
|
|
|
1,310
|
|
|
402
|
|
|
1,712
|
|
||||||||||
|
Capitalization of DAC
|
|
(100
|
)
|
|
(420
|
)
|
|
(82
|
)
|
|
(92
|
)
|
|
(34
|
)
|
|
(67
|
)
|
|
(1
|
)
|
|
(796
|
)
|
|
—
|
|
|
(796
|
)
|
||||||||||
|
Amortization of DAC and VOBA
|
|
114
|
|
|
291
|
|
|
78
|
|
|
87
|
|
|
74
|
|
|
200
|
|
|
1
|
|
|
845
|
|
|
(312
|
)
|
|
533
|
|
||||||||||
|
Amortization of negative VOBA
|
|
—
|
|
|
(37
|
)
|
|
—
|
|
|
(3
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(40
|
)
|
|
(3
|
)
|
|
(43
|
)
|
||||||||||
|
Interest expense on debt
|
|
2
|
|
|
—
|
|
|
1
|
|
|
—
|
|
|
15
|
|
|
32
|
|
|
246
|
|
|
296
|
|
|
—
|
|
|
296
|
|
||||||||||
|
Other expenses
|
|
909
|
|
|
875
|
|
|
326
|
|
|
316
|
|
|
340
|
|
|
612
|
|
|
90
|
|
|
3,468
|
|
|
106
|
|
|
3,574
|
|
||||||||||
|
Total expenses
|
|
6,511
|
|
2,345
|
|
1,038
|
|
601
|
|
2,388
|
|
1,683
|
|
345
|
|
14,911
|
|
541
|
|
15,452
|
|
|||||||||||||||||||
|
Provision for income tax expense (benefit)
|
|
252
|
|
|
146
|
|
|
38
|
|
|
12
|
|
|
185
|
|
|
66
|
|
|
(283
|
)
|
|
416
|
|
|
(428
|
)
|
|
(12
|
)
|
||||||||||
|
Operating earnings
|
|
$
|
503
|
|
$
|
295
|
|
$
|
143
|
|
$
|
75
|
|
$
|
385
|
|
$
|
244
|
|
$
|
(93
|
)
|
|
1,552
|
|
|
|
|
|
|||||||||||
|
Adjustments to:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||
|
Total revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(610
|
)
|
|
|
|
||||||||||||||||||||
|
Total expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(541
|
)
|
|
|
|
||||||||||||||||||||
|
Provision for income tax (expense) benefit
|
|
428
|
|
|
|
|
||||||||||||||||||||||||||||||||||
|
Net income (loss)
|
|
$
|
829
|
|
|
|
|
$
|
829
|
|
||||||||||||||||||||||||||||||
15
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
2. Segment Information (continued)
|
Operating Results
|
||||||||||||||||||||||||||||||||||||||||
|
Three Months Ended March 31, 2016
|
U.S.
|
Asia
|
Latin
America
|
EMEA
|
MetLife
Holdings
|
Brighthouse
Financial
|
Corporate &
Other
|
Total
|
Adjustments
|
Total
Consolidated |
||||||||||||||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||||||||||||||||
|
Revenues
|
||||||||||||||||||||||||||||||||||||||||
|
Premiums
|
$
|
5,020
|
|
$
|
1,658
|
|
$
|
601
|
|
$
|
500
|
|
$
|
1,097
|
|
$
|
393
|
|
$
|
(2
|
)
|
$
|
9,267
|
|
$
|
426
|
|
$
|
9,693
|
|
||||||||||
|
Universal life and investment-type product policy fees
|
250
|
|
350
|
|
268
|
|
95
|
|
355
|
|
858
|
|
(25
|
)
|
2,151
|
|
193
|
|
2,344
|
|
||||||||||||||||||||
|
Net investment income
|
1,460
|
|
618
|
|
255
|
|
80
|
|
1,475
|
|
813
|
|
5
|
|
4,706
|
|
(147
|
)
|
4,559
|
|
||||||||||||||||||||
|
Other revenues
|
204
|
|
17
|
|
7
|
|
20
|
|
204
|
|
86
|
|
(51
|
)
|
487
|
|
—
|
|
487
|
|
||||||||||||||||||||
|
Net investment gains (losses)
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
15
|
|
15
|
|
||||||||||||||||||||
|
Net derivative gains (losses)
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
1,335
|
|
1,335
|
|
||||||||||||||||||||
|
Total revenues
|
6,934
|
|
2,643
|
|
1,131
|
|
695
|
|
3,131
|
|
2,150
|
|
(73
|
)
|
16,611
|
|
1,822
|
|
18,433
|
|
||||||||||||||||||||
|
Expenses
|
||||||||||||||||||||||||||||||||||||||||
|
Policyholder benefits and claims and policyholder dividends
|
5,046
|
|
1,236
|
|
550
|
|
261
|
|
1,823
|
|
703
|
|
(26
|
)
|
9,593
|
|
400
|
|
9,993
|
|
||||||||||||||||||||
|
Interest credited to policyholder account balances
|
322
|
|
319
|
|
80
|
|
29
|
|
258
|
|
289
|
|
4
|
|
1,301
|
|
25
|
|
1,326
|
|
||||||||||||||||||||
|
Capitalization of DAC
|
(111
|
)
|
(385
|
)
|
(73
|
)
|
(101
|
)
|
(100
|
)
|
(102
|
)
|
(4
|
)
|
(876
|
)
|
(105
|
)
|
(981
|
)
|
||||||||||||||||||||
|
Amortization of DAC and VOBA
|
118
|
|
286
|
|
63
|
|
102
|
|
148
|
|
162
|
|
2
|
|
881
|
|
114
|
|
995
|
|
||||||||||||||||||||
|
Amortization of negative VOBA
|
—
|
|
(64
|
)
|
—
|
|
(3
|
)
|
—
|
|
—
|
|
—
|
|
(67
|
)
|
(32
|
)
|
(99
|
)
|
||||||||||||||||||||
|
Interest expense on debt
|
2
|
|
—
|
|
—
|
|
—
|
|
14
|
|
32
|
|
264
|
|
312
|
|
—
|
|
312
|
|
||||||||||||||||||||
|
Other expenses
|
942
|
|
851
|
|
310
|
|
333
|
|
596
|
|
624
|
|
54
|
|
3,710
|
|
255
|
|
3,965
|
|
||||||||||||||||||||
|
Total expenses
|
6,319
|
|
2,243
|
|
930
|
|
621
|
|
2,739
|
|
1,708
|
|
294
|
|
14,854
|
|
657
|
|
15,511
|
|
||||||||||||||||||||
|
Provision for income tax expense (benefit)
|
209
|
|
95
|
|
50
|
|
11
|
|
125
|
|
115
|
|
(183
|
)
|
422
|
|
297
|
|
719
|
|
||||||||||||||||||||
|
Operating earnings
|
$
|
406
|
|
$
|
305
|
|
$
|
151
|
|
$
|
63
|
|
$
|
267
|
|
$
|
327
|
|
$
|
(184
|
)
|
1,335
|
|
|||||||||||||||||
|
Adjustments to:
|
||||||||||||||||||||||||||||||||||||||||
|
Total revenues
|
1,822
|
|
||||||||||||||||||||||||||||||||||||||
|
Total expenses
|
(657
|
)
|
||||||||||||||||||||||||||||||||||||||
|
Provision for income tax (expense) benefit
|
(297
|
)
|
||||||||||||||||||||||||||||||||||||||
|
Net income (loss)
|
$
|
2,203
|
|
$
|
2,203
|
|
||||||||||||||||||||||||||||||||||
16
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
2. Segment Information (continued)
The following table presents total assets with respect to the Company’s segments, as well as Corporate & Other, at:
|
March 31, 2017
|
December 31, 2016
|
|||||||
|
(In millions)
|
||||||||
|
U.S.
|
$
|
254,041
|
|
$
|
253,683
|
|
||
|
Asia
|
128,932
|
|
120,656
|
|
||||
|
Latin America
|
71,697
|
|
67,233
|
|
||||
|
EMEA
|
26,786
|
|
25,596
|
|
||||
|
MetLife Holdings
|
184,187
|
|
184,276
|
|
||||
|
Brighthouse Financial
|
223,746
|
|
222,681
|
|
||||
|
Corporate & Other
|
25,298
|
|
24,639
|
|
||||
|
Total
|
$
|
914,687
|
|
$
|
898,764
|
|
||
3. Insurance
Guarantees
As discussed in Notes 1 and 4 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report, the Company issues directly and assumes through reinsurance variable annuity products with guaranteed minimum benefits. Guaranteed minimum accumulation benefits (“GMABs”) and the portions of both non-life-contingent guaranteed minimum withdrawal benefits (“GMWBs”) and the GMIBs that do not require annuitization are accounted for as embedded derivatives in policyholder account balances and are further discussed in
Note 6
.
The Company also issues other annuity contracts that apply a lower rate on funds deposited if the contractholder elects to surrender the contract for cash and a higher rate if the contractholder elects to annuitize. These guarantees include benefits that are payable in the event of death, maturity or at annuitization. Certain other annuity contracts contain guaranteed annuitization benefits that may be above what would be provided by the current account value of the contract. Additionally, the Company issues universal and variable life contracts where the Company contractually guarantees to the contractholder a secondary guarantee or a guaranteed paid-up benefit.
Information regarding the Company’s guarantee exposure, which includes direct and assumed business, but excludes offsets from hedging or ceded reinsurance, if any, was as follows at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||||||||||
|
In the
Event of Death |
At
Annuitization |
In the
Event of Death |
At
Annuitization |
|||||||||||||||||||||
|
(Dollars in millions)
|
||||||||||||||||||||||||
|
Annuity Contracts (1):
|
||||||||||||||||||||||||
|
Variable Annuity Guarantees:
|
||||||||||||||||||||||||
|
Total account value (2), (3)
|
$
|
181,504
|
|
$
|
91,461
|
|
$
|
177,895
|
|
$
|
89,839
|
|
||||||||||||
|
Separate account value
|
$
|
153,699
|
|
$
|
88,067
|
|
$
|
150,118
|
|
$
|
86,355
|
|
||||||||||||
|
Net amount at risk (2)
|
$
|
7,740
|
|
(4
|
)
|
$
|
3,647
|
|
(5
|
)
|
$
|
8,679
|
|
(4
|
)
|
$
|
3,834
|
|
(5
|
)
|
||||
|
Average attained age of contractholders
|
67 years
|
|
66 years
|
|
66 years
|
|
66 years
|
|
||||||||||||||||
|
Other Annuity Guarantees:
|
||||||||||||||||||||||||
|
Total account value (3)
|
N/A
|
|
$
|
1,382
|
|
N/A
|
|
$
|
1,393
|
|
||||||||||||||
|
Net amount at risk
|
N/A
|
|
$
|
486
|
|
(6
|
)
|
N/A
|
|
$
|
490
|
|
(6
|
)
|
||||||||||
|
Average attained age of contractholders
|
N/A
|
|
51 years
|
|
N/A
|
|
50 years
|
|
||||||||||||||||
17
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
3. Insurance (continued)
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||
|
Secondary
Guarantees |
Paid-Up
Guarantees |
Secondary
Guarantees |
Paid-Up
Guarantees |
|||||||||||||
|
(Dollars in millions)
|
||||||||||||||||
|
Universal and Variable Life Contracts (1):
|
||||||||||||||||
|
Total account value (3)
|
$
|
17,923
|
|
$
|
3,302
|
|
$
|
17,689
|
|
$
|
3,337
|
|
||||
|
Net amount at risk (7)
|
$
|
171,785
|
|
$
|
17,476
|
|
$
|
172,860
|
|
$
|
17,785
|
|
||||
|
Average attained age of policyholders
|
58 years
|
|
63 years
|
|
58 years
|
|
62 years
|
|
||||||||
__________________
|
(1)
|
The Company’s annuity and life contracts with guarantees may offer more than one type of guarantee in each contract. Therefore, the amounts listed above may not be mutually exclusive.
|
|
(2)
|
Includes amounts, which are not reported on the consolidated balance sheets, from assumed reinsurance of certain variable annuity products from the Company’s former operating joint venture in Japan.
|
|
(3)
|
Includes the contractholder’s investments in the general account and separate account, if applicable.
|
|
(4)
|
Defined as the death benefit less the total account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date and includes any additional contractual claims associated with riders purchased to assist with covering income taxes payable upon death.
|
|
(5)
|
Defined as the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. This amount represents the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date, even though the contracts contain terms that allow annuitization of the guaranteed amount only after the 10th anniversary of the contract, which not all contractholders have achieved.
|
|
(6)
|
Defined as either the excess of the upper tier, adjusted for a profit margin, less the lower tier, as of the balance sheet date or the amount (if any) that would be required to be added to the total account value to purchase a lifetime income stream, based on current annuity rates, equal to the minimum amount provided under the guaranteed benefit. These amounts represent the Company’s potential economic exposure to such guarantees in the event all contractholders were to annuitize on the balance sheet date.
|
|
(7)
|
Defined as the guarantee amount less the account value, as of the balance sheet date. It represents the amount of the claim that the Company would incur if death claims were filed on all contracts on the balance sheet date.
|
18
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
3. Insurance (continued)
Liabilities for Unpaid Claims and Claim Expenses
Rollforward of Claims and Claim Adjustment Expenses
Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows:
|
Three Months
Ended March 31, |
||||||||
|
2017
|
2016
|
|||||||
|
(In millions)
|
||||||||
|
Balance at December 31 of prior period
|
$
|
18,159
|
|
$
|
11,388
|
|
||
|
Less: Reinsurance recoverables
|
3,058
|
|
2,042
|
|
||||
|
Net Balance at December 31 of prior period
|
15,101
|
|
9,346
|
|
||||
|
Cumulative adjustment (1)
|
—
|
|
4,988
|
|
||||
|
Net balance, beginning of period
|
15,101
|
|
14,334
|
|
||||
|
Incurred related to:
|
||||||||
|
Current period
|
6,874
|
|
6,977
|
|
||||
|
Prior periods (2)
|
(42
|
)
|
(139
|
)
|
||||
|
Total incurred
|
6,832
|
|
6,838
|
|
||||
|
Paid related to:
|
|
|
||||||
|
Current period
|
(3,777
|
)
|
(3,710
|
)
|
||||
|
Prior periods
|
(2,698
|
)
|
(2,473
|
)
|
||||
|
Total paid
|
(6,475
|
)
|
(6,183
|
)
|
||||
|
Net balance, end of period
|
15,458
|
|
14,989
|
|
||||
|
Add: Reinsurance recoverables
|
3,058
|
|
2,843
|
|
||||
|
Balance, end of period (included in future policy benefits and other policy-related balances)
|
$
|
18,516
|
|
$
|
17,832
|
|
||
__________________
|
(1)
|
Reflects the accumulated adjustment, net of reinsurance, upon implementation of the new short-duration contracts guidance which clarified the requirement to include claim information for long-duration contracts. The accumulated adjustment primarily reflects unpaid claim liabilities, net of reinsurance, for long-duration contracts as of the beginning of the period presented.
|
|
(2)
|
During the three months ended March 31, 2017 and 2016, as a result of changes in estimates of insured events in the respective prior periods, the claims and claim adjustment expenses associated with prior periods decreased due to favorable claims experience.
|
4. Closed Block
On April 7, 2000 (the “Demutualization Date”), Metropolitan Life Insurance Company (“MLIC”) converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving MLIC’s plan of reorganization, as amended (the “Plan of Reorganization”). On the Demutualization Date, MLIC established a closed block for the benefit of holders of certain individual life insurance policies of MLIC.
Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon cumulative actual and expected earnings within the closed block. Accordingly, the Company’s net income continues to be sensitive to the actual performance of the closed block.
Closed block assets, liabilities, revenues and expenses are combined on a line-by-line basis with the assets, liabilities, revenues and expenses outside the closed block based on the nature of the particular item.
19
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
4. Closed Block (continued)
Information regarding the closed block liabilities and assets designated to the closed block was as follows at:
|
March 31, 2017
|
December 31, 2016
|
|||||||
|
(In millions)
|
||||||||
|
Closed Block Liabilities
|
||||||||
|
Future policy benefits
|
$
|
40,654
|
|
$
|
40,834
|
|
||
|
Other policy-related balances
|
223
|
|
257
|
|
||||
|
Policyholder dividends payable
|
470
|
|
443
|
|
||||
|
Policyholder dividend obligation
|
1,983
|
|
1,931
|
|
||||
|
Current income tax payable
|
11
|
|
4
|
|
||||
|
Other liabilities
|
245
|
|
196
|
|
||||
|
Total closed block liabilities
|
43,586
|
|
43,665
|
|
||||
|
Assets Designated to the Closed Block
|
||||||||
|
Investments:
|
||||||||
|
Fixed maturity securities available-for-sale, at estimated fair value
|
27,554
|
|
27,220
|
|
||||
|
Equity securities available-for-sale, at estimated fair value
|
102
|
|
100
|
|
||||
|
Mortgage loans
|
5,857
|
|
5,935
|
|
||||
|
Policy loans
|
4,550
|
|
4,553
|
|
||||
|
Real estate and real estate joint ventures
|
654
|
|
655
|
|
||||
|
Other invested assets
|
904
|
|
1,246
|
|
||||
|
Total investments
|
39,621
|
|
39,709
|
|
||||
|
Cash and cash equivalents
|
46
|
|
18
|
|
||||
|
Accrued investment income
|
483
|
|
467
|
|
||||
|
Premiums, reinsurance and other receivables
|
62
|
|
68
|
|
||||
|
Deferred income tax assets
|
171
|
|
177
|
|
||||
|
Total assets designated to the closed block
|
40,383
|
|
40,439
|
|
||||
|
Excess of closed block liabilities over assets designated to the closed block
|
3,203
|
|
3,226
|
|
||||
|
Amounts included in accumulated other comprehensive income (loss) (“AOCI”):
|
||||||||
|
Unrealized investment gains (losses), net of income tax
|
1,582
|
|
1,517
|
|
||||
|
Unrealized gains (losses) on derivatives, net of income tax
|
85
|
|
95
|
|
||||
|
Allocated to policyholder dividend obligation, net of income tax
|
(1,289
|
)
|
(1,255
|
)
|
||||
|
Total amounts included in AOCI
|
378
|
|
357
|
|
||||
|
Maximum future earnings to be recognized from closed block assets and liabilities
|
$
|
3,581
|
|
$
|
3,583
|
|
||
Information regarding the closed block policyholder dividend obligation was as follows:
|
Three Months
Ended March 31, 2017 |
Year
Ended December 31, 2016 |
|||||||
|
(In millions)
|
||||||||
|
Balance, beginning of period
|
$
|
1,931
|
|
$
|
1,783
|
|
||
|
Change in unrealized investment and derivative gains (losses)
|
52
|
|
148
|
|
||||
|
Balance, end of period
|
$
|
1,983
|
|
$
|
1,931
|
|
||
20
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
4. Closed Block (continued)
Information regarding the closed block revenues and expenses was as follows:
|
Three Months
Ended March 31, |
||||||||
|
2017
|
2016
|
|||||||
|
(In millions)
|
||||||||
|
Revenues
|
||||||||
|
Premiums
|
$
|
402
|
|
$
|
417
|
|
||
|
Net investment income
|
466
|
|
480
|
|
||||
|
Net investment gains (losses)
|
(8
|
)
|
(28
|
)
|
||||
|
Net derivative gains (losses)
|
(8
|
)
|
(11
|
)
|
||||
|
Total revenues
|
852
|
|
858
|
|
||||
|
Expenses
|
||||||||
|
Policyholder benefits and claims
|
568
|
|
610
|
|
||||
|
Policyholder dividends
|
250
|
|
245
|
|
||||
|
Other expenses
|
32
|
|
32
|
|
||||
|
Total expenses
|
850
|
|
887
|
|
||||
|
Revenues, net of expenses before provision for income tax expense (benefit)
|
2
|
|
(29
|
)
|
||||
|
Provision for income tax expense (benefit)
|
—
|
|
(11
|
)
|
||||
|
Revenues, net of expenses and provision for income tax expense (benefit)
|
$
|
2
|
|
$
|
(18
|
)
|
||
MLIC charges the closed block with federal income taxes, state and local premium taxes and other state or local taxes, as well as investment management expenses relating to the closed block as provided in the Plan of Reorganization. MLIC also charges the closed block for expenses of maintaining the policies included in the closed block.
21
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Investments
Fixed Maturity and Equity Securities Available-for-Sale
Fixed Maturity and Equity Securities Available-for-Sale by Sector
The following table presents the fixed maturity and equity securities AFS by sector. Redeemable preferred stock is reported within U.S. corporate and foreign corporate fixed maturity securities and non-redeemable preferred stock is reported within equity securities. Included within fixed maturity securities are structured securities including residential mortgage-backed securities (“RMBS”), asset-backed securities (“ABS”) and commercial mortgage-backed securities (“CMBS”) (collectively, “Structured Securities”).
|
March 31, 2017
|
December 31, 2016
|
||||||||||||||||||||||||||||||||||||||
|
Cost or
Amortized
Cost
|
Gross Unrealized
|
Estimated
Fair
Value
|
Cost or
Amortized
Cost
|
Gross Unrealized
|
Estimated
Fair
Value
|
||||||||||||||||||||||||||||||||||
|
Gains
|
Temporary
Losses
|
OTTI
Losses (1) |
Gains
|
Temporary
Losses
|
OTTI
Losses (1) |
||||||||||||||||||||||||||||||||||
|
(In millions)
|
|||||||||||||||||||||||||||||||||||||||
|
Fixed maturity securities:
|
|||||||||||||||||||||||||||||||||||||||
|
U.S. corporate
|
$
|
94,491
|
|
$
|
7,337
|
|
$
|
915
|
|
$
|
—
|
|
$
|
100,913
|
|
$
|
94,558
|
|
$
|
7,351
|
|
$
|
1,056
|
|
$
|
—
|
|
$
|
100,853
|
|
|||||||||
|
U.S. government and agency
|
52,486
|
|
5,058
|
|
664
|
|
—
|
|
56,880
|
|
53,326
|
|
4,977
|
|
780
|
|
—
|
|
57,523
|
|
|||||||||||||||||||
|
Foreign government
|
54,169
|
|
6,649
|
|
380
|
|
—
|
|
60,438
|
|
50,923
|
|
6,600
|
|
385
|
|
—
|
|
57,138
|
|
|||||||||||||||||||
|
Foreign corporate
|
56,664
|
|
3,304
|
|
1,503
|
|
—
|
|
58,465
|
|
55,676
|
|
3,132
|
|
1,752
|
|
(1
|
)
|
57,057
|
|
|||||||||||||||||||
|
RMBS
|
36,785
|
|
1,280
|
|
484
|
|
(23
|
)
|
37,604
|
|
36,293
|
|
1,244
|
|
554
|
|
(10
|
)
|
36,993
|
|
|||||||||||||||||||
|
State and political subdivision
|
14,555
|
|
1,768
|
|
96
|
|
2
|
|
16,225
|
|
14,566
|
|
1,733
|
|
122
|
|
1
|
|
16,176
|
|
|||||||||||||||||||
|
ABS
|
13,819
|
|
105
|
|
112
|
|
3
|
|
13,809
|
|
13,920
|
|
101
|
|
141
|
|
3
|
|
13,877
|
|
|||||||||||||||||||
|
CMBS
|
11,016
|
|
276
|
|
99
|
|
(1
|
)
|
11,194
|
|
11,092
|
|
282
|
|
103
|
|
(1
|
)
|
11,272
|
|
|||||||||||||||||||
|
Total fixed maturity securities
|
$
|
333,985
|
|
|
$
|
25,777
|
|
|
$
|
4,253
|
|
|
$
|
(19
|
)
|
|
$
|
355,528
|
|
|
$
|
330,354
|
|
|
$
|
25,420
|
|
|
$
|
4,893
|
|
|
$
|
(8
|
)
|
|
$
|
350,889
|
|
|
Equity securities:
|
|||||||||||||||||||||||||||||||||||||||
|
Common stock
|
$
|
2,174
|
|
$
|
449
|
|
$
|
11
|
|
$
|
—
|
|
$
|
2,612
|
|
$
|
1,927
|
|
$
|
488
|
|
$
|
14
|
|
$
|
—
|
|
$
|
2,401
|
|
|||||||||
|
Non-redeemable preferred stock
|
745
|
|
43
|
|
23
|
|
—
|
|
765
|
|
817
|
|
25
|
|
49
|
|
—
|
|
793
|
|
|||||||||||||||||||
|
Total equity securities
|
$
|
2,919
|
|
|
$
|
492
|
|
|
$
|
34
|
|
|
$
|
—
|
|
|
$
|
3,377
|
|
|
$
|
2,744
|
|
|
$
|
513
|
|
|
$
|
63
|
|
|
$
|
—
|
|
|
$
|
3,194
|
|
__________________
|
(1)
|
Noncredit OTTI losses included in AOCI in an unrealized gain position are due to increases in estimated fair value subsequent to initial recognition of noncredit losses on such securities. See also “— Net Unrealized Investment Gains (Losses).”
|
The Company held non-income producing fixed maturity securities with an estimated fair value of
$1 million
and
$6 million
, and unrealized gains (losses) of
($3) million
and
($2) million
, at
March 31, 2017
and
December 31, 2016
, respectively.
Maturities of Fixed Maturity Securities
The amortized cost and estimated fair value of fixed maturity securities, by contractual maturity date, were as follows at
March 31, 2017
:
|
Due in One
Year or Less |
Due After
One Year Through Five Years |
Due After
Five Years
Through Ten
Years
|
Due After
Ten Years
|
Structured
Securities
|
Total Fixed
Maturity
Securities
|
|||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||
|
Amortized cost
|
$
|
15,792
|
|
$
|
69,241
|
|
$
|
67,938
|
|
$
|
119,394
|
|
$
|
61,620
|
|
$
|
333,985
|
|
||||||
|
Estimated fair value
|
$
|
15,902
|
|
$
|
72,487
|
|
$
|
70,860
|
|
$
|
133,672
|
|
$
|
62,607
|
|
$
|
355,528
|
|
||||||
22
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Investments (continued)
Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities not due at a single maturity date have been presented in the year of final contractual maturity. Structured Securities are shown separately, as they are not due at a single maturity.
Continuous Gross Unrealized Losses for Fixed Maturity and Equity Securities AFS by Sector
The following table presents the estimated fair value and gross unrealized losses of fixed maturity and equity securities AFS in an unrealized loss position, aggregated by sector and by length of time that the securities have been in a continuous unrealized loss position at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||||||||||||||||||
|
Less than 12 Months
|
Equal to or Greater
than 12 Months
|
Less than 12 Months
|
Equal to or Greater
than 12 Months
|
|||||||||||||||||||||||||||||
|
Estimated
Fair
Value
|
Gross
Unrealized
Losses
|
Estimated
Fair
Value
|
Gross
Unrealized
Losses
|
Estimated
Fair
Value
|
Gross
Unrealized
Losses
|
Estimated
Fair
Value
|
Gross
Unrealized
Losses
|
|||||||||||||||||||||||||
|
(Dollars in millions)
|
||||||||||||||||||||||||||||||||
|
Fixed maturity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
U.S. corporate
|
$
|
15,249
|
|
|
$
|
570
|
|
|
$
|
3,480
|
|
|
$
|
345
|
|
|
$
|
16,147
|
|
|
$
|
656
|
|
|
$
|
3,684
|
|
|
$
|
400
|
|
|
|
U.S. government and agency
|
15,624
|
|
|
637
|
|
|
152
|
|
|
27
|
|
|
13,500
|
|
|
760
|
|
|
141
|
|
|
20
|
|
|||||||||
|
Foreign government
|
6,449
|
|
|
275
|
|
|
965
|
|
|
105
|
|
|
6,228
|
|
|
271
|
|
|
924
|
|
|
114
|
|
|||||||||
|
Foreign corporate
|
10,099
|
|
|
480
|
|
|
6,272
|
|
|
1,023
|
|
|
11,613
|
|
|
639
|
|
|
6,127
|
|
|
1,112
|
|
|||||||||
|
RMBS
|
12,886
|
|
|
356
|
|
|
2,154
|
|
|
105
|
|
|
12,943
|
|
|
403
|
|
|
2,618
|
|
|
141
|
|
|||||||||
|
State and political subdivision
|
2,215
|
|
|
87
|
|
|
93
|
|
|
11
|
|
|
2,636
|
|
|
114
|
|
|
85
|
|
|
9
|
|
|||||||||
|
ABS
|
2,054
|
|
|
19
|
|
|
2,184
|
|
|
96
|
|
|
2,702
|
|
|
33
|
|
|
2,789
|
|
|
111
|
|
|||||||||
|
CMBS
|
2,515
|
|
|
37
|
|
|
753
|
|
|
61
|
|
|
2,570
|
|
|
48
|
|
|
735
|
|
|
54
|
|
|||||||||
|
Total fixed maturity securities
|
$
|
67,091
|
|
|
$
|
2,461
|
|
|
$
|
16,053
|
|
|
$
|
1,773
|
|
|
$
|
68,339
|
|
|
$
|
2,924
|
|
|
$
|
17,103
|
|
|
$
|
1,961
|
|
|
|
Equity securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Common stock
|
256
|
|
|
10
|
|
|
$
|
9
|
|
|
$
|
1
|
|
|
$
|
105
|
|
|
$
|
14
|
|
|
$
|
11
|
|
|
$
|
—
|
|
|||
|
Non-redeemable preferred stock
|
97
|
|
|
1
|
|
|
159
|
|
|
22
|
|
|
196
|
|
|
9
|
|
|
165
|
|
|
40
|
|
|||||||||
|
Total equity securities
|
$
|
353
|
|
|
$
|
11
|
|
|
$
|
168
|
|
|
$
|
23
|
|
|
$
|
301
|
|
|
$
|
23
|
|
|
$
|
176
|
|
|
$
|
40
|
|
|
|
Total number of securities in an unrealized loss position
|
4,811
|
|
|
|
|
1,737
|
|
|
|
|
5,321
|
|
|
|
|
1,790
|
|
|
|
|||||||||||||
Evaluation of AFS Securities for OTTI and Evaluating Temporarily Impaired AFS Securities
As described more fully in Notes 1 and 8 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report, the Company performs a regular evaluation of all investment classes for impairment, including fixed maturity securities, equity securities and perpetual hybrid securities, in accordance with its impairment policy, in order to evaluate whether such investments are other-than-temporarily impaired.
Current Period Evaluation
Based on the Company’s current evaluation of its AFS securities in an unrealized loss position in accordance with its impairment policy, and the Company’s current intentions and assessments (as applicable to the type of security) about holding, selling and any requirements to sell these securities, the Company concluded that these securities were not other-than-temporarily impaired at
March 31, 2017
. Future OTTI will depend primarily on economic fundamentals, issuer performance (including changes in the present value of future cash flows expected to be collected), changes in credit ratings, collateral valuation, interest rates and credit spreads, as well as a change in the Company’s intention to hold or sell a security that is in an unrealized loss position. If economic fundamentals deteriorate or if there are adverse changes in the above factors, OTTI may be incurred in upcoming periods.
Gross unrealized losses on fixed maturity securities decreased
$651 million
during the
three months ended
March 31, 2017
to
$4.2 billion
. The decrease in gross unrealized losses for the
three months ended
March 31, 2017
was primarily attributable to narrowing credit spreads and decreasing longer-term interest rates, and to a lesser extent, the impact of strengthening foreign currencies on non-functional currency denominated fixed maturity securities.
23
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Investments (continued)
At
March 31, 2017
,
$182 million
of the total
$4.2 billion
of gross unrealized losses were from
56
fixed maturity securities with an unrealized loss position of
20%
or more of amortized cost for six months or greater.
The change in gross unrealized losses on equity securities was not significant during the
three months ended
March 31, 2017
.
Investment Grade Fixed Maturity Securities
Of the
$182 million
of gross unrealized losses on fixed maturity securities with an unrealized loss of
20%
or more of amortized cost for six months or greater,
$138 million
, or
76%
, were related to gross unrealized losses on
28
investment grade fixed maturity securities. Unrealized losses on investment grade fixed maturity securities are principally related to widening credit spreads since purchase and, with respect to fixed-rate fixed maturity securities, rising interest rates since purchase.
Below Investment Grade Fixed Maturity Securities
Of the
$182 million
of gross unrealized losses on fixed maturity securities with an unrealized loss of
20%
or more of amortized cost for six months or greater,
$44 million
, or
24%
, were related to gross unrealized losses on
28
below investment grade fixed maturity securities. Unrealized losses on below investment grade fixed maturity securities are principally related to foreign and U.S. corporate securities (primarily industrial securities) and are the result of significantly wider credit spreads resulting from higher risk premiums since purchase, largely due to economic and market uncertainties including concerns over lower oil prices in the energy sector. Management evaluates U.S. and foreign corporate securities based on factors such as expected cash flows and the financial condition and near-term and long-term prospects of the issuers.
Mortgage Loans
Mortgage Loans by Portfolio Segment
Mortgage loans are summarized as follows at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||
|
Carrying
Value
|
% of
Total |
Carrying
Value
|
% of
Total |
|||||||||||
|
(Dollars in millions)
|
||||||||||||||
|
Mortgage loans:
|
||||||||||||||
|
Commercial
|
$
|
49,101
|
|
64.1
|
%
|
$
|
48,035
|
|
64.4
|
%
|
||||
|
Agricultural
|
14,754
|
|
19.3
|
|
14,456
|
|
19.4
|
|
||||||
|
Residential
|
12,271
|
|
16.1
|
|
11,696
|
|
15.7
|
|
||||||
|
Subtotal (1)
|
76,126
|
|
99.5
|
|
74,187
|
|
99.5
|
|
||||||
|
Valuation allowances
|
(353
|
)
|
(0.5
|
)
|
(344
|
)
|
(0.5
|
)
|
||||||
|
Subtotal mortgage loans, net
|
75,773
|
|
99.0
|
|
73,843
|
|
99.0
|
|
||||||
|
Residential — FVO
|
639
|
|
0.8
|
|
566
|
|
0.8
|
|
||||||
|
Commercial mortgage loans held by CSEs — FVO
|
129
|
|
0.2
|
|
136
|
|
0.2
|
|
||||||
|
Total mortgage loans, net
|
$
|
76,541
|
|
100.0
|
%
|
$
|
74,545
|
|
100.0
|
%
|
||||
__________________
|
(1)
|
Purchases of mortgage loans were
$923 million
and
$292 million
for the
three months ended
March 31, 2017
and
2016
, respectively.
|
See “— Variable Interest Entities” for discussion of consolidated securitization entities (“CSEs”).
I
nformation on commercial, agricultural and residential mortgage loans is presented in the tables below. Information on residential — FVO and commercial mortgage loans held by CSEs — FVO is presented in Note
7
. The Company elects the FVO for certain mortgage loans and related long-term debt that are managed on a total return basis.
24
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Investments (continued)
Mortgage Loans, Valuation Allowance and Impaired Loans by Portfolio Segment
Mortgage loans by portfolio segment, by method of evaluation of credit loss, impaired mortgage loans including those modified in a troubled debt restructuring, and the related valuation allowances, were as follows at:
|
Evaluated Individually for Credit Losses
|
Evaluated Collectively for
Credit Losses
|
Impaired
Loans
|
||||||||||||||||||||||||||||||
|
Impaired Loans with a
Valuation Allowance
|
Impaired Loans without a
Valuation Allowance
|
|||||||||||||||||||||||||||||||
|
Unpaid
Principal
Balance
|
Recorded
Investment
|
Valuation
Allowances |
Unpaid
Principal
Balance
|
Recorded
Investment |
Recorded
Investment |
Valuation
Allowances |
Carrying
Value |
|||||||||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||||||||
|
March 31, 2017
|
||||||||||||||||||||||||||||||||
|
Commercial
|
$
|
—
|
|
$
|
—
|
|
$
|
—
|
|
$
|
12
|
|
$
|
12
|
|
$
|
49,089
|
|
$
|
240
|
|
$
|
12
|
|
||||||||
|
Agricultural
|
15
|
|
13
|
|
1
|
|
4
|
|
4
|
|
14,737
|
|
44
|
|
16
|
|
||||||||||||||||
|
Residential
|
—
|
|
—
|
|
—
|
|
293
|
|
266
|
|
12,005
|
|
68
|
|
266
|
|
||||||||||||||||
|
Total
|
$
|
15
|
|
|
$
|
13
|
|
|
$
|
1
|
|
|
$
|
309
|
|
|
$
|
282
|
|
|
$
|
75,831
|
|
|
$
|
352
|
|
|
$
|
294
|
|
|
|
December 31, 2016
|
||||||||||||||||||||||||||||||||
|
Commercial
|
$
|
—
|
|
$
|
—
|
|
$
|
—
|
|
$
|
12
|
|
$
|
12
|
|
$
|
48,023
|
|
$
|
234
|
|
$
|
12
|
|
||||||||
|
Agricultural
|
15
|
|
13
|
|
1
|
|
27
|
|
27
|
|
14,416
|
|
43
|
|
39
|
|
||||||||||||||||
|
Residential
|
—
|
|
—
|
|
—
|
|
266
|
|
242
|
|
11,454
|
|
66
|
|
242
|
|
||||||||||||||||
|
Total
|
$
|
15
|
|
|
$
|
13
|
|
|
$
|
1
|
|
|
$
|
305
|
|
|
$
|
281
|
|
|
$
|
73,893
|
|
|
$
|
343
|
|
|
$
|
293
|
|
|
The average recorded investment for impaired commercial, agricultural and residential mortgage loans was
$12 million
,
$28 million
and
$254 million
, respectively, for the
three months ended
March 31, 2017
, and
$128 million
,
$60 million
and
$147 million
, respectively, for the
three months ended
March 31, 2016
.
Valuation Allowance Rollforward by Portfolio Segment
The changes in the valuation allowance, by portfolio segment, were as follows:
|
Three Months
Ended March 31, |
||||||||||||||||||||||||||||||||
|
2017
|
2016
|
|||||||||||||||||||||||||||||||
|
Commercial
|
Agricultural
|
Residential
|
Total
|
Commercial
|
Agricultural
|
Residential
|
Total
|
|||||||||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||||||||
|
Balance, beginning of period
|
$
|
234
|
|
$
|
44
|
|
$
|
66
|
|
$
|
344
|
|
$
|
217
|
|
$
|
42
|
|
$
|
59
|
|
$
|
318
|
|
||||||||
|
Provision (release)
|
6
|
|
1
|
|
6
|
|
13
|
|
64
|
|
—
|
|
4
|
|
68
|
|
||||||||||||||||
|
Charge-offs, net of recoveries
|
—
|
|
—
|
|
(4
|
)
|
(4
|
)
|
—
|
|
(2
|
)
|
(3
|
)
|
(5
|
)
|
||||||||||||||||
|
Balance, end of period
|
$
|
240
|
|
|
$
|
45
|
|
|
$
|
68
|
|
|
$
|
353
|
|
|
$
|
281
|
|
|
$
|
40
|
|
|
$
|
60
|
|
|
$
|
381
|
|
|
25
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Investments (continued)
Credit Quality of Commercial Mortgage Loans
The credit quality of commercial mortgage loans was as follows at:
|
Recorded Investment
|
Estimated
Fair Value |
% of
Total
|
||||||||||||||||||||||||
|
Debt Service Coverage Ratios
|
% of
Total
|
|||||||||||||||||||||||||
|
> 1.20x
|
1.00x - 1.20x
|
< 1.00x
|
Total
|
|||||||||||||||||||||||
|
(Dollars in millions)
|
||||||||||||||||||||||||||
|
March 31, 2017
|
||||||||||||||||||||||||||
|
Loan-to-value ratios:
|
||||||||||||||||||||||||||
|
Less than 65%
|
$
|
42,831
|
|
$
|
1,802
|
|
$
|
526
|
|
$
|
45,159
|
|
92.0
|
%
|
$
|
45,892
|
|
92.2
|
%
|
|||||||
|
65% to 75%
|
3,319
|
|
8
|
|
211
|
|
3,538
|
|
7.2
|
|
3,508
|
|
7.0
|
|
||||||||||||
|
76% to 80%
|
146
|
|
—
|
|
—
|
|
146
|
|
0.3
|
|
130
|
|
0.3
|
|
||||||||||||
|
Greater than 80%
|
141
|
|
41
|
|
76
|
|
258
|
|
0.5
|
|
250
|
|
0.5
|
|
||||||||||||
|
Total
|
$
|
46,437
|
|
|
$
|
1,851
|
|
|
$
|
813
|
|
|
$
|
49,101
|
|
|
100
|
%
|
|
$
|
49,780
|
|
|
100
|
%
|
|
|
December 31, 2016
|
||||||||||||||||||||||||||
|
Loan-to-value ratios:
|
||||||||||||||||||||||||||
|
Less than 65%
|
$
|
41,811
|
|
$
|
1,307
|
|
$
|
874
|
|
$
|
43,992
|
|
91.6
|
%
|
$
|
44,459
|
|
91.8
|
%
|
|||||||
|
65% to 75%
|
3,335
|
|
—
|
|
221
|
|
3,556
|
|
7.4
|
|
3,488
|
|
7.2
|
|
||||||||||||
|
76% to 80%
|
229
|
|
—
|
|
—
|
|
229
|
|
0.5
|
|
215
|
|
0.5
|
|
||||||||||||
|
Greater than 80%
|
142
|
|
41
|
|
75
|
|
258
|
|
0.5
|
|
250
|
|
0.5
|
|
||||||||||||
|
Total
|
$
|
45,517
|
|
|
$
|
1,348
|
|
|
$
|
1,170
|
|
|
$
|
48,035
|
|
100.0
|
%
|
$
|
48,412
|
|
100.0
|
%
|
||||
Credit Quality of Agricultural Mortgage Loans
The credit quality of agricultural mortgage loans was as follows at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||
|
Recorded
Investment
|
% of
Total
|
Recorded
Investment
|
% of
Total
|
|||||||||||
|
(Dollars in millions)
|
||||||||||||||
|
Loan-to-value ratios:
|
||||||||||||||
|
Less than 65%
|
$
|
14,069
|
|
95.3
|
%
|
$
|
13,872
|
|
96.0
|
%
|
||||
|
65% to 75%
|
621
|
|
4.2
|
|
479
|
|
3.3
|
|
||||||
|
76% to 80%
|
9
|
|
0.1
|
|
17
|
|
0.1
|
|
||||||
|
Greater than 80%
|
55
|
|
0.4
|
|
88
|
|
0.6
|
|
||||||
|
Total
|
$
|
14,754
|
|
100.0
|
%
|
$
|
14,456
|
|
100.0
|
%
|
||||
The estimated fair value of agricultural mortgage loans was
$14.9 billion
and
$14.7 billion
at
March 31, 2017
and
December 31, 2016
, respectively.
Credit Quality of Residential Mortgage Loans
The credit quality of residential mortgage loans was as follows at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||
|
Recorded
Investment
|
% of
Total
|
Recorded
Investment
|
% of
Total
|
|||||||||||
|
(Dollars in millions)
|
||||||||||||||
|
Performance indicators:
|
||||||||||||||
|
Performing
|
$
|
11,926
|
|
97.2
|
%
|
$
|
11,304
|
|
96.6
|
%
|
||||
|
Nonperforming
|
345
|
|
2.8
|
|
392
|
|
3.4
|
|
||||||
|
Total
|
$
|
12,271
|
|
100.0
|
%
|
$
|
11,696
|
|
100.0
|
%
|
||||
26
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Investments (continued)
The estimated fair value of residential mortgage loans was
$12.6 billion
and
$12.1 billion
at
March 31, 2017
and
December 31, 2016
, respectively.
Past Due and Nonaccrual Mortgage Loans
The Company has a high quality, well performing mortgage loan portfolio, with
99%
of all mortgage loans classified as performing at both
March 31, 2017
and
December 31, 2016
. The Company defines delinquency consistent with industry practice, when mortgage loans are past due as follows: commercial and residential mortgage loans — 60 days and agricultural mortgage loans — 90 days. The past due and nonaccrual mortgage loans at recorded investment, prior to valuation allowances, by portfolio segment, were as follows at:
|
Past Due
|
Greater than 90 Days Past Due and Still
Accruing Interest
|
Nonaccrual
|
||||||||||||||||||||||
|
March 31, 2017
|
December 31, 2016
|
March 31, 2017
|
December 31, 2016
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||
|
Commercial
|
$
|
5
|
|
$
|
3
|
|
$
|
—
|
|
$
|
3
|
|
$
|
—
|
|
$
|
—
|
|
||||||
|
Agricultural
|
116
|
|
127
|
|
108
|
|
104
|
|
10
|
|
23
|
|
||||||||||||
|
Residential
|
345
|
|
392
|
|
—
|
|
37
|
|
319
|
|
355
|
|
||||||||||||
|
Total
|
$
|
466
|
|
$
|
522
|
|
$
|
108
|
|
$
|
144
|
|
$
|
329
|
|
$
|
378
|
|
||||||
Mortgage Loans Modified in a Troubled Debt Restructuring
During both the
three months ended
March 31, 2017
and
2016
, the Company did not have a significant amount of mortgage loans modified in a troubled debt restructuring.
Cash Equivalents
The carrying value of cash equivalents, which includes securities and other investments with an original or remaining maturity of three months or less at the time of purchase, was
$11.1 billion
and
$12.2 billion
at
March 31, 2017
and
December 31, 2016
, respectively.
Net Unrealized Investment Gains (Losses)
Unrealized investment gains (losses) on fixed maturity and equity securities AFS and the effect on DAC, VOBA, deferred sales inducements (“DSI”), future policy benefits and the policyholder dividend obligation, that would result from the realization of the unrealized gains (losses), are included in net unrealized investment gains (losses) in AOCI.
The components of net unrealized investment gains (losses), included in AOCI, were as follows:
|
March 31, 2017
|
December 31, 2016
|
|||||||
|
(In millions)
|
||||||||
|
Fixed maturity securities
|
$
|
21,334
|
|
$
|
20,300
|
|
||
|
Fixed maturity securities with noncredit OTTI losses included in AOCI
|
19
|
|
8
|
|
||||
|
Total fixed maturity securities
|
21,353
|
|
20,308
|
|
||||
|
Equity securities
|
521
|
|
485
|
|
||||
|
Derivatives
|
2,904
|
|
2,923
|
|
||||
|
Other
|
196
|
|
23
|
|
||||
|
Subtotal
|
24,974
|
|
23,739
|
|
||||
|
Amounts allocated from:
|
||||||||
|
Future policy benefits
|
(1,336
|
)
|
(1,114
|
)
|
||||
|
DAC and VOBA related to noncredit OTTI losses recognized in AOCI
|
(3
|
)
|
(3
|
)
|
||||
|
DAC, VOBA and DSI
|
(1,481
|
)
|
(1,430
|
)
|
||||
|
Policyholder dividend obligation
|
(1,983
|
)
|
(1,931
|
)
|
||||
|
Subtotal
|
(4,803
|
)
|
(4,478
|
)
|
||||
|
Deferred income tax benefit (expense) related to noncredit OTTI losses recognized in AOCI
|
(5
|
)
|
(1
|
)
|
||||
|
Deferred income tax benefit (expense)
|
(6,971
|
)
|
(6,623
|
)
|
||||
|
Net unrealized investment gains (losses)
|
13,195
|
|
12,637
|
|
||||
|
Net unrealized investment gains (losses) attributable to noncontrolling interests
|
(6
|
)
|
(6
|
)
|
||||
|
Net unrealized investment gains (losses) attributable to MetLife, Inc.
|
$
|
13,189
|
|
$
|
12,631
|
|
||
The changes in net unrealized investment gains (losses) were as follows:
|
Three Months
Ended March 31, 2017 |
||||
|
(In millions)
|
||||
|
Balance, beginning of period
|
$
|
12,631
|
|
|
|
Fixed maturity securities on which noncredit OTTI losses have been recognized
|
11
|
|
||
|
Unrealized investment gains (losses) during the period
|
1,224
|
|
||
|
Unrealized investment gains (losses) relating to:
|
||||
|
Future policy benefits
|
(222
|
)
|
||
|
DAC and VOBA related to noncredit OTTI losses recognized in AOCI
|
—
|
|
||
|
DAC, VOBA and DSI
|
(51
|
)
|
||
|
Policyholder dividend obligation
|
(52
|
)
|
||
|
Deferred income tax benefit (expense) related to noncredit OTTI losses recognized in AOCI
|
(4
|
)
|
||
|
Deferred income tax benefit (expense)
|
(348
|
)
|
||
|
Net unrealized investment gains (losses)
|
13,189
|
|
||
|
Net unrealized investment gains (losses) attributable to noncontrolling interests
|
—
|
|
||
|
Balance, end of period
|
$
|
13,189
|
|
|
|
Change in net unrealized investment gains (losses)
|
$
|
558
|
|
|
|
Change in net unrealized investment gains (losses) attributable to noncontrolling interests
|
—
|
|
||
|
Change in net unrealized investment gains (losses) attributable to MetLife, Inc.
|
$
|
558
|
|
|
27
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Investments (continued)
Concentrations of Credit Risk
Investments in any counterparty that were greater than
10%
of the Company’s equity, other than the U.S. government and its agencies, were in fixed income securities of the Japanese government and its agencies with an estimated fair value of
$26.2 billion
and
$24.9 billion
at
March 31, 2017
and
December 31, 2016
, respectively.
Securities Lending
Elements of the securities lending program are presented below at:
|
March 31, 2017
|
December 31, 2016
|
||||||
|
(In millions)
|
|||||||
|
Securities on loan: (1)
|
|||||||
|
Amortized cost
|
$
|
24,235
|
|
$
|
24,692
|
|
|
|
Estimated fair value
|
$
|
25,951
|
|
$
|
26,308
|
|
|
|
Cash collateral received from counterparties (2)
|
$
|
26,527
|
|
$
|
26,755
|
|
|
|
Security collateral received from counterparties (3)
|
$
|
15
|
|
$
|
46
|
|
|
|
Reinvestment portfolio — estimated fair value
|
$
|
26,726
|
|
$
|
26,704
|
|
|
__________________
|
(1)
|
Included within fixed maturity securities.
|
|
(2)
|
Included within payables for collateral under securities loaned and other transactions.
|
|
(3)
|
Security collateral received from counterparties may not be sold or re-pledged, unless the counterparty is in default, and is not reflected on the consolidated financial statements.
|
The cash collateral liability by loaned security type and remaining tenor of the agreements was as follows at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||||||||||||||||||
|
Remaining Tenor of Securities
Lending Agreements
|
Remaining Tenor of Securities
Lending Agreements
|
|||||||||||||||||||||||||||||||
|
Open (1)
|
1 Month
or Less
|
1 to 6
Months
|
Total
|
Open (1)
|
1 Month
or Less
|
1 to 6
Months
|
Total
|
|||||||||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||||||||
|
Cash collateral liability by loaned security type:
|
||||||||||||||||||||||||||||||||
|
U.S. government and agency
|
$
|
6,248
|
|
$
|
7,153
|
|
$
|
11,623
|
|
$
|
25,024
|
|
$
|
6,608
|
|
$
|
8,403
|
|
$
|
10,125
|
|
$
|
25,136
|
|
||||||||
|
Foreign government
|
—
|
|
676
|
|
—
|
|
676
|
|
—
|
|
620
|
|
144
|
|
764
|
|
||||||||||||||||
|
U.S. corporate
|
—
|
|
512
|
|
—
|
|
512
|
|
—
|
|
523
|
|
—
|
|
523
|
|
||||||||||||||||
|
Agency RMBS
|
—
|
|
257
|
|
—
|
|
257
|
|
—
|
|
—
|
|
274
|
|
274
|
|
||||||||||||||||
|
Foreign corporate
|
—
|
|
58
|
|
—
|
|
58
|
|
—
|
|
58
|
|
—
|
|
58
|
|
||||||||||||||||
|
Total
|
$
|
6,248
|
|
|
$
|
8,656
|
|
|
$
|
11,623
|
|
|
$
|
26,527
|
|
$
|
6,608
|
|
$
|
9,604
|
|
$
|
10,543
|
|
$
|
26,755
|
|
|||||
__________________
|
(1)
|
The related loaned security could be returned to the Company on the next business day which would require the Company to immediately return the cash collateral.
|
If the Company is required to return significant amounts of cash collateral on short notice and is forced to sell securities to meet the return obligation, it may have difficulty selling such collateral that is invested in securities in a timely manner, be forced to sell securities in a volatile or illiquid market for less than what otherwise would have been realized under normal market conditions, or both. The estimated fair value of the securities on loan related to the cash collateral on open at
March 31, 2017
was
$6.1 billion
, over
99%
of which were U.S. government and agency securities which, if put back to the Company, could be immediately sold to satisfy the cash requirement.
28
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Investments (continued)
The reinvestment portfolio acquired with the cash collateral consisted principally of fixed maturity securities (including agency RMBS, ABS, cash equivalents and U.S. corporate securities) and short-term investments, with
62%
invested in short-term investments, agency RMBS, cash equivalents and U.S. government and agency securities, or held in cash. If the securities on loan or the reinvestment portfolio become less liquid, the Company has the liquidity resources of most of its general account available to meet any potential cash demands when securities on loan are put back to the Company.
Repurchase Agreements
Elements of the short-term repurchase agreements are presented below at:
|
March 31, 2017
|
December 31, 2016
|
|||||||
|
(In millions)
|
||||||||
|
Securities on loan: (1)
|
||||||||
|
Amortized cost
|
$
|
1,367
|
|
$
|
98
|
|
||
|
Estimated fair value
|
$
|
1,432
|
|
$
|
113
|
|
||
|
Cash collateral received from counterparties (2)
|
$
|
1,400
|
|
$
|
102
|
|
||
|
Reinvestment portfolio — estimated fair value
|
$
|
1,409
|
|
$
|
100
|
|
||
__________________
|
(1)
|
Included within fixed maturity securities.
|
|
(2)
|
Included within payables for collateral under securities loaned and other transactions and other liabilities.
|
The cash collateral liability by loaned security type and remaining tenor of the agreements was as follows at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||||||||||
|
Remaining Tenor of
Repurchase Agreements
|
Remaining Tenor of
Repurchase Agreements
|
|||||||||||||||||||||||
|
1 Month
or Less
|
1 to 6
Months
|
Total
|
1 Month
or Less
|
1 to 6
Months
|
Total
|
|||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||
|
Cash collateral liability by loaned security type:
|
||||||||||||||||||||||||
|
U.S. government and agency
|
$
|
1,305
|
|
$
|
—
|
|
$
|
1,305
|
|
$
|
5
|
|
$
|
—
|
|
$
|
5
|
|
||||||
|
Foreign government and corporate
|
43
|
|
52
|
|
95
|
|
46
|
|
51
|
|
97
|
|
||||||||||||
|
Total
|
$
|
1,348
|
|
$
|
52
|
|
$
|
1,400
|
|
$
|
51
|
|
$
|
51
|
|
$
|
102
|
|
||||||
The reinvestment portfolio acquired with the cash collateral consisted principally of fixed maturity securities (including agency RMBS, ABS, U.S. government and agency securities and U.S. corporate securities) and short-term investments, with
65%
invested in short-term investments, agency RMBS, U.S. government and agency securities and cash equivalents, or held in cash. If the securities on loan or the reinvestment portfolio become less liquid, the Company has the liquidity resources of most of its general account available to meet any potential cash demands when securities on loan are put back to the Company.
Invested Assets on Deposit, Held in Trust and Pledged as Collateral
Invested assets on deposit, held in trust and pledged as collateral are presented below at estimated fair value for all asset classes, except mortgage loans, which are presented at carrying value at:
|
March 31, 2017
|
December 31, 2016
|
|||||||
|
(In millions)
|
||||||||
|
Invested assets on deposit (regulatory deposits)
|
$
|
9,710
|
|
$
|
9,573
|
|
||
|
Invested assets held in trust (collateral financing arrangements and reinsurance agreements)
|
10,882
|
|
11,111
|
|
||||
|
Invested assets pledged as collateral (1)
|
28,100
|
|
27,431
|
|
||||
|
Total invested assets on deposit, held in trust and pledged as collateral
|
$
|
48,692
|
|
|
$
|
48,115
|
|
|
__________________
29
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Investments (continued)
|
(1)
|
The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements (see Notes
4
and
12
of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report), collateral financing arrangements (see Note 13 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report) and derivative transactions (see
Note 6
). See Note
14
for subsequent information on the collateral financing arrangement termination.
|
See “— Securities Lending” and “— Repurchase Agreements” for information regarding securities on loan and Note
4
for information regarding investments designated to the closed block.
Variable Interest Entities
The Company has invested in legal entities that are VIEs. In certain instances, the Company holds both the power to direct the most significant activities of the entity, as well as an economic interest in the entity and, as such, is deemed to be the primary beneficiary or consolidator of the entity. The determination of the VIE’s primary beneficiary requires an evaluation of the contractual and implied rights and obligations associated with each party’s relationship with or involvement in the entity, an estimate of the entity’s expected losses and expected residual returns and the allocation of such estimates to each party involved in the entity.
Consolidated VIEs
Creditors or beneficial interest holders of VIEs where the Company is the pr
imary beneficiary have no recourse to the general credit of the Company, as the Company’s obligation to the VIEs is limited to the amount of its committed investment.
The following table presents the total assets and total liabilities re
lating to VIEs for which the Company has concluded that it is the primary beneficiary and which are consolidated at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||
|
Total
Assets |
Total
Liabilities |
Total
Assets |
Total
Liabilities |
|||||||||||||
|
(In millions)
|
||||||||||||||||
|
MRSC (collateral financing arrangement) (1)
|
$
|
3,423
|
|
$
|
—
|
|
$
|
3,422
|
|
$
|
—
|
|
||||
|
CSEs (assets (primarily loans) and liabilities (primarily debt)) (2)
|
142
|
|
32
|
|
146
|
|
35
|
|
||||||||
|
Other investments (3)
|
50
|
|
—
|
|
50
|
|
—
|
|
||||||||
|
Total
|
$
|
3,615
|
|
|
$
|
32
|
|
|
$
|
3,618
|
|
|
$
|
35
|
|
|
__________________
|
(1)
|
See Note 13 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report for a description of the MetLife Reinsurance Company of South Carolina (“MRSC”) collateral financing arrangement. See Note 14. The assets consist of fixed maturity securities, short-term investments and cash equivalents.
|
|
(2)
|
The Company consolidates entities that are structured as CMBS and as collateralized debt obligations. The assets of these entities can only be used to settle their respective liabilities, and under no circumstances is the Company liable for any principal or interest shortfalls should any arise.
|
|
(3)
|
Other investments is comprised of other invested assets and other limited partnership interests.
|
30
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Investments (continued)
Unconsolidated VIEs
The carrying amount and maximum exposure to loss relating to VIEs in which the Company holds a significant variable interest but is not the primary beneficiary and which have not been consolidated were as follows at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||
|
Carrying
Amount |
Maximum
Exposure to Loss (1) |
Carrying
Amount |
Maximum
Exposure to Loss (1) |
|||||||||||||
|
(In millions)
|
||||||||||||||||
|
Fixed maturity securities AFS:
|
||||||||||||||||
|
Structured Securities (2)
|
$
|
60,301
|
|
$
|
60,301
|
|
$
|
59,773
|
|
$
|
59,773
|
|
||||
|
U.S. and foreign corporate
|
2,926
|
|
2,926
|
|
2,845
|
|
2,845
|
|
||||||||
|
Other limited partnership interests
|
5,938
|
|
11,408
|
|
6,208
|
|
11,282
|
|
||||||||
|
Other invested assets
|
2,262
|
|
2,783
|
|
2,261
|
|
2,837
|
|
||||||||
|
Other (3)
|
375
|
|
394
|
|
252
|
|
271
|
|
||||||||
|
Total
|
$
|
71,802
|
|
|
$
|
77,812
|
|
|
$
|
71,339
|
|
|
$
|
77,008
|
|
|
__________________
|
(1)
|
The maximum exposure to loss relating to fixed maturity securities AFS and equity securities AFS is equal to their carrying amounts or the carrying amounts of retained interests. The maximum exposure to loss relating to other limited partnership interests, mortgage loans and real estate joint ventures is equal to the carrying amounts plus any unfunded commitments. For certain of its investments in other invested assets, the Company’s return is in the form of income tax credits which are guaranteed by creditworthy third parties. For such investments, the maximum exposure to loss is equal to the carrying amounts plus any unfunded commitments, reduced by income tax credits guaranteed by third parties of
$139 million
and
$150 million
at
March 31, 2017
and
December 31, 2016
, respectively. Such a maximum loss would be expected to occur only upon bankruptcy of the issuer or investee.
|
|
(2)
|
For these variable interests, the Company’s involvement is limited to that of a passive investor in mortgage-backed or asset-backed securities issued by trusts that do not have substantial equity.
|
|
(3)
|
Other is comprised of mortgage loans, common stock, non-redeemable preferred stock and real estate joint ventures.
|
As described in Note
13
, the Company makes commitments to fund partnership investments in the normal course of business. Excluding these commitments, the Company did not provide financial or other support to investees designated as VIEs during both the
three months ended
March 31, 2017
and
2016
.
31
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Investments (continued)
Net Investment Income
The components of net investment income were as follows:
|
Three Months
Ended March 31, |
|||||||
|
2017
|
2016
|
||||||
|
(In millions)
|
|||||||
|
Investment income:
|
|||||||
|
Fixed maturity securities
|
$
|
3,420
|
|
$
|
3,654
|
|
|
|
Equity securities
|
34
|
|
37
|
|
|||
|
FVO securities — FVO general account securities (1)
|
29
|
|
6
|
|
|||
|
Mortgage loans
|
845
|
|
807
|
|
|||
|
Policy loans
|
145
|
|
149
|
|
|||
|
Real estate and real estate joint ventures
|
165
|
|
157
|
|
|||
|
Other limited partnership interests
|
297
|
|
46
|
|
|||
|
Cash, cash equivalents and short-term investments
|
59
|
|
40
|
|
|||
|
Operating joint ventures
|
2
|
|
12
|
|
|||
|
Other
|
79
|
|
41
|
|
|||
|
Subtotal
|
5,075
|
|
|
4,949
|
|
||
|
Less: Investment expenses
|
297
|
|
296
|
|
|||
|
Subtotal, net
|
4,778
|
|
|
4,653
|
|
||
|
FVO securities — FVO contractholder-directed unit-linked investments (1)
|
416
|
|
(97
|
)
|
|||
|
FVO CSEs — interest income — commercial mortgage loans
|
2
|
|
3
|
|
|||
|
Subtotal
|
418
|
|
|
(94
|
)
|
||
|
Net investment income
|
$
|
5,196
|
|
|
$
|
4,559
|
|
__________________
|
(1)
|
Changes in estimated fair value subsequent to purchase for securities still held as of the end of the respective periods included in net investment income were
$340 million
and
($186) million
for the
three months ended
March 31, 2017
and
2016
, respectively. The amount for the three months ended March 31, 2016 included
($4) million
related to actively traded securities.
|
FVO securities are primarily comprised of securities for which the FVO has been elected. FVO securities are primarily comprised of contractholder-directed investments supporting unit-linked variable annuity type liabilities which do not qualify as separate accounts. The remainder is comprised of FVO general account securities and FVO securities held by CSEs. The Company previously maintained a trading securities portfolio, principally invested in fixed maturity securities. In June 2016, the Company commenced a reinvestment of this portfolio into other asset classes and, at
March 31, 2017
, the Company
no
longer held any actively traded securities.
See “— Variable Interest Entities” for discussion of CSEs.
32
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Investments (continued)
Net Investment Gains (Losses)
Components of Net Investment Gains (Losses)
The components of net investment gains (losses) were as follows:
|
Three Months
Ended March 31, |
|||||||
|
2017
|
2016
|
||||||
|
(In millions)
|
|||||||
|
Total gains (losses) on fixed maturity securities:
|
|||||||
|
Total OTTI losses recognized — by sector and industry:
|
|||||||
|
U.S. and foreign corporate securities — by industry:
|
|||||||
|
Industrial
|
$
|
—
|
|
$
|
(71
|
)
|
|
|
Communications
|
—
|
|
(3
|
)
|
|||
|
Total U.S. and foreign corporate securities
|
—
|
|
|
(74
|
)
|
||
|
RMBS
|
—
|
|
(4
|
)
|
|||
|
OTTI losses on fixed maturity securities recognized in earnings
|
—
|
|
|
(78
|
)
|
||
|
Fixed maturity securities — net gains (losses) on sales and disposals
|
(40
|
)
|
98
|
|
|||
|
Total gains (losses) on fixed maturity securities
|
(40
|
)
|
|
20
|
|
||
|
Total gains (losses) on equity securities:
|
|||||||
|
Total OTTI losses recognized — by sector:
|
|||||||
|
Common stock
|
(7
|
)
|
(51
|
)
|
|||
|
Non-redeemable preferred stock
|
(1
|
)
|
—
|
|
|||
|
OTTI losses on equity securities recognized in earnings
|
(8
|
)
|
|
(51
|
)
|
||
|
Equity securities — net gains (losses) on sales and disposals
|
43
|
|
6
|
|
|||
|
Total gains (losses) on equity securities
|
35
|
|
(45
|
)
|
|||
|
Mortgage loans
|
(15
|
)
|
(64
|
)
|
|||
|
Real estate and real estate joint ventures
|
(1
|
)
|
2
|
|
|||
|
Other limited partnership interests
|
(17
|
)
|
(27
|
)
|
|||
|
Other
|
(58
|
)
|
(18
|
)
|
|||
|
Subtotal
|
(96
|
)
|
|
(132
|
)
|
||
|
FVO CSEs:
|
|||||||
|
Commercial mortgage loans
|
(1
|
)
|
1
|
|
|||
|
Securities
|
—
|
|
1
|
|
|||
|
Long-term debt — related to commercial mortgage loans
|
1
|
|
—
|
|
|||
|
Non-investment portfolio gains (losses)
|
104
|
|
145
|
|
|||
|
Subtotal
|
104
|
|
147
|
|
|||
|
Total net investment gains (losses)
|
$
|
8
|
|
|
$
|
15
|
|
See “— Variable Interest Entities” for discussion of CSEs.
Gains (losses) from foreign currency transactions included within net investment gains (losses) were
$49 million
and
$79 million
for the
three months ended
March 31, 2017
and
2016
, respectively.
33
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
5. Investments (continued)
Sales or Disposals and Impairments of Fixed Maturity and Equity Securities
Investment gains and losses on sales of securities are determined on a specific identification basis. Proceeds from sales or disposals of fixed maturity and equity securities and the components of fixed maturity and equity securities net investment gains (losses) were as shown in the table below.
|
Three Months
Ended March 31, |
|||||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
|||||||||
|
Fixed Maturity Securities
|
Equity Securities
|
||||||||||||||
|
(In millions)
|
|||||||||||||||
|
Proceeds
|
$
|
16,437
|
|
$
|
31,994
|
|
$
|
120
|
|
$
|
59
|
|
|||
|
Gross investment gains
|
$
|
150
|
|
$
|
433
|
|
$
|
47
|
|
$
|
11
|
|
|||
|
Gross investment losses
|
(190
|
)
|
(335
|
)
|
(4
|
)
|
(5
|
)
|
|||||||
|
OTTI losses
|
—
|
|
(78
|
)
|
(8
|
)
|
(51
|
)
|
|||||||
|
Net investment gains (losses)
|
$
|
(40
|
)
|
|
$
|
20
|
|
|
$
|
35
|
|
|
$
|
(45
|
)
|
Credit Loss Rollforward
The table below presents a rollforward of the cumulative credit loss component of OTTI loss recognized in earnings on fixed maturity securities still held for which a portion of the OTTI loss was recognized in other comprehensive income (loss) (“OCI”):
|
Three Months
Ended March 31, |
|||||||
|
2017
|
2016
|
||||||
|
(In millions)
|
|||||||
|
Balance, beginning of period
|
$
|
215
|
|
$
|
277
|
|
|
|
Additions:
|
|||||||
|
Additional impairments — credit loss OTTI on securities previously impaired
|
—
|
|
2
|
|
|||
|
Reductions:
|
|||||||
|
Sales (maturities, pay downs or prepayments) of securities previously impaired as credit loss OTTI
|
(36
|
)
|
(9
|
)
|
|||
|
Balance, end of period
|
$
|
179
|
|
|
$
|
270
|
|
6. Derivatives
Accounting for Derivatives
Freestanding Derivatives
Freestanding derivatives are carried on the Company’s balance sheet either as assets within other invested assets or as liabilities within other liabilities at estimated fair value. The Company does not offset the estimated fair value amounts recognized for derivatives executed with the same counterparty under the same master netting agreement.
Accruals on derivatives are generally recorded in accrued investment income or within other liabilities. However, accruals that are not scheduled to settle within one year are included with the derivatives carrying value in other invested assets or other liabilities.
34
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
If a derivative is not designated as an accounting hedge or its use in managing risk does not qualify for hedge accounting, changes in the estimated fair value of the derivative are reported in net derivative gains (losses) except as follows:
|
Statement of Operations Presentation:
|
Derivative:
|
|
|
Policyholder benefits and claims
|
•
|
Economic hedges of variable annuity guarantees included in future policy benefits
|
|
Net investment income
|
•
|
Economic hedges of equity method investments in joint ventures
|
|
•
|
All derivatives held in relation to trading portfolios
|
|
|
•
|
Derivatives held within contractholder-directed unit-linked investments
|
|
Hedge Accounting
To qualify for hedge accounting, at the inception of the hedging relationship, the Company formally documents its risk management objective and strategy for undertaking the hedging transaction, as well as its designation of the hedge. Hedge designation and financial statement presentation of changes in estimated fair value of the hedging derivatives are as follows:
|
•
|
Fair value hedge
(a hedge of the estimated fair value of a recognized asset or liability) - in net derivative gains (losses), consistent with the change in estimated fair value of the hedged item attributable to the designated risk being hedged.
|
|
•
|
Cash flow hedge
(a hedge of a forecasted transaction or of the variability of cash flows to be received or paid related to a recognized asset or liability) - effectiveness in OCI (deferred gains or losses on the derivative are reclassified into the statement of operations when the Company’s earnings are affected by the variability in cash flows of the hedged item); ineffectiveness in net derivative gains (losses).
|
|
•
|
Net investment in a foreign operation hedge
- effectiveness in OCI, consistent with the translation adjustment for the hedged net investment in the foreign operation; ineffectiveness in net derivative gains (losses).
|
The changes in estimated fair values of the hedging derivatives are exclusive of any accruals that are separately reported on the statement of operations within interest income or interest expense to match the location of the hedged item. Accruals on derivatives in net investment hedges are recognized in OCI.
In its hedge documentation, the Company sets forth how the hedging instrument is expected to hedge the designated risks related to the hedged item and sets forth the method that will be used to retrospectively and prospectively assess the hedging instrument’s effectiveness and the method that will be used to measure ineffectiveness. A derivative designated as a hedging instrument must be assessed as being highly effective in offsetting the designated risk of the hedged item. Hedge effectiveness is formally assessed at inception and at least quarterly throughout the life of the designated hedging relationship. Assessments of hedge effectiveness and measurements of ineffectiveness are also subject to interpretation and estimation and different interpretations or estimates may have a material effect on the amount reported in net income.
The Company discontinues hedge accounting prospectively when: (i) it is determined that the derivative is no longer highly effective in offsetting changes in the estimated fair value or cash flows of a hedged item; (ii) the derivative expires, is sold, terminated, or exercised; (iii) it is no longer probable that the hedged forecasted transaction will occur; or (iv) the derivative is de-designated as a hedging instrument.
When hedge accounting is discontinued because it is determined that the derivative is not highly effective in offsetting changes in the estimated fair value or cash flows of a hedged item, the derivative continues to be carried on the balance sheet at its estimated fair value, with changes in estimated fair value recognized in net derivative gains (losses). The carrying value of the hedged recognized asset or liability under a fair value hedge is no longer adjusted for changes in its estimated fair value due to the hedged risk, and the cumulative adjustment to its carrying value is amortized into income over the remaining life of the hedged item. Provided the hedged forecasted transaction is still probable of occurrence, the changes in estimated fair value of derivatives recorded in OCI related to discontinued cash flow hedges are released into the statement of operations when the Company’s earnings are affected by the variability in cash flows of the hedged item.
35
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
When hedge accounting is discontinued because it is no longer probable that the forecasted transactions will occur on the anticipated date or within two months of that date, the derivative continues to be carried on the balance sheet at its estimated fair value, with changes in estimated fair value recognized currently in net derivative gains (losses). Deferred gains and losses of a derivative recorded in OCI pursuant to the discontinued cash flow hedge of a forecasted transaction that is no longer probable are recognized immediately in net derivative gains (losses).
In all other situations in which hedge accounting is discontinued, the derivative is carried at its estimated fair value on the balance sheet, with changes in its estimated fair value recognized in the current period as net derivative gains (losses).
Embedded Derivatives
The Company sells variable annuities and issues certain insurance products and investment contracts and is a party to certain reinsurance agreements that have embedded derivatives. The Company assesses each identified embedded derivative to determine whether it is required to be bifurcated. The embedded derivative is bifurcated from the host contract and accounted for as a freestanding derivative if:
|
•
|
the combined instrument is not accounted for in its entirety at estimated fair value with changes in estimated fair value recorded in earnings;
|
|
•
|
the terms of the embedded derivative are not clearly and closely related to the economic characteristics of the host contract; and
|
|
•
|
a separate instrument with the same terms as the embedded derivative would qualify as a derivative instrument.
|
Such embedded derivatives are carried on the balance sheet at estimated fair value with the host contract and changes in their estimated fair value are generally reported in net derivative gains (losses), except for those in policyholder benefits and claims related to ceded reinsurance of GMIB. If the Company is unable to properly identify and measure an embedded derivative for separation from its host contract, the entire contract is carried on the balance sheet at estimated fair value, with changes in estimated fair value recognized in the current period in net investment gains (losses) or net investment income. Additionally, the Company may elect to carry an entire contract on the balance sheet at estimated fair value, with changes in estimated fair value recognized in the current period in net investment gains (losses) or net investment income if that contract contains an embedded derivative that requires bifurcation. At inception, the Company attributes to the embedded derivative a portion of the projected future guarantee fees to be collected from the policyholder equal to the present value of projected future guaranteed benefits. Any additional fees represent “excess” fees and are reported in universal life and investment-type product policy fees.
See Note
7
for information about the fair value hierarchy for derivatives.
Derivative Strategies
The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives.
Derivatives are financial instruments with values derived from interest rates, foreign currency exchange rates, credit spreads and/or other financial indices. Derivatives may be exchange-traded or contracted in the over-the-counter (“OTC”) market. Certain of the Company’s OTC derivatives are cleared and settled through central clearing counterparties (“OTC-cleared”), while others are bilateral contracts between two counterparties (“OTC-bilateral”). The types of derivatives the Company uses include swaps, forwards, futures and option contracts. To a lesser extent, the Company uses credit default swaps and structured interest rate swaps to synthetically replicate investment risks and returns which are not readily available in the cash markets.
Interest Rate Derivatives
The Company uses a variety of interest rate derivatives to reduce its exposure to changes in interest rates, including interest rate swaps, interest rate total return swaps, caps, floors, swaptions, futures and forwards.
Interest rate swaps are used by the Company primarily to reduce market risks from changes in interest rates and to alter interest rate exposure arising from mismatches between assets and liabilities (duration mismatches). In an interest rate swap, the Company agrees with another party to exchange, at specified intervals, the difference between fixed rate and floating rate interest amounts as calculated by reference to an agreed notional amount. The Company utilizes interest rate swaps in fair value, cash flow and nonqualifying hedging relationships.
36
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
The Company uses structured interest rate swaps to synthetically create investments that are either more expensive to acquire or otherwise unavailable in the cash markets. These transactions are a combination of a derivative and a cash instrument such as a U.S. government and agency, or other fixed maturity security. Structured interest rate swaps are included in interest rate swaps and are not designated as hedging instruments.
Interest rate total return swaps are swaps whereby the Company agrees with another party to exchange, at specified intervals, the difference between the economic risk and reward of an asset or a market index and the London Interbank Offered Rate (“LIBOR”), calculated by reference to an agreed notional amount. No cash is exchanged at the outset of the contract. Cash is paid and received over the life of the contract based on the terms of the swap. These transactions are entered into pursuant to master agreements that provide for a single net payment to be made by the counterparty at each due date. Interest rate total return swaps are used by the Company to reduce market risks from changes in interest rates and to alter interest rate exposure arising from mismatches between assets and liabilities (duration mismatches). The Company utilizes interest rate total return swaps in nonqualifying hedging relationships.
The Company purchases interest rate caps and floors primarily to protect its floating rate liabilities against rises in interest rates above a specified level, and against interest rate exposure arising from mismatches between assets and liabilities, as well as to protect its minimum rate guarantee liabilities against declines in interest rates below a specified level, respectively. In certain instances, the Company locks in the economic impact of existing purchased caps and floors by entering into offsetting written caps and floors. The Company utilizes interest rate caps and floors in nonqualifying hedging relationships.
In exchange-traded interest rate (Treasury and swap) futures transactions, the Company agrees to purchase or sell a specified number of contracts, the value of which is determined by the different classes of interest rate securities, and to post variation margin on a daily basis in an amount equal to the difference in the daily market values of those contracts. The Company enters into exchange-traded futures with regulated futures commission merchants that are members of the exchange. Exchange-traded interest rate (Treasury and swap) futures are used primarily to hedge mismatches between the duration of assets in a portfolio and the duration of liabilities supported by those assets, to hedge against changes in value of securities the Company owns or anticipates acquiring, to hedge against changes in interest rates on anticipated liability issuances by replicating Treasury or swap curve performance, and to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. The Company utilizes exchange-traded interest rate futures in nonqualifying hedging relationships.
Swaptions are used by the Company to hedge interest rate risk associated with the Company’s long-term liabilities and invested assets. A swaption is an option to enter into a swap with a forward starting effective date. In certain instances, the Company locks in the economic impact of existing purchased swaptions by entering into offsetting written swaptions. The Company pays a premium for purchased swaptions and receives a premium for written swaptions. The Company utilizes swaptions in nonqualifying hedging relationships. Swaptions are included in interest rate options.
The Company enters into interest rate forwards to buy and sell securities. The price is agreed upon at the time of the contract and payment for such a contract is made at a specified future date. The Company utilizes interest rate forwards in cash flow and nonqualifying hedging relationships.
Foreign Currency Exchange Rate Derivatives
The Company uses foreign currency exchange rate derivatives, including foreign currency swaps, foreign currency forwards, currency options and exchange-traded currency futures, to reduce the risk from fluctuations in foreign currency exchange rates associated with its assets and liabilities denominated in foreign currencies. The Company also uses foreign currency derivatives to hedge the foreign currency exchange rate risk associated with certain of its net investments in foreign operations.
In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company utilizes foreign currency swaps in fair value, cash flow and nonqualifying hedging relationships.
37
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
In a foreign currency forward transaction, the Company agrees with another party to deliver a specified amount of an identified currency at a specified future date. The price is agreed upon at the time of the contract and payment for such a contract is made at the specified future date. The Company utilizes foreign currency forwards in fair value, net investment in foreign operations and nonqualifying hedging relationships.
The Company enters into currency options that give it the right, but not the obligation, to sell the foreign currency amount in exchange for a functional currency amount within a limited time at a contracted price. The contracts may also be net settled in cash, based on differentials in the foreign currency exchange rate and the strike price. The Company uses currency options to hedge against the foreign currency exposure inherent in certain of its variable annuity products. The Company also uses currency options as an economic hedge of foreign currency exposure related to the Company’s international subsidiaries. The Company utilizes currency options in net investment in foreign operations and nonqualifying hedging relationships.
To a lesser extent, the Company uses exchange-traded currency futures to hedge currency mismatches between assets and liabilities, and to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. The Company utilizes exchange-traded currency futures in nonqualifying hedging relationships.
Credit Derivatives
The Company enters into purchased credit default swaps to hedge against credit-related changes in the value of its investments. In a credit default swap transaction, the Company agrees with another party to pay, at specified intervals, a premium to hedge credit risk. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the delivery of par quantities of the referenced investment equal to the specified swap notional amount in exchange for the payment of cash amounts by the counterparty equal to the par value of the investment surrendered. Credit events vary by type of issuer but typically include bankruptcy, failure to pay debt obligations, repudiation, moratorium, involuntary restructuring or governmental intervention. In each case, payout on a credit default swap is triggered only after the Credit Derivatives Determinations Committee of the International Swaps and Derivatives Association, Inc. (“ISDA”) deems that a credit event has occurred. The Company utilizes credit default swaps in nonqualifying hedging relationships.
The Company enters into written credit default swaps to synthetically create credit investments that are either more expensive to acquire or otherwise unavailable in the cash markets. These transactions are a combination of a derivative and one or more cash instruments, such as U.S. government and agency securities, or other fixed maturity securities. These credit default swaps are not designated as hedging instruments.
The Company enters into forwards to lock in the price to be paid for forward purchases of certain securities. The price is agreed upon at the time of the contract and payment for the contract is made at a specified future date. When the primary purpose of entering into these transactions is to hedge against the risk of changes in purchase price due to changes in credit spreads, the Company designates these transactions as credit forwards. The Company utilizes credit forwards in cash flow hedging relationships.
Equity Derivatives
The Company uses a variety of equity derivatives to reduce its exposure to equity market risk, including equity index options, equity variance swaps, exchange-traded equity futures and equity total return swaps.
Equity index options are used by the Company primarily to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. To hedge against adverse changes in equity indices, the Company enters into contracts to sell the equity index within a limited time at a contracted price. The contracts will be net settled in cash based on differentials in the indices at the time of exercise and the strike price. Certain of these contracts may also contain settlement provisions linked to interest rates. In certain instances, the Company may enter into a combination of transactions to hedge adverse changes in equity indices within a pre-determined range through the purchase and sale of options. The Company utilizes equity index options in nonqualifying hedging relationships.
Equity variance swaps are used by the Company primarily to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. In an equity variance swap, the Company agrees with another party to exchange amounts in the future, based on changes in equity volatility over a defined period. The Company utilizes equity variance swaps in nonqualifying hedging relationships.
38
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
In exchange-traded equity futures transactions, the Company agrees to purchase or sell a specified number of contracts, the value of which is determined by the different classes of equity securities, and to post variation margin on a daily basis in an amount equal to the difference in the daily market values of those contracts. The Company enters into exchange-traded futures with regulated futures commission merchants that are members of the exchange. Exchange-traded equity futures are used primarily to hedge minimum guarantees embedded in certain variable annuity products offered by the Company. The Company utilizes exchange-traded equity futures in nonqualifying hedging relationships.
In an equity total return swap, the Company agrees with another party to exchange, at specified intervals, the difference between the economic risk and reward of an asset or a market index and LIBOR, calculated by reference to an agreed notional amount. No cash is exchanged at the outset of the contract. Cash is paid and received over the life of the contract based on the terms of the swap. The Company uses equity total return swaps to hedge its equity market guarantees in certain of its insurance products. Equity total return swaps can be used as hedges or to synthetically create investments. The Company utilizes equity total return swaps in nonqualifying hedging relationships.
39
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
Primary Risks Managed by Derivatives
The following table presents the gross notional amount, estimated fair value and primary underlying risk exposure of the Company’s derivatives, excluding embedded derivatives, held at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||||||||||||
|
Primary Underlying Risk Exposure
|
Gross
Notional Amount |
Estimated Fair Value
|
Gross
Notional Amount |
Estimated Fair Value
|
||||||||||||||||||||||
|
Assets
|
Liabilities
|
Assets
|
Liabilities
|
|||||||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||
|
Derivatives Designated as Hedging Instruments:
|
||||||||||||||||||||||||||
|
Fair value hedges:
|
||||||||||||||||||||||||||
|
Interest rate swaps
|
Interest rate
|
$
|
5,176
|
|
$
|
2,237
|
|
$
|
6
|
|
$
|
5,331
|
|
$
|
2,262
|
|
$
|
6
|
|
|||||||
|
Foreign currency swaps
|
Foreign currency exchange rate
|
1,221
|
|
31
|
|
223
|
|
1,221
|
|
34
|
|
224
|
|
|||||||||||||
|
Foreign currency forwards
|
Foreign currency exchange rate
|
1,805
|
|
11
|
|
26
|
|
1,085
|
|
—
|
|
54
|
|
|||||||||||||
|
Subtotal
|
8,202
|
|
2,279
|
|
255
|
|
7,637
|
|
2,296
|
|
284
|
|
||||||||||||||
|
Cash flow hedges:
|
||||||||||||||||||||||||||
|
Interest rate swaps
|
Interest rate
|
3,961
|
|
319
|
|
8
|
|
2,085
|
|
332
|
|
34
|
|
|||||||||||||
|
Interest rate forwards
|
Interest rate
|
3,692
|
|
—
|
|
310
|
|
4,032
|
|
—
|
|
370
|
|
|||||||||||||
|
Foreign currency swaps
|
Foreign currency exchange rate
|
28,791
|
|
1,986
|
|
1,872
|
|
28,173
|
|
2,079
|
|
2,065
|
|
|||||||||||||
|
Subtotal
|
36,444
|
|
2,305
|
|
2,190
|
|
34,290
|
|
2,411
|
|
2,469
|
|
||||||||||||||
|
Foreign operations hedges:
|
||||||||||||||||||||||||||
|
Foreign currency forwards
|
Foreign currency exchange rate
|
1,583
|
|
7
|
|
40
|
|
1,394
|
|
47
|
|
5
|
|
|||||||||||||
|
Currency options
|
Foreign currency exchange rate
|
8,279
|
|
25
|
|
141
|
|
8,878
|
|
148
|
|
45
|
|
|||||||||||||
|
Subtotal
|
9,862
|
|
32
|
|
181
|
|
10,272
|
|
195
|
|
50
|
|
||||||||||||||
|
Total qualifying hedges
|
54,508
|
|
4,616
|
|
2,626
|
|
52,199
|
|
4,902
|
|
2,803
|
|
||||||||||||||
|
Derivatives Not Designated or Not Qualifying as Hedging Instruments:
|
||||||||||||||||||||||||||
|
Interest rate swaps
|
Interest rate
|
81,178
|
|
3,284
|
|
1,378
|
|
81,524
|
|
6,017
|
|
3,328
|
|
|||||||||||||
|
Interest rate floors
|
Interest rate
|
14,201
|
|
147
|
|
2
|
|
14,201
|
|
187
|
|
9
|
|
|||||||||||||
|
Interest rate caps
|
Interest rate
|
80,060
|
|
121
|
|
3
|
|
90,400
|
|
137
|
|
2
|
|
|||||||||||||
|
Interest rate futures
|
Interest rate
|
5,134
|
|
6
|
|
6
|
|
6,081
|
|
12
|
|
12
|
|
|||||||||||||
|
Interest rate options
|
Interest rate
|
69,059
|
|
736
|
|
70
|
|
20,854
|
|
764
|
|
1
|
|
|||||||||||||
|
Interest rate forwards
|
Interest rate
|
405
|
|
—
|
|
39
|
|
613
|
|
—
|
|
25
|
|
|||||||||||||
|
Interest rate total return swaps
|
Interest rate
|
4,198
|
|
6
|
|
542
|
|
5,425
|
|
2
|
|
738
|
|
|||||||||||||
|
Synthetic GICs
|
Interest rate
|
6,428
|
|
—
|
|
—
|
|
5,566
|
|
—
|
|
—
|
|
|||||||||||||
|
Foreign currency swaps
|
Foreign currency exchange rate
|
12,938
|
|
1,314
|
|
411
|
|
12,912
|
|
1,600
|
|
466
|
|
|||||||||||||
|
Foreign currency forwards
|
Foreign currency exchange rate
|
15,688
|
|
138
|
|
519
|
|
15,580
|
|
126
|
|
977
|
|
|||||||||||||
|
Currency futures
|
Foreign currency exchange rate
|
837
|
|
—
|
|
2
|
|
915
|
|
—
|
|
—
|
|
|||||||||||||
|
Currency options
|
Foreign currency exchange rate
|
3,650
|
|
107
|
|
28
|
|
3,615
|
|
195
|
|
17
|
|
|||||||||||||
|
Credit default swaps — purchased
|
Credit
|
2,142
|
|
5
|
|
45
|
|
2,038
|
|
14
|
|
40
|
|
|||||||||||||
|
Credit default swaps — written
|
Credit
|
12,369
|
|
204
|
|
5
|
|
12,645
|
|
189
|
|
9
|
|
|||||||||||||
|
Equity futures
|
Equity market
|
9,195
|
|
19
|
|
8
|
|
12,494
|
|
68
|
|
3
|
|
|||||||||||||
|
Equity index options
|
Equity market
|
54,224
|
|
1,321
|
|
1,740
|
|
54,028
|
|
1,323
|
|
1,458
|
|
|||||||||||||
|
Equity variance swaps
|
Equity market
|
23,231
|
|
253
|
|
835
|
|
23,157
|
|
223
|
|
756
|
|
|||||||||||||
|
Equity total return swaps
|
Equity market
|
3,265
|
|
1
|
|
140
|
|
3,901
|
|
2
|
|
160
|
|
|||||||||||||
|
Total non-designated or nonqualifying derivatives
|
398,202
|
|
7,662
|
|
5,773
|
|
365,949
|
|
10,859
|
|
8,001
|
|
||||||||||||||
|
Total
|
$
|
452,710
|
|
$
|
12,278
|
|
$
|
8,399
|
|
$
|
418,148
|
|
$
|
15,761
|
|
$
|
10,804
|
|
||||||||
40
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
Based on gross notional amounts, a substantial portion of the Company’s derivatives was not designated or did not qualify as part of a hedging relationship at both
March 31, 2017
and
December 31, 2016
. The Company’s use of derivatives includes (i) derivatives that serve as macro hedges of the Company’s exposure to various risks and that generally do not qualify for hedge accounting due to the criteria required under the portfolio hedging rules; (ii) derivatives that economically hedge insurance liabilities that contain mortality or morbidity risk and that generally do not qualify for hedge accounting because the lack of these risks in the derivatives cannot support an expectation of a highly effective hedging relationship; (iii) derivatives that economically hedge embedded derivatives that do not qualify for hedge accounting because the changes in estimated fair value of the embedded derivatives are already recorded in net income; and (iv) written credit default swaps that are used to synthetically create credit investments and that do not qualify for hedge accounting because they do not involve a hedging relationship. For these nonqualified derivatives, changes in market factors can lead to the recognition of fair value changes on the statement of operations without an offsetting gain or loss recognized in earnings for the item being hedged.
Net Derivative Gains (Losses)
The components of net derivative gains (losses) were as follows:
|
Three Months
Ended March 31, |
||||||||
|
2017
|
2016
|
|||||||
|
(In millions)
|
||||||||
|
Freestanding derivatives and hedging gains (losses) (1)
|
$
|
(1,504
|
)
|
$
|
2,504
|
|
||
|
Embedded derivatives gains (losses)
|
578
|
|
(1,169
|
)
|
||||
|
Total net derivative gains (losses)
|
$
|
(926
|
)
|
$
|
1,335
|
|
||
__________________
|
(1)
|
Includes foreign currency transaction gains (losses) on hedged items in cash flow and nonqualifying hedging relationships, which are not presented elsewhere in this note.
|
The following table presents earned income on derivatives:
|
Three Months
Ended March 31, |
||||||||
|
2017
|
2016
|
|||||||
|
(In millions)
|
||||||||
|
Qualifying hedges:
|
||||||||
|
Net investment income
|
$
|
81
|
|
$
|
57
|
|
||
|
Interest credited to policyholder account balances
|
(6
|
)
|
6
|
|
||||
|
Other expenses
|
(3
|
)
|
(2
|
)
|
||||
|
Nonqualifying hedges:
|
||||||||
|
Net derivative gains (losses)
|
288
|
|
283
|
|
||||
|
Policyholder benefits and claims
|
6
|
|
5
|
|
||||
|
Total
|
$
|
366
|
|
$
|
349
|
|
||
41
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
Nonqualifying Derivatives and Derivatives for Purposes Other Than Hedging
The following table presents the amount and location of gains (losses) recognized in income for derivatives that were not designated or not qualifying as hedging instruments:
|
Net
Derivative Gains (Losses) |
Net
Investment Income (1) |
Policyholder
Benefits and Claims (2) |
||||||||||
|
(In millions)
|
||||||||||||
|
Three Months Ended March 31, 2017
|
||||||||||||
|
Interest rate derivatives
|
$
|
(659
|
)
|
$
|
2
|
|
$
|
1
|
|
|||
|
Foreign currency exchange rate derivatives
|
343
|
|
—
|
|
—
|
|
||||||
|
Credit derivatives — purchased
|
(8
|
)
|
—
|
|
—
|
|
||||||
|
Credit derivatives — written
|
38
|
|
—
|
|
—
|
|
||||||
|
Equity derivatives
|
(1,293
|
)
|
(3
|
)
|
(256
|
)
|
||||||
|
Total
|
$
|
(1,579
|
)
|
$
|
(1
|
)
|
$
|
(255
|
)
|
|||
|
Three Months Ended March 31, 2016
|
||||||||||||
|
Interest rate derivatives
|
$
|
1,972
|
|
$
|
—
|
|
$
|
42
|
|
|||
|
Foreign currency exchange rate derivatives
|
523
|
|
—
|
|
(1
|
)
|
||||||
|
Credit derivatives — purchased
|
(5
|
)
|
10
|
|
—
|
|
||||||
|
Credit derivatives — written
|
(6
|
)
|
(9
|
)
|
—
|
|
||||||
|
Equity derivatives
|
(47
|
)
|
(11
|
)
|
32
|
|
||||||
|
Total
|
$
|
2,437
|
|
$
|
(10
|
)
|
$
|
73
|
|
|||
__________________
|
(1)
|
Changes in estimated fair value related to economic hedges of equity method investments in joint ventures, derivatives held in relation to trading portfolios and derivatives held within contractholder-directed unit-linked investments.
|
|
(2)
|
Changes in estimated fair value related to economic hedges of variable annuity guarantees included in future policy benefits.
|
Fair Value Hedges
The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities; (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities; and (iii) foreign currency forwards to hedge the foreign currency fair value exposure of foreign currency denominated investments.
42
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
The Company recognizes gains and losses on derivatives and the related hedged items in fair value hedges within net derivative gains (losses). The following table presents the amount of such net derivative gains (losses):
|
Derivatives in Fair Value
Hedging Relationships
|
Hedged Items in Fair Value
Hedging Relationships
|
Net Derivative
Gains (Losses)
Recognized
for Derivatives
|
Net Derivative
Gains (Losses)
Recognized for
Hedged Items
|
Ineffectiveness
Recognized in
Net Derivative
Gains (Losses)
|
||||||||||
|
(In millions)
|
||||||||||||||
|
Three Months Ended March 31, 2017
|
||||||||||||||
|
Interest rate swaps:
|
Fixed maturity securities
|
$
|
1
|
|
$
|
(1
|
)
|
$
|
—
|
|
||||
|
Policyholder liabilities (1)
|
(53
|
)
|
52
|
|
(1
|
)
|
||||||||
|
Foreign currency swaps:
|
Foreign-denominated fixed maturity securities
|
(3
|
)
|
3
|
|
—
|
|
|||||||
|
Foreign-denominated policyholder account balances (2)
|
1
|
|
2
|
|
3
|
|
||||||||
|
Foreign currency forwards:
|
Foreign-denominated fixed maturity securities
|
45
|
|
(41
|
)
|
4
|
|
|||||||
|
Total
|
$
|
(9
|
)
|
$
|
15
|
|
$
|
6
|
|
|||||
|
Three Months Ended March 31, 2016
|
||||||||||||||
|
Interest rate swaps:
|
Fixed maturity securities
|
$
|
(8
|
)
|
$
|
7
|
|
$
|
(1
|
)
|
||||
|
Policyholder liabilities (1)
|
346
|
|
(348
|
)
|
(2
|
)
|
||||||||
|
Foreign currency swaps:
|
Foreign-denominated fixed maturity securities
|
(1
|
)
|
2
|
|
1
|
|
|||||||
|
Foreign-denominated policyholder account balances (2)
|
25
|
|
(25
|
)
|
—
|
|
||||||||
|
Foreign currency forwards:
|
Foreign-denominated fixed maturity securities
|
139
|
|
(128
|
)
|
11
|
|
|||||||
|
Total
|
$
|
501
|
|
$
|
(492
|
)
|
$
|
9
|
|
|||||
__________________
|
(1)
|
Fixed rate liabilities reported in policyholder account balances or future policy benefits.
|
|
(2)
|
Fixed rate or floating rate liabilities.
|
For the Company’s foreign currency forwards, the change in the estimated fair value of the derivative related to the changes in the difference between the spot price and the forward price is excluded from the assessment of hedge effectiveness. For all other derivatives, all components of each derivative’s gain or loss were included in the assessment of hedge effectiveness. For the
three months ended
March 31, 2017
and 2016, the component of the change in estimated fair value of derivatives that was excluded from the assessment of hedge effectiveness was
($7) million
and
($6) million
, respectively.
Cash Flow Hedges
The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities; (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities; (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments; (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed-rate investments; and (v) interest rate swaps and interest rate forwards to hedge forecasted fixed-rate borrowings.
In certain instances, the Company discontinued cash flow hedge accounting because the forecasted transactions were no longer probable of occurring. Because certain of the forecasted transactions also were not probable of occurring within two months of the anticipated date, the Company reclassified amounts from AOCI into net derivative gains (losses). These amounts were
$32 million
and
($4) million
for the
three months ended
March 31, 2017
and 2016, respectively.
At both
March 31, 2017
and
December 31, 2016
, the maximum length of time over which the Company was hedging its exposure to variability in future cash flows for forecasted transactions did not exceed
five years
.
At both
March 31, 2017
and
December 31, 2016
, the balance in AOCI associated with cash flow hedges was
$2.9 billion
.
43
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
The following table presents the effects of derivatives in cash flow hedging relationships on the consolidated statements of operations and comprehensive income (loss) and the consolidated statements of equity:
|
Derivatives in Cash Flow
Hedging Relationships
|
Amount of Gains
(Losses) Deferred in
AOCI on Derivatives
|
Amount and Location
of Gains (Losses)
Reclassified from
AOCI into Income (Loss)
|
Amount and Location
of Gains (Losses) Recognized in Income (Loss) on Derivatives |
|||||||||||||||||
|
(Effective Portion)
|
(Effective Portion)
|
(Ineffective Portion)
|
||||||||||||||||||
|
Net Derivative
Gains (Losses)
|
Net Investment
Income
|
Other
Expenses
|
Net Derivative
Gains (Losses)
|
|||||||||||||||||
|
(In millions)
|
||||||||||||||||||||
|
Three Months Ended March 31, 2017
|
||||||||||||||||||||
|
Interest rate swaps
|
$
|
5
|
|
$
|
8
|
|
$
|
5
|
|
$
|
—
|
|
$
|
1
|
|
|||||
|
Interest rate forwards
|
44
|
|
(4
|
)
|
1
|
|
—
|
|
—
|
|
||||||||||
|
Foreign currency swaps
|
161
|
|
218
|
|
—
|
|
1
|
|
2
|
|
||||||||||
|
Total
|
$
|
210
|
|
$
|
222
|
|
$
|
6
|
|
$
|
1
|
|
$
|
3
|
|
|||||
|
Three Months Ended March 31, 2016
|
||||||||||||||||||||
|
Interest rate swaps
|
$
|
213
|
|
$
|
10
|
|
$
|
3
|
|
$
|
—
|
|
$
|
(1
|
)
|
|||||
|
Interest rate forwards
|
9
|
|
2
|
|
1
|
|
—
|
|
—
|
|
||||||||||
|
Foreign currency swaps
|
474
|
|
306
|
|
—
|
|
1
|
|
(2
|
)
|
||||||||||
|
Total
|
$
|
696
|
|
$
|
318
|
|
$
|
4
|
|
$
|
1
|
|
$
|
(3
|
)
|
|||||
All components of e
ach derivative’s gain or loss were included in the assessment of hedge effectiveness.
At
March 31, 2017
, the Company expected to reclassify
$6 million
of deferred net gains (losses) on derivatives in AOCI to earnings within the next 12 months.
Hedges of Net Investments in Foreign Operations
The Company uses foreign currency exchange rate derivatives, which may include foreign currency forwards and currency options, to hedge portions of its net investments in foreign operations against adverse movements in exchange rates. The Company measures ineffectiveness on these derivatives based upon the change in forward rates.
When net investments in foreign operations are sold or substantially liquidated, the amounts in AOCI are reclassified to the statement of operations.
The following table presents the effects of derivatives in net investment hedging relationships on the consolidated statements of operations and comprehensive income (loss) and the consolidated statements of equity:
|
Derivatives in Net Investment Hedging Relationships (1), (2)
|
Amount of Gains (Losses) Deferred in AOCI
(Effective Portion) |
|||
|
(In millions)
|
||||
|
Three Months Ended March 31, 2017
|
||||
|
Foreign currency forwards
|
$
|
(95
|
)
|
|
|
Currency options
|
(231
|
)
|
||
|
Total
|
$
|
(326
|
)
|
|
|
Three Months Ended March 31, 2016
|
||||
|
Foreign currency forwards
|
$
|
(231
|
)
|
|
|
Currency options
|
(168
|
)
|
||
|
Total
|
$
|
(399
|
)
|
|
__________________
|
(1)
|
During both the
three months ended
March 31, 2017
and
2016
, there were
no
sales or substantial liquidations of net investments in foreign operations that would have required the reclassification of gains or losses from AOCI into earnings.
|
|
(2)
|
There was
no
ineffectiveness recognized for the Company’s hedges of net investments in foreign operations. All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness.
|
44
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
At
March 31, 2017
and
December 31, 2016
, the cumulative foreign currency translation gain (loss) recorded in AOCI related to hedges of net investments in foreign operations was
$428 million
and
$754 million
, respectively.
Credit Derivatives
In connection with synthetically created credit investment transactions, the Company writes credit default swaps for which it receives a premium to insure credit risk. Such credit derivatives are included within the nonqualifying derivatives and derivatives for purposes other than hedging table. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the Company paying the counterparty the specified swap notional amount in exchange for the delivery of par quantities of the referenced credit obligation. The Company’s maximum amount at risk, assuming the value of all referenced credit obligations is zero, was $
12.4 billion
and
$12.6 billion
at
March 31, 2017
and
December 31, 2016
, respectively. The Company can terminate these contracts at any time through cash settlement with the counterparty at an amount equal to the then current estimated fair value of the credit default swaps. At
March 31, 2017
and
December 31, 2016
, the Company would have received
$199 million
and
$180 million
, respectively, to terminate all of these contracts.
The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||||||||
|
Rating Agency Designation of Referenced
Credit Obligations (1)
|
Estimated
Fair Value
of Credit
Default
Swaps
|
Maximum
Amount of Future Payments under Credit Default Swaps |
Weighted
Average Years to Maturity (2) |
Estimated
Fair Value
of Credit
Default
Swaps
|
Maximum
Amount of Future Payments under Credit Default Swaps |
Weighted
Average Years to Maturity (2) |
||||||||||||||||
|
(Dollars in millions)
|
||||||||||||||||||||||
|
Aaa/Aa/A
|
||||||||||||||||||||||
|
Single name credit default swaps (3)
|
$
|
8
|
|
$
|
484
|
|
2.8
|
|
$
|
6
|
|
$
|
494
|
|
3.0
|
|
||||||
|
Credit default swaps referencing indices
|
43
|
|
2,500
|
|
3.4
|
|
42
|
|
2,768
|
|
3.6
|
|
||||||||||
|
Subtotal
|
51
|
|
2,984
|
|
3.3
|
|
48
|
|
3,262
|
|
3.6
|
|
||||||||||
|
Baa
|
||||||||||||||||||||||
|
Single name credit default swaps (3)
|
9
|
|
881
|
|
2.2
|
|
7
|
|
931
|
|
2.3
|
|
||||||||||
|
Credit default swaps referencing indices
|
119
|
|
7,984
|
|
5.3
|
|
106
|
|
7,946
|
|
5.0
|
|
||||||||||
|
Subtotal
|
128
|
|
8,865
|
|
5.0
|
|
113
|
|
8,877
|
|
4.7
|
|
||||||||||
|
Ba
|
||||||||||||||||||||||
|
Single name credit default swaps (3)
|
(2
|
)
|
180
|
|
3.9
|
|
(2
|
)
|
155
|
|
4.0
|
|
||||||||||
|
Credit default swaps referencing indices
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
||||||||||
|
Subtotal
|
(2
|
)
|
180
|
|
3.9
|
|
(2
|
)
|
155
|
|
4.0
|
|
||||||||||
|
B
|
||||||||||||||||||||||
|
Single name credit default swaps (3)
|
1
|
|
70
|
|
1.5
|
|
1
|
|
70
|
|
1.8
|
|
||||||||||
|
Credit default swaps referencing indices
|
21
|
|
270
|
|
5.2
|
|
20
|
|
281
|
|
5.0
|
|
||||||||||
|
Subtotal
|
22
|
|
340
|
|
4.5
|
|
21
|
|
351
|
|
4.3
|
|
||||||||||
|
Total
|
$
|
199
|
|
$
|
12,369
|
|
4.6
|
|
$
|
180
|
|
$
|
12,645
|
|
4.4
|
|
||||||
__________________
|
(1)
|
The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service (“Moody’s”), Standard & Poor’s Global Ratings (“S&P”) and Fitch Ratings. If no rating is available from a rating agency, then an internally developed rating is used.
|
|
(2)
|
The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts.
|
|
(3)
|
Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or state and political subdivisions.
|
45
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
The Company has also entered into credit default swaps to purchase credit protection on certain of the referenced credit obligations in the table above. As a result, the maximum amounts of potential future recoveries available to offset the
$12.4 billion
and
$12.6 billion
from the table above were
$217 million
and
$30 million
at
March 31, 2017
and
December 31, 2016
, respectively.
Credit Risk on Freestanding Derivatives
The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements.
The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties and establishing and monitoring exposure limits. The Company’s OTC-bilateral derivative transactions are generally governed by ISDA Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, the Company is permitted to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions. Substantially all of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives.
The Company’s OTC-cleared derivatives are effected through central clearing counterparties and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by counterparties to such derivatives.
See Note
7
for a description of the impact of credit risk on the valuation of derivatives.
46
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||
|
Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement (1)
|
Assets
|
Liabilities
|
Assets
|
Liabilities
|
||||||||||||
|
(In millions)
|
||||||||||||||||
|
Gross estimated fair value of derivatives:
|
||||||||||||||||
|
OTC-bilateral (1)
|
$
|
11,843
|
|
$
|
8,074
|
|
$
|
13,387
|
|
$
|
8,650
|
|
||||
|
OTC-cleared (1), (6)
|
603
|
|
245
|
|
2,543
|
|
2,047
|
|
||||||||
|
Exchange-traded
|
25
|
|
16
|
|
80
|
|
15
|
|
||||||||
|
Total gross estimated fair value of derivatives (1)
|
12,471
|
|
8,335
|
|
16,010
|
|
10,712
|
|
||||||||
|
Amounts offset on the consolidated balance sheets
|
—
|
|
—
|
|
—
|
|
—
|
|
||||||||
|
Estimated fair value of derivatives presented on the consolidated balance sheets (1), (6)
|
12,471
|
|
8,335
|
|
16,010
|
|
10,712
|
|
||||||||
|
Gross amounts not offset on the consolidated balance sheets:
|
||||||||||||||||
|
Gross estimated fair value of derivatives: (2)
|
||||||||||||||||
|
OTC-bilateral
|
(5,449
|
)
|
(5,449
|
)
|
(6,018
|
)
|
(6,018
|
)
|
||||||||
|
OTC-cleared
|
(48
|
)
|
(48
|
)
|
(1,068
|
)
|
(1,068
|
)
|
||||||||
|
Exchange-traded
|
(1
|
)
|
(1
|
)
|
(5
|
)
|
(5
|
)
|
||||||||
|
Cash collateral: (3), (4)
|
||||||||||||||||
|
OTC-bilateral
|
(4,302
|
)
|
(21
|
)
|
(4,897
|
)
|
(84
|
)
|
||||||||
|
OTC-cleared
|
(522
|
)
|
(187
|
)
|
(1,427
|
)
|
(974
|
)
|
||||||||
|
Exchange-traded
|
—
|
|
(10
|
)
|
—
|
|
(9
|
)
|
||||||||
|
Securities collateral: (5)
|
||||||||||||||||
|
OTC-bilateral
|
(1,929
|
)
|
(2,493
|
)
|
(2,069
|
)
|
(2,516
|
)
|
||||||||
|
OTC-cleared
|
—
|
|
(9
|
)
|
—
|
|
—
|
|
||||||||
|
Exchange-traded
|
—
|
|
(5
|
)
|
—
|
|
—
|
|
||||||||
|
Net amount after application of master netting agreements and collateral
|
$
|
220
|
|
$
|
112
|
|
$
|
526
|
|
$
|
38
|
|
||||
__________________
|
(1)
|
At
March 31, 2017
and
December 31, 2016
, derivative assets included income or (expense) accruals reported in accrued investment income or in other liabilities of
$193 million
and
$249 million
, respectively, and derivative liabilities included (income) or expense accruals reported in accrued investment income or in other liabilities of
($64) million
and
($92) million
, respectively.
|
|
(2)
|
Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals.
|
|
(3)
|
Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives is included in cash and cash equivalents, short-term investments or in fixed maturity securities, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet.
|
|
(4)
|
The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At
March 31, 2017
and
December 31, 2016
, the Company received excess cash collateral of
$232 million
and
$168 million
, respectively, and provided excess cash collateral of
$366 million
and
$486 million
, respectively, which is not included in the table above due to the foregoing limitation.
|
47
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
|
(5)
|
Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at
March 31, 2017
,
none
of the collateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At
March 31, 2017
and
December 31, 2016
, the Company received excess securities collateral with an estimated fair value of
$221 million
and
$217 million
, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At
March 31, 2017
and
December 31, 2016
, the Company provided excess securities collateral with an estimated fair value of
$158 million
and
$297 million
, respectively, for its OTC-bilateral derivatives, and
$732 million
and
$1.2 billion
, respectively, for its OTC-cleared derivatives, and
$325 million
and
$569 million
, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation.
|
|
(6)
|
Effective January 3, 2017, the CME amended its rulebook, resulting in the characterization of variation margin transfers as settlement payments, as opposed to adjustments to collateral. See Note 1 for further information on the CME amendments.
|
The Company’s collateral arrangements for its OTC-bilateral derivatives generally require the counterparty in a net liability position, after considering the effect of netting agreements, to pledge collateral when the collateral amount owed by that counterparty reaches a minimum transfer amount. A small number of these arrangements also include credit-contingent provisions that include a threshold above which collateral must be posted. Such agreements provide for a reduction of these thresholds (on a sliding scale that converges toward zero) in the event of downgrades in the credit ratings of MetLife, Inc. and/or the counterparty. In addition, substantially all of the Company’s netting agreements for derivatives contain provisions that require both the Company and the counterparty to maintain a specific investment grade credit rating from each of Moody’s and S&P. If a party’s credit or financial strength rating, as applicable, were to fall below that specific investment grade credit rating, that party would be in violation of these provisions, and the other party to the derivatives could terminate the transactions and demand immediate settlement and payment based on such party’s reasonable valuation of the derivatives.
The following table presents the estimated fair value of the Company’s OTC-bilateral derivatives that are in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged. The table also presents the incremental collateral that MetLife, Inc. would be required to provide if there was a one-notch downgrade in MetLife, Inc.’s senior unsecured debt rating at the reporting date or if the Company’s credit or financial strength rating, as applicable, sustained a downgrade to a level that triggered full overnight collateralization or termination of the derivative position at the reporting date. OTC-bilateral derivatives that are not subject to collateral agreements are excluded from this table.
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||||||||||
|
Derivatives
Subject to Credit- Contingent Provisions |
Derivatives
Not Subject to Credit- Contingent Provisions |
Total
|
Derivatives
Subject to
Credit-
Contingent
Provisions
|
Derivatives
Not Subject to Credit- Contingent Provisions |
Total
|
|||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||
|
Estimated Fair Value of Derivatives in a Net Liability Position (1)
|
$
|
2,603
|
|
$
|
22
|
|
$
|
2,625
|
|
$
|
2,607
|
|
$
|
25
|
|
$
|
2,632
|
|
||||||
|
Estimated Fair Value of Collateral Provided:
|
||||||||||||||||||||||||
|
Fixed maturity securities
|
$
|
2,609
|
|
$
|
22
|
|
$
|
2,631
|
|
$
|
2,742
|
|
$
|
31
|
|
$
|
2,773
|
|
||||||
|
Cash
|
$
|
22
|
|
$
|
—
|
|
$
|
22
|
|
$
|
91
|
|
$
|
—
|
|
$
|
91
|
|
||||||
|
Estimated Fair Value of Incremental Collateral Provided Upon:
|
|
|
||||||||||||||||||||||
|
One-notch downgrade in the Company’s credit or financial strength rating, as applicable
|
$
|
10
|
|
$
|
—
|
|
$
|
10
|
|
$
|
6
|
|
$
|
—
|
|
$
|
6
|
|
||||||
|
Downgrade in the Company’s credit or financial strength rating, as applicable, to a level that triggers full overnight collateralization or termination of the derivative position
|
$
|
10
|
|
$
|
—
|
|
$
|
10
|
|
$
|
9
|
|
$
|
—
|
|
$
|
9
|
|
||||||
__________________
48
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
6. Derivatives (continued)
|
(1)
|
After taking into consideration the existence of netting agreements.
|
Embedded Derivatives
The Company issues certain products or purchases certain investments that contain embedded derivatives that are required to be separated from their host contracts and accounted for as freestanding derivatives. These host contracts principally include: variable annuities with guaranteed minimum benefits, including GMWBs, GMABs and certain GMIBs; ceded reinsurance of guaranteed minimum benefits related to certain GMIBs; assumed reinsurance of guaranteed minimum benefits related to GMWBs and GMABs; funding agreements with equity or bond indexed crediting rates; funds withheld on assumed and ceded reinsurance; fixed annuities with equity-indexed returns; and certain debt and equity securities.
The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at:
|
Balance Sheet Location
|
March 31, 2017
|
December 31, 2016
|
||||||||
|
(In millions)
|
||||||||||
|
Embedded derivatives within asset host contracts:
|
||||||||||
|
Ceded guaranteed minimum benefits
|
Premiums, reinsurance and other receivables
|
$
|
372
|
|
$
|
380
|
|
|||
|
Options embedded in debt or equity securities
|
Investments
|
(206
|
)
|
(137
|
)
|
|||||
|
Embedded derivatives within asset host contracts
|
$
|
166
|
|
$
|
243
|
|
||||
|
Embedded derivatives within liability host contracts:
|
||||||||||
|
Direct guaranteed minimum benefits
|
Policyholder account balances
|
$
|
2,165
|
|
$
|
2,720
|
|
|||
|
Assumed guaranteed minimum benefits
|
Policyholder account balances
|
1,303
|
|
1,205
|
|
|||||
|
Funds withheld on ceded reinsurance
|
Other liabilities
|
(21
|
)
|
(30
|
)
|
|||||
|
Fixed annuities with equity indexed returns
|
Policyholder account balances
|
336
|
|
210
|
|
|||||
|
Embedded derivatives within liability host contracts
|
$
|
3,783
|
|
$
|
4,105
|
|
||||
The following table presents changes in estimated fair value related to embedded derivatives:
|
Three Months
Ended March 31, |
||||||||
|
2017
|
2016
|
|||||||
|
(In millions)
|
||||||||
|
Net derivative gains (losses) (1)
|
$
|
578
|
|
$
|
(1,169
|
)
|
||
|
Policyholder benefits and claims
|
$
|
(15
|
)
|
$
|
45
|
|
||
__________________
|
(1)
|
The valuation of guaranteed minimum benefits includes a nonperformance risk adjustment. The amounts included in net derivative gains (losses) in connection with this adjustment were
($43) million
and
$359 million
for the
three months ended
March 31, 2017
and
2016
, respectively.
|
7. Fair Value
Considerable judgment is often required in interpreting market data to develop estimates of fair value, and the use of different assumptions or valuation methodologies may have a material effect on the estimated fair value amounts.
Recurring Fair Value Measurements
The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at:
49
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
|
March 31, 2017
|
||||||||||||||||
|
Fair Value Hierarchy
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
Estimated Fair Value |
|||||||||||||
|
(In millions)
|
||||||||||||||||
|
Assets
|
||||||||||||||||
|
Fixed maturity securities:
|
||||||||||||||||
|
U.S. corporate
|
$
|
—
|
|
$
|
94,278
|
|
$
|
6,635
|
|
$
|
100,913
|
|
||||
|
U.S. government and agency
|
30,158
|
|
26,722
|
|
—
|
|
56,880
|
|
||||||||
|
Foreign government
|
—
|
|
60,149
|
|
289
|
|
60,438
|
|
||||||||
|
Foreign corporate
|
—
|
|
51,729
|
|
6,736
|
|
58,465
|
|
||||||||
|
RMBS
|
5
|
|
32,379
|
|
5,220
|
|
37,604
|
|
||||||||
|
State and political subdivision
|
—
|
|
16,218
|
|
7
|
|
16,225
|
|
||||||||
|
ABS
|
—
|
|
12,257
|
|
1,552
|
|
13,809
|
|
||||||||
|
CMBS
|
—
|
|
10,673
|
|
521
|
|
11,194
|
|
||||||||
|
Total fixed maturity securities
|
30,163
|
|
304,405
|
|
20,960
|
|
355,528
|
|
||||||||
|
Equity securities
|
1,587
|
|
1,168
|
|
622
|
|
3,377
|
|
||||||||
|
FVO securities (1)
|
11,618
|
|
2,446
|
|
335
|
|
14,399
|
|
||||||||
|
Short-term investments (2)
|
5,905
|
|
2,732
|
|
780
|
|
9,417
|
|
||||||||
|
Mortgage loans:
|
||||||||||||||||
|
Residential mortgage loans — FVO
|
—
|
|
—
|
|
639
|
|
639
|
|
||||||||
|
Commercial mortgage loans held by CSEs — FVO
|
—
|
|
129
|
|
—
|
|
129
|
|
||||||||
|
Total mortgage loans
|
—
|
|
129
|
|
639
|
|
768
|
|
||||||||
|
Other investments
|
87
|
|
90
|
|
—
|
|
177
|
|
||||||||
|
Derivative assets: (3)
|
||||||||||||||||
|
Interest rate
|
6
|
|
6,845
|
|
5
|
|
6,856
|
|
||||||||
|
Foreign currency exchange rate
|
—
|
|
3,516
|
|
103
|
|
3,619
|
|
||||||||
|
Credit
|
—
|
|
169
|
|
40
|
|
209
|
|
||||||||
|
Equity market
|
19
|
|
1,267
|
|
308
|
|
1,594
|
|
||||||||
|
Total derivative assets
|
25
|
|
11,797
|
|
456
|
|
12,278
|
|
||||||||
|
Embedded derivatives within asset host contracts (4)
|
—
|
|
—
|
|
372
|
|
372
|
|
||||||||
|
Separate account assets (5)
|
87,442
|
|
228,872
|
|
1,207
|
|
317,521
|
|
||||||||
|
Total assets
|
$
|
136,827
|
|
$
|
551,639
|
|
$
|
25,371
|
|
$
|
713,837
|
|
||||
|
Liabilities
|
||||||||||||||||
|
Derivative liabilities: (3)
|
||||||||||||||||
|
Interest rate
|
$
|
6
|
|
$
|
1,504
|
|
$
|
854
|
|
$
|
2,364
|
|
||||
|
Foreign currency exchange rate
|
2
|
|
3,217
|
|
43
|
|
3,262
|
|
||||||||
|
Credit
|
—
|
|
50
|
|
—
|
|
50
|
|
||||||||
|
Equity market
|
8
|
|
1,869
|
|
846
|
|
2,723
|
|
||||||||
|
Total derivative liabilities
|
16
|
|
6,640
|
|
1,743
|
|
8,399
|
|
||||||||
|
Embedded derivatives within liability host contracts (4)
|
—
|
|
—
|
|
3,783
|
|
3,783
|
|
||||||||
|
Separate account liabilities (5)
|
1
|
|
11
|
|
8
|
|
20
|
|
||||||||
|
Total liabilities
|
$
|
17
|
|
$
|
6,651
|
|
$
|
5,534
|
|
$
|
12,202
|
|
||||
50
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
|
December 31, 2016
|
||||||||||||||||
|
Fair Value Hierarchy
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
Estimated Fair Value |
|||||||||||||
|
(In millions)
|
||||||||||||||||
|
Assets
|
||||||||||||||||
|
Fixed maturity securities:
|
||||||||||||||||
|
U.S. corporate
|
$
|
—
|
|
$
|
93,639
|
|
$
|
7,214
|
|
$
|
100,853
|
|
||||
|
U.S. government and agency
|
31,153
|
|
26,370
|
|
—
|
|
57,523
|
|
||||||||
|
Foreign government
|
—
|
|
56,848
|
|
290
|
|
57,138
|
|
||||||||
|
Foreign corporate
|
—
|
|
50,344
|
|
6,713
|
|
57,057
|
|
||||||||
|
RMBS
|
—
|
|
31,896
|
|
5,097
|
|
36,993
|
|
||||||||
|
State and political subdivision
|
—
|
|
16,149
|
|
27
|
|
16,176
|
|
||||||||
|
ABS
|
—
|
|
12,624
|
|
1,253
|
|
13,877
|
|
||||||||
|
CMBS
|
—
|
|
10,757
|
|
515
|
|
11,272
|
|
||||||||
|
Total fixed maturity securities
|
31,153
|
|
298,627
|
|
21,109
|
|
350,889
|
|
||||||||
|
Equity securities
|
1,373
|
|
1,217
|
|
604
|
|
3,194
|
|
||||||||
|
FVO securities (1)
|
11,123
|
|
2,513
|
|
287
|
|
13,923
|
|
||||||||
|
Short-term investments (2)
|
4,808
|
|
2,436
|
|
47
|
|
7,291
|
|
||||||||
|
Mortgage loans:
|
||||||||||||||||
|
Residential mortgage loans — FVO
|
—
|
|
—
|
|
566
|
|
566
|
|
||||||||
|
Commercial mortgage loans held by CSEs — FVO
|
—
|
|
136
|
|
—
|
|
136
|
|
||||||||
|
Total mortgage loans
|
—
|
|
136
|
|
566
|
|
702
|
|
||||||||
|
Other investments
|
86
|
|
71
|
|
—
|
|
157
|
|
||||||||
|
Derivative assets: (3)
|
||||||||||||||||
|
Interest rate
|
12
|
|
9,699
|
|
2
|
|
9,713
|
|
||||||||
|
Foreign currency exchange rate
|
—
|
|
4,149
|
|
80
|
|
4,229
|
|
||||||||
|
Credit
|
—
|
|
165
|
|
38
|
|
203
|
|
||||||||
|
Equity market
|
68
|
|
1,249
|
|
299
|
|
1,616
|
|
||||||||
|
Total derivative assets
|
80
|
|
15,262
|
|
419
|
|
15,761
|
|
||||||||
|
Embedded derivatives within asset host contracts (4)
|
—
|
|
—
|
|
380
|
|
380
|
|
||||||||
|
Separate account assets (5)
|
83,538
|
|
223,923
|
|
1,159
|
|
308,620
|
|
||||||||
|
Total assets
|
$
|
132,161
|
|
$
|
544,185
|
|
$
|
24,571
|
|
$
|
700,917
|
|
||||
|
Liabilities
|
||||||||||||||||
|
Derivative liabilities: (3)
|
||||||||||||||||
|
Interest rate
|
$
|
12
|
|
$
|
3,402
|
|
$
|
1,111
|
|
$
|
4,525
|
|
||||
|
Foreign currency exchange rate
|
—
|
|
3,799
|
|
54
|
|
3,853
|
|
||||||||
|
Credit
|
—
|
|
49
|
|
—
|
|
49
|
|
||||||||
|
Equity market
|
3
|
|
1,604
|
|
770
|
|
2,377
|
|
||||||||
|
Total derivative liabilities
|
15
|
|
8,854
|
|
1,935
|
|
10,804
|
|
||||||||
|
Embedded derivatives within liability host contracts (4)
|
—
|
|
—
|
|
4,105
|
|
4,105
|
|
||||||||
|
Separate account liabilities (5)
|
—
|
|
16
|
|
7
|
|
23
|
|
||||||||
|
Total liabilities
|
$
|
15
|
|
$
|
8,870
|
|
$
|
6,047
|
|
$
|
14,932
|
|
||||
__________________
|
(1)
|
FVO securities at both March 31, 2017 and December 31, 2016 were comprised of over 90% FVO contractholder-directed unit-linked investments, with the remainder comprised of FVO general account securities and FVO securities held by CSEs.
|
|
(2)
|
Short-term investments as presented in the tables above differ from the amounts presented on the consolidated balance sheets because certain short-term investments are not measured at estimated fair value on a recurring basis.
|
|
(3)
|
Derivative assets are presented within other invested assets on the consolidated balance sheets and derivative liabilities are presented within other liabilities on the consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables.
|
51
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
|
(4)
|
Embedded derivatives within asset host contracts are presented within premiums, reinsurance and other receivables and other invested assets on the consolidated balance sheets. Embedded derivatives within liability host contracts are presented within policyholder account balances, future policy benefits and other liabilities on the consolidated balance sheets. At
March 31, 2017
and
December 31, 2016
, debt and equity securities also included embedded derivatives of
($206) million
and
($137) million
, respectively.
|
|
(5)
|
Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities. Separate account liabilities are set equal to the estimated fair value of separate account assets. Separate account liabilities presented in the tables above represent derivative liabilities.
|
The following describes the valuation methodologies used to measure assets and liabilities at fair value. The description includes the valuation techniques and key inputs for each category of assets or liabilities that are classified within Level 2 and Level 3 of the fair value hierarchy.
Investments
Valuation Controls and Procedures
On behalf of the Company’s Chief Investment Officer and Chief Financial Officer, a pricing and valuation committee that is independent of the trading and investing functions and comprised of senior management, provides oversight of control systems and valuation policies for securities, mortgage loans and derivatives. On a quarterly basis, this committee reviews and approves new transaction types and markets, ensures that observable market prices and market-based parameters are used for valuation, wherever possible, and determines that judgmental valuation adjustments, when applied, are based upon established policies and are applied consistently over time. This committee also provides oversight of the selection of independent third-party pricing providers and the controls and procedures to evaluate third-party pricing. Periodically, the Chief Accounting Officer reports to the Audit Committee of MetLife, Inc.’s Board of Directors regarding compliance with fair value accounting standards.
The Company reviews its valuation methodologies on an ongoing basis and revises those methodologies when necessary based on changing market conditions. Assurance is gained on the overall reasonableness and consistent application of input assumptions, valuation methodologies and compliance with fair value accounting standards through controls designed to ensure valuations represent an exit price. Several controls are utilized, including certain monthly controls, which include, but are not limited to, analysis of portfolio returns to corresponding benchmark returns, comparing a sample of executed prices of securities sold to the fair value estimates, comparing fair value estimates to management’s knowledge of the current market, reviewing the bid/ask spreads to assess activity, comparing prices from multiple independent pricing services and ongoing due diligence to confirm that independent pricing services use market-based parameters. The process includes a determination of the observability of inputs used in estimated fair values received from independent pricing services or brokers by assessing whether these inputs can be corroborated by observable market data. The Company ensures that prices received from independent brokers, also referred to herein as “consensus pricing,” represent a reasonable estimate of fair value by considering such pricing relative to the Company’s knowledge of the current market dynamics and current pricing for similar financial instruments. While independent non-binding broker quotations are utilized, they are not used for a significant portion of the portfolio. For example, fixed maturity securities priced using independent non-binding broker quotations represent less than
1%
of the total estimated fair value of fixed maturity securities and
7%
of the total estimated fair value of Level 3 fixed maturity securities at
March 31, 2017
.
The Company also applies a formal process to challenge any prices received from independent pricing services that are not considered representative of estimated fair value. If prices received from independent pricing services are not considered reflective of market activity or representative of estimated fair value, independent non-binding broker quotations are obtained, or an internally developed valuation is prepared. Internally developed valuations of current estimated fair value, which reflect internal estimates of liquidity and nonperformance risks, compared with pricing received from the independent pricing services, did not produce material differences in the estimated fair values for the majority of the portfolio; accordingly, overrides were not material. This is, in part, because internal estimates of liquidity and nonperformance risks are generally based on available market evidence and estimates used by other market participants. In the absence of such market-based evidence, management’s best estimate is used.
52
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
Securities, Short-term Investments and Other Investments
When available, the estimated fair value of these financial instruments is based on quoted prices in active markets that are readily and regularly obtainable. Generally, these are the most liquid of the Company’s securities holdings and valuation of these securities does not involve management’s judgment.
When quoted prices in active markets are not available, the determination of estimated fair value is based on market standard valuation methodologies, giving priority to observable inputs. The significant inputs to the market standard valuation methodologies for certain types of securities with reasonable levels of price transparency are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. When observable inputs are not available, the market standard valuation methodologies rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs can be based in large part on management’s judgment or estimation and cannot be supported by reference to market activity. Even though these inputs are unobservable, management believes they are consistent with what other market participants would use when pricing such securities and are considered appropriate given the circumstances.
The estimated fair value of investments in certain separate accounts included in FVO contractholder-directed unit-linked investments, FVO securities held by CSEs and other investments is determined on a basis consistent with the methodologies described herein for securities.
The valuation of most instruments listed below is determined using independent pricing sources, matrix pricing, discounted cash flow methodologies or other similar techniques that use either observable market inputs or unobservable inputs.
53
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
|
Instrument
|
Level 2
Observable Inputs
|
Level 3
Unobservable Inputs
|
|||
|
Fixed Maturity Securities
|
|||||
|
U.S. corporate and Foreign corporate securities
|
|||||
|
Valuation Approaches: Principally the market and income approaches.
|
Valuation Approaches: Principally the market approach.
|
||||
|
Key Inputs:
|
Key Inputs:
|
||||
|
•
|
quoted prices in markets that are not active
|
•
|
illiquidity premium
|
||
|
•
|
benchmark yields; spreads off benchmark yields; new issuances; issuer rating
|
•
|
delta spread adjustments to reflect specific credit-related issues
|
||
|
•
|
trades of identical or comparable securities; duration
|
•
|
credit spreads
|
||
|
•
|
Privately-placed securities are valued using the additional key inputs:
|
•
|
quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
|
||
|
•
|
market yield curve; call provisions
|
||||
|
•
|
observable prices and spreads for similar public or private securities that incorporate the credit quality and industry sector of the issuer
|
•
|
independent non-binding broker quotations
|
||
|
•
|
delta spread adjustments to reflect specific credit-related issues
|
||||
|
U.S. government and agency, Foreign government and State and political subdivision securities
|
|||||
|
Valuation Approaches: Principally the market approach.
|
Valuation Approaches: Principally the market approach.
|
||||
|
Key Inputs:
|
Key Inputs:
|
||||
|
•
|
quoted prices in markets that are not active
|
•
|
independent non-binding broker quotations
|
||
|
•
|
benchmark U.S. Treasury yield or other yields
|
•
|
quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
|
||
|
•
|
the spread off the U.S. Treasury yield curve for the identical security
|
||||
|
•
|
issuer ratings and issuer spreads; broker-dealer quotes
|
•
|
credit spreads
|
||
|
•
|
comparable securities that are actively traded
|
||||
|
Structured Securities
|
|||||
|
Valuation Approaches: Principally the market and income approaches.
|
Valuation Approaches: Principally the market and income approaches.
|
||||
|
Key Inputs:
|
Key Inputs:
|
||||
|
•
|
quoted prices in markets that are not active
|
•
|
credit spreads
|
||
|
•
|
spreads for actively traded securities; spreads off benchmark yields
|
•
|
quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
|
||
|
•
|
expected prepayment speeds and volumes
|
||||
|
•
|
current and forecasted loss severity; ratings; geographic region
|
•
|
independent non-binding broker quotations
|
||
|
•
|
weighted average coupon and weighted average maturity
|
||||
|
•
|
average delinquency rates; debt-service coverage ratios
|
||||
|
•
|
issuance-specific information, including, but not limited to:
|
||||
|
•
|
collateral type; structure of the security; vintage of the loans
|
||||
|
•
|
payment terms of the underlying assets
|
||||
|
•
|
payment priority within the tranche; deal performance
|
||||
54
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
|
Instrument
|
Level 2
Observable Inputs
|
Level 3
Unobservable Inputs
|
|||
|
Equity Securities
|
|||||
|
Valuation Approaches: Principally the market approach.
|
Valuation Approaches: Principally the market and income approaches.
|
||||
|
Key Input:
|
Key Inputs:
|
||||
|
•
|
quoted prices in markets that are not considered active
|
•
|
credit ratings; issuance structures
|
||
|
•
|
quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2
|
||||
|
•
|
independent non-binding broker quotations
|
||||
|
FVO securities, Short-term investments, and Other investments
|
|||||
|
•
|
Contractholder-directed unit-linked investments include mutual fund interests without readily determinable fair values given prices are not published publicly. Valuation of these mutual funds is based upon quoted prices or reported net asset value (“NAV”) provided by the fund managers, which were based on observable inputs.
|
•
|
FVO securities and short-term investments are of a similar nature and class to the fixed maturity and equity securities described above; accordingly, the valuation approaches and unobservable inputs used in their valuation are also similar to those described above.
|
||
|
•
|
All other investments are of a similar nature and class to the fixed maturity and equity securities described above; accordingly, the valuation approaches and observable inputs used in their valuation are also similar to those described above.
|
||||
|
Mortgage Loans — FVO
|
|||||
|
Residential mortgage loans — FVO
|
|||||
|
•
|
N/A
|
Valuation Approaches: Principally the market approach.
|
|||
|
Valuation Techniques: Matrix pricing or other similar techniques.
|
|||||
|
Key Inputs: Inputs that are unobservable or cannot be derived principally from, or corroborated by, observable market data
|
|||||
|
Commercial mortgage loans held by CSEs — FVO
|
|||||
|
Valuation Approaches: Principally the market approach.
|
•
|
N/A
|
|||
|
Key Input:
|
|||||
|
•
|
quoted securitization market price determined principally by independent pricing services using observable inputs
|
||||
|
Separate Account Assets and Separate Account Liabilities (1)
|
|||||
|
Mutual funds and hedge funds without readily determinable fair values as prices are not published publicly
|
|||||
|
Key Input:
|
•
|
N/A
|
|||
|
•
|
quoted prices or reported NAV provided by the fund managers
|
||||
|
Other limited partnership interests
|
|||||
|
•
|
N/A
|
•
|
Valued giving consideration to the underlying holdings of the partnerships and by applying a premium or discount, if appropriate.
|
||
|
Key Inputs:
|
|||||
|
•
|
liquidity; bid/ask spreads; performance record of the fund manager
|
||||
|
•
|
other relevant variables that may impact the exit value of the particular partnership interest
|
||||
__________________
|
(1)
|
Estimated fair value equals carrying value, based on the value of the underlying assets, including: mutual fund interests, fixed maturity securities, equity securities, derivatives, hedge funds, other limited partnership interests, short-term investments and cash and cash equivalents. Fixed maturity securities, equity securities, derivatives, short-term investments and cash and cash equivalents are similar in nature to the instruments described under “— Securities, Short-term Investments and Other Investments” and “— Derivatives — Freestanding Derivatives.”
|
55
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
Derivatives
The estimated fair value of derivatives is determined through the use of quoted market prices for exchange-traded derivatives, or through the use of pricing models for OTC-bilateral and OTC-cleared derivatives. The determination of estimated fair value, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments. Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity and changes in estimates and assumptions used in the pricing models. The valuation controls and procedures for derivatives are described in “— Investments.”
The significant inputs to the pricing models for most OTC-bilateral and OTC-cleared derivatives are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. Certain OTC-bilateral and OTC-cleared derivatives may rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs may involve significant management judgment or estimation. Even though unobservable, these inputs are based on assumptions deemed appropriate given the circumstances and management believes they are consistent with what other market participants would use when pricing such instruments.
Most inputs for OTC-bilateral and OTC-cleared derivatives are mid-market inputs but, in certain cases, liquidity adjustments are made when they are deemed more representative of exit value. Market liquidity, as well as the use of different methodologies, assumptions and inputs, may have a material effect on the estimated fair values of the Company’s derivatives and could materially affect net income.
The credit risk of both the counterparty and the Company are considered in determining the estimated fair value for all OTC-bilateral and OTC-cleared derivatives, and any potential credit adjustment is based on the net exposure by counterparty after taking into account the effects of netting agreements and collateral arrangements. The Company values its OTC-bilateral and OTC-cleared derivatives using standard swap curves which may include a spread to the risk-free rate, depending upon specific collateral arrangements. This credit spread is appropriate for those parties that execute trades at pricing levels consistent with similar collateral arrangements. As the Company and its significant derivative counterparties generally execute trades at such pricing levels and hold sufficient collateral, additional credit risk adjustments are not currently required in the valuation process. The Company’s ability to consistently execute at such pricing levels is in part due to the netting agreements and collateral arrangements that are in place with all of its significant derivative counterparties. An evaluation of the requirement to make additional credit risk adjustments is performed by the Company each reporting period.
Freestanding Derivatives
Level 2 Valuation Approaches and Key Inputs:
This level includes all types of derivatives utilized by the Company with the exception of exchange-traded derivatives included within Level 1 and those derivatives with unobservable inputs as described in Level 3.
Level 3 Valuation Approaches and Key Inputs:
These valuation methodologies generally use the same inputs as described in the corresponding sections for Level 2 measurements of derivatives. However, these derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data.
56
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
Freestanding derivatives are principally valued using the income approach. Valuations of non-option-based derivatives utilize present value techniques, whereas valuations of option-based derivatives utilize option pricing models. Key inputs are as follows:
|
Instrument
|
Interest Rate
|
Foreign Currency
Exchange Rate
|
Credit
|
Equity Market
|
||||
|
Inputs common to Level 2 and Level 3 by instrument type
|
•
|
swap yield curves
|
•
|
swap yield curves
|
•
|
swap yield curves
|
•
|
swap yield curves
|
|
•
|
basis curves
|
•
|
basis curves
|
•
|
credit curves
|
•
|
spot equity index levels
|
|
|
•
|
interest rate volatility (1)
|
•
|
currency spot rates
|
•
|
recovery rates
|
•
|
dividend yield curves
|
|
|
•
|
cross currency basis curves
|
•
|
equity volatility (1)
|
|||||
|
•
|
currency volatility (1)
|
|||||||
|
Level 3
|
•
|
swap yield curves (2)
|
•
|
swap yield curves (2)
|
•
|
swap yield curves (2)
|
•
|
dividend yield curves (2)
|
|
•
|
basis curves (2)
|
•
|
basis curves (2)
|
•
|
credit curves (2)
|
•
|
equity volatility (1), (2)
|
|
|
•
|
interest rate volatility (1), (2)
|
•
|
cross currency basis curves (2)
|
•
|
credit spreads
|
•
|
correlation between model inputs (1)
|
|
|
•
|
repurchase rates
|
•
|
currency correlation
|
•
|
repurchase rates
|
|||
|
•
|
currency volatility (1)
|
•
|
independent non-binding broker quotations
|
|||||
__________________
|
(1)
|
Option-based only.
|
|
(2)
|
Extrapolation beyond the observable limits of the curve(s).
|
Embedded Derivatives
Embedded derivatives principally include certain direct, assumed and ceded variable annuity guarantees, equity or bond indexed crediting rates within certain funding agreements and annuity contracts, and those related to funds withheld on ceded reinsurance agreements. Embedded derivatives are recorded at estimated fair value with changes in estimated fair value reported in net income.
The Company issues certain variable annuity products with guaranteed minimum benefits. GMWBs, GMABs and certain GMIBs contain embedded derivatives, which are measured at estimated fair value separately from the host variable annuity contract, with changes in estimated fair value reported in net derivative gains (losses). These embedded derivatives are classified within policyholder account balances and future policy benefits on the consolidated balance sheets.
The Company’s actuarial department calculates the fair value of these embedded derivatives, which are estimated as the present value of projected future benefits minus the present value of projected future fees using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, and is performed using standard actuarial valuation software which projects future cash flows from the embedded derivative over multiple risk neutral stochastic scenarios using observable risk-free rates.
Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience.
The valuation of these guarantee liabilities includes nonperformance risk adjustments and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc.
57
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions as annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees. These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions including, but not limited to, changes in interest rates, equity indices, market volatility and foreign currency exchange rates; changes in nonperformance risk; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, may result in significant fluctuations in the estimated fair value of the guarantees that could materially affect net income.
The Company ceded the risk associated with certain of the GMIBs previously described. These reinsurance agreements contain embedded derivatives which are included within premiums, reinsurance and other receivables on the consolidated balance sheets with changes in estimated fair value reported in net derivative gains (losses) or policyholder benefits and claims depending on the statement of operations classification of the direct risk. The value of the embedded derivatives on the ceded risk is determined using a methodology consistent with that described previously for the guarantees directly written by the Company with the exception of the input for nonperformance risk that reflects the credit of the reinsurer.
The estimated fair value of the embedded derivatives within funds withheld related to certain ceded reinsurance is determined based on the change in estimated fair value of the underlying assets held by the Company in a reference portfolio backing the funds withheld liability. The estimated fair value of the underlying assets is determined as previously described in “— Investments — Securities, Short-term Investments and Other Investments.” The estimated fair value of these embedded derivatives is included, along with their funds withheld hosts, in other liabilities on the consolidated balance sheets with changes in estimated fair value recorded in net derivative gains (losses). Changes in the credit spreads on the underlying assets, interest rates and market volatility may result in significant fluctuations in the estimated fair value of these embedded derivatives that could materially affect net income.
The estimated fair value of the embedded equity and bond indexed derivatives contained in certain funding agreements is determined using market standard swap valuation models and observable market inputs, including a nonperformance risk adjustment. The estimated fair value of these embedded derivatives are included, along with their funding agreements host, within policyholder account balances with changes in estimated fair value recorded in net derivative gains (losses). Changes in equity and bond indices, interest rates and the Company’s credit standing may result in significant fluctuations in the estimated fair value of these embedded derivatives that could materially affect net income.
The Company issues certain annuity contracts which allow the policyholder to participate in returns from equity indices. These equity indexed features are embedded derivatives which are measured at estimated fair value separately from the host fixed annuity contract, with changes in estimated fair value reported in net derivative gains (losses). These embedded derivatives are classified within policyholder account balances on the consolidated balance sheets.
The estimated fair value of the embedded equity indexed derivatives, based on the present value of future equity returns to the policyholder using actuarial and present value assumptions including expectations concerning policyholder behavior, is calculated by the Company’s actuarial department. The calculation is based on in-force business and uses standard capital market techniques, such as Black-Scholes, to calculate the value of the portion of the embedded derivative for which the terms are set. The portion of the embedded derivative covering the period beyond where terms are set is calculated as the present value of amounts expected to be spent to provide equity indexed returns in those periods. The valuation of these embedded derivatives also includes the establishment of a risk margin, as well as changes in nonperformance risk.
58
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
Embedded Derivatives Within Asset and Liability Host Contracts
Level 3 Valuation Approaches and Key Inputs:
Direct and assumed guaranteed minimum benefits
These embedded derivatives are principally valued using the income approach. Valuations are based on option pricing techniques, which utilize significant inputs that may include swap yield curves, currency exchange rates and implied volatilities. These embedded derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. Significant unobservable inputs generally include: the extrapolation beyond observable limits of the swap yield curves and implied volatilities, actuarial assumptions for policyholder behavior and mortality and the potential variability in policyholder behavior and mortality, nonperformance risk and cost of capital for purposes of calculating the risk margin.
Reinsurance ceded on certain guaranteed minimum benefits
These embedded derivatives are principally valued using the income approach. The valuation techniques and significant market standard unobservable inputs used in their valuation are similar to those described above in “— Direct and assumed guaranteed minimum benefits” and also include counterparty credit spreads.
Transfers between Levels
Overall, transfers between levels occur when there are changes in the observability of inputs and market activity. Transfers into or out of any level are assumed to occur at the beginning of the period.
Transfers between Levels 1 and 2:
Transfers between Levels 1 and 2 for assets and liabilities measured at estimated fair value and still held at
March 31, 2017
and
December 31, 2016
were not significant.
Transfers into or out of Level 3:
Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable.
59
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
Assets and Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)
The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at:
|
March 31, 2017
|
December 31, 2016
|
Impact of
Increase in Input on Estimated Fair Value (2) |
|||||||||||||||||
|
Valuation
Techniques |
Significant
Unobservable Inputs |
Range
|
Weighted
Average (1) |
Range
|
Weighted
Average (1) |
||||||||||||||
|
Fixed maturity securities (3)
|
|||||||||||||||||||
|
U.S. corporate and foreign corporate
|
•
|
Matrix pricing
|
•
|
Offered quotes (4)
|
18
|
-
|
144
|
107
|
18
|
-
|
138
|
105
|
Increase
|
||||||
|
•
|
Market pricing
|
•
|
Quoted prices (4)
|
13
|
-
|
627
|
120
|
6
|
-
|
700
|
114
|
Increase
|
|||||||
|
•
|
Consensus pricing
|
•
|
Offered quotes (4)
|
86
|
-
|
119
|
101
|
37
|
-
|
120
|
99
|
Increase
|
|||||||
|
Foreign government
|
•
|
Market pricing
|
•
|
Quoted prices (4)
|
41
|
-
|
132
|
110
|
98
|
-
|
124
|
104
|
Increase
|
||||||
|
RMBS
|
•
|
Market pricing
|
•
|
Quoted prices (4)
|
19
|
-
|
163
|
92
|
19
|
-
|
137
|
91
|
Increase (5)
|
||||||
|
ABS
|
•
|
Market pricing
|
•
|
Quoted prices (4)
|
5
|
-
|
106
|
100
|
5
|
-
|
106
|
99
|
Increase (5)
|
||||||
|
•
|
Consensus pricing
|
•
|
Offered quotes (4)
|
96
|
-
|
102
|
100
|
96
|
-
|
102
|
100
|
Increase (5)
|
|||||||
|
Derivatives
|
|
||||||||||||||||||
|
Interest rate
|
•
|
Present value techniques
|
•
|
Swap yield (6)
|
200
|
-
|
300
|
200
|
-
|
300
|
Increase (7)
|
||||||||
|
•
|
Repurchase rates (8)
|
(14)
|
-
|
15
|
(44)
|
18
|
Decrease (7)
|
||||||||||||
|
Foreign currency exchange rate
|
•
|
Present value techniques
|
•
|
Swap yield (6)
|
(21)
|
-
|
309
|
50
|
-
|
328
|
Increase (7)
|
||||||||
|
Credit
|
•
|
Present value techniques
|
•
|
Credit spreads (9)
|
97
|
-
|
98
|
97
|
-
|
98
|
Decrease (7)
|
||||||||
|
•
|
Consensus pricing
|
•
|
Offered quotes (10)
|
|
|||||||||||||||
|
Equity market
|
•
|
Present value techniques or option pricing models
|
•
|
Volatility (11)
|
9%
|
-
|
33%
|
12%
|
-
|
32%
|
Increase (7)
|
||||||||
|
•
|
Correlation (12)
|
70%
|
-
|
70%
|
40%
|
-
|
40%
|
||||||||||||
|
Embedded derivatives
|
|||||||||||||||||||
|
Direct, assumed and ceded guaranteed minimum benefits
|
•
|
Option pricing techniques
|
•
|
Mortality rates:
|
|||||||||||||||
|
Ages 0 - 40
|
0%
|
-
|
0.21%
|
0%
|
-
|
0.21%
|
Decrease (13)
|
||||||||||||
|
Ages 41 - 60
|
0.01%
|
-
|
0.78%
|
0.01%
|
-
|
0.78%
|
Decrease (13)
|
||||||||||||
|
Ages 61 - 115
|
0.04%
|
-
|
100%
|
0.04%
|
-
|
100%
|
Decrease (13)
|
||||||||||||
|
•
|
Lapse rates:
|
||||||||||||||||||
|
Durations 1 - 10
|
0.25%
|
-
|
100%
|
0.25%
|
-
|
100%
|
Decrease (14)
|
||||||||||||
|
Durations 11 - 20
|
2%
|
-
|
100%
|
2%
|
-
|
100%
|
Decrease (14)
|
||||||||||||
|
Durations 21 - 116
|
1.25%
|
-
|
100%
|
1.25%
|
-
|
100%
|
Decrease (14)
|
||||||||||||
|
•
|
Utilization rates
|
0%
|
-
|
25%
|
0%
|
-
|
25%
|
Increase (15)
|
|||||||||||
|
•
|
Withdrawal rates
|
0%
|
-
|
20%
|
0%
|
-
|
20%
|
(16)
|
|||||||||||
|
•
|
Long-term equity volatilities
|
9.10%
|
-
|
33%
|
9.95%
|
-
|
33%
|
Increase (17)
|
|||||||||||
|
•
|
Nonperformance risk spread
|
0.04%
|
-
|
1.64%
|
0.04%
|
-
|
1.70%
|
Decrease (18)
|
|||||||||||
__________________
|
(1)
|
The weighted average for fixed maturity securities is determined based on the estimated fair value of the securities.
|
|
(2)
|
The impact of a decrease in input would have the opposite impact on estimated fair value. For embedded derivatives, changes to direct and assumed guaranteed minimum benefits are based on liability positions; changes to ceded guaranteed minimum benefits are based on asset positions.
|
|
(3)
|
Significant increases (decreases) in expected default rates in isolation would result in substantially lower (higher) valuations.
|
|
(4)
|
Range and weighted average are presented in accordance with the market convention for fixed maturity securities of dollars per hundred dollars of par.
|
|
(5)
|
Changes in the assumptions used for the probability of default is accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates.
|
60
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
|
(6)
|
Ranges represent the rates across different yield curves and are presented in basis points. The swap yield curves are utilized among different types of derivatives to project cash flows, as well as to discount future cash flows to present value. Since this valuation methodology uses a range of inputs across a yield curve to value the derivative, presenting a range is more representative of the unobservable input used in the valuation.
|
|
(7)
|
Changes in estimated fair value are based on long U.S. dollar net asset positions and will be inversely impacted for short U.S. dollar net asset positions.
|
|
(8)
|
Ranges represent different repurchase rates utilized as components within the valuation methodology and are presented in basis points.
|
|
(9)
|
Represents the risk quoted in basis points of a credit default event on the underlying instrument. Credit derivatives with significant unobservable inputs are primarily comprised of written credit default swaps.
|
|
(10)
|
At both
March 31, 2017
and
December 31, 2016
, independent non-binding broker quotations were used in the determination of less than
1%
of the total net derivative estimated fair value.
|
|
(11)
|
Ranges represent the underlying equity volatility quoted in percentage points. Since this valuation methodology uses a range of inputs across multiple volatility surfaces to value the derivative, presenting a range is more representative of the unobservable input used in the valuation.
|
|
(12)
|
Ranges represent the different correlation factors utilized as components within the valuation methodology. Presenting a range of correlation factors is more representative of the unobservable input used in the valuation. Increases (decreases) in correlation in isolation will increase (decrease) the significance of the change in valuations.
|
|
(13)
|
Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative.
|
|
(14)
|
Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative.
|
|
(15)
|
The utilization rate assumption estimates the percentage of contractholders with a GMIB or lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative.
|
|
(16)
|
The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative. For GMWBs, any increase (decrease) in withdrawal rates results in an increase (decrease) in the estimated fair value of the guarantees. For GMABs and GMIBs, any increase (decrease) in withdrawal rates results in a decrease (increase) in the estimated fair value.
|
|
(17)
|
Long-term equity volatilities represent equity volatility beyond the period for which observable equity volatilities are available. For any given contract, long-term equity volatility rates vary throughout the period over which cash flows are projected for purposes of valuing the embedded derivative.
|
|
(18)
|
Nonperformance risk spread varies by duration and by currency. For any given contract, multiple nonperformance risk spreads will apply, depending on the duration of the cash flow being discounted for purposes of valuing the embedded derivative.
|
61
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
The following is a summary of the valuation techniques and significant unobservable inputs used in the fair value measurement of assets and liabilities classified within Level 3 that are not included in the preceding table. Generally, all other classes of securities classified within Level 3, including those within separate account assets, and embedded derivatives within funds withheld related to certain ceded reinsurance, use the same valuation techniques and significant unobservable inputs as previously described for Level 3 securities. This includes matrix pricing and discounted cash flow methodologies, inputs such as quoted prices for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2, as well as independent non-binding broker quotations. The residential mortgage loans — FVO are valued using independent non-binding broker quotations and internal models including matrix pricing and discounted cash flow methodologies using current interest rates. The sensitivity of the estimated fair value to changes in the significant unobservable inputs for these other assets and liabilities is similar in nature to that described in the preceding table. The valuation techniques and significant unobservable inputs used in the fair value measurement for the more significant assets measured at estimated fair value on a nonrecurring basis and determined using significant unobservable inputs (Level 3) are summarized in “— Nonrecurring Fair Value Measurements.”
The following tables summarize the change of all assets and (liabilities) measured at estimated fair value on a recurring basis using significant unobservable inputs (Level 3):
|
Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
|
||||||||||||||||||||||||||||
|
Fixed Maturity Securities
|
||||||||||||||||||||||||||||
|
Corporate (1)
|
U.S.
Government
and Agency
|
Foreign
Government |
Structured
Securities
|
State and
Political Subdivision |
Equity
Securities
|
FVO
Securities (2)
|
||||||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||||
|
Three Months Ended March 31, 2017
|
||||||||||||||||||||||||||||
|
Balance, beginning of period
|
$
|
13,927
|
|
$
|
—
|
|
$
|
290
|
|
$
|
6,865
|
|
$
|
27
|
|
$
|
604
|
|
$
|
287
|
|
|||||||
|
Total realized/unrealized gains (losses) included in net income (loss) (3), (4)
|
—
|
|
—
|
|
3
|
|
35
|
|
—
|
|
(11
|
)
|
7
|
|
||||||||||||||
|
Total realized/unrealized gains (losses) included in AOCI
|
345
|
|
—
|
|
6
|
|
63
|
|
—
|
|
24
|
|
—
|
|
||||||||||||||
|
Purchases (5)
|
1,063
|
|
—
|
|
12
|
|
1,071
|
|
—
|
|
5
|
|
69
|
|
||||||||||||||
|
Sales (5)
|
(476
|
)
|
—
|
|
(18
|
)
|
(499
|
)
|
—
|
|
—
|
|
(17
|
)
|
||||||||||||||
|
Issuances (5)
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
||||||||||||||
|
Settlements (5)
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
||||||||||||||
|
Transfers into Level 3 (6)
|
80
|
|
—
|
|
4
|
|
34
|
|
—
|
|
—
|
|
2
|
|
||||||||||||||
|
Transfers out of Level 3 (6)
|
(1,568
|
)
|
—
|
|
(8
|
)
|
(276
|
)
|
(20
|
)
|
—
|
|
(13
|
)
|
||||||||||||||
|
Balance, end of period
|
$
|
13,371
|
|
$
|
—
|
|
$
|
289
|
|
$
|
7,293
|
|
$
|
7
|
|
$
|
622
|
|
$
|
335
|
|
|||||||
|
Three Months Ended March 31, 2016
|
||||||||||||||||||||||||||||
|
Balance, beginning of period
|
$
|
12,796
|
|
$
|
—
|
|
$
|
856
|
|
$
|
7,116
|
|
$
|
46
|
|
$
|
432
|
|
$
|
270
|
|
|||||||
|
Total realized/unrealized gains (losses) included in net income (loss) (3), (4)
|
(33
|
)
|
—
|
|
8
|
|
31
|
|
—
|
|
(26
|
)
|
8
|
|
||||||||||||||
|
Total realized/unrealized gains (losses) included in AOCI
|
510
|
|
11
|
|
(22
|
)
|
(46
|
)
|
—
|
|
43
|
|
—
|
|
||||||||||||||
|
Purchases (5)
|
668
|
|
—
|
|
19
|
|
937
|
|
—
|
|
5
|
|
19
|
|
||||||||||||||
|
Sales (5)
|
(272
|
)
|
—
|
|
(17
|
)
|
(373
|
)
|
—
|
|
(1
|
)
|
(11
|
)
|
||||||||||||||
|
Issuances (5)
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
||||||||||||||
|
Settlements (5)
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
||||||||||||||
|
Transfers into Level 3 (6)
|
461
|
|
200
|
|
47
|
|
11
|
|
—
|
|
464
|
|
25
|
|
||||||||||||||
|
Transfers out of Level 3 (6)
|
(1,338
|
)
|
—
|
|
(179
|
)
|
(1,024
|
)
|
(10
|
)
|
(248
|
)
|
(62
|
)
|
||||||||||||||
|
Balance, end of period
|
$
|
12,792
|
|
$
|
211
|
|
$
|
712
|
|
$
|
6,652
|
|
$
|
36
|
|
$
|
669
|
|
$
|
249
|
|
|||||||
|
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at March 31, 2017 (7)
|
$
|
6
|
|
$
|
—
|
|
$
|
2
|
|
$
|
28
|
|
$
|
—
|
|
$
|
(11
|
)
|
$
|
7
|
|
|||||||
|
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at March 31, 2016 (7)
|
$
|
(31
|
)
|
$
|
—
|
|
$
|
8
|
|
$
|
30
|
|
$
|
—
|
|
$
|
(26
|
)
|
$
|
8
|
|
|||||||
62
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
|
Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
|
||||||||||||||||||||
|
Short-term
Investments
|
Residential
Mortgage
Loans — FVO |
Net
Derivatives (8)
|
Net Embedded
Derivatives (9)
|
Separate
Accounts (10) |
||||||||||||||||
|
(In millions)
|
||||||||||||||||||||
|
Three Months Ended March 31, 2017
|
||||||||||||||||||||
|
Balance, beginning of period
|
$
|
47
|
|
$
|
566
|
|
$
|
(1,516
|
)
|
$
|
(3,725
|
)
|
$
|
1,152
|
|
|||||
|
Total realized/unrealized gains (losses) included in net income (loss) (3), (4)
|
—
|
|
(3
|
)
|
23
|
|
588
|
|
(24
|
)
|
||||||||||
|
Total realized/unrealized gains (losses) included in AOCI
|
—
|
|
—
|
|
44
|
|
(60
|
)
|
—
|
|
||||||||||
|
Purchases (5)
|
777
|
|
135
|
|
—
|
|
—
|
|
136
|
|
||||||||||
|
Sales (5)
|
(3
|
)
|
(33
|
)
|
—
|
|
—
|
|
(43
|
)
|
||||||||||
|
Issuances (5)
|
—
|
|
—
|
|
(7
|
)
|
—
|
|
39
|
|
||||||||||
|
Settlements (5)
|
—
|
|
(26
|
)
|
169
|
|
(214
|
)
|
(33
|
)
|
||||||||||
|
Transfers into Level 3 (6)
|
—
|
|
—
|
|
—
|
|
—
|
|
74
|
|
||||||||||
|
Transfers out of Level 3 (6)
|
(41
|
)
|
—
|
|
—
|
|
—
|
|
(102
|
)
|
||||||||||
|
Balance, end of period
|
$
|
780
|
|
$
|
639
|
|
$
|
(1,287
|
)
|
$
|
(3,411
|
)
|
$
|
1,199
|
|
|||||
|
Three Months Ended March 31, 2016
|
||||||||||||||||||||
|
Balance, beginning of period
|
$
|
291
|
|
$
|
314
|
|
$
|
(411
|
)
|
$
|
(544
|
)
|
$
|
1,704
|
|
|||||
|
Total realized/unrealized gains (losses) included in net income (loss) (3), (4)
|
1
|
|
10
|
|
67
|
|
(1,111
|
)
|
32
|
|
||||||||||
|
Total realized/unrealized gains (losses) included in AOCI
|
2
|
|
—
|
|
9
|
|
(75
|
)
|
—
|
|
||||||||||
|
Purchases (5)
|
108
|
|
80
|
|
8
|
|
—
|
|
55
|
|
||||||||||
|
Sales (5)
|
(248
|
)
|
(5
|
)
|
—
|
|
—
|
|
(201
|
)
|
||||||||||
|
Issuances (5)
|
—
|
|
—
|
|
(1
|
)
|
—
|
|
—
|
|
||||||||||
|
Settlements (5)
|
—
|
|
(7
|
)
|
(10
|
)
|
(209
|
)
|
—
|
|
||||||||||
|
Transfers into Level 3 (6)
|
18
|
|
—
|
|
—
|
|
—
|
|
—
|
|
||||||||||
|
Transfers out of Level 3 (6)
|
(2
|
)
|
—
|
|
—
|
|
—
|
|
(124
|
)
|
||||||||||
|
Balance, end of period
|
$
|
170
|
|
$
|
392
|
|
$
|
(338
|
)
|
$
|
(1,939
|
)
|
$
|
1,466
|
|
|||||
|
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at March 31, 2017 (7)
|
$
|
—
|
|
$
|
(3
|
)
|
$
|
14
|
|
$
|
598
|
|
$
|
—
|
|
|||||
|
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at March 31, 2016 (7)
|
$
|
1
|
|
$
|
10
|
|
$
|
50
|
|
$
|
(1,114
|
)
|
$
|
—
|
|
|||||
__________________
|
(1)
|
Comprised of U.S. and foreign corporate securities.
|
|
(2)
|
Comprised of FVO contractholder-directed unit-linked investments, FVO general account securities and FVO general account securities held by CSEs.
|
|
(3)
|
Amortization of premium/accretion of discount is included within net investment income. Impairments charged to net income (loss) on securities are included in net investment gains (losses), while changes in estimated fair value of residential mortgage loans — FVO are included in net investment income. Lapses associated with net embedded derivatives are included in net derivative gains (losses). Substantially all realized/unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivatives gains (losses).
|
|
(4)
|
Interest and dividend accruals, as well as cash interest coupons and dividends received, are excluded from the rollforward.
|
|
(5)
|
Items purchased/issued and then sold/settled in the same period are excluded from the rollforward. Fees attributed to embedded derivatives are included in settlements.
|
|
(6)
|
Gains and losses, in net income (loss) and OCI, are calculated assuming transfers into and/or out of Level 3 occurred at the beginning of the period. Items transferred into and then out of Level 3 in the same period are excluded from the rollforward.
|
63
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
|
(7)
|
Changes in unrealized gains (losses) included in net income (loss) relate to assets and liabilities still held at the end of the respective periods. Substantially all changes in unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses).
|
|
(8)
|
Freestanding derivative assets and liabilities are presented net for purposes of the rollforward.
|
|
(9)
|
Embedded derivative assets and liabilities are presented net for purposes of the rollforward.
|
|
(10)
|
Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders within separate account liabilities. Therefore, such changes in estimated fair value are not recorded in net income (loss). For the purpose of this disclosure, these changes are presented within net investment gains (losses). Separate account assets and liabilities are presented net for the purposes of the rollforward.
|
Fair Value Option
T
he following table presents information for certain assets accounted for under the FVO.
|
Residential Mortgage
Loans — FVO |
Certain Assets
of CSEs — FVO (1) |
|||||||||||||||
|
March 31, 2017
|
December 31, 2016
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||
|
(In millions)
|
||||||||||||||||
|
Assets
|
||||||||||||||||
|
Unpaid principal balance
|
$
|
883
|
|
$
|
794
|
|
$
|
81
|
|
$
|
88
|
|
||||
|
Difference between estimated fair value and unpaid principal balance
|
(244
|
)
|
(228
|
)
|
48
|
|
48
|
|
||||||||
|
Carrying value at estimated fair value
|
$
|
639
|
|
$
|
566
|
|
$
|
129
|
|
$
|
136
|
|
||||
|
Loans in nonaccrual status
|
$
|
232
|
|
$
|
214
|
|
$
|
—
|
|
$
|
—
|
|
||||
|
Loans more than 90 days past due
|
$
|
144
|
|
$
|
137
|
|
$
|
—
|
|
$
|
—
|
|
||||
|
Loans in nonaccrual status or more than 90 days past due, or both — difference between aggregate estimated fair value and unpaid principal balance
|
$
|
(162
|
)
|
$
|
(150
|
)
|
$
|
—
|
|
$
|
—
|
|
||||
__________________
|
(1)
|
These assets are comprised of commercial mortgage loans. Changes in estimated fair value on these assets and gains or losses on sales of these assets are recognized in net investment gains (losses). Interest income on commercial mortgage loans held by CSEs — FVO is recognized in net investment income.
|
64
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
Nonrecurring Fair Value Measurements
The following table presents information for assets measured at estimated fair value on a nonrecurring basis during the periods and still held at the reporting dates (for example, when there is evidence of impairment). The estimated fair values for these assets were determined using significant unobservable inputs (Level 3).
|
At
March 31, |
Three Months
Ended March 31, |
|||||||||||||||
|
2017
|
2016
|
2017
|
2016
|
|||||||||||||
|
Carrying Value After Measurement
|
Gains (Losses)
|
|||||||||||||||
|
(In millions)
|
||||||||||||||||
|
Mortgage loans (1)
|
$
|
12
|
|
$
|
99
|
|
$
|
—
|
|
$
|
(58
|
)
|
||||
|
Other limited partnership interests (2)
|
$
|
43
|
|
$
|
39
|
|
$
|
(12
|
)
|
$
|
(20
|
)
|
||||
|
Other assets (3)
|
$
|
—
|
|
$
|
—
|
|
$
|
(3
|
)
|
$
|
(14
|
)
|
||||
__________________
|
(1)
|
Estimated fair values for impaired mortgage loans are based on independent broker quotations or valuation models using unobservable inputs or, if the loans are in foreclosure or are otherwise determined to be collateral dependent, are based on the estimated fair value of the underlying collateral or the present value of the expected future cash flows.
|
|
(2)
|
For these cost method investments, estimated fair value is determined from information provided on the financial statements of the underlying entities including NAV data. These investments include private equity and debt funds that typically invest primarily in various strategies including domestic and international leveraged buyout funds; power, energy, timber and infrastructure development funds; venture capital funds; and below investment grade debt and mezzanine debt funds. Distributions will be generated from investment gains, from operating income from the underlying investments of the funds and from liquidation of the underlying assets of the funds. It is estimated that the underlying assets of the funds will be liquidated over the next
two
to
10 years
. Unfunded commitments for these investments at both
March 31, 2017
and
2016
were not significant.
|
|
(3)
|
During the three months ended March 31, 2016, the Company recognized an impairment of computer software in connection with the sale to Massachusetts Mutual Life Insurance Company (“MassMutual”). See Note
3
of the Notes to the Consolidated Financial Statements included in the 2016 Annual Report.
|
Fair Value of Financial Instruments Carried at Other Than Fair Value
The following tables provide fair value information for financial instruments that are carried on the balance sheet at amounts other than fair value. These tables exclude the following financial instruments: cash and cash equivalents, accrued investment income, payables for collateral under securities loaned and other transactions, short-term debt and those short-term investments that are not securities, such as time deposits, and therefore are not included in the three level hierarchy table disclosed in the “— Recurring Fair Value Measurements” section. The estimated fair value of the excluded financial instruments, which are primarily classified in Level 2, approximates carrying value as they are short-term in nature such that the Company believes there is minimal risk of material changes in interest rates or credit quality. All remaining balance sheet amounts excluded from the tables below are not considered financial instruments subject to this disclosure.
65
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
The carrying values and estimated fair values for such financial instruments, and their corresponding placement in the fair value hierarchy, are summarized as follows at:
|
March 31, 2017
|
||||||||||||||||||||
|
Fair Value Hierarchy
|
|
|||||||||||||||||||
|
Carrying
Value |
Level 1
|
Level 2
|
Level 3
|
Total
Estimated Fair Value |
||||||||||||||||
|
(In millions)
|
||||||||||||||||||||
|
Assets
|
||||||||||||||||||||
|
Mortgage loans
|
$
|
75,773
|
|
$
|
—
|
|
$
|
—
|
|
$
|
77,336
|
|
$
|
77,336
|
|
|||||
|
Policy loans
|
$
|
11,115
|
|
$
|
—
|
|
$
|
1,115
|
|
$
|
12,029
|
|
$
|
13,144
|
|
|||||
|
Real estate joint ventures
|
$
|
8
|
|
$
|
—
|
|
$
|
—
|
|
$
|
58
|
|
$
|
58
|
|
|||||
|
Other limited partnership interests
|
$
|
350
|
|
$
|
—
|
|
$
|
—
|
|
$
|
344
|
|
$
|
344
|
|
|||||
|
Other invested assets
|
$
|
553
|
|
$
|
168
|
|
$
|
—
|
|
$
|
385
|
|
$
|
553
|
|
|||||
|
Premiums, reinsurance and other receivables
|
$
|
4,302
|
|
$
|
—
|
|
$
|
1,167
|
|
$
|
3,239
|
|
$
|
4,406
|
|
|||||
|
Other assets
|
$
|
277
|
|
$
|
—
|
|
$
|
196
|
|
$
|
113
|
|
$
|
309
|
|
|||||
|
Liabilities
|
||||||||||||||||||||
|
Policyholder account balances
|
$
|
127,320
|
|
$
|
—
|
|
$
|
—
|
|
$
|
130,441
|
|
$
|
130,441
|
|
|||||
|
Long-term debt
|
$
|
16,472
|
|
$
|
—
|
|
$
|
18,125
|
|
$
|
—
|
|
$
|
18,125
|
|
|||||
|
Collateral financing arrangements
|
$
|
4,059
|
|
$
|
—
|
|
$
|
—
|
|
$
|
3,775
|
|
$
|
3,775
|
|
|||||
|
Junior subordinated debt securities
|
$
|
3,169
|
|
$
|
—
|
|
$
|
4,041
|
|
$
|
—
|
|
$
|
4,041
|
|
|||||
|
Other liabilities
|
$
|
3,171
|
|
$
|
—
|
|
$
|
2,641
|
|
$
|
530
|
|
$
|
3,171
|
|
|||||
|
Separate account liabilities
|
$
|
123,872
|
|
$
|
—
|
|
$
|
123,872
|
|
$
|
—
|
|
$
|
123,872
|
|
|||||
|
December 31, 2016
|
||||||||||||||||||||
|
Fair Value Hierarchy
|
||||||||||||||||||||
|
Carrying
Value |
Level 1
|
Level 2
|
Level 3
|
Total
Estimated Fair Value |
||||||||||||||||
|
(In millions)
|
||||||||||||||||||||
|
Assets
|
||||||||||||||||||||
|
Mortgage loans
|
$
|
73,843
|
|
$
|
—
|
|
$
|
—
|
|
$
|
75,129
|
|
$
|
75,129
|
|
|||||
|
Policy loans
|
$
|
11,028
|
|
$
|
—
|
|
$
|
1,115
|
|
$
|
11,900
|
|
$
|
13,015
|
|
|||||
|
Real estate joint ventures
|
$
|
17
|
|
$
|
—
|
|
$
|
—
|
|
$
|
69
|
|
$
|
69
|
|
|||||
|
Other limited partnership interests
|
$
|
384
|
|
$
|
—
|
|
$
|
—
|
|
$
|
413
|
|
$
|
413
|
|
|||||
|
Other invested assets
|
$
|
506
|
|
$
|
145
|
|
$
|
—
|
|
$
|
360
|
|
$
|
505
|
|
|||||
|
Premiums, reinsurance and other receivables
|
$
|
5,140
|
|
$
|
—
|
|
$
|
1,982
|
|
$
|
3,179
|
|
$
|
5,161
|
|
|||||
|
Other assets
|
$
|
237
|
|
$
|
—
|
|
$
|
198
|
|
$
|
71
|
|
$
|
269
|
|
|||||
|
Liabilities
|
||||||||||||||||||||
|
Policyholder account balances
|
$
|
124,475
|
|
$
|
—
|
|
$
|
—
|
|
$
|
127,833
|
|
$
|
127,833
|
|
|||||
|
Long-term debt
|
$
|
16,459
|
|
$
|
—
|
|
$
|
18,016
|
|
$
|
—
|
|
$
|
18,016
|
|
|||||
|
Collateral financing arrangements
|
$
|
4,071
|
|
$
|
—
|
|
$
|
—
|
|
$
|
3,775
|
|
$
|
3,775
|
|
|||||
|
Junior subordinated debt securities
|
$
|
3,169
|
|
$
|
—
|
|
$
|
3,982
|
|
$
|
—
|
|
$
|
3,982
|
|
|||||
|
Other liabilities
|
$
|
2,028
|
|
$
|
—
|
|
$
|
1,540
|
|
$
|
488
|
|
$
|
2,028
|
|
|||||
|
Separate account liabilities
|
$
|
119,498
|
|
$
|
—
|
|
$
|
119,498
|
|
$
|
—
|
|
$
|
119,498
|
|
|||||
66
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
The methods, assumptions and significant valuation techniques and inputs used to estimate the fair value of financial instruments are summarized as follows:
Mortgage Loans
The estimated fair value of mortgage loans is primarily determined by estimating expected future cash flows and discounting them using current interest rates for similar mortgage loans with similar credit risk, or is determined from pricing for similar loans.
Policy Loans
Policy loans with fixed interest rates are classified within Level 3. The estimated fair values for these loans are determined using a discounted cash flow model applied to groups of similar policy loans determined by the nature of the underlying insurance liabilities. Cash flow estimates are developed by applying a weighted-average interest rate to the outstanding principal balance of the respective group of policy loans and an estimated average maturity determined through experience studies of the past performance of policyholder repayment behavior for similar loans. These cash flows are discounted using current risk-free interest rates with no adjustment for borrower credit risk, as these loans are fully collateralized by the cash surrender value of the underlying insurance policy. Policy loans with variable interest rates are classified within Level 2 and the estimated fair value approximates carrying value due to the absence of borrower credit risk and the short time period between interest rate resets, which presents minimal risk of a material change in estimated fair value due to changes in market interest rates.
Real Estate Joint Ventures and Other Limited Partnership Interests
The estimated fair values of these cost method investments are generally based on the Company’s share of the NAV as provided on the financial statements of the investees. In certain circumstances, management may adjust the NAV by a premium or discount when it has sufficient evidence to support applying such adjustments.
Other Invested Assets
These other invested assets are principally comprised of various interest-bearing assets held in foreign subsidiaries and certain amounts due under contractual indemnifications. For the various interest-bearing assets held in foreign subsidiaries, the Company evaluates the specific facts and circumstances of each instrument to determine the appropriate estimated fair values. These estimated fair values were not materially different from the recognized carrying values.
Premiums, Reinsurance and Other Receivables
Premiums, reinsurance and other receivables are principally comprised of certain amounts recoverable under reinsurance agreements, amounts on deposit with financial institutions to facilitate daily settlements related to certain derivatives and amounts receivable for securities sold but not yet settled.
Amounts recoverable under ceded reinsurance agreements, which the Company has determined do not transfer significant risk such that they are accounted for using the deposit method of accounting, have been classified as Level 3. The valuation is based on discounted cash flow methodologies using significant unobservable inputs. The estimated fair value is determined using interest rates determined to reflect the appropriate credit standing of the assuming counterparty.
The amounts on deposit for derivative settlements, classified within Level 2, essentially represent the equivalent of demand deposit balances and amounts due for securities sold are generally received over short periods such that the estimated fair value approximates carrying value.
Other Assets
These other assets are principally comprised of a receivable for cash paid to an unaffiliated financial institution under the MetLife Reinsurance Company of Charleston (“MRC”) collateral financing arrangement described in Note 13 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report. The estimated fair value of the receivable for the cash paid to the unaffiliated financial institution under the MRC collateral financing arrangement is determined by discounting the expected future cash flows using a discount rate that reflects the credit rating of the unaffiliated financial institution.
67
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
7. Fair Value (continued)
Policyholder Account Balances
These policyholder account balances include investment contracts which primarily include certain funding agreements, fixed deferred annuities, modified guaranteed annuities, fixed term payout annuities and total control accounts (“TCA”). The valuation of these investment contracts is based on discounted cash flow methodologies using significant unobservable inputs. The estimated fair value is determined using current market risk-free interest rates adding a spread to reflect the nonperformance risk in the liability.
Long-term Debt, Collateral Financing Arrangements and Junior Subordinated Debt Securities
The estimated fair values of long-term debt, collateral financing arrangements and junior subordinated debt securities are principally determined using market standard valuation methodologies.
Valuations of instruments classified as Level 2 are based primarily on quoted prices in markets that are not active or using matrix pricing that use standard market observable inputs such as quoted prices in markets that are not active and observable yields and spreads in the market. Instruments valued using discounted cash flow methodologies use standard market observable inputs including market yield curve, duration, call provisions, observable prices and spreads for similar publicly traded or privately traded issues.
Valuations of instruments classified as Level 3 are based primarily on discounted cash flow methodologies that utilize unobservable discount rates that can vary significantly based upon the specific terms of each individual arrangement. The determination of estimated fair values of collateral financing arrangements incorporates valuations obtained from the counterparties to the arrangements, as part of the collateral management process.
Other Liabilities
Other liabilities consist primarily of interest payable, amounts due for securities purchased but not yet settled, and funds withheld amounts payable, which are contractually withheld by the Company in accordance with the terms of the reinsurance agreements. The Company evaluates the specific terms, facts and circumstances of each instrument to determine the appropriate estimated fair values, which are not materially different from the carrying values, with the exception of certain deposit type reinsurance payables. For such payables, the estimated fair value is determined as the present value of expected future cash flows, which are discounted using an interest rate determined to reflect the appropriate credit standing of the assuming counterparty.
Separate Account Liabilities
Separate account liabilities represent those balances due to policyholders under contracts that are classified as investment contracts.
Separate account liabilities classified as investment contracts primarily represent variable annuities with no significant mortality risk to the Company such that the death benefit is equal to the account balance, funding agreements related to group life contracts and certain contracts that provide for benefit funding.
Since separate account liabilities are fully funded by cash flows from the separate account assets which are recognized at estimated fair value as described in the section “— Recurring Fair Value Measurements,” the value of those assets approximates the estimated fair value of the related separate account liabilities. The valuation techniques and inputs for separate account liabilities are similar to those described for separate account assets.
68
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
8. Junior Subordinated Debt Securities
On February 10, 2017, MetLife, Inc. exchanged
$750 million
aggregate principal amount of its
9.250%
Fixed-to-Floating Rate Junior Subordinated Debentures due 2068 for
$750 million
aggregate liquidation preference of the
9.250%
Fixed-to-Floating Rate Exchangeable Surplus Trust Securities of MetLife Capital Trust X (the “Trust”).
As a result of the exchange, MetLife, Inc. became the sole beneficial owner of the Trust, a special purpose entity which issued the exchangeable surplus trust securities to third-party investors. On March 23, 2017, MetLife, Inc. dissolved the Trust.
9. Equity
Preferred Stock
Preferred stock authorized, issued and outstanding was as follows at both
March 31, 2017
and
December 31, 2016
:
|
Series
|
Shares
Authorized
|
Shares
Issued
|
Shares
Outstanding
|
||||||
|
Floating Rate Non-Cumulative Preferred Stock, Series A
|
27,600,000
|
|
24,000,000
|
|
24,000,000
|
|
|||
|
5.25% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series C
|
1,500,000
|
|
1,500,000
|
|
1,500,000
|
|
|||
|
Series A Junior Participating Preferred Stock
|
10,000,000
|
|
—
|
|
—
|
|
|||
|
Not designated
|
160,900,000
|
|
—
|
|
—
|
|
|||
|
Total
|
200,000,000
|
|
25,500,000
|
|
25,500,000
|
|
|||
Common Stock
During
the
three months ended
March 31, 2017
and
2016
, MetLife, Inc. repurchased
16,038,791
and
1,445,864
shares through open market purchases for
$858 million
and
$70 million
, respectively.
At
March 31, 2017
, MetLife, Inc. had
$1.8 billion
remaining under the common stock repurchase authorization. Common stock repurchases are dependent upon several factors, including the Company’s capital position, liquidity, financial strength and credit ratings, general market conditions, the market price of MetLife, Inc.’s common stock compared to management’s assessment of the stock’s underlying value and applicable regulatory approvals, as well as other legal and accounting factors.
Stock-Based Compensation Plans
Performance Shares and Performance Units
Awards under the MetLife, Inc. 2005 Stock and Incentive Compensation Plan and the MetLife, Inc. 2015 Stock and Incentive Compensation Plan (the “2015 Stock Plan”) were outstanding at
March 31, 2017
. All awards granted in 2015 or later were granted under the 2015 Stock Plan.
For Performance Share and Performance Unit awards outstanding as of
March 31, 2017
, any vested Performance Shares and Performance Units will be multiplied by a performance factor of
0%
to
175%
. Assuming that MetLife, Inc. has met threshold performance goals related to its adjusted income or total shareholder return, the MetLife, Inc. Compensation Committee will determine the performance factor in its discretion. In doing so, the Compensation Committee may consider MetLife, Inc.’s total shareholder return relative to the performance of its competitors and
operating return on MetLife, Inc.’s common stockholders’ equity relative to its financial plan. MetLife estimates the fair value of Performance Shares each quarter until they become payable.
Payout of 2014 – 2016 Performance Shares and Performance Units
Final Performance Shares are paid in shares of MetLife, Inc. common stock. Final Performance Units are payable in cash equal to the closing price of MetLife, Inc. common stock on a date following the last day of the three-year performance period. The performance factor for the January 1, 2014 – December 31, 2016 performance period was
44.4%
. This factor has been applied to the
1,066,076
Performance Shares and
165,587
Performance Units associated with that performance period that vested on
December 31, 2016
. As a result, in the first quarter of 2017, MetLife, Inc. issued
473,338
shares of its common stock (less withholding for taxes and other items, as applicable), excluding shares that payees choose to defer, and MetLife, Inc. or its affiliates paid the cash value of
73,521
Performance Units (less withholding for taxes and other items, as applicable).
69
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Equity (continued)
Accumulated Other Comprehensive Income (Loss)
Information regarding changes in the balances of each component of AOCI attributable to MetLife, Inc., was as follows:
|
Three Months
Ended March 31, 2017 |
||||||||||||||||||||
|
Unrealized
Investment Gains
(Losses), Net of
Related Offsets (1)
|
Unrealized
Gains (Losses)
on Derivatives
|
Foreign
Currency
Translation
Adjustments
|
Defined
Benefit
Plans
Adjustment
|
Total
|
||||||||||||||||
|
(In millions)
|
||||||||||||||||||||
|
Balance, beginning of period
|
$
|
10,766
|
|
$
|
1,865
|
|
$
|
(5,312
|
)
|
$
|
(1,972
|
)
|
$
|
5,347
|
|
|||||
|
OCI before reclassifications
|
733
|
|
210
|
|
348
|
|
(20
|
)
|
1,271
|
|
||||||||||
|
Deferred income tax benefit (expense)
|
(284
|
)
|
(73
|
)
|
122
|
|
2
|
|
(233
|
)
|
||||||||||
|
AOCI before reclassifications, net of income tax
|
11,215
|
|
2,002
|
|
(4,842
|
)
|
(1,990
|
)
|
6,385
|
|
||||||||||
|
Amounts reclassified from AOCI
|
196
|
|
(229
|
)
|
—
|
|
44
|
|
11
|
|
||||||||||
|
Deferred income tax benefit (expense)
|
(75
|
)
|
80
|
|
—
|
|
(5
|
)
|
—
|
|
||||||||||
|
Amounts reclassified from AOCI, net of income tax
|
121
|
|
(149
|
)
|
—
|
|
39
|
|
11
|
|
||||||||||
|
Balance, end of period
|
$
|
11,336
|
|
$
|
1,853
|
|
$
|
(4,842
|
)
|
$
|
(1,951
|
)
|
$
|
6,396
|
|
|||||
|
Three Months
Ended March 31, 2016 |
||||||||||||||||||||
|
Unrealized
Investment Gains
(Losses), Net of
Related Offsets (1)
|
Unrealized
Gains (Losses)
on Derivatives
|
Foreign
Currency
Translation
Adjustments
|
Defined
Benefit
Plans
Adjustment
|
Total
|
||||||||||||||||
|
(In millions)
|
||||||||||||||||||||
|
Balance, beginning of period
|
$
|
10,315
|
|
$
|
1,458
|
|
$
|
(4,950
|
)
|
$
|
(2,052
|
)
|
$
|
4,771
|
|
|||||
|
OCI before reclassifications
|
7,670
|
|
696
|
|
551
|
|
—
|
|
8,917
|
|
||||||||||
|
Deferred income tax benefit (expense)
|
(2,549
|
)
|
(199
|
)
|
117
|
|
—
|
|
(2,631
|
)
|
||||||||||
|
AOCI before reclassifications, net of income tax
|
15,436
|
|
1,955
|
|
(4,282
|
)
|
(2,052
|
)
|
11,057
|
|
||||||||||
|
Amounts reclassified from AOCI
|
17
|
|
(323
|
)
|
—
|
|
48
|
|
(258
|
)
|
||||||||||
|
Deferred income tax benefit (expense)
|
(7
|
)
|
93
|
|
—
|
|
(20
|
)
|
66
|
|
||||||||||
|
Amounts reclassified from AOCI, net of income tax
|
10
|
|
(230
|
)
|
—
|
|
28
|
|
(192
|
)
|
||||||||||
|
Balance, end of period
|
$
|
15,446
|
|
$
|
1,725
|
|
$
|
(4,282
|
)
|
$
|
(2,024
|
)
|
$
|
10,865
|
|
|||||
__________________
|
(1)
|
See Note
5
for information on offsets to investments related to future policy benefits, DAC, VOBA and DSI, and the policyholder dividend obligation.
|
70
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
9. Equity (continued)
Information regarding amounts reclassified out of each component of AOCI was as follows:
|
AOCI Components
|
Amounts Reclassified from AOCI
|
Consolidated Statements of
Operations and
Comprehensive Income (Loss)
Locations
|
||||||||
|
Three Months
Ended March 31, |
||||||||||
|
2017
|
2016
|
|||||||||
|
(In millions)
|
||||||||||
|
Net unrealized investment gains (losses):
|
||||||||||
|
Net unrealized investment gains (losses)
|
$
|
(8
|
)
|
$
|
(33
|
)
|
Net investment gains (losses)
|
|||
|
Net unrealized investment gains (losses)
|
7
|
|
3
|
|
Net investment income
|
|||||
|
Net unrealized investment gains (losses)
|
(195
|
)
|
13
|
|
Net derivative gains (losses)
|
|||||
|
Net unrealized investment gains (losses), before income tax
|
(196
|
)
|
(17
|
)
|
||||||
|
Income tax (expense) benefit
|
75
|
|
7
|
|
||||||
|
Net unrealized investment gains (losses), net of income tax
|
(121
|
)
|
(10
|
)
|
||||||
|
Unrealized gains (losses) on derivatives - cash flow hedges:
|
||||||||||
|
Interest rate swaps
|
8
|
|
10
|
|
Net derivative gains (losses)
|
|||||
|
Interest rate swaps
|
5
|
|
3
|
|
Net investment income
|
|||||
|
Interest rate forwards
|
(4
|
)
|
2
|
|
Net derivative gains (losses)
|
|||||
|
Interest rate forwards
|
1
|
|
1
|
|
Net investment income
|
|||||
|
Foreign currency swaps
|
218
|
|
306
|
|
Net derivative gains (losses)
|
|||||
|
Foreign currency swaps
|
1
|
|
1
|
|
Other expenses
|
|||||
|
Gains (losses) on cash flow hedges, before income tax
|
229
|
|
323
|
|
||||||
|
Income tax (expense) benefit
|
(80
|
)
|
(93
|
)
|
||||||
|
Gains (losses) on cash flow hedges, net of income tax
|
149
|
|
230
|
|
||||||
|
Defined benefit plans adjustment: (1)
|
||||||||||
|
Amortization of net actuarial gains (losses)
|
(49
|
)
|
(51
|
)
|
||||||
|
Amortization of prior service (costs) credit
|
5
|
|
3
|
|
||||||
|
Amortization of defined benefit plan items, before income tax
|
(44
|
)
|
(48
|
)
|
||||||
|
Income tax (expense) benefit
|
5
|
|
20
|
|
||||||
|
Amortization of defined benefit plan items, net of income tax
|
(39
|
)
|
(28
|
)
|
||||||
|
Total reclassifications, net of income tax
|
$
|
(11
|
)
|
$
|
192
|
|
||||
__________________
|
(1)
|
These AOCI components are included in the computation of net periodic benefit costs. See Note
11
.
|
71
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
10. Other Expenses
Information on other expenses was as follows:
|
Three Months
Ended March 31, |
||||||||
|
2017
|
2016
|
|||||||
|
(In millions)
|
||||||||
|
Compensation
|
$
|
1,189
|
|
$
|
1,310
|
|
||
|
Pension, postretirement and postemployment benefit costs
|
80
|
|
140
|
|
||||
|
Commissions
|
1,010
|
|
1,134
|
|
||||
|
Volume-related costs
|
198
|
|
266
|
|
||||
|
Capitalization of DAC
|
(796
|
)
|
(981
|
)
|
||||
|
Amortization of DAC and VOBA
|
533
|
|
995
|
|
||||
|
Amortization of negative VOBA
|
(43
|
)
|
(99
|
)
|
||||
|
Interest expense on debt
|
296
|
|
312
|
|
||||
|
Premium taxes, licenses and fees
|
188
|
|
215
|
|
||||
|
Professional services
|
387
|
|
330
|
|
||||
|
Rent and related expenses, net of sublease income
|
81
|
|
97
|
|
||||
|
Other
|
441
|
|
473
|
|
||||
|
Total other expenses
|
$
|
3,564
|
|
$
|
4,192
|
|
||
Restructuring Charges
The Company commenced in 2016 a unit cost improvement program related to the Company’s refreshed enterprise strategy. This global strategy focuses on transforming the Company to become more digital, driving efficiencies and innovation to achieve competitive advantage, and simplified, decreasing the costs and risks associated with the Company’s highly complex industry to customers and shareholders. Restructuring charges related to this program are included in other expenses. As the expenses relate to an enterprise-wide initiative, they are reported in Corporate & Other. Management anticipates further restructuring charges through the year ending December 31, 2019. However, such restructuring plans were not sufficiently developed to enable management to make an estimate of such restructuring charges at March 31, 2017. Such restructuring charges were as follows:
|
Three Months Ended March 31, 2017
|
|||
|
Severance
|
|||
|
(In millions)
|
|||
|
Balance, beginning of period
|
$
|
35
|
|
|
Restructuring charges
|
11
|
|
|
|
Cash payments
|
(8
|
)
|
|
|
Balance, end of period
|
$
|
38
|
|
|
Total restructuring charges incurred since inception of initiative
|
$
|
46
|
|
72
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
11. Employee Benefit Plans
Pension and Other Postretirement Benefit Plans
Certain subsidiaries of MetLife, Inc. sponsor and/or administer various U.S. qualified and nonqualified defined benefit pension plans and other postretirement employee benefit plans covering employees and sales representatives who meet specified eligibility requirements. These subsidiaries also provide certain postemployment benefits and certain postretirement medical and life insurance benefits for U.S. retired employees.
The components of net periodic benefit costs were as follows:
|
Three Months
Ended March 31, |
||||||||||||||||
|
2017
|
2016
|
|||||||||||||||
|
Pension
Benefits
|
Other
Postretirement
Benefits
|
Pension
Benefits
|
Other
Postretirement
Benefits
|
|||||||||||||
|
(In millions)
|
||||||||||||||||
|
Service costs
|
$
|
61
|
|
$
|
1
|
|
$
|
72
|
|
$
|
2
|
|
||||
|
Interest costs
|
108
|
|
19
|
|
111
|
|
21
|
|
||||||||
|
Curtailment costs (1)
|
—
|
|
—
|
|
—
|
|
30
|
|
||||||||
|
Expected return on plan assets
|
(132
|
)
|
(18
|
)
|
(127
|
)
|
(18
|
)
|
||||||||
|
Amortization of net actuarial (gains) losses
|
49
|
|
—
|
|
49
|
|
2
|
|
||||||||
|
Amortization of prior service costs (credit)
|
—
|
|
(5
|
)
|
—
|
|
(3
|
)
|
||||||||
|
Net periodic benefit costs (credit)
|
$
|
86
|
|
$
|
(3
|
)
|
$
|
105
|
|
$
|
34
|
|
||||
__________________
|
(1)
|
During the three months ended March 31, 2016, the Company recognized curtailment charges on certain postretirement benefit plans in connection with the sale to MassMutual. See Note 3 of the Notes to the Consolidated Financial Statements included in the 2016 Annual Report.
|
73
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
12. Earnings Per Common Share
The following table presents the weighted average shares, basic earnings per common share and diluted earnings per common share:
|
Three Months
Ended March 31, |
||||||||
|
2017
|
2016
|
|||||||
|
(In millions, except per share data)
|
||||||||
|
Weighted Average Shares:
|
||||||||
|
Weighted average common stock outstanding for basic earnings per common share
|
1,090.4
|
|
1,100.8
|
|
||||
|
Incremental common shares from assumed exercise or issuance of stock-based awards
|
8.3
|
|
7.8
|
|
||||
|
Weighted average common stock outstanding for diluted earnings per common share
|
1,098.7
|
|
1,108.6
|
|
||||
|
Net Income (Loss):
|
||||||||
|
Net income (loss)
|
$
|
829
|
|
$
|
2,203
|
|
||
|
Less: Net income (loss) attributable to noncontrolling interests
|
3
|
|
2
|
|
||||
|
Less: Preferred stock dividends
|
6
|
|
6
|
|
||||
|
Net income (loss) available to MetLife, Inc.’s common shareholders
|
$
|
820
|
|
$
|
2,195
|
|
||
|
Basic
|
$
|
0.75
|
|
$
|
1.99
|
|
||
|
Diluted
|
$
|
0.75
|
|
$
|
1.98
|
|
||
13. Contingencies, Commitments and Guarantees
Contingencies
Litigation
The Company is a defendant in a large number of litigation matters. In some of the matters, very large and/or indeterminate amounts, including punitive and treble damages, are sought. Modern pleading practice in the U.S. permits considerable variation in the assertion of monetary damages or other relief. Jurisdictions may permit claimants not to specify the monetary damages sought or may permit claimants to state only that the amount sought is sufficient to invoke the jurisdiction of the trial court. In addition, jurisdictions may permit plaintiffs to allege monetary damages in amounts well exceeding reasonably possible verdicts in the jurisdiction for similar matters. This variability in pleadings, together with the actual experience of the Company in litigating or resolving through settlement numerous claims over an extended period of time, demonstrates to management that the monetary relief which may be specified in a lawsuit or claim bears little relevance to its merits or disposition value.
Due to the vagaries of litigation, the outcome of a litigation matter and the amount or range of potential loss at particular points in time may normally be difficult to ascertain. Uncertainties can include how fact finders will evaluate documentary evidence and the credibility and effectiveness of witness testimony, and how trial and appellate courts will apply the law in the context of the pleadings or evidence presented, whether by motion practice, at trial or on appeal. Disposition valuations are also subject to the uncertainty of how opposing parties and their counsel will view the relevant evidence and applicable law.
The Company establishes liabilities for litigation and regulatory loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Liabilities have been established for a number of the matters noted below. It is possible that some of the matters could require the Company to pay damages or make other expenditures or establish accruals in amounts that could not be reasonably estimated at
March 31, 2017
. While the potential future charges could be material in the particular quarterly or annual periods in which they are recorded, based on information currently known to management, management does not believe any such charges are likely to have a material effect on the Company’s financial position.
Matters as to Which an Estimate Can Be Made
For some of the matters disclosed below, the Company is able to estimate a reasonably possible range of loss. For such matters where a loss is believed to be reasonably possible, but not probable, the Company has not made an accrual. As of
March 31, 2017
, the Company estimates the aggregate range of reasonably possible losses in excess of amounts accrued for these matters to be
$0
to
$400 million
.
74
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
13. Contingencies, Commitments and Guarantees (continued)
Matters as to Which an Estimate Cannot Be Made
For other matters disclosed below, the Company is not currently able to estimate the reasonably possible loss or range of loss. The Company is often unable to estimate the possible loss or range of loss until developments in such matters have provided sufficient information to support an assessment of the range of possible loss, such as quantification of a damage demand from plaintiffs, discovery from other parties and investigation of factual allegations, rulings by the court on motions or appeals, analysis by experts, and the progress of settlement negotiations. On a quarterly and annual basis, the Company reviews relevant information with respect to litigation contingencies and updates its accruals, disclosures and estimates of reasonably possible losses or ranges of loss based on such reviews.
Asbestos-Related Claims
MLIC is and has been a defendant in a large number of asbestos-related suits filed primarily in state courts. These suits principally allege that the plaintiff or plaintiffs suffered personal injury resulting from exposure to asbestos and seek both actual and punitive damages. MLIC has never engaged in the business of manufacturing, producing, distributing, or selling asbestos or asbestos-containing products nor has MLIC issued liability or workers’ compensation insurance to companies in the business of manufacturing, producing, distributing, or selling asbestos or asbestos-containing products. The lawsuits principally have focused on allegations with respect to certain research, publication and other activities of one or more of MLIC’s employees during the period from the 1920’s through approximately the 1950’s and allege that MLIC learned or should have learned of certain health risks posed by asbestos and, among other things, improperly publicized or failed to disclose those health risks. MLIC believes that it should not have legal liability in these cases. The outcome of most asbestos litigation matters, however, is uncertain and can be impacted by numerous variables, including differences in legal rulings in various jurisdictions, the nature of the alleged injury and factors unrelated to the ultimate legal merit of the claims asserted against MLIC. MLIC employs a number of resolution strategies to manage its asbestos loss exposure, including seeking resolution of pending litigation by judicial rulings and settling individual or groups of claims or lawsuits under appropriate circumstances.
Claims asserted against MLIC have included negligence, intentional tort and conspiracy concerning the health risks associated with asbestos. MLIC’s defenses (beyond denial of certain factual allegations) include that: (i) MLIC owed no duty to the plaintiffs— it had no special relationship with the plaintiffs and did not manufacture, produce, distribute, or sell the asbestos products that allegedly injured plaintiffs; (ii) plaintiffs did not rely on any actions of MLIC; (iii) MLIC’s conduct was not the cause of the plaintiffs’ injuries; (iv) plaintiffs’ exposure occurred after the dangers of asbestos were known; and (v) the applicable time with respect to filing suit has expired. During the course of the litigation, certain trial courts have granted motions dismissing claims against MLIC, while other trial courts have denied MLIC’s motions. There can be no assurance that MLIC will receive favorable decisions on motions in the future. While most cases brought to date have settled, MLIC intends to continue to defend aggressively against claims based on asbestos exposure, including defending claims at trials.
As reported in the
2016
Annual Report, MLIC received approximately
4,146
asbestos-related claims in
2016
. During the
three months ended
March 31, 2017
and
2016
, MLIC received approximately
1,104
and
1,386
new asbestos-related claims, respectively. See Note 21 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report for historical information concerning asbestos claims and MLIC’s increase in its recorded liability at December 31, 2014. The number of asbestos cases that may be brought, the aggregate amount of any liability that MLIC may incur, and the total amount paid in settlements in any given year are uncertain and may vary significantly from year to year.
The ability of MLIC to estimate its ultimate asbestos exposure is subject to considerable uncertainty, and the conditions impacting its liability can be dynamic and subject to change. The availability of reliable data is limited and it is difficult to predict the numerous variables that can affect liability estimates, including the number of future claims, the cost to resolve claims, the disease mix and severity of disease in pending and future claims, the impact of the number of new claims filed in a particular jurisdiction and variations in the law in the jurisdictions in which claims are filed, the possible impact of tort reform efforts, the willingness of courts to allow plaintiffs to pursue claims against MLIC when exposure to asbestos took place after the dangers of asbestos exposure were well known, and the impact of any possible future adverse verdicts and their amounts.
75
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
13. Contingencies, Commitments and Guarantees (continued)
The ability to make estimates regarding ultimate asbestos exposure declines significantly as the estimates relate to years further in the future. In the Company’s judgment, there is a future point after which losses cease to be probable and reasonably estimable. It is reasonably possible that the Company’s total exposure to asbestos claims may be materially greater than the asbestos liability currently accrued and that future charges to income may be necessary. While the potential future charges could be material in the particular quarterly or annual periods in which they are recorded, based on information currently known by management, management does not believe any such charges are likely to have a material effect on the Company’s financial position.
The Company believes adequate provision has been made in its consolidated financial statements for all probable and reasonably estimable losses for asbestos-related claims. MLIC’s recorded asbestos liability is based on its estimation of the following elements, as informed by the facts presently known to it, its understanding of current law and its past experiences: (i) the probable and reasonably estimable liability for asbestos claims already asserted against MLIC, including claims settled but not yet paid; (ii) the probable and reasonably estimable liability for asbestos claims not yet asserted against MLIC, but which MLIC believes are reasonably probable of assertion; and (iii) the legal defense costs associated with the foregoing claims. Significant assumptions underlying MLIC’s analysis of the adequacy of its recorded liability with respect to asbestos litigation include: (i) the number of future claims; (ii) the cost to resolve claims; and (iii) the cost to defend claims.
MLIC reevaluates on a quarterly and annual basis its exposure from asbestos litigation, including studying its claims experience, reviewing external literature regarding asbestos claims experience in the United States, assessing relevant trends impacting asbestos liability and considering numerous variables that can affect its asbestos liability exposure on an overall or per claim basis. These variables include bankruptcies of other companies involved in asbestos litigation, legislative and judicial developments, the number of pending claims involving serious disease, the number of new claims filed against it and other defendants and the jurisdictions in which claims are pending. Based upon its regular reevaluation of its exposure from asbestos litigation, MLIC has updated its liability analysis for asbestos-related claims through
March 31, 2017
.
Regulatory Matters
The Company receives and responds to subpoenas or other inquiries seeking a broad range of information from state regulators, including state insurance commissioners; state attorneys general or other state governmental authorities; federal regulators, including the SEC; federal governmental authorities, including congressional committees; and the Financial Industry Regulatory Authority (“FINRA”), as well as from local and national regulators and government authorities in countries outside the United States where MetLife conducts business. The issues involved in information requests and regulatory matters vary widely. The Company cooperates in these inquiries.
In the Matter of Chemform, Inc. Site, Pompano Beach, Broward County, Florida
In July 2010, the Environmental Protection Agency (“EPA”) advised MLIC that it believed payments were due under
two
settlement agreements, known as “Administrative Orders on Consent,” that New England Mutual Life Insurance Company (“New England Mutual”) signed in 1989 and 1992 with respect to the cleanup of a Superfund site in Florida (the “Chemform Site”). The EPA originally contacted MLIC (as successor to New England Mutual) and a third party in 2001, and advised that they owed additional clean-up costs for the Chemform Site. The matter was not resolved at that time. The EPA is requesting payment of an amount under
$1 million
from MLIC and such third party for past costs and an additional amount for future environmental testing costs at the Chemform Site. In September 2012, the EPA, MLIC and the third party executed an Administrative Order on Consent under which MLIC and the third party have agreed to be responsible for certain environmental testing at the Chemform Site. The Company estimates that its costs for the environmental testing will not exceed
$100 thousand
. The September 2012 Administrative Order on Consent does not resolve the EPA’s claim for past clean-up costs. The EPA may seek additional costs if the environmental testing identifies issues. The Company estimates that the aggregate cost to resolve this matter will not exceed
$1 million
.
76
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
13. Contingencies, Commitments and Guarantees (continued)
Sales Practices Regulatory Matters
Regulatory authorities in a number of states and FINRA, and occasionally the SEC, have had investigations or inquiries relating to sales of individual life insurance policies or annuities or other products by MLIC, MetLife USA, NELICO, General American Life Insurance Company, FMLI and broker-dealer, MetLife Securities, Inc. (“MSI”). These investigations often focus on the conduct of particular financial services representatives and the sale of unregistered or unsuitable products or the misuse of client assets. Over the past several years, these and a number of investigations by other regulatory authorities were resolved for monetary payments and certain other relief, including restitution payments. The Company may continue to resolve investigations in a similar manner. The Company believes adequate provision has been made in its consolidated financial statements for all probable and reasonably estimable losses for these sales practices-related investigations or inquiries.
Unclaimed Property Litigation
City of Westland Police and Fire Retirement System v. MetLife, Inc., et. al. (S.D.N.Y., filed January 12, 2012)
Seeking to represent a class of persons who purchased MetLife, Inc. common shares between February 2, 2010, and October 6, 2011, the plaintiff filed a third amended complaint alleging that MetLife, Inc. and several current and former directors and executive officers of MetLife, Inc. violated the Securities Act of 1933 (“Securities Act”), as well as the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by issuing, or causing MetLife, Inc. to issue, materially false and misleading statements concerning MetLife, Inc.’s potential liability for millions of dollars in insurance benefits that should have been paid to beneficiaries or escheated to the states. Plaintiff seeks unspecified compensatory damages and other relief. The defendants intend to defend this action vigorously.
City of Birmingham Retirement and Relief System v. MetLife, Inc., et al. (Circuit Court of Jefferson County, Alabama, filed July 5, 2012)
Seeking to represent a class of persons who purchased MetLife, Inc. common equity units in or traceable to a public offering in March 2011, the plaintiff filed an action alleging that MetLife, Inc., certain current and former directors and executive officers of MetLife, Inc., and various underwriters violated several provisions of the Securities Act related to the filing of the registration statement by issuing, or causing MetLife, Inc. to issue, materially false and misleading statements and/or omissions concerning MetLife, Inc.’s potential liability for millions of dollars in insurance benefits that should have been paid to beneficiaries or escheated to the states. Plaintiff seeks unspecified compensatory damages and other relief. In August 2016, the parties reached a mediated settlement under which MetLife, Inc. agreed to a certified class and to pay
$9.75 million
. On March 9, 2017, the court approved the settlement and dismissed the case with prejudice.
Total Control Accounts Litigation
MLIC is a defendant in a lawsuit related to its use of retained asset accounts, known as TCA, as a settlement option for death benefits.
Owens v. Metropolitan Life Insurance Company (N.D. Ga., filed April 17, 2014)
Plaintiff filed this putative class action lawsuit on behalf of all persons for whom MLIC established a retained asset account, known as a TCA, to pay death benefits under an Employee Retirement Income Security Act of 1974 (“ERISA”) plan. The action alleges that MLIC’s use of the TCA as the settlement option for life insurance benefits under some group life insurance policies violates MLIC’s fiduciary duties under ERISA. As damages, plaintiff seeks disgorgement of profits that MLIC realized on accounts owned by members of the putative class. On September 27, 2016, the court denied MLIC’s summary judgment motion in full and granted plaintiff’s partial summary judgment motion. The Company intends to defend this action vigorously.
77
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
13. Contingencies, Commitments and Guarantees (continued)
Diversified Lending Group Litigations
Hartshorne v. MetLife Inc., et al. (Los Angeles County Superior Court, filed March 25, 2015)
Plaintiffs named MetLife, Inc., MSI, and NELICO in
12
related lawsuits in California state court alleging various causes of action including multiple negligence and statutory claims relating to a Ponzi scheme involving the Diversified Lending Group. In August 2016, a trial of claims by one of the plaintiffs, Christine Ramirez, resulted in a verdict against MetLife, Inc., MSI, and NELICO for approximately
$200 thousand
in compensatory damages and
$15 million
in punitive damages. On November 30, 2016, Ramirez consented to the court’s reduction of punitive damages to approximately
$7 million
. These companies have filed a notice appealing this judgment to the Second Appellate District of the State of California. On May 2, 2017, the court awarded the plaintiff approximately
$6.5 million
in attorneys’ fees and costs. The Company intends to appeal this decision.
Other Litigation
Sun Life Assurance Company of Canada Indemnity Claim
In 2006, Sun Life Assurance Company of Canada (“Sun Life”), as successor to the purchaser of MLIC’s Canadian operations, filed a lawsuit in Toronto, seeking a declaration that MLIC remains liable for “market conduct claims” related to certain individual life insurance policies sold by MLIC that were subsequently transferred to Sun Life. In January 2010, the court found that Sun Life had given timely notice of its claim for indemnification but, because it found that Sun Life had not yet incurred an indemnifiable loss, granted MLIC’s motion for summary judgment. Both parties agreed to consider the indemnity claim through arbitration. In September 2010, Sun Life notified MLIC that a purported class action lawsuit was filed against Sun Life in Toronto alleging sales practices claims regarding the policies sold by MLIC and transferred to Sun Life. On August 30, 2011, Sun Life notified MLIC that another purported class action lawsuit was filed against Sun Life in Vancouver, BC alleging sales practices claims regarding certain of the same policies sold by MLIC and transferred to Sun Life. Sun Life contends that MLIC is obligated to indemnify Sun Life for some or all of the claims in these lawsuits. These sales practices cases against Sun Life are ongoing, and the Company is unable to estimate the reasonably possible loss or range of loss arising from this litigation.
MetLife, Inc. v. Financial Stability Oversight Council (D. D.C., January 13, 2015)
MetLife, Inc. filed this action in U.S. District Court for the District of Columbia (“D.C. District Court”) seeking to overturn the Financial Stability Oversight Council’s (“FSOC”) designation of MetLife, Inc. as a non-bank systemically important financial institution (“non-bank SIFI”). The suit is brought under the section of the Dodd-Frank Wall Street Reform and Consumer Protection Act providing that a company designated as a non-bank SIFI may petition the federal courts for review, and seeks an order requiring that the final determination be rescinded. The D.C. District Court issued a decision on March 30, 2016 granting, in part, MetLife, Inc.’s cross motion for summary judgment and rescinding the FSOC’s designation of MetLife, Inc. as a non-bank SIFI. On April 8, 2016, the FSOC appealed the D.C. District Court’s order to the United States Court of Appeals for the District of Columbia.
Voshall v. Metropolitan Life Insurance Company (Superior Court of the State of California, County of Los Angeles, April 8, 2015)
Plaintiff filed this putative class action lawsuit on behalf of himself and all persons covered under a long-term group disability income insurance policy issued by MLIC to public entities in California between April 8, 2011 and April 8, 2015. Plaintiff alleges that MLIC improperly reduced benefits by including cost of living adjustments and employee paid contributions in the employer retirement benefits and other income that reduces the benefit payable under such policies. Plaintiff asserts causes of action for declaratory relief, violation of the California Business & Professions Code, breach of contract and breach of the implied covenant of good faith and fair dealing. The Company intends to defend this action vigorously.
78
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
13. Contingencies, Commitments and Guarantees (continued)
Martin v. Metropolitan Life Insurance Company, (Superior Court of the State of California, County of Contra Costa, filed December 17, 2015)
Plaintiffs filed this putative class action lawsuit on behalf of themselves and all California persons who have been charged compound interest by MLIC in life insurance policy and/or premium loan balances within the last four years. Plaintiffs allege that MLIC has engaged in a pattern and practice of charging compound interest on life insurance policy and premium loans without the borrower authorizing such compounding, and that this constitutes an unlawful business practice under California law. Plaintiff asserts causes of action for declaratory relief, violation of California’s Unfair Competition Law and Usury Law, and unjust enrichment. Plaintiff seeks declaratory and injunctive relief, restitution of interest, and damages in an unspecified amount. On April 12, 2016, the court granted MLIC’s motion to dismiss. Plaintiffs have filed an appeal of this ruling.
Lau v. Metropolitan Life Insurance Company (S.D.N.Y. filed, December 3, 2015)
This putative class action lawsuit was filed by a single defined contribution plan participant on behalf of all ERISA plans whose assets were invested in MetLife’s “Group Annuity Contract Stable Value Funds” within the past six years. The suit alleges breaches of fiduciary duty under ERISA and challenges the “spread” with respect to the stable value fund group annuity products sold to retirement plans. The allegations focus on the methodology MetLife uses to establish and reset the crediting rate, the terms under which plan participants are permitted to transfer funds from a stable value option to another investment option, the procedures followed if an employer terminates a contract, and the level of disclosure provided. Plaintiff seeks declaratory and injunctive relief, as well as damages in an unspecified amount. The Company intends to defend this action vigorously.
Newman v. Metropolitan Life Insurance Company (N.D. Ill., filed March 23, 2016)
Plaintiff filed this putative class action alleging causes of action for breach of contract, fraud, and violations of the Illinois Consumer Fraud and Deceptive Business Practices Act, based on MLIC’s class-wide increase in premiums charged for long-term care insurance policies. Plaintiff alleges a class consisting of herself and all persons over age 65 who selected a Reduced Pay at Age 65 payment feature and whose premium rates were increased after age 65. Plaintiff asserts that premiums could not be increased for these class members and/or that marketing material was misleading as to MLIC’s right to increase premiums. Plaintiff seeks unspecified compensatory, statutory and punitive damages as well as recessionary and injunctive relief. On April 12, 2017, the court granted MLIC’s motion, dismissing the action with prejudice. On April 21, 2017, plaintiff appealed this ruling.
Miller, et al. v. MetLife Inc., et al. (C.D. Cal., filed April 7, 2017)
Plaintiff filed this putative class action against MetLife, Inc. and MLIC purporting to assert claims on behalf of all persons who replaced their MetLife Optional Term Life or Group Universal Life policy for a Group Variable Universal Life (GVUL) policy wherein MetLife allegedly charged smoker rates for certain non-smokers. Plaintiff seeks unspecified compensatory and punitive damages, as well as other relief. The Company intends to defend this action vigorously.
Sales Practices Claims
Over the past several years, the Company has faced numerous claims, including class action lawsuits, alleging improper marketing or sales of individual life insurance policies, annuities, mutual funds, other products or the misuse of client assets. Some of the current cases seek substantial damages, including punitive and treble damages and attorneys’ fees. The Company continues to defend vigorously against the claims in these matters. The Company believes adequate provision has been made in its consolidated financial statements for all probable and reasonably estimable losses for sales practices matters.
Summary
Putative or certified class action litigation and other litigation and claims and assessments against the Company, in addition to those discussed previously and those otherwise provided for in the Company’s consolidated financial statements, have arisen in the course of the Company’s business, including, but not limited to, in connection with its activities as an insurer, mortgage lending bank, employer, investor, investment advisor and taxpayer. Further, state insurance regulatory authorities and other federal and state authorities regularly make inquiries and conduct investigations concerning the Company’s compliance with applicable insurance and other laws and regulations.
79
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
13. Contingencies, Commitments and Guarantees (continued)
It is not possible to predict the ultimate outcome of all pending investigations and legal proceedings. In some of the matters referred to previously, very large and/or indeterminate amounts, including punitive and treble damages, are sought. Although in light of these considerations it is possible that an adverse outcome in certain cases could have a material effect upon the Company’s financial position, based on information currently known by the Company’s management, in its opinion, the outcomes of such pending investigations and legal proceedings are not likely to have such an effect. However, given the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation, it is possible that an adverse outcome in certain matters could, from time to time, have a material effect on the Company’s consolidated net income or cash flows in particular quarterly or annual periods.
Commitments
Mortgage Loan Commitments
The Company commits to lend funds under mortgage loan commitments. The amounts of these mortgage loan commitments were
$4.2 billion
and
$4.3 billion
at
March 31, 2017
and
December 31, 2016
, respectively.
Commitments to Fund Partnership Investments, Bank Credit Facilities, Bridge Loans and Private Corporate Bond Investments
The Company commits to fund partnership investments and to lend funds under bank credit facilities, bridge loans and private corporate bond investments. The amounts of these unfunded commitments were
$7.6 billion
and
$8.2 billion
at
March 31, 2017
and
December 31, 2016
, respectively.
Guarantees
In the normal course of its business, the Company has provided certain indemnities, guarantees and commitments to third parties such that it may be required to make payments now or in the future. In the context of acquisition, disposition, investment and other transactions, the Company has provided indemnities and guarantees, including those related to tax, environmental and other specific liabilities and other indemnities and guarantees that are triggered by, among other things, breaches of representations, warranties or covenants provided by the Company. In addition, in the normal course of business, the Company provides indemnifications to counterparties in contracts with triggers similar to the foregoing, as well as for certain other liabilities, such as third-party lawsuits. These obligations are often subject to time limitations that vary in duration, including contractual limitations and those that arise by operation of law, such as applicable statutes of limitation. In some cases, the maximum potential obligation under the indemnities and guarantees is subject to a contractual limitation ranging from less than
$1 million
to
$329 million
, with a cumulative maximum of
$981 million
, while in other cases such limitations are not specified or applicable. Since certain of these obligations are not subject to limitations, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future. Management believes that it is unlikely the Company will have to make any material payments under these indemnities, guarantees, or commitments.
In addition, the Company indemnifies its directors and officers as provided in its charters and by-laws. Also, the Company indemnifies its agents for liabilities incurred as a result of their representation of the Company’s interests. Since these indemnities are generally not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these indemnities in the future.
The Company has also minimum fund yield requirements on certain international pension funds in accordance with local laws. Since these guarantees are not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future.
The Company’s recorded liabilities were
$9 million
and
$10 million
at
March 31, 2017
and
December 31, 2016
, respectively, for indemnities, guarantees and commitments.
80
MetLife, Inc.
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited) — (continued)
14. Subsequent Events
Common Stock Repurchases
In the second quarter of 2017 through
April 28, 2017
, MetLife, Inc. repurchased
5,458,993
shares of its common stock in the open market for
$285 million
.
The Separation
On April 28, 2017, following receipt of applicable regulatory approvals, the Company completed the following financing transactions in connection with the Separation:
Collateral Financing Arrangement
MetLife, Inc. and MRSC terminated the collateral financing arrangement associated with secondary guarantees. As a result, the
$2.8 billion
collateral financing arrangement liability outstanding was extinguished utilizing
$2.8 billion
of assets held in trust, which had been repositioned into short-term investments and cash equivalents, with the remaining assets held in trust returned to MetLife, Inc. Total fees associated with the termination were
$37 million
, which will be expensed in the second quarter of 2017.
Committed Facilities
MetLife, Inc. and MetLife Reinsurance Company of Vermont terminated the
$4.3 billion
committed facility, and MetLife, Inc. and MRSC terminated the
$3.5 billion
committed facility. Total fees associated with the terminations were
$257 million
, which will be expensed in the second quarter of 2017.
Reinsurance Financing
Brighthouse Reinsurance Company of Delaware entered into a
$7.8 billion
financing arrangement supported by a pool o
f highly rated third-party reinsurers.
In connection with the foregoing transactions and the related mergers of certain captive reinsurance companies into Brighthouse Reinsurance Company of Delaware, MetLife, Inc. terminated various support arrangements with those non-surviving captive reinsurance companies.
Common Stock Dividend
On April 25, 2017, the MetLife, Inc. Board of Directors declared a second quarter 2017 common stock dividend of
$0.40
per share payable on June 13, 2017 to shareholders of record as of May 8, 2017. The Company estimates that the aggregate dividend payment will be
$432 million
.
81
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Index to Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
Page
|
|
82
Forward-Looking Statements and Other Financial Information
For purposes of this discussion, “MetLife,” the “Company,” “we,” “our” and “us” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. Following this summary is a discussion addressing the consolidated results of operations and financial condition of the Company for the periods indicated. This discussion should be read in conjunction with MetLife, Inc.’s Annual Report on Form 10-K for the year ended
December 31, 2016
(the “2016 Annual Report”), the cautionary language regarding forward-looking statements included below, the “Risk Factors” set forth in Part II, Item 1A, and the additional risk factors referred to therein, “Quantitative and Qualitative Disclosures About Market Risk” and the Company’s interim condensed consolidated financial statements included elsewhere herein.
This Management’s Discussion and Analysis of Financial Condition and Results of Operations may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning, or are tied to future periods, in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective services or products, future performance or results of current and anticipated services or products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, trends in operations and financial results. Any or all forward-looking statements may turn out to be wrong. Actual results could differ materially from those expressed or implied in the forward-looking statements. See “Note Regarding Forward-Looking Statements.”
This Management’s Discussion and Analysis of Financial Condition and Results of Operations includes references to our performance measures, operating earnings and operating earnings available to common shareholders, that are not based on accounting principles generally accepted in the United States of America (“GAAP”). These measures are used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, operating earnings is also our GAAP measure of segment performance. Operating earnings and other financial measures based on operating earnings are also the measures by which senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Operating earnings and other financial measures based on operating earnings allow analysis of our performance relative to our business plan and facilitate comparisons to industry results. Forward-looking guidance provided on a non-GAAP basis cannot be reconciled to the most directly comparable GAAP measures on a forward-looking basis because net income may fluctuate significantly if net investment gains and losses and net derivative gains and losses move outside of estimated ranges. See “— Non-GAAP and Other Financial Disclosures” for definitions and a discussion of these measures, and “— Results of Operations” for reconciliations of historical non-GAAP financial measures to the most directly comparable GAAP measures.
Executive Summary
Overview
MetLife is a global provider of life insurance, annuities, employee benefits and asset management. MetLife is organized into six segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa (“EMEA”); MetLife Holdings; and Brighthouse Financial. In addition, the Company reports certain of its results of operations in Corporate & Other. See “— Other Key Information — Segment Information” and Note
2
of the Notes to the Interim Condensed Consolidated Financial Statements for further information on the Company’s segments and Corporate & Other. Management continues to evaluate the Company’s segment performance and allocated resources and may adjust related measurements in the future to better reflect segment profitability.
Current Period Highlights
During the three months ended March 31, 2017, overall sales increased as compared to the three months ended March 31, 2016, reflecting improved sales from our segments abroad, as well as an increase in domestic sales of our Group Benefits and Retirement and Income Solutions products, partially offset by declines in our life and annuity products. In addition, investment yields were higher in response to improved equity market performance and positive net flows drove an increase in our investment portfolio.
83
The following represents segment level results and percentage contributions to total segment level operating earnings for the three months ended
March 31, 2017
:
__________________
|
(1)
|
Excludes Corporate & Other.
|
|
(2)
|
Consistent with GAAP guidance for segment reporting, operating earnings is our GAAP measure of segment performance.
See “— Non-GAAP and Other Financial Disclosures.”
|
84
Three Months Ended
March 31, 2017
Compared with the
Three Months Ended
March 31, 2016
|
Consolidated Results - Highlights
|
|||
|
Net income (loss) down $1.4 billion:
|
||||
|
•
|
Unfavorable change in net derivative gains (losses) of $2.3 billion ($1.5 billion, net of income tax) primarily driven by the impact of changes in interest rates. Asymmetrical and non-economic accounting also resulted from derivative losses on non-qualifying hedges, driven by changes in interest rates, foreign currencies and equity markets.
|
|||
|
•
|
Operating earnings available to common shareholders up $217 million
|
|||
|
(1) See “— Results of Operations — Consolidated Results” and “— Non-GAAP and Other Financial Disclosures” for reconciliations and definitions of non-GAAP financial measures.
|
||||
|
Consolidated Results - Operating Highlights
|
||||
|
Operating earnings available to common shareholders up $217 million:
|
||||
|
•
|
Results of operations impacted by: (i) higher net investment income due to yield and portfolio growth; (ii) a higher tax benefit; (iii) higher asset-based fees resulting from improved equity market performance; (iv) unfavorable refinements made to
deferred policy acquisition costs (“
DAC”) and certain insurance-related liabilities; and (v) unfavorable underwriting.
|
|||
|
•
|
Our results for the three months ended March 31, 2017 included the following:
|
|||
|
•
|
a $44 million, net of income tax, charge for expenses incurred related to a guaranty fund assessment for Penn Treaty Network America Insurance Company (“Penn Treaty”) and an increase in litigation reserves
|
|||
|
•
|
favorable reserve adjustments of $34 million, net of income tax, resulting from modeling improvements in the reserving process in certain of our life businesses
|
|||
|
•
|
a $21 million, net of income tax, increase in expenses associated with the Company’s previously announced unit cost initiative
|
|||
|
•
|
Our results for the three months ended March 31, 2016 included the following:
|
|||
|
•
|
tax benefit of $20 million related to a change in tax rates in Japan that pertains to periods prior to 2016
|
|||
|
•
|
tax charge in Chile of $10 million as a result of tax reform legislation that pertains to periods prior to 2016
|
|||
For a more in-depth discussion of our consolidated results, see “— Results of Operations — Consolidated Results” and “— Results of Operations — Consolidated Results — Operating.”
85
Consolidated Company Outlook
The proposed plan to separate a substantial portion of our former Retail segment, as well as certain portions of our former Corporate Benefit Funding segment and Corporate & Other (the “Separation”) and the completion of the sale to Massachusetts Mutual Life Insurance Company (“MassMutual”) of our U.S. retail advisor force and certain assets associated with the MetLife Premier Client Group, including all of the issued and outstanding shares of MetLife’s affiliated broker-dealer, MetLife Securities, Inc. (“MSI”), a wholly-owned subsidiary of MetLife, Inc. (the “U.S. Retail Advisor Force Divestiture”) evidence our commitment to Accelerating Value and our refreshed enterprise strategy, the center of which is still One MetLife. Digital and simplified are the key enablers of our strategic initiatives which include (i) optimizing value and risk by prioritizing businesses with high internal rates of return, lower capital intensity, and maximum cash generation, (ii) driving operational excellence, by becoming a high-performance operating company with a competitive cost structure, (iii) transforming our distribution channels to drive efficiency and productivity through digital enablement and improved customer persistency, and (iv) undertaking a targeted approach to find the right solutions for the right customers through the commitment to creating differentiated customer value propositions. This new enterprise strategy will enhance our ability to focus on the right markets, build clear differentiators, and continue to make the right investments to deliver shareholder value.
In 2017, we will focus on executing the Separation and making critical investments to drive efficiency. While this will put downward pressure on operating earnings in 2017, we expect post-Separation MetLife operating earnings to grow in 2018 driven by both business growth and expense discipline. Following the Separation, MetLife will also be significantly less sensitive to interest rates. Notably, the Separation will also make MetLife a more globally diversified company; we expect MetLife will generate over 40% of its operating earnings from outside the United States and that percentage should continue to grow over time.
We have engaged and expect to continue to engage in a number of Separation-related transactions that will impact our holding companies’ liquid assets. In 2016, we incurred $2.3 billion of Separation-related items which reduced our holding companies’ liquid assets, as well as our free cash flow. These Separation-related items consisted of Separation-related outflows comprised of an incremental capital contribution to Brighthouse Life Insurance Company (formerly, MetLife Insurance Company USA (“MetLife USA”)) (“Brighthouse Insurance”), capital contributions to Brighthouse subsidiaries and Separation-related costs, forgone subsidiary dividends from Brighthouse Insurance and forgone incremental debt at MetLife, Inc., net of Separation-related inflows comprised of incremental subsidiary dividends from New England Life Insurance Company (“NELICO”) and Brighthouse Insurance. However, we have increased and expect to continue to increase our holding companies’ liquid assets over time as a result of (i) $291 million in cash proceeds that we received in 2016 from the U.S. Retail Advisor Force Divestiture; (ii) dividends in the range of $3.3 billion to $3.8 billion that we expect to receive in 2017 from Brighthouse (which may be partially funded by the issuance of debt by Brighthouse) and a MetLife-affiliated reinsurance company prior to the Separation; and (iii) proceeds from the disposition of our retained shares of Brighthouse common stock that we expect to receive over time. In addition to these Separation-related items, we expect to have cash commitments of between $1.0 billion and $2.0 billion over the two-year period of 2017 and 2018 relating to liability management transactions, including the repayment of certain debt maturities. Following the Separation, we plan to maintain a liquidity buffer of $3.0 to $4.0 billion of liquid assets at the holding companies. See “Risk Factors — Risks Related to Acquisitions, Dispositions or Other Structural Changes — We May Not Complete the Separation of Brighthouse Financial on the Terms or Timeline Currently Contemplated, if at All” and “Risk Factors — Capital-Related Risks — Legal and Regulatory Restrictions and Uncertainty and Restrictions Under the Terms of Certain of Our Securities May Prevent Us from Repurchasing Our Stock and Paying Dividends at the Level We Wish” included in the 2016 Annual Report.
Assuming interest rates follow the observable forward yield curves as of December 31, 2016, we expect the average ratio of free cash flow to operating earnings over the two-year period of 2017 and 2018, excluding the impact of the Separation, to be 65% to 75%. This expectation reflects our unit cost improvement program and the related initiative to invest $1 billion by 2020 to generate $800 million pre-tax run rate annual savings, net of stranded overhead. We believe that free cash flow is a key determinant of dividends and share repurchases.
86
When making these and other projections, we must rely on the accuracy of our assumptions about future economic and business conditions, which can be affected by known and unknown risks and other uncertainties. Our assumptions have been and will continue to be impacted by (i) MetLife, Inc.’s plan to pursue the Separation, (ii) regulatory uncertainty regarding capital requirements that would have been applicable to MetLife, Inc. as a result of the Financial Stability Oversight Council’s (“FSOC”) former designation of MetLife, Inc. as a non-bank systemically important financial institution (“non-bank SIFI”), which, among other things, impacted the level of our share repurchases, (iii) lower investment margins (primarily in the United States) as a result of the sustained low interest rate environment, (iv) lower than anticipated merger and acquisition activity, and (v) the effect on our foreign operations of the strengthening of the U.S. dollar. See “— Other Key Information — Significant Events” for information regarding the Separation, U.S. Retail Advisor Force Divestiture, and the status of court proceedings relating to MetLife, Inc.’s challenge to the FSOC’s former designation of it as a non-bank SIFI.
Other Key Information
Segment Information
As previously announced, in the third quarter of 2016, the Company reorganized its businesses in anticipation of the proposed Separation. Prior period results have been revised in connection with the reorganization and did not have an impact on total consolidated net income or operating earnings. See
Note 2
of the Notes to the Interim Condensed Consolidated Financial Statements for further information on the Company’s segments.
Significant Events
On January 12, 2016, MetLife, Inc. announced its plan to pursue the Separation. MetLife, Inc. subsequently re-segmented the business to be separated and rebranded it as “Brighthouse Financial.”
On October 5, 2016, Brighthouse Financial, Inc., a subsidiary of MetLife, Inc. (“Brighthouse”), filed a registration statement on Form 10 (the “Form 10”) with the U.S. Securities and Exchange Commission (“SEC”). On December 6, 2016 and on April 18, 2017, Brighthouse filed amendments to its registration statement on Form 10 with the SEC. The information statement filed as an exhibit to the Form 10 disclosed that the Company intends to include Brighthouse Insurance, NELICO, Brighthouse Life Insurance Company of NY (formerly, First MetLife Investors Insurance Company) (“Brighthouse NY”), Brighthouse Investment Advisers, LLC (formerly, MetLife Advisers, LLC) and certain captive reinsurance companies in the proposed separated business and distribute at least 80.1% of the shares of Brighthouse’s common stock on a pro rata basis to the holders of MetLife, Inc. common stock.
Effective April 28, 2017, following receipt of applicable regulatory approvals, MetLife contributed certain captive reinsurance companies to Brighthouse Insurance, which were then merged into a newly-formed captive reinsurance company that is wholly-owned by Brighthouse Insurance. See Note 14 of the Notes to the Interim Condensed Consolidated Financial Statements for information on related financing arrangements.
The ultimate form and timing of the Separation will be influenced by a number of factors, including regulatory considerations and economic conditions. MetLife continues to evaluate and pursue structural alternatives for the proposed Separation. MetLife expects that the life insurance closed block and the life and annuity business sold through Metropolitan Life Insurance Company (“MLIC”) will not be a part of Brighthouse Financial. The Separation remains subject to certain conditions including, among others, obtaining final approval from the MetLife, Inc. Board of Directors, receipt of a favorable ruling from the Internal Revenue Service (“IRS”) and an opinion from MetLife’s tax advisor regarding certain U.S. federal income tax matters, insurance and other regulatory approvals, and an SEC declaration of the effectiveness of the Form 10.
In July 2016, MetLife, Inc. completed the U.S. Retail Advisor Force Divestiture for
$291 million
. MassMutual assumed all of the liabilities related to such assets that arise or occur at or after the closing of the sale. As part of the transactions, MetLife, Inc. and MassMutual entered into a product development agreement under which MetLife’s U.S. retail business will be the exclusive developer of certain annuity products to be issued by MassMutual. In the MassMutual purchase agreement, MetLife, Inc. agreed to indemnify MassMutual for certain claims, liabilities and breaches of representations and warranties up to limits described in the purchase agreement.
87
On December 18, 2014, the FSOC designated MetLife, Inc. as a non-bank SIFI subject to regulation by the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”) and the Federal Reserve Bank of New York (collectively with the Federal Reserve Board, the “Federal Reserve”) and the Federal Deposit Insurance Corporation (the “FDIC”), as well as to enhanced supervision and prudential standards. On March 30, 2016, the D.C. District Court ordered that the designation of MetLife, Inc. as a non-bank SIFI by the FSOC be rescinded. On April 8, 2016, the FSOC appealed the D.C. District Court’s order to the United States Court of Appeals for the District of Columbia, and oral argument was heard on October 24, 2016. In a Presidential Memorandum for the Secretary of the Treasury dated April 21, 2017, President Trump directed the Secretary of the Treasury to review the FSOC SIFI designation process for transparency, due process and other factors, and, pending the completion of the review and submission of the Secretary’s recommendations, to refrain from voting for any non-emergency designations. The Secretary’s review and report are due by October 18, 2017. On April 24, 2017, MetLife requested that the Court issue an order holding the appeal in abeyance pending the upcoming determination of the Secretary of the Treasury. If the FSOC prevails on appeal or designates MetLife, Inc. as systemically important as part of its ongoing review of non-bank financial companies, MetLife, Inc. could once again be subject to regulation as a non-bank SIFI. See “Business — Regulation — U.S. Regulation — Potential Regulation as a Non-Bank SIFI” included in the
2016
Annual Report.
Industry Trends
The following information on industry trends should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Industry Trends” in Part II, Item 7, of the
2016
Annual Report.
We continue to be impacted by the unstable global financial and economic environment that has been affecting the industry.
Financial and Economic Environment
Our business and results of operations are materially affected by conditions in the global capital markets and the economy generally. Stressed conditions, volatility and disruptions in global capital markets, particular markets, or financial asset classes can have an adverse effect on us, in part because we have a large investment portfolio and our insurance liabilities and derivatives are sensitive to changing market factors. See “Risk Factors — Economic Environment and Capital Markets-Related Risks — We Are Exposed to Significant Global Financial and Capital Markets Risks Which May Adversely Affect Our Results of Operations, Financial Condition and Liquidity, and May Cause Our Net Investment Income to Vary from Period to Period” in the 2016 Annual Report. The impact on global capital markets and the economy generally of the transition occurring in the United States government and the priorities of the Trump Administration is uncertain. See “Risk Factors — Economic Environment and Capital Markets-Related Risks — If Difficult Conditions in the Global Capital Markets and the Economy Generally Persist, They May Materially Adversely Affect Our Business and Results of Operations” in the 2016 Annual Report.
We have market presence in numerous countries and increased exposure to risks posed by local and regional economic conditions. See “Risk Factors — Risks Related to Our Business — Our International Operations Face Political, Legal, Operational and Other Risks, Including Exposure to Local and Regional Economic Conditions, That Could Negatively Affect Those Operations or Our Profitability.” Concerns about the political and/or economic instability in the United Kingdom (“U.K.”), Mexico, Italy, Turkey and Puerto Rico have recently contributed to global market volatility. See “— Investments — Current Environment — Selected Country Investments.” Events following the U.K.’s referendum on June 23, 2016 and the uncertainties, including foreign currency exchange risks, associated with its pending withdrawal from the European Union (“EU”), have also contributed to market volatility, both in the U.S. and beyond. These factors could contribute to weakening gross domestic product growth, primarily in the U.K. and Europe. The magnitude and longevity of the potential negative economic impacts would depend on the detailed agreements reached by the U.K. and the EU as a result of the exit negotiations and negotiations regarding trade and other arrangements.
Central banks around the world have used monetary policies to combat global market volatility. For example, the European Central Bank continues to institute support measures, including quantitative easing, to lessen the risk of deflation, lower borrowing costs in the Euro zone and encourage corporations to issue more asset-backed securities. These measures, however, could affect the Euro exchange rate and have uncertain impacts on interest rates and risk markets. In Japan, the Japanese government and the Bank of Japan have implemented a coordinated strategy which includes the imposition of a negative rate on commercial bank deposits, continued government bond purchases and tax reform, including the lowering of the Japanese corporate tax rate and the delay until 2019 of an increase in the consumption tax to 10%. Going forward, Japan’s structural and demographic challenges may continue to limit its potential growth unless reforms that boost productivity are put into place. Japan’s high public sector debt levels are mitigated by low refinancing risks. For information regarding actions taken by the Federal Reserve Board’s Federal Open Market Committee (“FOMC”) in the United States, see “— Impact of a Sustained Low Interest Rate Environment.”
88
Impact of a Sustained Low Interest Rate Environment
As a global insurance company, we are affected by the monetary policy of central banks around the world, as well as the monetary policy of the Federal Reserve Board in the United States. The Federal Reserve Board has taken a number of actions in recent years to spur economic activity, including asset purchases and keeping interest rates low. However, in December 2015, the FOMC increased the federal funds rate for the first time in 10 years and raised it again at the December 2016 meeting. The FOMC increased target range for the federal funds rate from 0.75% to 1.0% in March 2017. Further increases in the federal funds rate in the future may affect interest rates and risk markets in the U.S. and other developed and emerging economies. However, we cannot predict with certainty the effect of these programs and policies on interest rates or the impact on the pricing levels of risk-bearing investments at this time. See “— Investments — Current Environment.”
During periods of declining interest rates, we may have to invest insurance cash flows and reinvest the cash flows we received as interest or return of principal on our investments in lower yielding instruments. Moreover, borrowers may prepay or redeem the fixed income securities, mortgage loans and mortgage-backed securities in our investment portfolio with greater frequency in order to borrow at lower market rates. Therefore, some of our products expose us to the risk that a reduction in interest rates will reduce the difference between the amounts that we are required to credit on contracts in our general account and the rate of return we are able to earn on investments intended to support obligations under these contracts. This difference between interest earned and interest credited, or margin, is a key metric for the management of, and reporting for, many of our businesses.
Our expectations regarding future margins are an important component impacting the amortization of certain intangible assets such as DAC and value of business acquired (“VOBA”). Significantly lower margins may cause us to accelerate the amortization, thereby reducing net income in the affected reporting period. Additionally, lower margins may also impact the recoverability of intangible assets such as goodwill, require the establishment of additional liabilities or trigger loss recognition events on certain policyholder liabilities. We review this long-term margin assumption, along with other assumptions, as part of our annual actuarial assumption review.
Competitive Pressures
The life insurance industry remains highly competitive. The product development and product life cycles have shortened in many product segments, leading to more intense competition with respect to product features. Larger companies have the ability to invest in brand equity, product development, technology and risk management, which are among the fundamentals for sustained profitable growth in the life insurance industry. In addition, several of the industry’s products can be quite homogeneous and subject to intense price competition. Sufficient scale, financial strength and financial flexibility are becoming prerequisites for sustainable growth in the life insurance industry. Larger market participants tend to have the capacity to invest in additional distribution capability and the information technology needed to offer the superior customer service demanded by an increasingly sophisticated industry client base. We believe that the continued volatility of the financial markets, its impact on the capital position of many competitors, and subsequent actions by regulators and rating agencies have altered the competitive environment. In particular, we believe that these factors have highlighted financial strength as the most significant differentiator and, as a result, we believe the Company is well positioned to compete in this environment.
Regulatory Developments
In the United States, our life insurance companies are regulated primarily at the state level, with some products and services also subject to federal regulation. In addition, MetLife, Inc. and its U.S. insurance subsidiaries are subject to regulation under the insurance holding company laws of various U.S. jurisdictions. Furthermore, some of MetLife’s operations, products and services are subject to consumer protection laws, securities, broker-dealer and investment adviser regulations, environmental and unclaimed property laws and regulations, and to the Employee Retirement Income Security Act of 1974 (“ERISA”). If MetLife, Inc. were re-designated as a non-bank SIFI, it could also be subject to regulation by the Federal Reserve and the FDIC. See “— U.S. Regulation” below, as well as “Business — Regulation — U.S. Regulation,” “Risk Factors — Regulatory and Legal Risks — Our Insurance and Brokerage Businesses Are Highly Regulated, and Changes in Regulation and in Supervisory and Enforcement Policies May Reduce Our Profitability and Limit Our Growth,” “Risk Factors — Risks Related to Our Business — Our Statutory Life Insurance Reserve Financings May Be Subject to Cost Increases and New Financings May Be Subject to Limited Market Capacity,” and “Risk Factors — Regulatory and Legal Risks — Changes in U.S. Federal, State Securities and State Insurance Laws and Regulations May Affect Our Operations and Our Profitability” included in the 2016 Annual Report, as amended or supplemented in our subsequently filed Quarterly Reports on Form 10-Q under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Industry Trends — Regulatory Developments” and similarly named sections under the caption “Risk Factors.”
89
The Dodd-Frank Wall Street Reform and Consumer Protection Act (“Dodd-Frank”) effected the most far-reaching overhaul of financial regulation in the United States in decades. However, President Trump and the majority party have expressed goals to amend Dodd-Frank. See “Business — Regulation — U.S. Regulation” and “Risk Factors — Regulatory and Legal Risks — Our Insurance and Brokerage Businesses Are Highly Regulated, and Changes in Regulation and In Supervisory and Enforcement Policies May Reduce Our Profitability and Limit Our Growth” in the 2016 Annual Report for a discussion of Dodd-Frank.
Our international insurance operations are principally regulated by insurance regulatory authorities in the jurisdictions in which they are located or operate. In addition, our investment and pension companies outside of the U.S. are subject to oversight by the relevant securities, pension and other authorities of the countries in which the companies operate. Our non-U.S. insurance businesses are also subject to current and developing solvency regimes which impose various capital and other requirements. Having been named a global systemically important insurer (“G-SII”), MetLife, Inc. may also become subject to additional capital requirements. See “— International Regulation” below, as well as “Business — Regulation — International Regulation” included in the 2016 Annual Report, as amended or supplemented in our subsequently filed Quarterly Reports on Form 10-Q under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Industry Trends — Regulatory Developments.”
90
U.S. Regulation
Insurance Regulation
Health Care Regulation
The Patient Protection and Affordable Care Act (“PPACA”), signed into law on March 23, 2010, and The Health Care and Education Reconciliation Act of 2010, signed into law on March 30, 2010 (together, the “Affordable Care Act”), impose obligations on MetLife as an enterprise, and as a provider of non-medical health insurance benefits and as a purchaser of certain of these products. In 2014, we became subject to an excise tax called the “health insurer fee,” the cost of which is primarily passed on to group purchasers of certain of our dental and vision insurance products. The health insurer fee has been suspended pursuant to legislation during the 2017 calendar year. Without any further legislation from Congress, the health insurer fee will again become payable in 2018. Additionally, with respect to dental insurance products sold to groups with 50 or fewer employees, we have changed certain of our product offerings in response to the Affordable Care Act. The cost of these product changes will also be reflected in our pricing of such products. The Affordable Care Act and its related regulations have already resulted in increased and unpredictable costs to provide certain products and may have additional adverse effects. See “Risk Factors — Regulatory and Legal Risks — Legislative and Regulatory Activity in Health Care and Other Employee Benefits Could Affect our Profitability as a Provider of Life Insurance, Annuities, and Non-Medical Health Insurance Benefit Products.” It has also harmed our competitive position, as the Affordable Care Act has a disparate impact on our products compared to products offered by our not-for-profit competitors. The current administration and members of Congress have proposed repealing or modifying portions of the Affordable Care Act.
ERISA Considerations
We provide products and services to certain employee benefit plans that are subject to ERISA or the Internal Revenue Code of 1986, as amended (the “Code”). As such, our activities are subject to the restrictions imposed by ERISA and the Code, including the requirement under ERISA that fiduciaries must perform their duties solely in the interests of ERISA plan participants and beneficiaries, and that fiduciaries may not cause a covered plan to engage in certain prohibited transactions. The applicable provisions of ERISA and the Code are subject to enforcement by the Department of Labor (“DOL”), the IRS and the Pension Benefit Guaranty Corporation.
The prohibited transaction rules of ERISA and the Code generally restrict the provision of investment advice to ERISA plans and participants and Individual Retirement Accounts (“IRAs”) if the investment recommendation results in fees paid to an individual advisor, the firm that employs the advisor or their affiliates that vary according to the investment recommendation chosen.
The DOL issued new regulations on April 6, 2016, which, in accordance with an April 4, 2017 DOL final rule which delayed the original applicable date by 60 days, will for the most part become applicable on June 9, 2017. These rules when they become applicable, substantially expand the definition of “investment advice” and require that an impartial or “best interests” standard be met in providing such advice, thereby broadening the circumstances under which MetLife or its representatives, in providing investment advice with respect to ERISA plans, plan participants or IRAs, could be deemed a fiduciary under ERISA or the Code. Pursuant to the final regulations, certain communications with plans, plan participants and IRA holders, including the sales of products, and investment management or advisory services, could be deemed fiduciary investment advice, thus causing increased exposure to fiduciary liability if the distributor does not recommend what is in the client’s best interests. The DOL also issued amendments to certain of its prohibited transaction exemptions, and issued a new exemption, that applies more onerous disclosure and contract requirements to, and increases fiduciary requirements and fiduciary liability exposure in respect of, certain transactions involving ERISA plans, plan participants and IRAs. In general, the changes the rule made to existing prohibited transaction exemptions and contract and disclosure requirements of the new exemption (other than the impartial interest standard) were delayed until January 1, 2018.
On February 3, 2017 President Trump, in a memorandum to the Secretary of Labor, requested that the DOL prepare an updated economic and legal analysis concerning the likely impact of the new rules, and possible revisions to the rules. The applicable date for the new rules could be further extended to provide the DOL with additional time to address the requests in the President’s memorandum.
91
We anticipate that we will need to undertake certain additional tasks in order to comply with certain of the exemptions provided in the DOL regulations, including additional compliance reviews of material shared with distributors, wholesaler and call center training and product reporting and analysis. The change of administration and DOL officials leaves uncertainty over whether the regulations will be substantially modified or repealed. Application of the rules on June 9, 2017, in light of the overall reconsideration of the rules requested by President Trump, could create confusion among our distribution partners which could negatively impact product sales. We cannot predict what other proposals may be made, what legislation may be introduced or enacted, or what impact any such legislation may have on our business, results of operations and financial condition. See “Risk Factors — Regulatory and Legal Risks — Our Insurance and Brokerage Businesses Are Highly Regulated, and Changes in Regulation and In Supervisory and Enforcement Policies May Reduce Our Profitability and Limit Our Growth.”
Potential Regulation as a Non-Bank SIFI
See “— Executive Summary
—
Other Key Information
—
Significant Events” above for recent developments concerning FSOC’s appeal of the D.C. District Court’s order that the designation of MetLife, Inc. as a non-bank SIFI by the FSOC be rescinded.
International Regulation
On June 23, 2016, the U.K. held a referendum regarding its membership in the EU, resulting in a vote in favor of leaving the EU. The U.K. Prime Minister, Theresa May triggered the withdrawal process by notifying the EU on March 29, 2017 of the U.K.’s intention to withdraw from the EU. The member withdrawal provisions in the applicable EU treaty have not been used before so it is unclear how the provisions will work in practice. This treaty provides that the U.K. and the EU will negotiate a withdrawal agreement during a maximum two-year period (unless such period is extended by unanimous vote of the EU member states). It is possible that the withdrawal agreement would deal with the details of the immediate exit but would not set out final trade arrangements or deal comprehensively with other potentially significant matters. The U.K. Parliament approved Prime Minister Theresa May’s plan to hold an early general election on June 8, 2017, the results of which may affect the U.K. strategy for its withdrawal from the EU. With effectiveness of the withdrawal agreement or, if no agreement is concluded in the two-year period, at the end of the period on March 29, 2019, the U.K. will no longer be a member of the EU. It is likely, however, that a transitional period or implementation phase will be discussed during the negotiations. In the meantime, the U.K. remains a member of the EU with unchanged rights to access the single EU market in goods and services. Our U.K. business model utilizes certain rights to operate cross-border insurance and investment operations which may be modified or eliminated as a result of the U.K. exiting the EU. Operating expenses within our businesses could increase as a result of uncertainties during the negotiation period and upon the U.K.’s withdrawal.
Other changes in the laws and regulations of jurisdictions that affect our customers and independent sales intermediaries or their operations also may affect our business relationships with them and their ability to purchase or distribute our products. Such actions may negatively affect our business in these jurisdictions. In Chile, in September 2015, a Presidential Advisory Committee issued several recommendations to reform the pension system, and in April 2017, President Bachelet announced that she would submit a pension reform bill to Congress. It is highly unlikely that the bill will pass before the end of the year when her administration concludes.
Solvency Regimes
Our insurance business throughout the European Economic Area is subject to Solvency II, which became effective on January 1, 2016, after an extensive preparatory phase. Solvency II codifies and harmonizes the EU insurance regulation. Capital requirements are forward-looking and based on the risk profile of each individual insurance company in order to promote comparability, transparency and competitiveness. In line with the requirements, MetLife entities calculate and report their capital requirement using a standard formula prescribed by the EU Directive and further regulation by the European Insurance and Occupational Pensions Authority. In addition, as required, the entities have performed their regular Own Risk and Solvency Assessment (“ORSA”) and submitted their respective annual reports to the Central Bank of Ireland, the Bank of Greece and the Polish Financial Supervisory Authority by December 31, 2016.
Mexico adopted a reform of its Insurance Law in February 2013. In accordance with this reform, a Solvency II-type regulatory framework became effective on January 1, 2016 which instituted changes to reserve and capital requirements and corporate governance and fostered greater transparency. In line with the requirements of the local Solvency II, insurance companies calculate and report their capital requirement using a standard formula designed by the local regulators (“CNSF”). In addition, as required, the Company completed and submitted its first ORSA report to the CNSF on October 31, 2016, as previously approved by the Board of Directors. The next ORSA report will be due for submission to the CNSF in July 2017.
92
In Chile, the law implementing Solvency II-like regulation continues in the studies stage. However, the Chilean insurance regulator has already issued two resolutions, one for governance, and the other for risk management and control framework requirements. MetLife Chile has already implemented governance changes and risk policies to comply with these resolutions. A fourth impact study was completed and submitted in July 2016. On March 31, 2016, the local regulator issued a final regulation which requires insurance companies to implement a risk appetite framework and produce an ORSA. The first such report must be submitted to the local regulator no later than September 30, 2017. Even though a formal implementation date has not yet been set, it is estimated that the new solvency and supervisory regime could be in force between 2018 and 2020.
In July 2015, the Superintendence of Private Insurance, the Brazilian insurance regulator (“SUSEP”), issued a regulation establishing (i) a framework for minimum capital requirements based on risk and (ii) criteria for investment activities in insurance companies. In November 2015, SUSEP issued an additional regulation requiring insurance companies operating in Brazil to adopt a formal risk management function by the end of 2016 and to implement a formal enterprise risk management framework in 2017. In December 2016, MetLife Brazil formalized the designation of a local Risk Manager in Brazil in compliance with local regulation.
In China, the business of our joint venture (as well as the industry) has been implementing China Risk Oriented Solvency System (“C-ROSS”), a new risk-based solvency regime which became effective on January 1, 2016. Like Solvency II, C-ROSS focuses on risk management and has three pillars (strengthen quantitative capital requirements, enhance qualitative supervision and establish a governance and market discipline process).
Global Systemically Important Insurers
The International Association of Insurance Supervisors (“IAIS”), an association of insurance supervisors and regulators and a member of the Financial Stability Board (“FSB”), an international entity established to coordinate, develop and promote regulatory, supervisory and other financial sector policies in the interest of financial stability, is participating in the FSB’s initiative to identify and manage global systemically important financial institutions. To this end, the IAIS published a methodology to assess the systemic relevance of global insurers and a framework of policy measures to be applied to G-SIIs. The IAIS/FSB process is separate from the U.S. FSOC designation process and MetLife, Inc. remains a G-SII in spite of the rescission of its U.S. non-bank SIFI designation on March 30, 2016.
The global designation process is an annual process and IAIS policy requires that the IAIS evaluate whether updates to its assessment methodology are necessary every three years. Accordingly, the IAIS published an updated assessment methodology on June 16, 2016, which was used as the basis for the 2016 assessment of a pool of approximately 50 insurers, including MetLife, Inc. The new methodology reflects changes in the previous definitions of non-traditional and non-insurance activity, along with certain other changes in both quantitative and qualitative assessments, most notably introducing greater transparency into the process. On November 21, 2016, the FSB issued its 2016 list of G-SIIs, which included MetLife, Inc.
Current standards call for G-SIIs to be subject to higher loss absorbency requirements (“HLA”). Given the absence of a common global base on which to calculate HLA for insurers, the FSB directed the IAIS to develop basic capital requirements (“BCR”). The first version of the IAIS HLA framework was endorsed by the FSB and the G20 in September and November 2015, respectively. On February 28, 2017 the IAIS confirmed that the risk-based global insurance capital standard (“ICS”) will replace BCR as the basis for a revised HLA and that work on revisions are deferred until adoption of the ICS by the IAIS in 2019 (see below). Consequently, HLA implementation is delayed until 2022 for the 2020 group of G-SIIs.
On December 17, 2014, the IAIS released a first exposure draft of the ICS which will apply to all internationally active insurance groups, including G-SIIs. A second exposure draft was published for comment on July 19, 2016. The IAIS expects to publish a draft of an interim version of the ICS in 2017 for further consultation and refinement by the end of 2019, the target for implementation by individual jurisdictions. The date by which the ICS will be finalized has not yet been specified.
The FSB and IAIS propose that national authorities consider additional requirements for G-SIIs, which include preparation of a systemic risk management plan, preparation of a recovery and resolution plan, enhanced liquidity planning and management, more intensive supervision, closer coordination among regulators through global supervisory colleges led by a regulator with group-wide supervisory authority. The IAIS continues to revise its view of how best to identify and manage systemic risk in the insurance sector and are exploring an activities-based approach which could result in the future in a focus on management of activities as opposed to designation of entities and a shift toward a better identification of activities that link to systemic risk transmission channels. The IAIS proposals would need to be implemented at the consolidated group level by legislation or regulation in each applicable jurisdiction. As MetLife, Inc. is no longer a U.S. non-bank SIFI and none of its regulators have proposed implementing the G-SII requirements, the impact on MetLife, Inc. of such global proposals is uncertain.
93
Mortgage and Foreclosure-Related Exposures
MetLife no longer engages in the origination, sale and servicing of forward and reverse residential mortgage loans. See Note 21 of the Notes to the Consolidated Financial Statements included in the 2016 Annual Report for further information regarding our mortgage and foreclosure-related exposures.
Notwithstanding MetLife Bank, National Association’s (“MetLife Bank”) exit from the origination and servicing businesses, MetLife Home Loans LLC remains obligated to repurchase loans or compensate for losses upon demand due to alleged defects by MetLife Bank or its predecessor servicers in past servicing of the loans and material representations made in connection with MetLife Bank’s sale of the loans. Reserves for representation and warranty repurchases and indemnifications were $34 million at both March 31, 2017 and December 31, 2016. Reserves for estimated future losses due to alleged deficiencies on loans originated and sold, as well as servicing of the loans including servicing acquired, are estimated based on unresolved claims and projected losses under investor servicing contracts where MetLife Bank’s past actions or inactions are likely to result in missing certain stipulated investor timelines. Reserves for servicing defects were $10 million and $11 million at March 31, 2017 and December 31, 2016, respectively. Management is satisfied that adequate provision has been made in the Company’s consolidated financial statements for those representation and warranty obligations that are currently probable and reasonably estimable.
Summary of Critical Accounting Estimates
The preparation of financial statements in conformity with GAAP requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the Interim Condensed Consolidated Financial Statements. The most critical estimates include those used in determining:
|
(i)
|
liabilities for future policy benefits and the accounting for reinsurance;
|
|
(ii)
|
capitalization and amortization of DAC and the establishment and amortization of VOBA;
|
|
(iii)
|
estimated fair values of investments in the absence of quoted market values;
|
|
(iv)
|
investment impairments;
|
|
(v)
|
estimated fair values of freestanding derivatives and the recognition and estimated fair value of embedded derivatives requiring bifurcation;
|
|
(vi)
|
measurement of goodwill and related impairment;
|
|
(vii)
|
measurement of employee benefit plan liabilities;
|
|
(viii)
|
measurement of income taxes and the valuation of deferred tax assets; and
|
|
(ix)
|
liabilities for litigation and regulatory matters.
|
In addition, the application of acquisition accounting requires the use of estimation techniques in determining the estimated fair values of assets acquired and liabilities assumed — the most significant of which relate to aforementioned critical accounting estimates. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to our business and operations. Actual results could differ from these estimates.
The above critical accounting estimates are described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Summary of Critical Accounting Estimates” and Note 1 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report.
Economic Capital
Economic capital is an internally developed risk capital model, the purpose of which is to measure the risk in the business and to provide a basis upon which capital is deployed. The economic capital model accounts for the unique and specific nature of the risks inherent in our business.
94
Our economic capital model, coupled with considerations of local capital requirements, aligns segment allocated equity with emerging standards and consistent risk principles. The model applies statistics-based risk evaluation principles to the material risks to which the Company is exposed. These consistent risk principles include calibrating required economic capital shock factors to a specific confidence level and time horizon while applying an industry standard method for the inclusion of diversification benefits among risk types. Economic capital-based risk estimation is an evolving science and industry best practices have emerged and continue to evolve. Areas of evolving industry best practices include stochastic liability valuation techniques, alternative methodologies for the calculation of diversification benefits, and the quantification of appropriate shock levels. MetLife’s management is responsible for the ongoing production and enhancement of the economic capital model and reviews its approach periodically to ensure that it remains consistent with emerging industry practice standards.
Segment net investment income, with the exception of the Brighthouse Financial segment, is credited or charged based on the level of allocated equity; however, changes in allocated equity do not impact our consolidated net investment income, net income (loss) or operating earnings. The Brighthouse Financial segment’s net investment income represents that of the legal entities which comprise Brighthouse and its subsidiaries on a historical basis, however, Brighthouse Financial segment’s net investment income may not be indicative of that on a combined standalone basis.
Net investment income is based upon the actual results of each segment’s specifically identifiable investment portfolios adjusted for allocated equity. Other costs are allocated to each of the segments based upon: (i) a review of the nature of such costs; (ii) time studies analyzing the amount of employee compensation costs incurred by each segment; and (iii) cost estimates included in the Company’s product pricing.
Acquisitions and Dispositions
See “— Executive Summary — Other Key Information — Significant Events” for information on the U.S. Retail Advisor Force Divestiture and the proposed Separation.
95
Results of Operations
Consolidated Results
Business Overview.
Overall sales for the three months ended March 31, 2017 increased over prior period levels reflecting higher sales from most of our segments. An overall increase in sales from our U.S. segment was primarily driven by a 29% increase in sales from our Group Benefits business, as well as sales of stable value products and funding agreement issuances in our Retirement and Income Solutions business. Sales from our segments abroad increased primarily in our Asia segment. Our Asia segment experienced growth in life products in Japan, one large group case in Australia, higher sales in Korea and Hong Kong in advance of upcoming regulatory changes, as well as increased sales in emerging markets due to business growth. In our MetLife Holdings and Brighthouse Financial segments, the U.S. Retail Advisor Force Divestiture and the proposed Separation negatively impacted sales, including the suspension of sales through one distributor.
|
Three Months
Ended March 31, |
||||||||
|
2017
|
2016
|
|||||||
|
(In millions)
|
||||||||
|
Revenues
|
||||||||
|
Premiums
|
$
|
9,315
|
|
$
|
9,693
|
|
||
|
Universal life and investment-type product policy fees
|
2,302
|
|
2,344
|
|
||||
|
Net investment income
|
5,196
|
|
4,559
|
|
||||
|
Other revenues
|
374
|
|
487
|
|
||||
|
Net investment gains (losses)
|
8
|
|
15
|
|
||||
|
Net derivative gains (losses)
|
(926
|
)
|
1,335
|
|
||||
|
Total revenues
|
16,269
|
|
18,433
|
|
||||
|
Expenses
|
||||||||
|
Policyholder benefits and claims and policyholder dividends
|
10,176
|
|
9,993
|
|
||||
|
Interest credited to policyholder account balances
|
1,712
|
|
1,326
|
|
||||
|
Capitalization of DAC
|
(796
|
)
|
(981
|
)
|
||||
|
Amortization of DAC and VOBA
|
533
|
|
995
|
|
||||
|
Amortization of negative VOBA
|
(43
|
)
|
(99
|
)
|
||||
|
Interest expense on debt
|
296
|
|
312
|
|
||||
|
Other expenses
|
3,574
|
|
3,965
|
|
||||
|
Total expenses
|
15,452
|
|
15,511
|
|
||||
|
Income (loss) before provision for income tax
|
817
|
|
2,922
|
|
||||
|
Provision for income tax expense (benefit)
|
(12
|
)
|
719
|
|
||||
|
Net income (loss)
|
829
|
|
2,203
|
|
||||
|
Less: Net income (loss) attributable to noncontrolling interests
|
3
|
|
2
|
|
||||
|
Net income (loss) attributable to MetLife, Inc.
|
826
|
|
2,201
|
|
||||
|
Less: Preferred stock dividends
|
6
|
|
6
|
|
||||
|
Net income (loss) available to MetLife, Inc.’s common shareholders
|
$
|
820
|
|
$
|
2,195
|
|
||
Three Months Ended
March 31, 2017
Compared with the
Three Months Ended
March 31, 2016
During the three months ended March 31, 2017, income (loss) before provision for income tax decreased $2.1 billion ($1.4 billion, net of income tax) from the prior period primarily driven by an unfavorable change in net derivative gains (losses).
96
Management of Investment Portfolio and Hedging Market Risks with Derivatives.
We manage our investment portfolio using disciplined asset/liability management (“ALM”) principles, focusing on cash flow and duration to support our current and future liabilities. Our intent is to match the timing and amount of liability cash outflows with invested assets that have cash inflows of comparable timing and amount, while optimizing risk-adjusted net investment income and risk-adjusted total return. Our investment portfolio is heavily weighted toward fixed income investments, with over 80% of our portfolio invested in fixed maturity securities and mortgage loans. These securities and loans have varying maturities and other characteristics which cause them to be generally well suited for matching the cash flow and duration of insurance liabilities. In addition, our general account investment portfolio includes, within fair value option (“FVO”), contractholder-directed unit-linked investments supporting unit-linked variable annuity type liabilities, which do not qualify as separate account assets. The returns on these contractholder-directed unit-linked investments, which can vary significantly from period to period, include changes in estimated fair value subsequent to purchase, inure to contractholders and are offset in earnings by a corresponding change in policyholder account balances through interest credited to policyholder account balances.
We purchase investments to support our insurance liabilities and not to generate net investment gains and losses. However, net investment gains and losses are incurred and can change significantly from period to period due to changes in external influences, including changes in market factors such as interest rates, foreign currency exchange rates, credit spreads and equity markets; counterparty specific factors such as financial performance, credit rating and collateral valuation; and internal factors such as portfolio rebalancing. Changes in these factors from period to period can significantly impact the levels of both impairments and realized gains and losses on investments sold.
We also use derivatives as an integral part of our management of the investment portfolio and insurance liabilities to hedge certain risks, including changes in interest rates, foreign currency exchange rates, credit spreads and equity market levels. We use freestanding interest rate, equity, credit and currency derivatives to hedge certain invested assets and insurance liabilities. A small portion of these hedges are designated and qualify as accounting hedges, which reduce volatility in earnings. For those hedges not designated as accounting hedges, changes in market factors lead to the recognition of fair value changes in net derivative gains (losses) generally without an offsetting gain or loss recognized in earnings for the item being hedged, which creates volatility in earnings. During the first quarter of 2017, we began restructuring certain derivative hedges to partially stabilize volatility from nonqualified interest rate derivatives and to help meet prospective dividend and free cash flow objectives under varying interest rate scenarios. The restructuring of the hedge program outside of the Brighthouse Financial segment is substantially complete in meeting our initial objectives. As part of this restructuring, we replaced certain nonqualified derivatives with derivatives that qualify for hedge accounting treatment. In addition, we also entered into replication transactions using interest rate swaps, which
are accounted for at amortized cost under statutory guidelines and are nonqualified derivatives under GAAP.
We actively evaluate market risk hedging needs and strategies to ensure our free cash flow and capital objectives are met under a range of market conditions.
Certain variable annuity products with guaranteed minimum benefits contain embedded derivatives that are measured at estimated fair value separately from the host variable annuity contract, with changes in estimated fair value recorded in net derivative gains (losses). We use freestanding derivatives to hedge the market risks inherent in these variable annuity guarantees. The valuation of these embedded derivatives includes a nonperformance risk adjustment, which is unhedged, and can be a significant driver of net derivative gains (losses) and volatility in earnings, but does not have an economic impact on us.
97
Net Derivative Gains (Losses).
The variable annuity embedded derivatives and associated freestanding derivative hedges are collectively referred to as “VA program derivatives” in the following table. All other derivatives that are economic hedges of certain invested assets and insurance liabilities are referred to as “non-VA program derivatives” in the following table. The table below presents the impact on net derivative gains (losses) from non-VA program derivatives and VA program derivatives:
|
Three Months Ended March 31,
|
|||||||
|
2017
|
2016
|
||||||
|
(In millions)
|
|||||||
|
Non-VA program derivatives
|
|||||||
|
Interest rate
|
$
|
(192
|
)
|
$
|
1,078
|
|
|
|
Foreign currency exchange rate
|
76
|
|
202
|
|
|||
|
Credit
|
53
|
|
15
|
|
|||
|
Equity
|
(2
|
)
|
(50
|
)
|
|||
|
Non-VA embedded derivatives
|
(162
|
)
|
(53
|
)
|
|||
|
Total non-VA program derivatives
|
(227
|
)
|
1,192
|
|
|||
|
VA program derivatives
|
|||||||
|
Market risks in embedded derivatives
|
952
|
|
(1,336
|
)
|
|||
|
Nonperformance risk adjustment on embedded derivatives
|
(43
|
)
|
359
|
|
|||
|
Other risks in embedded derivatives
|
(169
|
)
|
(139
|
)
|
|||
|
Total embedded derivatives
|
740
|
|
(1,116
|
)
|
|||
|
Freestanding derivatives hedging embedded derivatives
|
(1,439
|
)
|
1,259
|
|
|||
|
Total VA program derivatives
|
(699
|
)
|
143
|
|
|||
|
Net derivative gains (losses)
|
$
|
(926
|
)
|
$
|
1,335
|
|
|
The unfavorable change in net derivative gains (losses) on non-VA program derivatives was $1.4 billion ($922 million, net of income tax). This was primarily due to long-term interest rates increasing in the current period and decreasing in the prior period, unfavorably impacting receive-fixed interest rate swaps and swaptions primarily hedging long-duration liability portfolios. In addition, the Japanese yen, relative to other key currencies, strengthened less in the current period versus the prior period, unfavorably impacting foreign currency options and futures that primarily hedge foreign currency-denominated bonds. Because certain of these hedging strategies are not designated or do not qualify as accounting hedges, the changes in the estimated fair value of these freestanding derivatives are recognized in net derivative gains (losses) without an offsetting gain or loss recognized in earnings for the item being hedged.
Additionally, there was an unfavorable change in non-VA embedded derivatives as a result of equity market index levels increasing more in the current period than in the prior period on certain annuities with equity-indexed returns.
The unfavorable change in net derivative gains (losses) on VA program derivatives was $842 million ($547 million, net of income tax). This was due to an unfavorable change of $410 million ($267 million, net of income tax) in market risks in embedded derivatives, net of the impact of freestanding derivatives hedging those risks, an unfavorable change of $402 million ($261 million, net of income tax) related to the change in the nonperformance risk adjustment on embedded derivatives and an unfavorable change of $30 million ($20 million, net of income tax) in other risks in embedded derivatives. Other risks relate primarily to the impact of policyholder behavior and other non-market risks that generally cannot be hedged.
The foregoing $410 million ($267 million, net of income tax) unfavorable change reflects a $2.7 billion ($1.8 billion, net of income tax) unfavorable change in freestanding derivatives hedging market risks in embedded derivatives, partially offset by a $2.3 billion ($1.5 billion, net of income tax) favorable change in market risks in embedded derivatives.
The unfavorable change is due to changes in market factors, as well as due to freestanding derivative losses on certain macro hedges which are transitionary in nature given the separation of Brighthouse and which are designed to protect statutory capitalization.
98
The primary changes in market factors are summarized as follows:
|
•
|
Long-term interest rates increased in the current period and decreased in the prior period, contributing to an unfavorable change in our freestanding derivatives and a favorable change in our embedded derivatives. For example, the 30-year U.S. swap rate increased 5 basis points in the current period and decreased 48 basis points in the prior period.
|
|
•
|
Key equity index levels increased more in the current period than in the prior period, contributing to an unfavorable change in our freestanding derivatives and a favorable change in our embedded derivatives. For example, the Standard & Poor’s Global Ratings (“S&P”) 500 Index increased 6% in the current period and increased 1% in the prior period.
|
The aforementioned $402 million ($261 million, net of income tax) unfavorable change in the nonperformance risk adjustment on embedded derivatives resulted from an unfavorable change of $203 million, before income tax, as a result of model changes and changes in capital market inputs, such as long-term interest rates and key equity index levels, on variable annuity guarantees, in addition to an unfavorable change of $199 million, before income tax, related to changes in our own credit spread.
When equity index levels decrease in isolation, the variable annuity guarantees become more valuable to policyholders, which results in an increase in the undiscounted embedded derivative liability. Discounting this unfavorable change by the risk adjusted rate yields a smaller loss than by discounting at the risk-free rate, thus creating a gain from including an adjustment for nonperformance risk.
When the risk-free interest rate decreases in isolation, discounting the embedded derivative liability produces a higher valuation of the liability than if the risk-free interest rate had remained constant. Discounting this unfavorable change by the risk adjusted rate yields a smaller loss than by discounting at the risk-free interest rate, thus creating a gain from including an adjustment for nonperformance risk.
When our own credit spread increases in isolation, discounting the embedded derivative liability produces a lower valuation of the liability than if our own credit spread had remained constant. As a result, a gain is created from including an adjustment for nonperformance risk. For each of these primary market drivers, the opposite effect occurs when they move in the opposite direction.
Net Investment Gains (Losses).
The unfavorable change in net investment gains (losses) of $7 million ($5 million, net of income tax) primarily reflects current period losses on sales of fixed maturity securities and lower foreign currency transaction gains. These unfavorable changes were partially offset by lower impairments on equity securities and lower provisions for loan losses on mortgage loans.
Divested Businesses and Lag Elimination.
Income (loss) before provision for income tax related to the divested businesses and lag elimination, excluding net investment gains (losses) and net derivative gains (losses), decreased $159 million ($110 million, net of income tax) to a loss of $102 million ($68 million, net of income tax) in the current period from income of $57 million ($42 million, net of income tax) in the prior period. Included in this decline was a decrease in total revenues of $663 million, before income tax, and a decrease in total expenses of $504 million, before income tax. Results for both periods include expenses and charges associated with the U.S Retail Advisor Force Divestiture and the proposed Separation. Results for the prior period include the financial impact of converting the Company’s Japan operations to calendar year-end reporting without retrospective application of this change to prior years.
Taxes.
Income tax benefit for the three months ended March 31, 2017 was $12 million, or 1% of income (loss) before provision for income tax, compared with income tax expense of $719 million, or 25% of income (loss) before provision for income tax, for the three months ended March 31, 2016. The Company’s effective tax rates differ from the U.S. statutory rate of 35% typically due to non-taxable investment income, tax credits for low income housing, and foreign earnings taxed at lower rates than the U.S. statutory rate. Our current period results include a tax benefit of $9 million related to the settlement of an audit. Our prior period results include a tax benefit of $110 million in Japan and a tax charge of $19 million in Chile, both related to changes in tax rates.
Operating Earnings
.
As more fully described in “— Non-GAAP and Other Financial Disclosures,” we use operating earnings, which does not equate to net income (loss), as determined in accordance with GAAP, to analyze our performance, evaluate segment performance, and allocate resources. We believe that the presentation of operating earnings and operating earnings available to common shareholders, as we measure it for management purposes, enhances the understanding of our performance by highlighting the results of operations and the underlying profitability drivers of the business. Operating earnings and other financial measures based on operating earnings allow analysis of our performance relative to our business plan and facilitate comparisons to industry results. Operating earnings and operating earnings available to common shareholders should not be viewed as substitutes for net income (loss) and net income (loss) available to MetLife, Inc.’s common shareholders, respectively. Operating earnings available to common shareholders increased $217 million, net of income tax, to $1.5 billion, net of income tax, for the three months ended March 31, 2017 from $1.3 billion, net of income tax, for the three months ended March 31, 2016.
99
Reconciliation of net income (loss) to operating earnings available to common shareholders
Three Months Ended March 31, 2017
|
U.S.
|
Asia
|
Latin America
|
EMEA
|
MetLife Holdings
|
Brighthouse Financial
|
Corporate& Other
|
Total
|
||||||||||||||||||||||||
|
(In millions)
|
|||||||||||||||||||||||||||||||
|
Net income (loss)
|
$
|
347
|
|
$
|
480
|
|
$
|
231
|
|
$
|
81
|
|
$
|
322
|
|
$
|
(402
|
)
|
$
|
(230
|
)
|
$
|
829
|
|
|||||||
|
Less: Net investment gains (losses)
|
(26
|
)
|
117
|
|
12
|
|
2
|
|
4
|
|
(56
|
)
|
(45
|
)
|
8
|
|
|||||||||||||||
|
Less: Net derivative gains (losses)
|
(148
|
)
|
177
|
|
136
|
|
13
|
|
(18
|
)
|
(965
|
)
|
(121
|
)
|
(926
|
)
|
|||||||||||||||
|
Less: Other adjustments to net income (1)
|
(66
|
)
|
(4
|
)
|
(29
|
)
|
5
|
|
(83
|
)
|
27
|
|
(83
|
)
|
(233
|
)
|
|||||||||||||||
|
Less: Provision for income tax (expense) benefit
|
84
|
|
(105
|
)
|
(31
|
)
|
(14
|
)
|
34
|
|
348
|
|
112
|
|
428
|
|
|||||||||||||||
|
Operating earnings
|
$
|
503
|
|
$
|
295
|
|
$
|
143
|
|
$
|
75
|
|
$
|
385
|
|
$
|
244
|
|
(93
|
)
|
1,552
|
|
|||||||||
|
Less: Preferred stock dividends
|
6
|
|
6
|
|
|||||||||||||||||||||||||||
|
Operating earnings available to common shareholders
|
$
|
(99
|
)
|
$
|
1,546
|
|
|||||||||||||||||||||||||
Three Months Ended March 31, 2016
|
U.S.
|
Asia
|
Latin America
|
EMEA
|
MetLife Holdings
|
Brighthouse Financial
|
Corporate& Other
|
Total
|
||||||||||||||||||||||||
|
(In millions)
|
|||||||||||||||||||||||||||||||
|
Net income (loss)
|
$
|
430
|
|
$
|
863
|
|
$
|
142
|
|
$
|
74
|
|
$
|
480
|
|
$
|
385
|
|
$
|
(171
|
)
|
$
|
2,203
|
|
|||||||
|
Less: Net investment gains (losses)
|
(101
|
)
|
223
|
|
(22
|
)
|
8
|
|
(114
|
)
|
(61
|
)
|
82
|
|
15
|
|
|||||||||||||||
|
Less: Net derivative gains (losses)
|
204
|
|
411
|
|
84
|
|
(1
|
)
|
414
|
|
293
|
|
(70
|
)
|
1,335
|
|
|||||||||||||||
|
Less: Other adjustments to net income (1)
|
(66
|
)
|
67
|
|
(51
|
)
|
18
|
|
27
|
|
(143
|
)
|
(37
|
)
|
(185
|
)
|
|||||||||||||||
|
Less: Provision for income tax (expense) benefit
|
(13
|
)
|
(143
|
)
|
(20
|
)
|
(14
|
)
|
(114
|
)
|
(31
|
)
|
38
|
|
(297
|
)
|
|||||||||||||||
|
Operating earnings
|
$
|
406
|
|
$
|
305
|
|
$
|
151
|
|
$
|
63
|
|
$
|
267
|
|
$
|
327
|
|
(184
|
)
|
1,335
|
|
|||||||||
|
Less: Preferred stock dividends
|
6
|
|
6
|
|
|||||||||||||||||||||||||||
|
Operating earnings available to common shareholders
|
$
|
(190
|
)
|
$
|
1,329
|
|
|||||||||||||||||||||||||
__________________
|
(1)
|
See definitions of operating revenues and operating expenses under “— Non-GAAP and Other Financial Disclosures” for the components of such adjustments.
|
100
Reconciliation of revenues to operating revenues and expenses to operating expenses
Three Months Ended March 31, 2017
|
U.S.
|
Asia
|
Latin America
|
EMEA
|
MetLife Holdings
|
Brighthouse Financial
|
Corporate& Other
|
Total
|
||||||||||||||||||||||||
|
(In millions)
|
|||||||||||||||||||||||||||||||
|
Total revenues
|
$
|
7,026
|
|
$
|
3,103
|
|
$
|
1,398
|
|
$
|
1,059
|
|
$
|
2,911
|
|
$
|
966
|
|
$
|
(194
|
)
|
$
|
16,269
|
|
|||||||
|
Less: Net investment gains (losses)
|
(26
|
)
|
117
|
|
12
|
|
2
|
|
4
|
|
(56
|
)
|
(45
|
)
|
8
|
|
|||||||||||||||
|
Less: Net derivative gains (losses)
|
(148
|
)
|
177
|
|
136
|
|
13
|
|
(18
|
)
|
(965
|
)
|
(121
|
)
|
(926
|
)
|
|||||||||||||||
|
Less: Adjustments related to net investment gains (losses) and net derivative gains (losses)
|
—
|
|
1
|
|
—
|
|
—
|
|
—
|
|
(1
|
)
|
—
|
|
—
|
|
|||||||||||||||
|
Less: Other adjustments to revenues (1)
|
(66
|
)
|
22
|
|
31
|
|
356
|
|
(33
|
)
|
(5
|
)
|
3
|
|
308
|
|
|||||||||||||||
|
Total operating revenues
|
$
|
7,266
|
|
$
|
2,786
|
|
$
|
1,219
|
|
$
|
688
|
|
$
|
2,958
|
|
$
|
1,993
|
|
$
|
(31
|
)
|
$
|
16,879
|
|
|||||||
|
Total expenses
|
$
|
6,511
|
|
$
|
2,372
|
|
$
|
1,098
|
|
$
|
952
|
|
$
|
2,438
|
|
$
|
1,650
|
|
$
|
431
|
|
$
|
15,452
|
|
|||||||
|
Less: Adjustments related to net investment gains (losses) and net derivative gains (losses)
|
—
|
|
1
|
|
—
|
|
—
|
|
(2
|
)
|
(240
|
)
|
—
|
|
(241
|
)
|
|||||||||||||||
|
Less: Other adjustments to expenses (1)
|
—
|
|
26
|
|
60
|
|
351
|
|
52
|
|
207
|
|
86
|
|
782
|
|
|||||||||||||||
|
Total operating expenses
|
$
|
6,511
|
|
$
|
2,345
|
|
$
|
1,038
|
|
$
|
601
|
|
$
|
2,388
|
|
$
|
1,683
|
|
$
|
345
|
|
$
|
14,911
|
|
|||||||
Three Months Ended March 31, 2016
|
U.S.
|
Asia
|
Latin America
|
EMEA
|
MetLife Holdings
|
Brighthouse Financial
|
Corporate& Other
|
Total
|
||||||||||||||||||||||||
|
(In millions)
|
|||||||||||||||||||||||||||||||
|
Total revenues
|
$
|
6,978
|
|
$
|
3,756
|
|
$
|
1,209
|
|
$
|
790
|
|
$
|
3,377
|
|
$
|
2,389
|
|
$
|
(66
|
)
|
$
|
18,433
|
|
|||||||
|
Less: Net investment gains (losses)
|
(101
|
)
|
223
|
|
(22
|
)
|
8
|
|
(114
|
)
|
(61
|
)
|
82
|
|
15
|
|
|||||||||||||||
|
Less: Net derivative gains (losses)
|
204
|
|
411
|
|
84
|
|
(1
|
)
|
414
|
|
293
|
|
(70
|
)
|
1,335
|
|
|||||||||||||||
|
Less: Adjustments related to net investment gains (losses) and net derivative gains (losses)
|
—
|
|
25
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
25
|
|
|||||||||||||||
|
Less: Other adjustments to revenues (1)
|
(59
|
)
|
454
|
|
16
|
|
88
|
|
(54
|
)
|
7
|
|
(5
|
)
|
447
|
|
|||||||||||||||
|
Total operating revenues
|
$
|
6,934
|
|
$
|
2,643
|
|
$
|
1,131
|
|
$
|
695
|
|
$
|
3,131
|
|
$
|
2,150
|
|
$
|
(73
|
)
|
$
|
16,611
|
|
|||||||
|
Total expenses
|
$
|
6,326
|
|
$
|
2,655
|
|
$
|
997
|
|
$
|
691
|
|
$
|
2,658
|
|
$
|
1,858
|
|
$
|
326
|
|
$
|
15,511
|
|
|||||||
|
Less: Adjustments related to net investment gains (losses) and net derivative gains (losses)
|
—
|
|
40
|
|
—
|
|
—
|
|
(68
|
)
|
34
|
|
—
|
|
6
|
|
|||||||||||||||
|
Less: Other adjustments to expenses (1)
|
7
|
|
372
|
|
67
|
|
70
|
|
(13
|
)
|
116
|
|
32
|
|
651
|
|
|||||||||||||||
|
Total operating expenses
|
$
|
6,319
|
|
$
|
2,243
|
|
$
|
930
|
|
$
|
621
|
|
$
|
2,739
|
|
$
|
1,708
|
|
$
|
294
|
|
$
|
14,854
|
|
|||||||
__________________
|
(1)
|
See definitions of operating revenues and operating expenses under “— Non-GAAP and Other Financial Disclosures” for the components of such adjustments.
|
101
Consolidated Results — Operating
Three Months Ended
March 31, 2017
Compared with the
Three Months Ended
March 31, 2016
Unless otherwise stated, all amounts discussed below are net of income tax.
Overview.
The primary drivers of the increase in operating earnings were stronger equity market performance which improved investment yields and asset-based fees, higher net investment income from portfolio growth and a higher tax benefit, partially offset by refinements made to DAC and certain insurance-related liabilities and unfavorable underwriting.
Foreign Currency.
Changes in foreign currency exchange rates had a
$10 million
negative impact on operating earnings for the first quarter of 2017 compared to the prior period. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations. Foreign currency fluctuations can result in significant variances in the financial statement line items.
Business Growth.
An increase of $
73 million
in operating earnings was attributable to business growth. We benefited from positive net flows from many of our products. As a result, growth in the investment portfolios of our U.S., Asia, Brighthouse Financial and Latin America segments generated higher net investment income. However, this was partially offset by a corresponding increase in interest credited expense on certain insurance-related liabilities. In addition, improved results from our start-up operations also increased operating earnings.
Market Factors.
Market factors, including low interest rates, volatile equity markets, and foreign currency exchange rate fluctuations, continued to impact our investment yields; however, certain impacts were mitigated by derivatives used to hedge these risks. Excluding the impact of changes in foreign currency exchange rates on reported net investment income in our non-U.S. segments and inflation-indexed investments, investment yields increased. Investment yields were positively affected by higher income on other limited partnership interests, driven by improvements in equity market performance, and higher income on currency derivatives and real estate investments. These increases in net investment income were partially offset by lower prepayments fees and lower investment earnings on our securities lending program which resulted primarily from lower margins due to the impact of a flatter yield curve. In our Brighthouse Financial and MetLife Holdings segments, favorable equity market performance in the current period drove an increase in average separate account balances, resulting in higher asset-based fees. The changes in market factors discussed above resulted in a $
172 million
increase in operating earnings.
Underwriting, and Other Insurance Adjustments
.
Unfavorable underwriting resulted in a
$56 million
decrease in operating earnings primarily as a result of unfavorable mortality, higher non-catastrophe claim costs, and unfavorable claims experience, partially offset by favorable morbidity. Unfavorable mortality in our Brighthouse Financial, Latin America and U.S. segments was partially offset by favorable mortality in our MetLife Holdings segment. Favorable morbidity experience in our U.S. segment was partially offset by unfavorable morbidity experience in our MetLife Holdings segment. Refinements to DAC and certain insurance-related liabilities, which were recorded in both periods across the majority of our segments, resulted in a
$71 million
decrease in operating earnings. This includes unfavorable current period refinements of (i) a $37 million increase in insurance-related liabilities from the on-going impact from no longer being able to aggregate all of our universal life business for loss recognition testing since the Company’s reorganization of its businesses in the third quarter of 2016, and (ii) a $20 million increase in insurance-related liabilities as a result of additional loss recognition on certain of our universal life businesses, partially offset by (iii) a favorable current period reserve adjustment of $34 million resulting from modeling improvements in the reserving process in certain of our individual life businesses.
Expenses and Taxes.
A
$4 million
decline in expenses included lower costs as a result of the U.S. Retail Advisor Force Divestiture in our MetLife Holdings segment, as well as lower expenses in our U.S. and Asia segments, partially offset by an increase in expenses incurred related to the guaranty fund assessment for Penn Treaty, an increase in litigation reserves and an increase in costs associated with corporate initiatives and projects, including expenses associated with the Company’s unit cost initiative. The Company’s effective tax rates differ from the U.S. statutory rate of 35% typically due to non-taxable investment income, tax credits for low income housing, and foreign earnings taxed at lower rates than the U.S. statutory rate. Higher utilization of tax preferenced items and foreign rate differential improved current period operating earnings by $84 million over the prior period. Our current period results include a tax benefit of $9 million related to the settlement of an audit in Argentina. Our prior period includes a tax benefit of $20 million in Japan and a tax charge of $10 million in Chile, both related to changes in tax rates that pertain to periods prior to 2016.
102
Segment Results and Corporate & Other
U.S.
Business Overview.
An increase in sales was primarily driven by sales of stable value products, as well as funding agreement issuances in our Retirement and Income Solutions business. In addition, sales increased in our specialized life insurance products business. Changes in premiums for the Retirement and Income Solutions business were almost entirely offset by the related changes in policyholder benefits and claims. Sales increased 29% compared to the prior period in the Group Benefits business, with strong sales across our core and voluntary products. In our Property & Casualty business, sales of new policies were slightly lower for both the auto and homeowners lines of business reflecting management actions to improve value. The number of policies that were not renewed exceeded new policy sales, resulting in a decrease in exposures.
|
Three Months
Ended March 31, |
||||||||
|
2017
|
2016
|
|||||||
|
(In millions)
|
||||||||
|
Operating revenues
|
||||||||
|
Premiums
|
$
|
5,185
|
|
$
|
5,020
|
|
||
|
Universal life and investment-type product policy fees
|
265
|
|
250
|
|
||||
|
Net investment income
|
1,612
|
|
1,460
|
|
||||
|
Other revenues
|
204
|
|
204
|
|
||||
|
Total operating revenues
|
7,266
|
|
6,934
|
|
||||
|
Operating expenses
|
||||||||
|
Policyholder benefits and claims and policyholder dividends
|
5,235
|
|
5,046
|
|
||||
|
Interest credited to policyholder account balances
|
351
|
|
322
|
|
||||
|
Capitalization of DAC
|
(100
|
)
|
(111
|
)
|
||||
|
Amortization of DAC and VOBA
|
114
|
|
118
|
|
||||
|
Interest expense on debt
|
2
|
|
2
|
|
||||
|
Other operating expenses
|
909
|
|
942
|
|
||||
|
Total operating expenses
|
6,511
|
|
6,319
|
|
||||
|
Provision for income tax expense (benefit)
|
252
|
|
209
|
|
||||
|
Operating earnings
|
$
|
503
|
|
$
|
406
|
|
||
Three Months Ended March 31, 2017
Compared with the
Three Months Ended March 31, 2016
Unless otherwise stated, all amounts discussed below are net of income tax.
Business Growth.
The impact of deposits, funding agreement issuances and increased premiums resulted in higher average invested assets, improving net investment income. However, consistent with the growth in average invested assets from increased premiums, interest credited on long-duration contracts increased. An increase in average premium per policy in our auto business improved operating earnings. The remaining increase in premiums, fees and other revenues, coupled with a decline in direct and allocated expenses, was partially offset by higher volume related expenses. The current period abatement of the annual health insurer fee under PPACA was offset by a corresponding decrease in premiums, fees and other revenues. The combined impact of the items discussed above increased operating earnings by $58 million.
Market Factors.
Market factors, including low interest rates, volatile equity markets, and foreign currency exchange rate fluctuations, continued to impact our investment yields; however, certain impacts were mitigated by derivatives used to hedge these risks. Investment yields increased primarily due to higher returns on other limited partnership interests, driven by improvements in equity market performance. This increase in investment yields was partially offset by lower prepayment fees. In addition, lower investment earnings on our securities lending program resulted primarily from lower margins due to the impact of a flatter yield curve. Certain of our funding agreements and guaranteed interest contract liabilities have interest credited rates that are contractually tied to current market rates, specifically the 3-month London Interbank Offered Rate (“LIBOR”) and, as a result, a higher average interest credited rate drove an increase in interest credited expense. However, the crediting rate on certain long-duration insurance contracts decreased, which increased operating earnings. The changes in market factors discussed above resulted in a $60 million increase in operating earnings.
103
Underwriting and Other Insurance Adjustments.
Favorable claims experience in our group disability business, as well as favorable prior period development and current period utilization in our dental business, was partially offset by unfavorable claims experience in our individual disability business, which resulted in a $33 million increase in operating earnings. Unfavorable mortality in the current period, mainly due to higher severity in our universal life business and an increase in both incidence and severity in our accidental death and dismemberment business, resulted in a $12 million decrease in operating earnings. Favorable mortality from our pension risk transfer business was offset by less favorable mortality in our specialized life insurance products and income annuities businesses. In our Property & Casualty business, non-catastrophe claim costs increased by $15 million, the result of higher severities in both our auto and homeowners businesses, as well as higher frequencies in our homeowners business, partially offset by lower frequencies in our auto business. In addition, elevated catastrophe losses, net of prior year development, reduced operating earnings by $45 million in both periods.. Refinements to certain insurance and other liabilities, which were recorded in both periods, resulted in a $27 million decrease in operating earnings.
Asia
Business Overview.
Sales increased compared to the prior period primarily driven by growth in foreign currency-denominated life products in Japan, one large group case in Australia and higher sales in Korea and Hong Kong in advance of upcoming regulatory changes. Sales also increased in emerging markets, mainly in China and Bangladesh, due to business growth.
|
Three Months
Ended March 31, |
|||||||
|
2017
|
2016
|
||||||
|
(In millions)
|
|||||||
|
Operating revenues
|
|||||||
|
Premiums
|
$
|
1,708
|
|
$
|
1,658
|
|
|
|
Universal life and investment-type product policy fees
|
366
|
|
350
|
|
|||
|
Net investment income
|
702
|
|
618
|
|
|||
|
Other revenues
|
10
|
|
17
|
|
|||
|
Total operating revenues
|
2,786
|
|
2,643
|
|
|||
|
Operating expenses
|
|||||||
|
Policyholder benefits and claims and policyholder dividends
|
1,315
|
|
1,236
|
|
|||
|
Interest credited to policyholder account balances
|
321
|
|
319
|
|
|||
|
Capitalization of DAC
|
(420
|
)
|
(385
|
)
|
|||
|
Amortization of DAC and VOBA
|
291
|
|
286
|
|
|||
|
Amortization of negative VOBA
|
(37
|
)
|
(64
|
)
|
|||
|
Other operating expenses
|
875
|
|
851
|
|
|||
|
Total operating expenses
|
2,345
|
|
2,243
|
|
|||
|
Provision for income tax expense (benefit)
|
146
|
|
95
|
|
|||
|
Operating earnings
|
$
|
295
|
|
$
|
305
|
|
|
Three Months Ended March 31, 2017
Compared with the
Three Months Ended March 31, 2016
Unless otherwise stated, all amounts discussed below are net of income tax.
Foreign Currency.
The impact of changes in foreign currency exchange rates increased operating earnings by $6 million for the first quarter of 2017 compared to the prior period, primarily due to the strengthening of the Japanese yen and Korean won against the U.S. dollar. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations. Foreign currency fluctuations can result in significant variances in the financial statement line items.
Business Growth.
Asia’s premiums, fees and other revenues increased over the prior period mainly driven by growth in our foreign currency-denominated life and accident & health businesses in Japan, as well as our group insurance business in Australia. Changes in premiums for these businesses were partially offset by related changes in policyholder benefits. Positive net flows in Japan and Korea resulted in higher average invested assets, which improved net investment income. The combined impact of the items discussed above improved operating earnings by $21 million.
104
Market Factors.
Market factors, including low interest rates, volatile equity markets, and foreign currency exchange rate fluctuations, continued to impact our investment yields; however, certain impacts were mitigated by derivatives used to hedge these risks. Investment returns were favorably impacted by higher returns on other limited partnership interests, driven by improvements in equity market performance, a real estate lease termination fee and higher income on currency derivatives. These increases in net investment income were partially offset by the unfavorable impact of lower interest rates on fixed maturity securities in Japan. The decrease in returns from lower interest rates in Japan was partially offset by the favorable impact of increased sales of foreign currency-denominated fixed annuities in Japan, primarily in its Australian currency-denominated portfolio, which drove an increase in higher yielding foreign currency-denominated fixed maturity securities. The combined impact of the items discussed above increased operating earnings by $11 million.
Underwriting and Other Insurance Adjustments.
Higher lapses and claims in Japan, as well as a product mix change in Hong Kong, decreased operating earnings by $12 million. Refinements to certain insurance liabilities in the current period resulted in a $15 million decrease in operating earnings.
Expenses and Taxes.
Lower expenses, primarily driven by decreases in headcount and consulting costs in Japan and a decline in corporate overhead, increased operating earnings by $15 million. Current period results include a charge of $19 million related to a U.S. tax on dividends from our Japan operations. Prior period results include a tax benefit of $20 million related to a change in the corporate tax rate in Japan that pertains to periods prior to 2016.
Latin America
Business Overview.
Total sales for Latin America increased compared to the prior period, driven by higher sales of group accident & health and life products, partially offset by lower pension sales in Mexico.
|
Three Months
Ended March 31, |
|||||||
|
2017
|
2016
|
||||||
|
(In millions)
|
|||||||
|
Operating revenues
|
|||||||
|
Premiums
|
$
|
647
|
|
$
|
601
|
|
|
|
Universal life and investment-type product policy fees
|
260
|
|
268
|
|
|||
|
Net investment income
|
303
|
|
255
|
|
|||
|
Other revenues
|
9
|
|
7
|
|
|||
|
Total operating revenues
|
1,219
|
|
1,131
|
|
|||
|
Operating expenses
|
|||||||
|
Policyholder benefits and claims and policyholder dividends
|
633
|
|
550
|
|
|||
|
Interest credited to policyholder account balances
|
82
|
|
80
|
|
|||
|
Capitalization of DAC
|
(82
|
)
|
(73
|
)
|
|||
|
Amortization of DAC and VOBA
|
78
|
|
63
|
|
|||
|
Interest expense on debt
|
1
|
|
—
|
|
|||
|
Other operating expenses
|
326
|
|
310
|
|
|||
|
Total operating expenses
|
1,038
|
|
930
|
|
|||
|
Provision for income tax expense (benefit)
|
38
|
|
50
|
|
|||
|
Operating earnings
|
$
|
143
|
|
$
|
151
|
|
|
Three Months Ended March 31, 2017
Compared with the
Three Months Ended March 31, 2016
Unless otherwise stated, all amounts discussed below are net of income tax.
Foreign Currency.
The impact of changes in foreign currency exchange rates decreased operating earnings by $9 million for the first quarter of 2017 compared to the prior period mainly due to the weakening of the Mexican and Argentinean pesos against the U.S. dollar. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations. Foreign currency fluctuations can result in significant variances in the financial statement line items.
105
Business Growth.
Latin America experienced business growth across several lines of business within Mexico and Chile. This business growth resulted in increased premiums and policy fee income which was partially offset by related changes in policyholder benefits. Positive net flows, primarily from Mexico, Chile and Argentina, resulted in an increase in average invested assets and generated higher net investment income. This was partially offset by an increase in interest credited expense on certain insurance liabilities. Business growth also drove an increase in operating expenses and commissions, which were partially offset by higher DAC capitalization and amortization. The items discussed above resulted in an $11 million increase in operating earnings.
Market Factors.
Changes in market factors resulted in a $17 million increase in operating earnings primarily due to higher investment yields. The increase in investment yields was primarily driven by higher returns on alternative investments in Chile and higher derivative income in Mexico. These increases were partially offset by lower yields on fixed maturity securities in Argentina.
Underwriting and Other Insurance Adjustments.
Unfavorable underwriting resulted in a $17 million decrease to operating earnings driven by higher claims experience in Mexico. In addition, refinements to certain insurance liabilities, primarily in the ProVida pension business, and other adjustments in both the current and prior periods resulted in a $12 million decrease to operating earnings.
Expenses and Taxes.
Higher expenses, primarily driven by employee-related costs, decreased operating earnings by $5 million as compared to the prior period. In the first quarter of 2016, our Chilean business incurred a tax charge of $10 million as a result of tax reform legislation in Chile that pertains to periods prior to 2016. Operating earnings decreased by $6 million primarily due to a decrease of $15 million as a result of changes in the valuation of the peso in Argentina in both periods, partially offset by a $9 million benefit related to the settlement of a tax audit, also in Argentina.
EMEA
Business Overview.
Sales have increased due to growth in the Middle East and several European markets.
|
Three Months
Ended March 31, |
|||||||
|
2017
|
2016
|
||||||
|
(In millions)
|
|||||||
|
Operating revenues
|
|||||||
|
Premiums
|
$
|
502
|
|
$
|
500
|
|
|
|
Universal life and investment-type product policy fees
|
95
|
|
95
|
|
|||
|
Net investment income
|
74
|
|
80
|
|
|||
|
Other revenues
|
17
|
|
20
|
|
|||
|
Total operating revenues
|
688
|
|
695
|
|
|||
|
Operating expenses
|
|||||||
|
Policyholder benefits and claims and policyholder dividends
|
269
|
|
261
|
|
|||
|
Interest credited to policyholder account balances
|
24
|
|
29
|
|
|||
|
Capitalization of DAC
|
(92
|
)
|
(101
|
)
|
|||
|
Amortization of DAC and VOBA
|
87
|
|
102
|
|
|||
|
Amortization of negative VOBA
|
(3
|
)
|
(3
|
)
|
|||
|
Other operating expenses
|
316
|
|
333
|
|
|||
|
Total operating expenses
|
601
|
|
621
|
|
|||
|
Provision for income tax expense (benefit)
|
12
|
|
11
|
|
|||
|
Operating earnings
|
$
|
75
|
|
$
|
63
|
|
|
Three Months Ended March 31, 2017
Compared with the
Three Months Ended March 31, 2016
Unless otherwise stated, all amounts discussed below are net of income tax.
Foreign Currency.
The impact of changes in foreign currency exchange rates reduced operating earnings by $7 million for the first quarter of 2017 compared to the prior period, primarily driven by the strengthening of the U.S. dollar against the British pound, Turkish lira, Egyptian pound and euro. Unless otherwise stated, all amounts discussed below are net of foreign currency fluctuations. Foreign currency fluctuations can result in significant variances in the financial statement line items.
106
Business Growth.
Growth in the Middle East, primarily in our accident & health and credit life businesses in Turkey, and in several European markets increased operating earnings by $8 million.
Underwriting.
Favorable underwriting, primarily in our accident & health business in Greece, was largely offset by unfavorable underwriting, primarily in our accident & health and credit businesses in the Middle East. This resulted in a slight increase in operating earnings.
Expenses.
Operating earnings increased by $8 million due to timing and expense discipline across the region.
Taxes and Other.
Lower effective tax rates along with a number of small items across many countries resulted in a $4 million increase to operating earnings. This was partially offset by a $3 million prior period benefit following the cancellation of a distribution agreement with one of our bancassurance partners.
MetLife Holdings
Business Overview.
As a result of the proposed Separation and the U.S. Retail Advisor Force Divestiture, we have discontinued the marketing of life and annuity products in this segment, which has led to lower sales. This will result in a declining DAC asset over time and we anticipate an average decline in premiums, fees and other revenues of approximately 5% per year from expected business run-off. A significant portion of our operating earnings is driven by separate account balances. Most directly, these balances determine asset-based fee income but they also impact DAC amortization and asset-based commissions. Separate account balances are driven by sales, movements in the market, surrenders, withdrawals, benefit payments, transfers and policy charges. Separate account balances increased due to equity market performance, partially offset by the impact of negative net flows, as benefits, surrenders and withdrawals exceeded sales. Although we have discontinued selling our long-term care product, we continue to collect premiums and administer the existing block of business, which contributed to asset growth in the segment, and we expect the related reserves to grow as this block matures.
|
Three Months
Ended March 31, |
|||||||
|
2017
|
2016
|
||||||
|
(In millions)
|
|||||||
|
Operating revenues
|
|||||||
|
Premiums
|
$
|
1,059
|
|
$
|
1,097
|
|
|
|
Universal life and investment-type product policy fees
|
362
|
|
355
|
|
|||
|
Net investment income
|
1,441
|
|
1,475
|
|
|||
|
Other revenues
|
96
|
|
204
|
|
|||
|
Total operating revenues
|
2,958
|
|
3,131
|
|
|||
|
Operating expenses
|
|||||||
|
Policyholder benefits and claims and policyholder dividends
|
1,736
|
|
1,823
|
|
|||
|
Interest credited to policyholder account balances
|
257
|
|
258
|
|
|||
|
Capitalization of DAC
|
(34
|
)
|
(100
|
)
|
|||
|
Amortization of DAC and VOBA
|
74
|
|
148
|
|
|||
|
Interest expense on debt
|
15
|
|
14
|
|
|||
|
Other operating expenses
|
340
|
|
596
|
|
|||
|
Total operating expenses
|
2,388
|
|
2,739
|
|
|||
|
Provision for income tax expense (benefit)
|
185
|
|
125
|
|
|||
|
Operating earnings
|
$
|
385
|
|
$
|
267
|
|
|
Three Months Ended March 31, 2017
Compared with the
Three Months Ended March 31, 2016
Unless otherwise stated, all amounts discussed below are net of income tax.
107
Business Growth
. Lower net investment income due to a reduced invested asset base decreased operating earnings. The reduced asset base is primarily the result of the recapture of two assumed single-premium deferred annuity reinsurance agreements (by affiliates included in the Brighthouse Financial segment) in 2016. This decline was partially offset by net asset growth in our long-term care and life businesses. Consistent with this asset growth, interest credited on insurance liabilities increased. In our deferred annuities business, negative net flows contributed to a decrease in average separate account balances, and consequently, asset based-fee income. Operating earnings also decreased due to higher DAC amortization and higher costs associated with our variable annuity guaranteed minimum death benefits (“GMDBs”). In our life business, lower universal life sales resulted in lower fee income, decreasing operating earnings. The combined impact of the items discussed above resulted in a $73 million decrease in operating earnings.
Market Factors.
Market factors, including low interest rates, volatile equity markets, and foreign currency exchange rate fluctuations, continued to impact our investment yields; however, certain impacts were mitigated by derivatives used to hedge these risks. Investment yields increased primarily due to higher returns on other limited partnership interests, driven by improvements in equity market performance. This increase in investment yields was partially offset by declines in prepayment fees, derivative income and mortgage loan yields. In our deferred annuity business, higher equity returns drove an increase in average separate account balances which resulted in higher asset-based fee income. Operating earnings increased due to declines in DAC amortization and lower costs associated with our variable annuity GMDBs. The changes in market factors discussed above resulted in a $36 million increase in operating earnings.
Underwriting and Other Insurance Adjustments.
Favorable mortality in our life businesses, partially offset by unfavorable claims experience in our long-term care business, resulted in a slight increase in operating earnings. Refinements to DAC and certain insurance-related liabilities that were recorded in both periods resulted in a $72 million increase in operating earnings. This includes favorable current period refinements of (i) a $36 million DAC adjustment related to certain participating whole life business assumed from affiliates, one of which is included in the Brighthouse Financial segment; and (ii) a $34 million reserve adjustment resulting from modeling improvements in the reserving process in our life businesses.
Expenses.
Operating earnings increased by $34 million as a result of lower expenses, primarily due to lower costs as a result of the U.S. Retail Advisor Force Divestiture, partially offset by separation related costs.
Other.
In connection with the proposed Separation, annuities reinsurance activity with affiliates, that are included in the Brighthouse Financial segment, increased operating earnings by $42 million. This favorable impact was primarily due to the recapture in 2016 of certain single-premium deferred annuities and the elimination of interest credited payments on the related reinsurance payable, as well as lower DAC amortization. This increase was also due to the recapture and novation, in the current period, of assumed and ceded agreements with affiliates covering certain variable annuity business.
108
Brighthouse Financial
Business Overview.
While sales of our index-linked annuities increased, overall annuity sales decreased by 35%, driven by a 51% decline in variable annuity products and a 12% decline in fixed annuity products. These declines were primarily due to the suspension of sales by a major distributor and the discontinuance of sales of guaranteed minimum income benefits (“GMIB”) riders on our variable annuity contracts, both of which occurred in 2016. Life sales decreased 54%, driven by a 67% decrease in term life and a 65% decrease in whole life. These declines were primarily due to the U.S. Retail Advisor Force Divestiture in 2016 and our discontinuance of new sales of whole life and certain term life products in the current period.
In our annuities business, average separate account balances increased as favorable equity market performance in the current period more than offset the impact of continued negative net flows, which were higher in the current period compared to the prior period.
|
Three Months
Ended March 31, |
|||||||
|
2017
|
2016
|
||||||
|
(In millions)
|
|||||||
|
Operating revenues
|
|||||||
|
Premiums
|
$
|
177
|
|
$
|
393
|
|
|
|
Universal life and investment-type product policy fees
|
884
|
|
858
|
|
|||
|
Net investment income
|
858
|
|
813
|
|
|||
|
Other revenues
|
74
|
|
86
|
|
|||
|
Total operating revenues
|
1,993
|
|
2,150
|
|
|||
|
Operating expenses
|
|
|
|||||
|
Policyholder benefits and claims and policyholder dividends
|
631
|
|
703
|
|
|||
|
Interest credited to policyholder account balances
|
275
|
|
289
|
|
|||
|
Capitalization of DAC
|
(67
|
)
|
(102
|
)
|
|||
|
Amortization of DAC and VOBA
|
200
|
|
162
|
|
|||
|
Interest expense on debt
|
32
|
|
32
|
|
|||
|
Other operating expenses
|
612
|
|
624
|
|
|||
|
Total operating expenses
|
1,683
|
|
1,708
|
|
|||
|
Provision for income tax expense (benefit)
|
66
|
|
115
|
|
|||
|
Operating earnings
|
$
|
244
|
|
$
|
327
|
|
|
Three Months Ended March 31, 2017
Compared with the
Three Months Ended March 31, 2016
Unless otherwise stated, all amounts discussed below are net of income tax.
Business Growth.
A $40 million increase in operating earnings was attributable to business growth, primarily due to higher net investment income, lower amortization of DAC and deferred sales inducements (“DSI”) and lower interest credited expense, partially offset by lower asset-based fees. Net investment income increased due to a larger invested asset base resulting primarily from the recapture (from an affiliate included in the MetLife Holdings segment) of ceded reinsurance agreements covering certain single-premium deferred annuity contracts and a capital contribution from MetLife, Inc., both of which occurred in 2016, as well as positive general account net flows in our annuities and life businesses, partially offset by funding agreement repayments in our run-off business. Amortization of DAC and DSI decreased due to lower asset-based fees in our deferred annuities business. Interest credited expense decreased due to lower liability balances related to our funding agreements, which is in run-off, partially offset by higher average policyholder account balances in our annuities business due to increased sales of our index-linked annuities and lower withdrawals. Negative net flows in our variable annuity business resulted in lower average separate account balances which decreased asset-based fees.
109
Market Factors.
Market factors, including interest rates, volatile equity markets and foreign currency exchange rate fluctuations, continued to impact our investment yields; however, certain impacts were mitigated by derivatives used to hedge these risks. These market factors resulted in a $41 million increase in operating earnings, primarily due to an increase in asset-based fees, lower costs associated with our variable annuity GMDBs and higher net investment income. Favorable equity market performance in the current period drove higher separate account returns, resulting in the increase in asset-based fees. Net investment income increased primarily due to higher returns on other limited partnership interests, also driven by favorable equity market performance, an increase in fixed maturity yields and an increase in derivative income. These favorable yield impacts were partially offset by lower investment earnings on our securities lending program, primarily the result of lower margins due to the impact of a flatter yield curve, and lower prepayment fees.
Underwriting and Other Insurance Adjustments.
Unfavorable mortality experience, primarily in our traditional life business, decreased operating earnings by $37 million. Refinements to DAC and certain insurance-related liabilities resulted in a decrease in operating earnings of $89 million. This decrease was primarily driven by a $39 million increase in insurance-related liabilities from the on-going impact from no longer being able to aggregate our universal life business for loss recognition testing since the Company’s reorganization of its businesses in the third quarter of 2016, a $20 million increase in insurance-related liabilities from additional loss recognition on our universal life business in the current period and $32 million DAC adjustment mostly related to participating whole life business ceded to an affiliate included in the MetLife Holdings segment.
Other.
In connection with the proposed Separation, annuities reinsurance activity with an affiliate, that is included in the MetLife Holdings segment, decreased operating earnings by $42 million. This unfavorable impact was primarily due to the elimination of interest credited payments on a reinsurance receivable related to certain single premium deferred annuities that we recaptured in 2016 and higher DAC amortization resulting from this same recapture activity. This decrease was also due to the recapture and novation, in the current period, of assumed and ceded agreements covering certain variable annuity business.
Corporate & Other
|
Three Months
Ended March 31, |
|||||||
|
2017
|
2016
|
||||||
|
(In millions)
|
|||||||
|
Operating revenues
|
|||||||
|
Premiums
|
$
|
37
|
|
$
|
(2
|
)
|
|
|
Universal life and investment-type product policy fees
|
(31
|
)
|
(25
|
)
|
|||
|
Net investment income
|
5
|
|
5
|
|
|||
|
Other revenues
|
(42
|
)
|
(51
|
)
|
|||
|
Total operating revenues
|
(31
|
)
|
(73
|
)
|
|||
|
Operating expenses
|
|||||||
|
Policyholder benefits and claims and policyholder dividends
|
9
|
|
(26
|
)
|
|||
|
Interest credited to policyholder account balances
|
—
|
|
4
|
|
|||
|
Capitalization of DAC
|
(1
|
)
|
(4
|
)
|
|||
|
Amortization of DAC and VOBA
|
1
|
|
2
|
|
|||
|
Interest expense on debt
|
246
|
|
264
|
|
|||
|
Other operating expenses
|
90
|
|
54
|
|
|||
|
Total operating expenses
|
345
|
|
294
|
|
|||
|
Provision for income tax expense (benefit)
|
(283
|
)
|
(183
|
)
|
|||
|
Operating earnings
|
(93
|
)
|
(184
|
)
|
|||
|
Less: Preferred stock dividends
|
6
|
|
6
|
|
|||
|
Operating earnings available to common shareholders
|
$
|
(99
|
)
|
$
|
(190
|
)
|
|
110
The table below presents operating earnings available to common shareholders by source, net of income tax:
|
Three Months
Ended March 31, |
|||||||
|
2017
|
2016
|
||||||
|
(In millions)
|
|||||||
|
Other business activities
|
$
|
5
|
|
$
|
(8
|
)
|
|
|
Other net investment income
|
3
|
|
4
|
|
|||
|
Interest expense on debt
|
(160
|
)
|
(171
|
)
|
|||
|
Preferred stock dividends
|
(6
|
)
|
(6
|
)
|
|||
|
Corporate initiatives and projects
|
(32
|
)
|
(25
|
)
|
|||
|
Incremental tax benefit (expense)
|
151
|
|
54
|
|
|||
|
Other
|
(60
|
)
|
(38
|
)
|
|||
|
Operating earnings available to common shareholders
|
$
|
(99
|
)
|
$
|
(190
|
)
|
|
Three Months Ended March 31, 2017
Compared with the
Three Months Ended March 31, 2016
Unless otherwise stated, all amounts discussed below are net of income tax.
Other Business Activities.
Operating earnings from other business activities increased $13 million. This was primarily related to improved results from our start-up operations.
Other Net Investment Income.
Other net investment income declined slightly primarily driven by lower investment earnings on mortgage loans and fixed maturity securities, largely offset by a decrease in both rates and the amount credited to the segments due to a reduction in the economic capital managed by Corporate & Other on their behalf.
Interest Expense on Debt.
Interest expense on debt decreased by $11 million, mainly due to the maturity of $1.25 billion of senior notes in June 2016.
Corporate Initiatives and Projects.
Expenses associated with corporate initiatives and projects increased by $7 million, primarily due to higher costs associated with enterprise-wide initiatives taken by the Company, which includes expenses associated with the Company’s unit cost initiative.
Incremental Tax Benefit.
Corporate & Other benefits from the impact of certain permanent tax preferenced items, including non-taxable investment income and tax credits for investments in low income housing. As a result, our effective tax rate differs from the U.S. statutory rate of 35%. In the current period, we had higher utilization of tax preferenced investments, which increased our operating earnings by $97 million over the prior period.
Other.
In the current period, operating earnings decreased $44 million as a result of expenses incurred related to the guaranty fund assessment for Penn Treaty and an increase in litigation reserves. The prior period included a $21 million decrease in operating earnings resulting from net adjustments to certain reinsurance assets and liabilities.
111
Investments
Investment Risks
Our primary investment objective is to optimize, net of income tax, risk-adjusted net investment income and risk-adjusted total return while ensuring that assets and liabilities are managed on a cash flow and duration basis. The Investments Department, led by the Chief Investment Officer, manages investment risks using a risk control framework comprised of policies, procedures and limits, as discussed further below. The Investments Risk Committee, chaired by the Global Risk Management Department, reviews and monitors investment risk limits and tolerances. We are exposed to the following primary sources of investment risks:
|
•
|
credit risk, relating to the uncertainty associated with the continued ability of a given obligor to make timely payments of principal and interest;
|
|
•
|
interest rate risk, relating to the market price and cash flow variability associated with changes in market interest rates. Changes in market interest rates will impact the net unrealized gain or loss position of our fixed income investment portfolio and the rates of return we receive on both new funds invested and reinvestment of existing funds;
|
|
•
|
liquidity risk, relating to the diminished ability to sell certain investments, in times of strained market conditions;
|
|
•
|
market valuation risk, relating to the variability in the estimated fair value of investments associated with changes in market factors such as credit spreads and equity market levels. A widening of credit spreads will adversely impact the net unrealized gain (loss) position of the fixed income investment portfolio, will increase losses associated with credit-based non-qualifying derivatives where we assume credit exposure, and, if credit spreads widen significantly or for an extended period of time, will likely result in higher other-than-temporary impairment (“OTTI”). Credit spread tightening will reduce net investment income associated with purchases of fixed maturity securities and will favorably impact the net unrealized gain (loss) position of the fixed income investment portfolio;
|
|
•
|
currency risk, relating to the variability in currency exchange rates for foreign denominated investments. This risk relates to potential decreases in estimated fair value and net investment income resulting from changes in currency exchange rates versus the U.S. dollar. In general, the weakening of foreign currencies versus the U.S. dollar will adversely affect the estimated fair value of our foreign denominated investments; and
|
|
•
|
real estate risk, relating to commercial, agricultural and residential real estate, and stemming from factors, which include, but are not limited to, market conditions, including the demand and supply of leasable commercial space, creditworthiness of borrowers and their tenants and joint venture partners, capital markets volatility and inherent interest rate movements.
|
We manage investment risk through in-house fundamental credit analysis of the underlying obligors, issuers, transaction structures and real estate properties. We also manage credit risk, market valuation risk and liquidity risk through industry and issuer diversification and asset allocation. Risk limits to promote diversification by asset sector, avoid concentrations in any single issuer and limit overall aggregate credit and equity risk exposure, as measured by our economic capital framework, are approved annually by a committee of directors that oversees our investment portfolio. For real estate assets, we manage credit risk and market valuation risk through geographic, property type and product type diversification and asset allocation. We manage interest rate risk as part of our ALM strategies. These strategies include maintaining an investment portfolio with diversified maturities that has a weighted average duration that reflects the duration of our estimated liability cash flow profile, and utilizing product design, such as the use of market value adjustment features and surrender charges, to manage interest rate risk. We also manage interest rate risk through proactive monitoring and management of certain non-guaranteed elements of our products, such as the resetting of credited interest and dividend rates for policies that permit such adjustments. In addition to hedging with foreign currency derivatives, we manage currency risk by matching much of our foreign currency liabilities in our foreign subsidiaries with their respective foreign currency assets, thereby reducing our risk to foreign currency exchange rate fluctuation. We also use certain derivatives in the management of credit, interest rate, and market valuation risk.
We use purchased credit default swaps to mitigate credit risk in our investment portfolio. Generally, we purchase credit protection by entering into credit default swaps referencing the issuers of specific assets we own. In certain cases, basis risk exists between these credit default swaps and the specific assets we own. For example, we may purchase credit protection on a macro basis to reduce exposure to specific industries or other portfolio concentrations. In such instances, the referenced entities and obligations under the credit default swaps may not be identical to the individual obligors or securities in our investment portfolio. In addition, our purchased credit default swaps may have shorter tenors than the underlying investments they are hedging. However, we dynamically hedge this risk through the rebalancing and rollover of our credit default swaps at their most liquid tenors. We believe that our purchased credit default swaps serve as effective economic hedges of our credit exposure.
112
We enter into market standard purchased and written credit default swap contracts. Payout under such contracts is triggered by certain credit events experienced by the referenced entities. For credit default swaps covering North American corporate issuers, credit events typically include bankruptcy and failure to pay on borrowed money. For European corporate issuers, credit events typically also include involuntary restructuring. With respect to credit default contracts on Western European sovereign debt, credit events typically include failure to pay debt obligations, repudiation, moratorium, or involuntary restructuring. In each case, payout on a credit default swap is triggered only after the Credit Derivatives Determinations Committee of the International Swaps and Derivatives Association determines that a credit event has occurred.
Current Environment
The global economy and markets continue to be affected by stress and volatility, which has adversely affected the financial services sector, in particular, and global capital markets. Recently, political and/or economic instability in the U.K., Mexico, Italy, Turkey and Puerto Rico have contributed to global market volatility. Events following the U.K.’s referendum on June 23, 2016 and the uncertainties, including foreign currency exchange risks, associated with its pending withdrawal from the EU have also contributed to market volatility, both in the U.S. and beyond. See “ — Industry Trends — Financial and Economic Environment.”
As a global insurance company, we are affected by the monetary policy of central banks around the world. See “— Industry Trends — Financial and Economic Environment” for further information on such measures, as well as for information regarding actions taken by Japan’s central government and the Bank of Japan to boost inflation expectations and achieve sustainable economic growth in Japan. See also “— Industry Trends — Impact of a Sustained Low Interest Rate Environment” for information regarding the March 2017 action taken by the FOMC to raise the federal funds rate. The Federal Reserve may take further actions to influence interest rates in the future, which may have an impact on the pricing levels of risk-bearing investments and may adversely impact the level of product sales.
European Investments
We maintain general account investments in Europe to support our insurance operations and related policyholder liabilities in these countries and certain of our non-European operations invest in Europe for diversification. In Europe, we have proactively mitigated risk in both direct and indirect exposures by investing in a diversified portfolio of high quality investments with a focus on the higher-rated countries, including the U.K., Germany, France, the Netherlands, Poland, Norway and Sweden. The sovereign debt of these countries continues to maintain investment grade credit ratings from all major rating agencies. Our European fixed maturity and perpetual hybrid securities classified as non-redeemable preferred stock are invested in a diversified portfolio of primarily non-financial services securities. At March 2017, our exposure to such securities in Europe totaled
$40.0 billion
, at estimated fair value, of which
$8.8 billion
was in sovereign fixed maturity securities. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Investments — Current Environment — European Investments” included in the
2016
Annual Report for further information.
Selected Country Investments
Recent country specific volatility due to local economic and/or political concerns has affected the performance of certain of our investments. See “ — Industry Trends — Financial and Economic Environment.”
We have exposure to such volatility, as we maintain general account investments in the U.K., Mexico, Italy, Turkey and Puerto Rico to support our insurance operations and related policyholder liabilities in these countries; and we also have exposure through our global portfolio diversification. Our exposure to sovereign fixed maturity securities and total fixed maturity securities of the U.K., Mexico, Italy, Turkey and Puerto Rico totaled
$4.8 billion
and
$20.3 billion
, at estimated fair value, respectively, at
March 31, 2017
. Our exposure to Puerto Rico political subdivision fixed maturities is in the form of revenue bonds and we have no general obligation bonds. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Investments — Current Environment — Selected Country Investments” included in the
2016
Annual Report for further information by country.
We manage direct and indirect investment exposure in the selected countries through fundamental credit analysis and we continually monitor and adjust our level of investment exposure. We do not expect that our general account investments in these countries will have a material adverse effect on our results of operations or financial condition.
113
Current Environment — Summary
All of these factors have had and could continue to have an adverse effect on the financial results of companies in the financial services industry, including MetLife. Such global economic conditions, as well as the global financial markets, continue to impact our net investment income, net investment gains (losses), net derivative gains (losses), level of unrealized gains (losses) within the various asset classes in our investment portfolio, and our level of investment in lower yielding cash equivalents, short-term investments and government securities. See “— Industry Trends,” and “Risk Factors — Economic Environment and Capital Markets-Related Risks — We Are Exposed to Significant Global Financial and Capital Markets Risks Which May Adversely Affect Our Results of Operations, Financial Condition and Liquidity, and May Cause Our Net Investment Income to Vary from Period to Period” included in the
2016
Annual Report.
Investment Portfolio Results
The following yield table presents the yield and net investment income for our investment portfolio for the periods indicated. Yields are calculated using reported net investment income which is not adjusted for the impact of changes in foreign currency exchange rates. As described below, this table reflects certain differences from the presentation of net investment income presented in the GAAP consolidated statements of operations. This yield table presentation is consistent with how we measure our investment performance for management purposes, and we believe it enhances understanding of our investment portfolio results.
|
|
For the Three Months Ended March 31,
|
||||||||||||
|
|
2017
|
2016
|
|||||||||||
|
|
Yield % (1)
|
Amount
|
Yield % (1)
|
Amount
|
|||||||||
|
|
(Dollars in millions)
|
||||||||||||
|
Fixed maturity securities (2), (3)
|
4.35
|
|
%
|
$
|
3,414
|
|
4.43
|
|
%
|
$
|
3,628
|
|
|
|
Mortgage loans (3)
|
4.48
|
|
%
|
845
|
|
4.68
|
|
%
|
807
|
|
|||
|
Real estate and real estate joint ventures
|
3.68
|
|
%
|
85
|
|
3.39
|
|
%
|
76
|
|
|||
|
Policy loans
|
5.23
|
|
%
|
145
|
|
5.19
|
|
%
|
149
|
|
|||
|
Equity securities
|
4.92
|
|
%
|
34
|
|
5.02
|
|
%
|
37
|
|
|||
|
Other limited partnership interests
|
17.52
|
|
%
|
297
|
|
2.71
|
|
%
|
46
|
|
|||
|
Cash and short-term investments
|
1.07
|
|
%
|
37
|
|
0.99
|
|
%
|
25
|
|
|||
|
Other invested assets
|
|
|
295
|
|
|
|
271
|
|
|||||
|
Investment income
|
4.70
|
|
%
|
5,152
|
|
4.55
|
|
%
|
5,039
|
|
|||
|
Investment fees and expenses
|
(0.14
|
)
|
(157
|
)
|
(0.16
|
)
|
(167
|
)
|
|||||
|
Net investment income including divested businesses and lag elimination (4), (5)
|
4.56
|
|
%
|
4,995
|
|
4.39
|
|
%
|
4,872
|
|
|||
|
Less: net investment income from divested businesses and lag elimination (4), (5)
|
—
|
|
(166
|
)
|
|||||||||
|
Net investment income (5)
|
$
|
4,995
|
|
$
|
4,706
|
|
|||||||
__________________
|
(1)
|
Yields are calculated as investment income as a percent of average quarterly asset carrying values. Investment income excludes recognized gains and losses and reflects the adjustments presented in footnote (5) below. Asset carrying values exclude unrealized gains (losses), collateral received in connection with our securities lending program, freestanding derivative assets, collateral received from derivative counterparties, the effects of consolidating certain variable interest entities (“VIEs”) under GAAP that are treated as consolidated securitization entities (“CSEs”) and contractholder-directed unit-linked investments. A yield is not presented for other invested assets, as it is not considered a meaningful measure of performance for this asset class.
|
|
(2)
|
Investment income includes amounts from FVO securities of
$29 million
and
$6 million
for the
three months ended
March 31, 2017
and
2016
, respectively.
|
|
(3)
|
Investment income from fixed maturity securities and mortgage loans includes prepayment fees.
|
|
(4)
|
Net investment income included in yield calculations includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment (“investment hedge adjustments”).
|
114
|
(5)
|
Net investment income presented in the yield table varies from the most directly comparable GAAP measure due to certain reclassifications and adjustments and excludes the effects of consolidating certain VIEs under GAAP that are treated as CSEs and contractholder-directed unit-linked investments, as presented below.
|
|
Three Months
Ended March 31, |
|||||||
|
2017
|
2016
|
||||||
|
(In millions)
|
|||||||
|
Net investment income — in the above yield table
|
$
|
4,995
|
|
$
|
4,706
|
|
|
|
Investment hedge adjustments
|
(214
|
)
|
(221
|
)
|
|||
|
Operating joint ventures adjustment
|
(1
|
)
|
5
|
|
|||
|
Divested businesses and lag elimination (1)
|
—
|
|
166
|
|
|||
|
Contractholder-directed unit-linked investments
|
416
|
|
(97
|
)
|
|||
|
Net investment income — GAAP consolidated statements of operations
|
$
|
5,196
|
|
$
|
4,559
|
|
|
__________________
|
(1)
|
The amount of
$166 million
for the
three months ended
March 31, 2016
, relates to the impact of converting the Company’s Japan operations to calendar year-end reporting. See Note
2
of the Notes to the Interim Condensed Consolidated Financial Statements for further information.
|
See “— Results of Operations — Consolidated Results —
Three Months Ended March 31, 2017
Compared with the
Three Months Ended March 31, 2016
” for an analysis of the period over period changes in net investment income.
Fixed Maturity and Equity Securities AFS
The following table presents fixed maturity and equity securities available-for-sale (“AFS”) by type (public or private) and information about perpetual and redeemable securities held at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||
|
Estimated Fair Value
|
% of Total
|
Estimated Fair Value
|
% of Total
|
|||||||||
|
(Dollars in millions)
|
||||||||||||
|
Fixed maturity securities
|
||||||||||||
|
Publicly-traded
|
$
|
302,328
|
|
85.0
|
%
|
$
|
298,604
|
|
85.1
|
%
|
||
|
Privately-placed
|
53,200
|
|
15.0
|
52,285
|
|
14.9
|
||||||
|
Total fixed maturity securities
|
$
|
355,528
|
|
100.0
|
%
|
$
|
350,889
|
|
100.0
|
%
|
||
|
Percentage of cash and invested assets
|
67.8
|
%
|
67.7
|
%
|
||||||||
|
Equity securities
|
||||||||||||
|
Publicly-traded
|
$
|
2,256
|
|
66.8
|
%
|
$
|
2,066
|
|
64.7
|
%
|
||
|
Privately-held
|
1,121
|
|
33.2
|
1,128
|
|
35.3
|
||||||
|
Total equity securities
|
$
|
3,377
|
|
100.0
|
%
|
$
|
3,194
|
|
100.0
|
%
|
||
|
Percentage of cash and invested assets
|
0.6
|
%
|
0.6
|
%
|
||||||||
|
Perpetual securities included within fixed maturity and equity securities AFS
|
$
|
537
|
|
$
|
599
|
|
||||||
|
Redeemable preferred stock with a stated maturity included within fixed maturity securities AFS
|
$
|
663
|
|
$
|
1,080
|
|
||||||
Perpetual securities are included within fixed maturity and equity securities. Upon acquisition, we classify perpetual securities that have attributes of both debt and equity as fixed maturity securities if the securities have an interest rate step-up feature which, when combined with other qualitative factors, indicates that the securities have more debt-like characteristics; while those with more equity-like characteristics are classified as equity securities. Many of such securities, commonly referred to as “perpetual hybrid securities,” have been issued by non-U.S. financial institutions that are accorded the highest two capital treatment categories by their respective regulatory bodies (i.e. core capital, or “Tier 1 capital” and perpetual deferrable securities, or “Upper Tier 2 capital”).
115
Redeemable preferred stock with a stated maturity is included within fixed maturity securities. These securities, which are commonly referred to as “capital securities,” primarily have cumulative interest deferral features and are primarily issued by U.S. financial institutions.
In connection with our investment management business, we manage privately-placed and infrastructure fixed maturity securities on behalf of institutional clients, which are unaffiliated investors. These privately-placed and infrastructure fixed maturity securities had an estimated fair value of
$8.2 billion
and
$8.0 billion
at
March 31, 2017
and
December 31, 2016
, respectively. We also
manage below investment grade fixed maturity securities on behalf of institutional clients, which are unaffiliated investors. These fixed maturity securities had an estimated fair value of
$318 million and $316 million
at
March 31, 2017
and December 31, 2016, respectively. As these assets are managed on behalf of, and owned by, our institutional clients, they are not included in our consolidated financial statements.
Also in connection with our investment management business, we manage index investment portfolios that track the return of industry fixed income and equity market indices such as the Barclay’s U.S. Aggregate Bond Index and S&P 500
®
Index. These assets had an estimated fair value of
$28.0 billion
and
$27.2 billion
at
March 31, 2017
and
December 31, 2016
, respectively, and are included within separate account assets in our interim condensed consolidated financial statements.
See also “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Investments — Fixed Maturity and Equity Securities AFS — Valuation of Securities” included in the
2016
Annual Report for further information on the processes used to value securities and the related controls.
Fair Value of Fixed Maturity and Equity Securities – AFS
Fixed maturity and equity securities AFS measured at estimated fair value on a recurring basis and their corresponding fair value pricing sources are as follows:
|
|
March 31, 2017
|
||||||||||||
|
|
Fixed Maturity
Securities
|
Equity
Securities
|
|||||||||||
|
|
(Dollars in millions)
|
||||||||||||
|
Level 1
|
|||||||||||||
|
Quoted prices in active markets for identical assets
|
$
|
30,163
|
|
8.5
|
%
|
$
|
1,587
|
|
47.0
|
%
|
|||
|
Level 2
|
|||||||||||||
|
Independent pricing sources
|
301,544
|
|
84.8
|
1,073
|
|
31.8
|
|||||||
|
Internal matrix pricing or discounted cash flow techniques
|
2,861
|
|
0.8
|
95
|
|
2.8
|
|||||||
|
Significant other observable inputs
|
304,405
|
|
85.6
|
1,168
|
|
34.6
|
|||||||
|
Level 3
|
|||||||||||||
|
Independent pricing sources
|
15,718
|
|
4.4
|
469
|
|
13.9
|
|||||||
|
Internal matrix pricing or discounted cash flow techniques
|
3,697
|
|
1.0
|
147
|
|
4.4
|
|||||||
|
Independent broker quotations
|
1,545
|
|
0.5
|
6
|
|
0.1
|
|||||||
|
Significant unobservable inputs
|
20,960
|
|
5.9
|
622
|
|
18.4
|
|||||||
|
Total estimated fair value
|
$
|
355,528
|
|
100.0
|
%
|
$
|
3,377
|
|
100.0
|
%
|
|||
See Note
7
of the Notes to the Interim Condensed Consolidated Financial Statements for the fixed maturity securities and equity securities AFS fair value hierarchy.
116
The composition of fair value pricing sources for and significant changes in Level 3 securities at
March 31, 2017
are as follows:
|
•
|
The majority of the Level 3 fixed maturity and equity securities AFS were concentrated in three sectors: foreign and United States corporate securities and residential mortgage-backed securities (“RMBS”).
|
|
•
|
Level 3 fixed maturity securities are priced principally through market standard valuation methodologies, independent pricing services and, to a much lesser extent, independent non-binding broker quotations using inputs that are not market observable or cannot be derived principally from or corroborated by observable market data. Level 3 fixed maturity securities consist of less liquid securities with very limited trading activity or where less price transparency exists around the inputs to the valuation methodologies. Level 3 fixed maturity securities include: sub-prime RMBS; certain below investment grade private securities and less liquid investment grade corporate securities (included in United States and foreign corporate securities) and less liquid asset-backed securities (“ABS”); and foreign government securities.
|
|
•
|
During the
three months ended
March 31, 2017
, Level 3 fixed maturity securities decreased by
$149 million
, or
1%
. The decrease was driven by transfers out of Level 3 in excess of transfers into Level 3, partially offset by purchases in excess of sales.
|
See Note
7
of the Notes to the Interim Condensed Consolidated Financial Statements for a rollforward of the fair value measurements for fixed maturity securities and equity securities AFS measured at estimated fair value on a recurring basis using significant unobservable (Level 3) inputs; transfers into and/or out of Level 3; and further information about the valuation approaches and inputs by level by major classes of invested assets that affect the amounts reported above. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Summary of Critical Accounting Estimates — Estimated Fair Value of Investments” included in the
2016
Annual Report for further information on the estimates and assumptions that affect the amounts reported above.
Fixed Maturity Securities AFS
See Note
5
of the Notes to the Interim Condensed Consolidated Financial Statements for information about fixed maturity securities AFS by sector, contractual maturities and continuous gross unrealized losses.
Fixed Maturity Securities Credit Quality — Ratings
See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Investments — Fixed Maturity and Equity Securities AFS — Fixed Maturity Securities Credit Quality — Ratings” included in the
2016
Annual Report for a discussion of the credit quality ratings assigned by Nationally Recognized Statistical Rating Organizations (“NRSRO”), credit quality designations assigned by and methodologies used by the Securities Valuation Office of the National Association of Insurance Commissioners (“NAIC”) for fixed maturity securities and the revised methodologies adopted by the NAIC for certain structured securities.
The following table presents total fixed maturity securities by NRSRO rating and the applicable NAIC designation from the NAIC published comparison of NRSRO ratings to NAIC designations, except for certain structured securities, which are presented using the revised NAIC methodologies, as well as the percentage, based on estimated fair value that each NAIC designation is comprised of at:
|
|
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||||||||||||||||
|
NAIC
Designation
|
NRSRO Rating
|
Amortized
Cost
|
Unrealized
Gain (Loss)
|
Estimated
Fair
Value
|
% of
Total
|
Amortized
Cost
|
Unrealized
Gain (Loss)
|
Estimated
Fair
Value
|
% of
Total
|
|||||||||||||||||||||||
|
|
|
(Dollars in millions)
|
||||||||||||||||||||||||||||||
|
1
|
Aaa/Aa/A
|
$
|
235,751
|
|
$
|
16,607
|
|
$
|
252,358
|
|
71.0
|
%
|
$
|
232,875
|
|
$
|
16,191
|
|
$
|
249,066
|
|
71.0
|
%
|
|||||||||
|
2
|
Baa
|
78,406
|
|
4,238
|
|
82,644
|
|
23.2
|
77,281
|
|
3,816
|
|
81,097
|
|
23.1
|
|||||||||||||||||
|
Subtotal investment grade
|
314,157
|
|
|
20,845
|
|
|
335,002
|
|
94.2
|
310,156
|
|
20,007
|
|
330,163
|
|
94.1
|
||||||||||||||||
|
3
|
Ba
|
13,674
|
|
562
|
|
14,236
|
|
4.0
|
13,885
|
|
437
|
|
14,322
|
|
4.1
|
|||||||||||||||||
|
4
|
B
|
5,225
|
|
114
|
|
5,339
|
|
1.5
|
5,410
|
|
84
|
|
5,494
|
|
1.6
|
|||||||||||||||||
|
5
|
Caa and lower
|
925
|
|
25
|
|
950
|
|
0.3
|
895
|
|
9
|
|
904
|
|
0.2
|
|||||||||||||||||
|
6
|
In or near default
|
4
|
|
(3
|
)
|
1
|
|
—
|
8
|
|
(2
|
)
|
6
|
|
—
|
|||||||||||||||||
|
Subtotal below investment grade
|
19,828
|
|
|
698
|
|
|
20,526
|
|
5.8
|
20,198
|
|
528
|
|
20,726
|
|
5.9
|
||||||||||||||||
|
Total fixed maturity securities
|
$
|
333,985
|
|
|
$
|
21,543
|
|
|
$
|
355,528
|
|
100.0
|
%
|
$
|
330,354
|
|
$
|
20,535
|
|
$
|
350,889
|
|
100.0
|
%
|
||||||||
117
The following tables present total fixed maturity securities, based on estimated fair value, by sector classification and by NRSRO rating and the applicable NAIC designations from the NAIC published comparison of NRSRO ratings to NAIC designations, except for certain structured securities, which are presented using the NAIC methodologies at:
|
|
Fixed Maturity Securities — by Sector & Credit Quality Rating
|
||||||||||||||||||||||||||
|
NAIC Designation:
|
1
|
2
|
3
|
4
|
5
|
6
|
Total
Estimated
Fair Value
|
||||||||||||||||||||
|
NRSRO Rating:
|
Aaa/Aa/A
|
Baa
|
Ba
|
B
|
Caa and Lower
|
In or Near
Default
|
|||||||||||||||||||||
|
|
(Dollars in millions)
|
||||||||||||||||||||||||||
|
March 31, 2017
|
|||||||||||||||||||||||||||
|
U.S. corporate
|
$
|
44,878
|
|
$
|
43,276
|
|
$
|
8,140
|
|
$
|
3,826
|
|
$
|
793
|
|
$
|
—
|
|
$
|
100,913
|
|
||||||
|
U.S. government and agency
|
56,410
|
|
470
|
|
—
|
|
—
|
|
—
|
|
—
|
|
56,880
|
|
|||||||||||||
|
Foreign government
|
51,753
|
|
5,368
|
|
2,413
|
|
853
|
|
51
|
|
—
|
|
60,438
|
|
|||||||||||||
|
Foreign corporate
|
23,355
|
|
31,339
|
|
3,088
|
|
628
|
|
55
|
|
—
|
|
58,465
|
|
|||||||||||||
|
RMBS
|
36,728
|
|
449
|
|
356
|
|
31
|
|
40
|
|
—
|
|
37,604
|
|
|||||||||||||
|
State and political subdivision
|
15,558
|
|
579
|
|
80
|
|
—
|
|
8
|
|
—
|
|
16,225
|
|
|||||||||||||
|
ABS
|
12,632
|
|
1,013
|
|
159
|
|
1
|
|
3
|
|
1
|
|
13,809
|
|
|||||||||||||
|
CMBS
|
11,044
|
|
150
|
|
—
|
|
—
|
|
—
|
|
—
|
|
11,194
|
|
|||||||||||||
|
Total fixed maturity securities
|
$
|
252,358
|
|
|
$
|
82,644
|
|
|
$
|
14,236
|
|
|
$
|
5,339
|
|
|
$
|
950
|
|
|
$
|
1
|
|
|
$
|
355,528
|
|
|
Percentage of total
|
71.0
|
%
|
23.2
|
%
|
4.0
|
%
|
1.5
|
%
|
0.3
|
%
|
—
|
%
|
100.0
|
%
|
|||||||||||||
|
December 31, 2016
|
|||||||||||||||||||||||||||
|
U.S. corporate
|
$
|
44,732
|
|
$
|
43,063
|
|
$
|
8,414
|
|
$
|
3,884
|
|
$
|
760
|
|
$
|
—
|
|
$
|
100,853
|
|
||||||
|
U.S. government and agency
|
57,038
|
|
485
|
|
—
|
|
—
|
|
—
|
|
—
|
|
57,523
|
|
|||||||||||||
|
Foreign government
|
48,951
|
|
5,035
|
|
2,230
|
|
870
|
|
52
|
|
—
|
|
57,138
|
|
|||||||||||||
|
Foreign corporate
|
22,951
|
|
30,189
|
|
3,141
|
|
709
|
|
67
|
|
—
|
|
57,057
|
|
|||||||||||||
|
RMBS
|
35,916
|
|
707
|
|
322
|
|
30
|
|
13
|
|
5
|
|
36,993
|
|
|||||||||||||
|
State and political subdivision
|
15,575
|
|
502
|
|
90
|
|
—
|
|
9
|
|
—
|
|
16,176
|
|
|||||||||||||
|
ABS
|
12,776
|
|
971
|
|
125
|
|
1
|
|
3
|
|
1
|
|
13,877
|
|
|||||||||||||
|
CMBS
|
11,127
|
|
145
|
|
—
|
|
—
|
|
—
|
|
—
|
|
11,272
|
|
|||||||||||||
|
Total fixed maturity securities
|
$
|
249,066
|
|
|
$
|
81,097
|
|
|
$
|
14,322
|
|
|
$
|
5,494
|
|
|
$
|
904
|
|
|
$
|
6
|
|
|
$
|
350,889
|
|
|
Percentage of total
|
71.0
|
%
|
23.1
|
%
|
4.1
|
%
|
1.6
|
%
|
0.2
|
%
|
—
|
%
|
100.0
|
%
|
|||||||||||||
U.S. and Foreign Corporate Fixed Maturity Securities
We maintain a diversified portfolio of corporate fixed maturity securities across industries and issuers. This portfolio does not have any exposure to any single issuer in excess of
1%
of total investments and the top ten holdings comprised
2%
of total investments at both
March 31, 2017
and
December 31, 2016
. The tables below present our U.S. and foreign corporate securities holdings by industry at:
|
|
March 31, 2017
|
December 31, 2016
|
|||||||||||
|
|
Estimated
Fair
Value
|
% of
Total
|
Estimated
Fair
Value
|
% of
Total
|
|||||||||
|
|
(Dollars in millions)
|
||||||||||||
|
Industrial
|
$
|
48,550
|
|
30.5
|
%
|
$
|
48,109
|
|
30.4
|
%
|
|||
|
Consumer
|
37,050
|
|
23.2
|
|
36,952
|
|
23.4
|
|
|||||
|
Finance
|
33,783
|
|
21.2
|
|
33,431
|
|
21.2
|
|
|||||
|
Utility
|
24,456
|
|
15.3
|
|
23,949
|
|
15.2
|
|
|||||
|
Communications
|
12,993
|
|
8.2
|
|
12,955
|
|
8.2
|
|
|||||
|
Other
|
2,546
|
|
1.6
|
|
2,514
|
|
1.6
|
|
|||||
|
Total
|
$
|
159,378
|
|
100.0
|
%
|
$
|
157,910
|
|
100.0
|
%
|
|||
118
Structured Securities
We held
$62.6 billion
and
$62.1 billion
of structured securities, at estimated fair value, at
March 31, 2017
and
December 31, 2016
, respectively, as presented in the RMBS, ABS and commercial mortgage-backed securities (“CMBS”) sections below.
RMBS
The table below presents our RMBS holdings at:
|
March 31, 2017
|
December 31, 2016
|
||||||||||||||||||||
|
Estimated
Fair
Value
|
% of
Total
|
Net
Unrealized
Gains (Losses)
|
Estimated
Fair
Value
|
% of
Total
|
Net
Unrealized
Gains (Losses)
|
||||||||||||||||
|
(Dollars in millions)
|
|||||||||||||||||||||
|
By security type:
|
|||||||||||||||||||||
|
Collateralized mortgage obligations
|
$
|
21,738
|
|
57.8
|
%
|
$
|
744
|
|
$
|
22,286
|
|
60.2
|
%
|
$
|
624
|
|
|||||
|
Pass-through securities
|
15,866
|
|
42.2
|
|
75
|
|
14,707
|
|
39.8
|
|
76
|
|
|||||||||
|
Total RMBS
|
$
|
37,604
|
|
100.0
|
%
|
$
|
819
|
|
$
|
36,993
|
|
100.0
|
%
|
$
|
700
|
|
|||||
|
By risk profile:
|
|||||||||||||||||||||
|
Agency
|
$
|
24,647
|
|
65.5
|
%
|
$
|
274
|
|
$
|
23,579
|
|
63.7
|
%
|
$
|
276
|
|
|||||
|
Prime
|
1,857
|
|
4.9
|
|
86
|
|
1,787
|
|
4.8
|
|
81
|
|
|||||||||
|
Alt-A
|
6,090
|
|
16.3
|
|
263
|
|
6,527
|
|
17.7
|
|
180
|
|
|||||||||
|
Sub-prime
|
5,010
|
|
13.3
|
|
196
|
|
5,100
|
|
13.8
|
|
163
|
|
|||||||||
|
Total RMBS
|
$
|
37,604
|
|
100.0
|
%
|
$
|
819
|
|
$
|
36,993
|
|
100.0
|
%
|
$
|
700
|
|
|||||
|
Ratings profile:
|
|||||||||||||||||||||
|
Rated Aaa/AAA
|
$
|
25,209
|
|
67.0
|
%
|
$
|
24,162
|
|
65.3
|
%
|
|||||||||||
|
Designated NAIC 1
|
$
|
36,728
|
|
97.7
|
%
|
$
|
35,916
|
|
97.1
|
%
|
|||||||||||
See also “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Investments — Fixed Maturity and Equity Securities AFS — Structured Securities — RMBS” included in the
2016
Annual Report for further information about collateralized mortgage obligations and pass-through mortgage-backed securities, as well as agency, prime, alternative residential mortgage loan and sub-prime RMBS.
Historically, we have managed our exposure to sub-prime RMBS holdings by focusing primarily on senior tranche securities, stress testing the portfolio with severe loss assumptions and closely monitoring the performance of the portfolio. Our sub-prime RMBS portfolio consists predominantly of securities that were purchased after 2012 at significant discounts to par value and discounts to the expected principal recovery value of these securities. The vast majority of these securities are investment grade under the NAIC designations (e.g., NAIC 1 and NAIC 2). The estimated fair value of our sub-prime RMBS holdings purchased since 2012 was
$4.6 billion
at both March 31, 2017 and December 31, 2016, with unrealized gains (losses) of
$169 million
and
$140 million
at
March 31, 2017
and
December 31, 2016
, respectively.
119
ABS
Our ABS holdings are diversified both by collateral type and by issuer. The following table presents our ABS holdings at:
|
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||||||
|
|
Estimated
Fair
Value
|
% of
Total
|
Net
Unrealized
Gains (Losses)
|
Estimated
Fair
Value
|
% of
Total
|
Net
Unrealized
Gains (Losses)
|
|||||||||||||||
|
|
(Dollars in millions)
|
||||||||||||||||||||
|
By collateral type:
|
|||||||||||||||||||||
|
Collateralized obligations
|
$
|
6,532
|
|
47.3
|
%
|
$
|
(32
|
)
|
$
|
6,866
|
|
49.5
|
%
|
$
|
(42
|
)
|
|||||
|
Automobile loans
|
1,214
|
|
8.8
|
|
2
|
|
1,477
|
|
10.6
|
|
1
|
|
|||||||||
|
Foreign residential loans
|
1,324
|
|
9.6
|
|
9
|
|
1,256
|
|
9.1
|
|
8
|
|
|||||||||
|
Student loans
|
1,180
|
|
8.5
|
|
(6
|
)
|
1,144
|
|
8.2
|
|
(29
|
)
|
|||||||||
|
Credit card loans
|
1,457
|
|
10.6
|
|
10
|
|
1,079
|
|
7.8
|
|
13
|
|
|||||||||
|
Other loans
|
2,102
|
|
15.2
|
|
7
|
|
2,055
|
|
14.8
|
|
6
|
|
|||||||||
|
Total
|
$
|
13,809
|
|
100.0
|
%
|
$
|
(10
|
)
|
$
|
13,877
|
|
100.0
|
%
|
$
|
(43
|
)
|
|||||
|
Ratings profile:
|
|||||||||||||||||||||
|
Rated Aaa/AAA
|
$
|
6,955
|
|
50.4
|
%
|
$
|
6,811
|
|
49.1
|
%
|
|||||||||||
|
Designated NAIC 1
|
$
|
12,632
|
|
91.5
|
%
|
$
|
12,776
|
|
92.1
|
%
|
|||||||||||
120
CMBS
Our CMBS holdings are diversified by vintage year. The following tables present our CMBS holdings by NRSRO rating and by vintage year at:
|
|
March 31, 2017
|
||||||||||||||||||||||||||||||||||||||||||||||
|
|
Aaa
|
Aa
|
A
|
Baa
|
Below
Investment
Grade
|
Total
|
|||||||||||||||||||||||||||||||||||||||||
|
|
Amortized
Cost
|
Estimated
Fair
Value
|
Amortized
Cost
|
Estimated
Fair
Value
|
Amortized
Cost
|
Estimated
Fair
Value
|
Amortized
Cost
|
Estimated
Fair
Value
|
Amortized
Cost
|
Estimated
Fair
Value
|
Amortized
Cost
|
Estimated
Fair
Value
|
|||||||||||||||||||||||||||||||||||
|
|
(Dollars in millions)
|
||||||||||||||||||||||||||||||||||||||||||||||
|
2003 - 2010
|
$
|
137
|
|
$
|
143
|
|
$
|
92
|
|
$
|
100
|
|
$
|
87
|
|
$
|
88
|
|
$
|
5
|
|
$
|
5
|
|
$
|
49
|
|
$
|
52
|
|
$
|
370
|
|
$
|
388
|
|
|||||||||||
|
2011
|
32
|
|
32
|
|
489
|
|
519
|
|
22
|
|
23
|
|
—
|
|
—
|
|
—
|
|
—
|
|
543
|
|
574
|
|
|||||||||||||||||||||||
|
2012
|
459
|
|
477
|
|
369
|
|
379
|
|
313
|
|
325
|
|
9
|
|
9
|
|
—
|
|
—
|
|
1,150
|
|
1,190
|
|
|||||||||||||||||||||||
|
2013
|
995
|
|
1,045
|
|
854
|
|
893
|
|
412
|
|
403
|
|
—
|
|
—
|
|
—
|
|
—
|
|
2,261
|
|
2,341
|
|
|||||||||||||||||||||||
|
2014
|
977
|
|
990
|
|
937
|
|
952
|
|
270
|
|
263
|
|
—
|
|
—
|
|
—
|
|
—
|
|
2,184
|
|
2,205
|
|
|||||||||||||||||||||||
|
2015
|
2,242
|
|
2,244
|
|
440
|
|
435
|
|
212
|
|
212
|
|
9
|
|
9
|
|
—
|
|
—
|
|
2,903
|
|
2,900
|
|
|||||||||||||||||||||||
|
2016
|
882
|
|
875
|
|
127
|
|
123
|
|
59
|
|
59
|
|
97
|
|
99
|
|
—
|
|
—
|
|
1,165
|
|
1,156
|
|
|||||||||||||||||||||||
|
2017
|
440
|
|
440
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
440
|
|
440
|
|
|||||||||||||||||||||||
|
Total
|
$
|
6,164
|
|
|
$
|
6,246
|
|
|
$
|
3,308
|
|
|
$
|
3,401
|
|
|
$
|
1,375
|
|
|
$
|
1,373
|
|
|
$
|
120
|
|
|
$
|
122
|
|
|
$
|
49
|
|
|
$
|
52
|
|
|
$
|
11,016
|
|
|
$
|
11,194
|
|
|
Ratings Distribution
|
55.8
|
%
|
30.4
|
%
|
12.2
|
%
|
1.1
|
%
|
0.5
|
%
|
100.0
|
%
|
|||||||||||||||||||||||||||||||||||
|
|
December 31, 2016
|
||||||||||||||||||||||||||||||||||||||||||||||
|
|
Aaa
|
Aa
|
A
|
Baa
|
Below
Investment
Grade
|
Total
|
|||||||||||||||||||||||||||||||||||||||||
|
|
Amortized
Cost |
Estimated
Fair Value |
Amortized
Cost |
Estimated
Fair Value |
Amortized
Cost |
Estimated
Fair Value |
Amortized
Cost |
Estimated
Fair Value |
Amortized
Cost |
Estimated
Fair Value |
Amortized
Cost |
Estimated
Fair Value |
|||||||||||||||||||||||||||||||||||
|
|
(Dollars in millions)
|
||||||||||||||||||||||||||||||||||||||||||||||
|
2003 - 2010
|
$
|
338
|
|
$
|
352
|
|
$
|
61
|
|
$
|
61
|
|
$
|
102
|
|
$
|
105
|
|
$
|
24
|
|
$
|
25
|
|
$
|
28
|
|
$
|
32
|
|
$
|
553
|
|
$
|
575
|
|
|||||||||||
|
2011
|
458
|
|
486
|
|
52
|
|
54
|
|
32
|
|
32
|
|
—
|
|
—
|
|
—
|
|
—
|
|
542
|
|
572
|
|
|||||||||||||||||||||||
|
2012
|
403
|
|
422
|
|
383
|
|
394
|
|
330
|
|
339
|
|
9
|
|
9
|
|
—
|
|
—
|
|
1,125
|
|
1,164
|
|
|||||||||||||||||||||||
|
2013
|
1,000
|
|
1,059
|
|
846
|
|
893
|
|
410
|
|
397
|
|
—
|
|
—
|
|
—
|
|
—
|
|
2,256
|
|
2,349
|
|
|||||||||||||||||||||||
|
2014
|
972
|
|
986
|
|
940
|
|
952
|
|
265
|
|
258
|
|
—
|
|
—
|
|
—
|
|
—
|
|
2,177
|
|
2,196
|
|
|||||||||||||||||||||||
|
2015
|
2,373
|
|
2,374
|
|
460
|
|
452
|
|
217
|
|
216
|
|
8
|
|
8
|
|
—
|
|
—
|
|
3,058
|
|
3,050
|
|
|||||||||||||||||||||||
|
2016
|
1,052
|
|
1,043
|
|
141
|
|
136
|
|
58
|
|
57
|
|
130
|
|
130
|
|
—
|
|
—
|
|
1,381
|
|
1,366
|
|
|||||||||||||||||||||||
|
Total
|
$
|
6,596
|
|
|
$
|
6,722
|
|
|
$
|
2,883
|
|
|
$
|
2,942
|
|
|
$
|
1,414
|
|
|
$
|
1,404
|
|
|
$
|
171
|
|
|
$
|
172
|
|
|
$
|
28
|
|
|
$
|
32
|
|
|
$
|
11,092
|
|
|
$
|
11,272
|
|
|
Ratings Distribution
|
59.6
|
%
|
26.1
|
%
|
12.5
|
%
|
1.5
|
%
|
0.3
|
%
|
100.0
|
%
|
|||||||||||||||||||||||||||||||||||
The tables above reflect NRSRO ratings including Moody’s Investors Service, S&P, Fitch and Morningstar, Inc. CMBS designated NAIC 1 were
98.7%
of total CMBS at both
March 31, 2017
and
December 31, 2016
.
Evaluation of AFS Securities for OTTI and Evaluating Temporarily Impaired AFS Securities
See Note
5
of the Notes to the Interim Condensed Consolidated Financial Statements for information about the evaluation of fixed maturity securities and equity securities AFS for OTTI and evaluation of temporarily impaired AFS securities.
OTTI Losses on Fixed Maturity and Equity Securities AFS Recognized in Earnings
See Note
5
of the Notes to the Interim Condensed Consolidated Financial Statements for information about OTTI losses and gross gains and gross losses on AFS securities sold.
Overview of Fixed Maturity and Equity Security OTTI Losses Recognized in Earnings
Impairments of fixed maturity and equity securities were
$8 million
and
$129 million
for the
three months ended
March 31, 2017
and
2016
, respectively. Impairments of fixed maturity securities were less than $1 million and
$78 million
for the
three months ended
March 31, 2017
and
2016
, respectively. Impairments of equity securities were
$8 million
and
$51 million
for the
three months ended
March 31, 2017
and
2016
, respectively.
Credit-related impairments of fixed maturity securities were less than $1 million and
$71 million
for the
three months ended
March 31, 2017
and
2016
, respectively.
121
Explanations of changes in fixed maturity and equity securities impairments are as follows:
Three Months Ended
March 31, 2017
Compared with the
Three Months Ended
March 31, 2016
Overall OTTI losses recognized in earnings on fixed maturity and equity securities were
$8 million
for the
three months ended
March 31, 2017
as compared to
$129 million
for the prior period. Substantially all of the $121 million decrease in OTTI losses was in U.S. and foreign corporate securities and common stock. A decrease of
$74 million
in OTTI losses on U.S. and foreign corporate securities was concentrated in the industrial sector and reflected the more significant impact of lower oil prices on the energy sector in the prior year and weakening foreign currencies on non-functional currency denominated securities in the prior year. The decrease in OTTI losses on common stock was
$43 million
for the
three months ended
March 31, 2017
, as compared to the
three months ended
March 31, 2016
, and was also concentrated in industrial securities and reflected the more significant impact of lower oil prices impacting the energy sector in the prior year.
Future Impairments
Future OTTI will depend primarily on economic fundamentals, issuer performance (including changes in the present value of future cash flows expected to be collected), and changes in credit ratings, collateral valuation, interest rates and credit spreads, as well as a change in our intention to hold or sell a security that is in an unrealized loss position. If economic fundamentals deteriorate or if there are adverse changes in the above factors, OTTI may be incurred in upcoming periods.
FVO Securities
FVO securities are primarily comprised of securities for which the FVO has been elected. FVO securities were
$14.4 billion
and
$13.9 billion
at estimated fair value, or
2.7%
and 2.7% of cash and invested assets, at
March 31, 2017
and
December 31, 2016
, respectively. See Notes
5
and
7
of the Notes to the Interim Condensed Consolidated Financial Statements for a description of our FVO securities portfolio, the FVO securities fair value hierarchy and a rollforward of the fair value measurements for FVO securities measured at estimated fair value on a recurring basis using significant unobservable (Level 3) inputs.
Securities Lending
We participate in a securities lending program whereby securities are loaned to third parties, primarily brokerage firms and commercial banks. We obtain collateral, usually cash, in an amount generally equal to 102% of the estimated fair value of the securities loaned, which is obtained at the inception of a loan and maintained at a level greater than or equal to 100% for the duration of the loan. We monitor the estimated fair value of the securities loaned on a daily basis with additional collateral obtained as necessary throughout the duration of the loan. Securities loaned under such transactions may be sold or re-pledged by the transferee. We are liable to return to our counterparties the cash collateral under our control. Security collateral received from counterparties may not be sold or re-pledged, unless the counterparty is in default, and is not reflected on the consolidated financial statements. These transactions are treated as financing arrangements and the associated cash collateral liability is recorded at the amount of the cash received.
See “— Liquidity and Capital Resources — The Company — Liquidity and Capital Uses — Securities Lending” and Note
5
of the Notes to the Interim Condensed Consolidated Financial Statements for information regarding our securities lending program.
Repurchase Agreements
The Company participates in short-term repurchase agreements with unaffiliated financial institutions. Under these agreements, the Company lends fixed maturity securities and receives cash as collateral in an amount generally equal to 98% of the estimated fair value of the securities loaned at the inception of the transaction. The associated liability is recorded at the amount of cash received. The Company monitors the estimated fair value of the collateral and the securities loaned throughout the duration of the transaction and additional collateral is obtained as necessary. Securities loaned under such transactions may be sold or re-pledged by the transferee.
See Note
5
of the Notes to the Interim Condensed Consolidated Financial Statements for additional information regarding our repurchase agreements.
122
Mortgage Loans
Our mortgage loans are principally collateralized by commercial, agricultural and residential properties. Mortgage loans and the related valuation allowances are summarized as follows at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||||||||||||||
|
Recorded
Investment
|
% of
Total
|
Valuation
Allowance
|
% of
Recorded Investment
|
Recorded
Investment
|
% of
Total
|
Valuation
Allowance
|
% of
Recorded Investment
|
|||||||||||||||||||||
|
(Dollars in millions)
|
||||||||||||||||||||||||||||
|
Commercial
|
$
|
49,101
|
|
64.5
|
%
|
$
|
240
|
|
0.5
|
%
|
$
|
48,035
|
|
64.7
|
%
|
$
|
234
|
|
0.5
|
%
|
||||||||
|
Agricultural
|
14,754
|
|
19.4
|
|
45
|
|
0.3
|
%
|
14,456
|
|
19.5
|
|
44
|
|
0.3
|
%
|
||||||||||||
|
Residential
|
12,271
|
|
16.1
|
|
68
|
|
0.6
|
%
|
11,696
|
|
15.8
|
|
66
|
|
0.6
|
%
|
||||||||||||
|
Total
|
$
|
76,126
|
|
100.0
|
%
|
$
|
353
|
|
0.5
|
%
|
$
|
74,187
|
|
100.0
|
%
|
$
|
344
|
|
0.5
|
%
|
||||||||
The information presented in the tables herein exclude mortgage loans where we elected the FVO. Such amounts are presented in Note
5
of the Notes to the Interim Condensed Consolidated Financial Statements. The carrying value of all mortgage loans, net was
14.6%
and
14.4%
of cash and invested assets at March 31, 2017 and December 31, 2016, respectively.
We diversify our mortgage loan portfolio by both geographic region and property type to reduce the risk of concentration. Of our commercial and agricultural mortgage loan portfolios,
85%
are collateralized by properties located in the United States, with the remaining
15%
collateralized by properties located outside the United States, which includes
5%
of properties located in the U.K., at
March 31, 2017
. The carrying values of our commercial and agricultural mortgage loans located in California, New York and Texas were
20%
,
12%
and
8%
, respectively, of total commercial and agricultural mortgage loans at
March 31, 2017
. Additionally, we manage risk when originating commercial and agricultural mortgage loans by generally lending up to
75%
of the estimated fair value of the underlying real estate collateral.
We manage our residential mortgage loan portfolio in a similar manner to reduce risk of concentration, with
92%
collateralized by properties located in the United States, and the remaining
8%
collateralized by properties located outside the United States, at
March 31, 2017
. The carrying values of our residential mortgage loans located in California, Florida, and New York were
32%
,
9%
, and
6%
, respectively, of total residential mortgage loans at
March 31, 2017
.
In connection with our investment management business, we manage commercial mortgage loans on behalf of institutional clients, which are unaffiliated investors. These commercial mortgage loans had an estimated fair value of
$3.2 billion
and
$3.0 billion
at
March 31, 2017
and
December 31, 2016
, respectively. As these assets are managed on behalf of, and owned by, our institutional clients, they are not included in our interim condensed consolidated financial statements.
123
Commercial Mortgage Loans by Geographic Region and Property Type
.
Commercial mortgage loans are the largest component of the mortgage loan invested asset class. The tables below present the diversification across geographic regions and property types of commercial mortgage loans at:
|
March 31, 2017
|
December 31, 2016
|
||||||||||||||
|
Amount
|
% of
Total
|
Amount
|
% of
Total
|
||||||||||||
|
(Dollars in millions)
|
|||||||||||||||
|
Region
|
|||||||||||||||
|
Pacific
|
$
|
11,707
|
23.8
|
%
|
|
$
|
11,254
|
23.4
|
%
|
||||||
|
Middle Atlantic
|
8,862
|
18.0
|
|
8,708
|
18.1
|
|
|||||||||
|
International
|
8,260
|
16.8
|
|
8,084
|
16.8
|
|
|||||||||
|
South Atlantic
|
6,211
|
12.6
|
|
6,304
|
13.1
|
|
|||||||||
|
West South Central
|
4,254
|
8.7
|
|
4,271
|
8.9
|
|
|||||||||
|
East North Central
|
2,691
|
5.5
|
|
2,447
|
5.1
|
|
|||||||||
|
Mountain
|
1,459
|
3.0
|
|
1,460
|
3.0
|
|
|||||||||
|
New England
|
1,408
|
2.9
|
|
1,414
|
3.0
|
|
|||||||||
|
West North Central
|
581
|
1.2
|
|
599
|
1.3
|
|
|||||||||
|
East South Central
|
547
|
1.1
|
|
436
|
0.9
|
|
|||||||||
|
Multi-Region and Other
|
3,121
|
6.4
|
|
3,058
|
6.4
|
|
|||||||||
|
Total recorded investment
|
49,101
|
100.0
|
%
|
48,035
|
100.0
|
%
|
|||||||||
|
Less: valuation allowances
|
240
|
234
|
|||||||||||||
|
Carrying value, net of valuation allowances
|
$
|
48,861
|
$
|
47,801
|
|||||||||||
|
Property Type
|
|||||||||||||||
|
Office
|
$
|
24,724
|
50.3
|
%
|
$
|
23,843
|
49.6
|
%
|
|||||||
|
Retail
|
10,531
|
21.5
|
|
10,619
|
22.1
|
|
|||||||||
|
Apartment
|
6,024
|
12.3
|
|
5,870
|
12.2
|
|
|||||||||
|
Hotel
|
4,412
|
9.0
|
|
4,367
|
9.1
|
|
|||||||||
|
Industrial
|
3,110
|
6.3
|
|
2,998
|
6.3
|
|
|||||||||
|
Other
|
300
|
0.6
|
|
338
|
0.7
|
|
|||||||||
|
Total recorded investment
|
49,101
|
100.0
|
%
|
48,035
|
100.0
|
%
|
|||||||||
|
Less: valuation allowances
|
240
|
234
|
|||||||||||||
|
Carrying value, net of valuation allowances
|
$
|
48,861
|
$
|
47,801
|
|||||||||||
Mortgage Loan Credit Quality - Monitoring Process.
We monitor our mortgage loan investments on an ongoing basis, including a review of loans that are current, past due, restructured and under foreclosure. See Note
5
of the Notes to the Interim Condensed Consolidated Financial Statements for tables that present mortgage loans by credit quality indicator, past due and nonaccrual mortgage loans, as well as impaired mortgage loans. See “— Real Estate and Real Estate Joint Ventures” for real estate acquired through foreclosure.
We review our commercial mortgage loans on an ongoing basis. These reviews may include an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, loan-to-value ratios, debt service coverage ratios and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher loan-to-value ratios and lower debt service coverage ratios. The monitoring process for agricultural mortgage loans is generally similar, with a focus on higher risk loans, such as loans with higher loan-to-value ratios, including reviews on a geographic and sector basis. We review our residential mortgage loans on an ongoing basis. See Note 8 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report for information on our evaluation of residential mortgage loans and related valuation allowance methodology.
124
Loan-to-value ratios and debt service coverage ratios are common measures in the assessment of the quality of commercial mortgage loans. Loan-to-value ratios are a common measure in the assessment of the quality of agricultural mortgage loans. Loan-to-value ratios compare the amount of the loan to the estimated fair value of the underlying collateral. A loan-to-value ratio greater than 100% indicates that the loan amount is greater than the collateral value. A loan-to-value ratio of less than 100% indicates an excess of collateral value over the loan amount. Generally, the higher the loan-to-value ratio, the higher the risk of experiencing a credit loss. The debt service coverage ratio compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the debt service coverage ratio, the higher the risk of experiencing a credit loss. For our commercial mortgage loans, our average loan-to-value ratio was
52%
at both
March 31, 2017
and
December 31, 2016
and our average debt service coverage ratio was
2.7x
and
2.6x
at
March 31, 2017
and
December 31, 2016
, respectively. Our debt service coverage ratio and the values utilized in calculating the ratio are updated annually, on a rolling basis, with a portion of the portfolio updated each quarter. In addition, the loan-to-value ratio is routinely updated for all but the lowest risk loans as part of our ongoing review of our commercial mortgage loan portfolio. For our agricultural mortgage loans, our average loan-to-value ratio was
43%
at both
March 31, 2017
and
December 31, 2016
, respectively. The values utilized in calculating the agricultural mortgage loan loan-to-value ratio are developed in connection with the ongoing review of the agricultural loan portfolio and are routinely updated.
Mortgage Loan Valuation Allowances
.
Our valuation allowances are established both on a loan specific basis for those loans considered impaired where a property specific or market specific risk has been identified that could likely result in a future loss, as well as for pools of loans with similar risk characteristics where a property specific or market specific risk has not been identified, but for which we expect to incur a loss. Accordingly, a valuation allowance is provided to absorb these estimated probable credit losses.
The determination of the amount of valuation allowances is based upon our periodic evaluation and assessment of known and inherent risks associated with our loan portfolios. Such evaluations and assessments are based upon several factors, including our experience for loan losses, defaults and loss severity, and loss expectations for loans with similar risk characteristics. These evaluations and assessments are revised as conditions change and new information becomes available, which can cause the valuation allowances to increase or decrease over time as such evaluations are revised. Negative credit migration, including an actual or expected increase in the level of problem loans, will result in an increase in the valuation allowance. Positive credit migration, including an actual or expected decrease in the level of problem loans, will result in a decrease in the valuation allowance.
See Notes
5
and
7
of the Notes to the Interim Condensed Consolidated Financial Statements for information about how valuation allowances are established and monitored, activity in and balances of the valuation allowance, and the estimated fair value of impaired mortgage loans and related impairments included within net investment gains (losses) as of and for the
three months ended
March 31, 2017
and
2016
.
Real Estate and Real Estate Joint Ventures
Real estate and real estate joint ventures is comprised of wholly-owned real estate and joint ventures with interests in single property income-producing real estate, and to a lesser extent joint ventures with interests in multi-property projects with varying strategies ranging from the development of properties to the operation of income-producing properties, as well as a runoff portfolio of real estate private equity funds. The carrying values of real estate and real estate joint ventures was
$9.5 billion
and
$9.0 billion
, or
1.8%
and
1.7%
of cash and invested assets, at March 31, 2017 and December 31, 2016, respectively.
Included within real estate and real estate joint ventures are properties acquired through foreclosure of
$48 million
and
$59 million
at March 31, 2017 and December 31, 2016, respectively.
The estimated fair value of our real estate investments was
$14.6 billion
and
$14.3 billion
at March 31, 2017 and December 31, 2016, respectively. The total gross market value of such real estate investments was $19.8 billion and
$19.0 billion
at March 31, 2017 and December 31, 2016, respectively. Gross market value is the total fair value of these investments regardless of encumbering debt.
We diversify our real estate investments by both geographic region and property type to reduce risk of concentration. Of our real estate investments, excluding funds,
71%
were located in the United States, with the remaining
29%
located outside the United States, at March 31, 2017. The carrying value of our real estate investments, excluding funds, located in Japan, California and District of Columbia were
25%
,
16%
and
9%
, respectively, of total real estate investments, excluding funds, at March 31, 2017. Real estate funds were
13%
of our real estate investments, at March 31, 2017. The majority of these funds hold underlying real estate investments that are well diversified across the United States.
125
In connection with our investment management business, we manage real estate investments on behalf of institutional clients, which are unaffiliated investors. These real estate investments had an estimated fair value of $4.4 billion and
$4.3 billion
at March 31, 2017 and December 31, 2016, respectively. The total gross market value of commercial real estate investments under management for unaffiliated investors was $6.5 billion and
$6.4 billion
at March 31, 2017 and December 31, 2016, respectively. Gross market value is the total fair value of these investments regardless of encumbering debt. As these assets are managed on behalf of, and owned by our institutional clients, they are not included in our consolidated financial statements.
Other Limited Partnership Interests
Other limited partnership interests are comprised of private equity funds and hedge funds. The carrying value of other limited partnership interests was
$6.8 billion
, or 1.3% of cash and invested assets, at both
March 31, 2017
and
December 31, 2016
, which included
$855 million
and
$1.0 billion
of hedge funds, at
March 31, 2017
and
December 31, 2016
, respectively. Cash distributions on these investments are generated from investment gains, operating income from the underlying investments of the funds and liquidation of the underlying investments of the funds. We estimate that the underlying investments of the funds will be liquidated over the next two to 10 years.
Other Invested Assets
The following table presents the carrying value of our other invested assets by type at:
|
|
March 31, 2017
|
December 31, 2016
|
|||||||||||
|
|
Carrying
Value
|
% of
Total
|
Carrying
Value
|
% of
Total |
|||||||||
|
|
(Dollars in millions)
|
||||||||||||
|
Freestanding derivatives with positive estimated fair values
|
$
|
12,278
|
|
62.2
|
%
|
$
|
15,761
|
|
68.0
|
%
|
|||
|
Tax credit and renewable energy partnerships
|
3,267
|
|
16.6
|
|
3,231
|
|
13.9
|
|
|||||
|
Leveraged leases, net of non-recourse debt
|
1,472
|
|
7.5
|
|
1,590
|
|
6.9
|
|
|||||
|
Direct financing leases
|
1,168
|
|
5.9
|
|
1,115
|
|
4.8
|
|
|||||
|
Operating joint ventures
|
604
|
|
3.1
|
|
643
|
|
2.8
|
|
|||||
|
Funds withheld
|
115
|
|
0.6
|
|
110
|
|
0.5
|
|
|||||
|
Other
|
820
|
|
4.1
|
|
735
|
|
3.1
|
|
|||||
|
Total
|
$
|
19,724
|
|
100.0
|
%
|
$
|
23,185
|
|
100.0
|
%
|
|||
|
Percentage of cash and invested assets
|
3.8
|
%
|
4.5
|
%
|
|||||||||
Derivatives
Derivative Risks
We are exposed to various risks relating to our ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. We use a variety of strategies to manage these risks, including the use of derivatives. See Note
6
of the Notes to the Interim Condensed Consolidated Financial Statements for:
|
•
|
A comprehensive description of the nature of our derivatives, including the strategies for which derivatives are used in managing various risks.
|
|
•
|
Information about the gross notional amount, estimated fair value, and primary underlying risk exposure of our derivatives by type of hedge designation, excluding embedded derivatives held at
March 31, 2017
and
December 31, 2016
.
|
|
•
|
The statement of operations effects of derivatives in net investments in foreign operations, cash flow, fair value, or nonqualifying hedge relationships for the
three months ended
March 31, 2017
and
2016
.
|
See “Quantitative and Qualitative Disclosures About Market Risk — Management of Market Risk Exposures — Hedging Activities” included in the
2016
Annual Report for more information about our use of derivatives by major hedge program.
Fair Value Hierarchy
See Note
7
of the Notes to the Interim Condensed Consolidated Financial Statements for derivatives measured at estimated fair value on a recurring basis and their corresponding fair value hierarchy.
126
The valuation of Level 3 derivatives involves the use of significant unobservable inputs and generally requires a higher degree of management judgment or estimation than the valuations of Level 1 and Level 2 derivatives. Although Level 3 inputs are unobservable, management believes they are consistent with what other market participants would use when pricing such instruments and are considered appropriate given the circumstances. The use of different inputs or methodologies could have a material effect on the estimated fair value of Level 3 derivatives and could materially affect net income.
Derivatives categorized as Level 3 at
March 31, 2017
include: interest rate forwards with maturities which extend beyond the observable portion of the yield curve; interest rate total return swaps with unobservable repurchase rates; foreign currency swaps and forwards with certain unobservable inputs, including the unobservable portion of the yield curve; credit default swaps priced using unobservable credit spreads, or that are priced through independent broker quotations; equity variance swaps with unobservable volatility inputs; and equity index options with unobservable correlation inputs. At
March 31, 2017
, less than 1% of the estimated fair value of our derivatives was priced through independent broker quotations.
See Note
7
of the Notes to the Interim Condensed Consolidated Financial Statements for a rollforward of the fair value measurements for derivatives measured at estimated fair value on a recurring basis using significant unobservable (Level 3) inputs.
The gain (loss) on Level 3 derivatives primarily relates to interest rate total return swaps with unobservable repurchase rates, certain purchased equity index options that are valued using models dependent on an unobservable market correlation input, equity variance swaps that are valued using observable equity volatility data plus an unobservable equity variance spread and foreign currency swaps and forwards that are valued using an unobservable portion of the swap yield curves. Other significant inputs, which are observable, include equity index levels, equity volatility and the swap yield curves. We validate the reasonableness of these inputs by valuing the positions using internal models and comparing the results to broker quotations.
The gain (loss) on Level 3 derivatives, percentage of gain (loss) attributable to observable and unobservable inputs, and the primary drivers of observable gain (loss) are summarized as follows:
|
Three Months
Ended March 31, 2017 |
||
|
Gain (loss) recognized in net income (loss)
|
$23 million
|
|
|
Percentage of gain (loss) attributable to observable inputs
|
82%
|
|
|
Primary drivers of observable gain (loss)
|
Decreases in interest rates on interest rate total return swaps; weakening of the U.S. dollar versus foreign currencies on receive inflation-linked foreign currency, pay U.S. dollar forwards and swaps; partially offset by decreases in certain equity volatility levels; and increases in certain equity index levels.
|
|
|
Percentage of gain (loss) attributable to unobservable inputs
|
18%
|
|
See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Summary of Critical Accounting Estimates — Derivatives” included in the
2016
Annual Report for further information on the estimates and assumptions that affect derivatives.
Credit Risk
See Note
6
of the Notes to the Interim Condensed Consolidated Financial Statements for information about how we manage credit risk related to derivatives and for the estimated fair value of our net derivative assets and net derivative liabilities after the application of master netting agreements and collateral.
Our policy is not to offset the fair value amounts recognized for derivatives executed with the same counterparty under the same master netting agreement. This policy applies to the recognition of derivatives on the consolidated balance sheets, and does not affect our legal right of offset.
127
Credit Derivatives
The following table presents the gross notional amount and estimated fair value of credit default swaps at:
|
March 31, 2017
|
December 31, 2016
|
|||||||||||||||
|
Credit Default Swaps
|
Gross
Notional
Amount
|
Estimated
Fair Value
|
Gross
Notional
Amount
|
Estimated
Fair Value
|
||||||||||||
|
(In millions)
|
||||||||||||||||
|
Purchased
|
$
|
2,142
|
|
$
|
(40
|
)
|
$
|
2,038
|
|
$
|
(26
|
)
|
||||
|
Written
|
12,369
|
|
199
|
|
12,645
|
|
180
|
|
||||||||
|
Total
|
$
|
14,511
|
|
$
|
159
|
|
$
|
14,683
|
|
$
|
154
|
|
||||
The following table presents the gross gains, gross losses and net gain (losses) recognized in income for credit default swaps as follows:
|
Three Months
Ended March 31, |
||||||||||||||||||||||||
|
2017
|
2016
|
|||||||||||||||||||||||
|
Credit Default Swaps
|
Gross
Gains
|
Gross
Losses
|
Net
Gains
(Losses)
|
Gross
Gains
(1)
|
Gross
Losses
(1)
|
Net
Gains
(Losses)
|
||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||
|
Purchased (2), (4)
|
$
|
8
|
|
$
|
(16
|
)
|
$
|
(8
|
)
|
$
|
27
|
|
$
|
(22
|
)
|
$
|
5
|
|
||||||
|
Written (3), (4)
|
44
|
|
(6
|
)
|
38
|
|
25
|
|
(40
|
)
|
(15
|
)
|
||||||||||||
|
Total
|
$
|
52
|
|
$
|
(22
|
)
|
$
|
30
|
|
$
|
52
|
|
$
|
(62
|
)
|
$
|
(10
|
)
|
||||||
__________________
|
(1)
|
Gains (losses) are reported in net derivative gains (losses), except for gains (losses) on the trading portfolio, which are reported in net investment income.
|
|
(2)
|
At
March 31, 2017
, the Company no longer maintained a trading portfolio for derivatives. The gross gains and gross (losses) for purchased credit default swaps in the trading portfolio were $12 million and ($2) million, respectively, for the
three months ended
March 31, 2016
.
|
|
(3)
|
At
March 31, 2017
, the Company no longer maintained a trading portfolio for derivatives. The gross gains and gross (losses) for written credit default swaps in the trading portfolio were $2 million and ($11) million for the
three months ended
March 31, 2016
.
|
|
(4)
|
Gains (losses) do not include earned income (expense) on credit default swaps.
|
The unfavorable change in net gains (losses) on purchased credit default swaps of ($13) million was due to the narrowing in the current period as compared to the prior period of certain credit spreads on credit default swaps hedging certain bonds. The favorable change in net gains (losses) on written credit default swaps of $53 million was due to the narrowing in the current period as compared to the prior period of credit spreads on certain credit default swaps used as replications.
The maximum amount at risk related to our written credit default swaps is equal to the corresponding gross notional amount. In a replication transaction, we pair an asset on our balance sheet with a written credit default swap to synthetically replicate a corporate bond, a core asset holding of life insurance companies. Replications are entered into in accordance with the guidelines approved by state insurance regulators and the NAIC and are an important tool in managing the overall corporate credit risk within the Company. In order to match our long-dated insurance liabilities, we seek to buy long-dated corporate bonds. In some instances, these may not be readily available in the market, or they may be issued by corporations to which we already have significant corporate credit exposure. For example, by purchasing Treasury bonds (or other high-quality assets) and associating them with written credit default swaps on the desired corporate credit name, we can replicate the desired bond exposures and meet our ALM needs. In addition, given the shorter tenor of the credit default swaps (generally five-year tenors) versus a long dated corporate bond, we have more flexibility in managing our credit exposures.
Embedded Derivatives
See Note
7
of the Notes to the Interim Condensed Consolidated Financial Statements for information about embedded derivatives measured at estimated fair value on a recurring basis and their corresponding fair value hierarchy.
128
See Note
7
of the Notes to the Interim Condensed Consolidated Financial Statements for a rollforward of the fair value measurements for embedded derivatives measured at estimated fair value on a recurring basis using significant unobservable (Level 3) inputs.
See Note
6
of the Notes to the Interim Condensed Consolidated Financial Statements for information about the nonperformance risk adjustment included in the valuation of guaranteed minimum benefits accounted for as embedded derivatives.
See “— “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Summary of Critical Accounting Estimates — Derivatives” included in the
2016
Annual Report for further information on the estimates and assumptions that affect embedded derivatives.
Off-Balance Sheet Arrangements
Credit and Committed Facilities
We maintain an unsecured revolving credit facility, as well as committed facilities with various financial institutions. Brighthouse maintains an unsecured term loan agreement and an unsecured revolving credit facility with various financial institutions. See “— Liquidity and Capital Resources — The Company — Liquidity and Capital Sources — Global Funding Sources — Credit and Committed Facilities” for further descriptions of such arrangements. For the classification of expenses on such credit and committed facilities and the nature of the associated liability for letters of credit issued and drawdowns on these credit and committed facilities, see Note 12 of the Notes to the Consolidated Financial Statements included in the 2016 Annual Report.
Collateral for Securities Lending, Third-Party Custodian Administered Repurchase Programs and Derivatives
We participate in a securities lending program in the normal course of business for the purpose of enhancing the total return on our investment portfolio. Periodically, we receive non-cash collateral for securities lending from counterparties, which cannot be sold or re-pledged, and which has not been recorded on our consolidated balance sheets. The amount of this collateral was
$15 million
and
$46 million
at estimated fair value at
March 31, 2017
and
December 31, 2016
, respectively. See Note
5
of the Notes to the Interim Condensed Consolidated Financial Statements and “— Investments — Securities Lending,” as well as “Summary of Significant Accounting Policies — Investments — Securities Lending Program” in Note 1 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report for discussion of our securities lending program, the classification of revenues and expenses, and the nature of the secured financing arrangement and associated liability.
We also participate in third-party custodian administered repurchase programs for the purpose of enhancing the total return on our investment portfolio. We loan certain of our fixed maturity securities to financial institutions and, in exchange, non-cash collateral is put on deposit by the financial institutions on our behalf with third-party custodians. The estimated fair value of securities loaned in connection with these transactions was
$463 million
and
$382 million
at
March 31, 2017
and
December 31, 2016
, respectively. Non-cash collateral on deposit with third-party custodians on our behalf was
$494 million
and
$401 million
at
March 31, 2017
and
December 31, 2016
, respectively, which cannot be sold or re-pledged, and which has not been recorded on our consolidated balance sheets.
We enter into derivatives to manage various risks relating to our ongoing business operations. We have non-cash collateral from counterparties for derivatives, which can be sold or re-pledged subject to certain constraints, and which has not been recorded on our consolidated balance sheets. The amount of this non-cash collateral was $
2.2 billion
and $
2.3 billion
at
March 31, 2017
and
December 31, 2016
, respectively. See “— Liquidity and Capital Resources — The Company — Liquidity and Capital Uses — Pledged Collateral” and Note
6
of the Notes to the Interim Condensed Consolidated Financial Statements for information regarding the earned income on and the gross notional amount, estimated fair value of assets and liabilities and primary underlying risk exposure of our derivatives.
Lease Commitments
As lessee, we have entered into various lease and sublease agreements for office space, information technology and other equipment. Our commitments under such lease agreements are included within the contractual obligations table. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — The Company — Contractual Obligations” and Note 21 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report.
Guarantees
See “Guarantees” in Note
13
of the Notes to the Interim Condensed Consolidated Financial Statements.
129
Other
Additionally, we make mortgage loan commitments and commitments to fund partnerships, bank credit facilities, bridge loans and private corporate bond investments in the normal course of business for the purpose of enhancing the total return on our investment portfolio. Other than these investment-related commitments which are disclosed in Note
13
of the Notes to the Interim Condensed Consolidated Financial Statements, there are no other material obligations or liabilities arising from these investment- related commitments. For further information on these investment-related commitments see “— Liquidity and Capital Resources — The Company — Contractual Obligations.” See “Net Investment Income” and “Net Investment Gains (Losses)” in Note
5
of the Notes to the Interim Condensed Consolidated Financial Statements for information on the investment income, investment expense, gains and losses from such investments. See also “— Investments — Fixed Maturity and Equity Securities AFS,” “— Investments — Mortgage Loans,” “— Investments — Real Estate and Real Estate Joint Ventures” and “— Investments — Other Limited Partnership Interests” for information on our investments in fixed maturity and equity securities, mortgage loans and partnerships.
Policyholder Liabilities
We establish, and carry as liabilities, actuarially determined amounts that are calculated to meet policy obligations or to provide for future annuity payments. Amounts for actuarial liabilities are computed and reported on the interim condensed consolidated financial statements in conformity with GAAP. For more details on Policyholder Liabilities, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Summary of Critical Accounting Estimates” included in the
2016
Annual Report.
Due to the nature of the underlying risks and the uncertainty associated with the determination of actuarial liabilities, we cannot precisely determine the amounts that will ultimately be paid with respect to these actuarial liabilities, and the ultimate amounts may vary from the estimated amounts, particularly when payments may not occur until well into the future.
We periodically review our estimates of actuarial liabilities for future benefits and compare them with our actual experience. We revise estimates, to the extent permitted or required under GAAP, if we determine that future expected experience differs from assumptions used in the development of actuarial liabilities. We charge or credit changes in our liabilities to expenses in the period the liabilities are established or re-estimated. If the liabilities originally established for future benefit payments prove inadequate, we must increase them. Such an increase could adversely affect our earnings and have a material adverse effect on our business, results of operations and financial condition.
We have experienced, and will likely in the future experience, catastrophe losses and possibly acts of terrorism, as well as turbulent financial markets that may have an adverse impact on our business, results of operations and financial condition. Due to their nature, we cannot predict the incidence, timing, severity or amount of losses from catastrophes and acts of terrorism, but we make broad use of catastrophic and non-catastrophic reinsurance to manage risk from these perils. We also use hedging, reinsurance and other risk management activities to mitigate financial market volatility.
Insurance regulators in many of the non-U.S. countries in which we operate require certain MetLife entities to prepare a sufficiency analysis of the reserves presented in the locally required regulatory financial statements, and to submit that analysis to the regulatory authorities. See “Business — Regulation — U.S. Regulation — Insurance Regulation — Policy and Contract Reserve Adequacy Analysis” and “Business — Regulation — International Regulation” included in the
2016
Annual Report.
Future Policy Benefits
We establish liabilities for amounts payable under insurance policies. See Notes 1 and 4 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report for additional information. See also “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Industry Trends — Impact of a Sustained Low Interest Rate Environment — Low Interest Rate Scenario” included in the
2016
Annual Report and “— Variable Annuity Guarantees.” A discussion of future policy benefits by segment (as well as Corporate & Other) follows.
130
U.S.
Amounts payable under insurance policies for this segment are comprised of group insurance and annuities, as well as property & casualty policies. For group insurance, future policyholder benefits are comprised mainly of liabilities for disabled lives under disability waiver of premium policy provisions, liabilities for survivor income benefit insurance, active life policies and premium stabilization and other contingency liabilities held under life insurance contracts. For group annuity contracts, future policyholder benefits are primarily related to payout annuities, including pension risk transfers, structured settlement annuities and institutional income annuities. There is no interest rate crediting flexibility on these liabilities. As a result, a sustained low interest rate environment could negatively impact earnings; however, we mitigate our risks by applying various ALM strategies, including the use of various interest rate derivative positions. The components of future policy benefits related to our property & casualty policies are liabilities for unpaid claims, estimated based upon assumptions such as rates of claim frequencies, levels of severities, inflation, judicial trends, legislative changes or regulatory decisions. Assumptions are based upon our historical experience and analysis of historical development patterns of the relationship of loss adjustment expenses to losses for each line of business, and we consider the effects of current developments, anticipated trends and risk management programs, reduced for anticipated salvage and subrogation.
Asia
Future policy benefits for this segment are held primarily for traditional life, endowment, annuity and accident & health contracts. They are also held for total return pass-through provisions included in certain universal life and savings products. They include certain liabilities for variable annuity and variable life guarantees of minimum death benefits, and longevity guarantees. Factors impacting these liabilities include sustained periods of lower yields than rates established at policy issuance, lower than expected asset reinvestment rates, market volatility, actual lapses resulting in lower than expected income, and actual mortality or morbidity resulting in higher than expected benefit payments. We mitigate our risks by applying various ALM strategies.
Latin America
Future policy benefits for this segment are held primarily for immediate annuities in Chile, Argentina and Mexico and traditional life contracts mainly in Mexico, Brazil and Colombia. There are also liabilities held for total return pass-through provisions included in certain universal life and savings products in Mexico. Factors impacting these liabilities include sustained periods of lower yields than rates established at policy issuance, lower than expected asset reinvestment rates, and mortality and lapses different than expected. We mitigate our risks by applying various ALM strategies.
EMEA
Future policy benefits for this segment include unearned premium reserves for group life and credit insurance contracts. Future policy benefits are also held for traditional life, endowment and annuity contracts with significant mortality risk and accident & health contracts. Factors impacting these liabilities include lower than expected asset reinvestment rates, market volatility, actual lapses resulting in lower than expected income, and actual mortality or morbidity resulting in higher than expected benefit payments. We mitigate our risks by having premiums which are adjustable or cancellable in some cases, and by applying various ALM strategies.
MetLife Holdings
Future policy benefits for the life business are comprised mainly of liabilities for traditional life and for universal and variable life insurance contracts. In order to manage risk, we have often reinsured a portion of the mortality risk on life insurance policies. The reinsurance programs are routinely evaluated and this may result in increases or decreases to existing coverage. We have entered into various interest rate derivative positions to mitigate the risk that investment of premiums received and reinvestment of maturing assets over the life of the policy will be at rates below those assumed in the original pricing of these contracts. For the annuities business, future policy benefits are comprised mainly of liabilities for life-contingent income annuities, and liabilities for the variable annuity guaranteed minimum benefits which are accounted for as insurance. Other future policyholder benefits are comprised mainly of liabilities for disabled lives under disability waiver of premium policy provisions, and active life policies. In addition, for our other products, future policyholder benefits related to the reinsurance of our former Japan joint venture are comprised of liabilities for the variable annuity guaranteed minimum benefits which are accounted for as insurance.
131
Brighthouse Financial
Future policy benefits for the life business are comprised mainly of liabilities for traditional life and for universal and variable life insurance contracts. In order to manage risk, we have often reinsured a portion of the mortality risk on life insurance policies. The reinsurance programs are routinely evaluated and this may result in increases or decreases to existing coverage. We have entered into various interest rate derivative positions to mitigate the risk that investment of premiums received and reinvestment of maturing assets over the life of the policy will be at rates below those assumed in the original pricing of these contracts. For the annuities business, future policy benefits are comprised mainly of liabilities for life-contingent income annuities, and liabilities for the variable annuity guaranteed minimum benefits accounted for as insurance. For our other products, future policyholder benefits are comprised mainly of group annuity contracts, primarily related to payout annuities, including pension risk transfers, structured settlement annuities and institutional income annuities. There is no interest rate crediting flexibility on these liabilities. As a result, a sustained low interest rate environment could negatively impact earnings; however, we mitigate our risks by applying various ALM strategies, including the use of various interest rate derivative positions.
Corporate & Other
Future policy benefits primarily include liabilities for the global employee benefits reinsurance business. Additionally, future policy benefits include liabilities for the U.S direct business sold directly to consumers.
Policyholder Account Balances
Policyholder account balances are generally equal to the account value, which includes accrued interest credited, but excludes the impact of any applicable charge that may be incurred upon surrender. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Industry Trends — Impact of a Sustained Low Interest Rate Environment — Low Interest Rate Scenario” included in the
2016
Annual Report and “— Variable Annuity Guarantees.” See also Notes 1 and 4 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report for additional information. A discussion of policyholder account balances by segment (as well as Corporate & Other) follows.
U.S.
Policyholder account balances in this segment are comprised of funding agreements, retained asset accounts, universal life policies, the fixed account of variable life insurance policies and specialized life insurance products for benefit programs.
Group Benefits
Policyholder account balances in this business are held for retained asset accounts, universal life policies, the fixed account of variable life insurance policies and specialized life insurance products for benefit programs. Policyholder account balances are credited interest at a rate we determine, which is influenced by current market rates. A sustained low interest rate environment could negatively impact earnings as a result of the minimum credited rate guarantees present in most of these policyholder account balances. We have various interest rate derivative positions to partially mitigate the risks associated with such a scenario.
The table below presents the breakdown of account value subject to minimum guaranteed crediting rates for Group Benefits:
|
March 31, 2017
|
|||||||
|
Guaranteed Minimum Crediting Rate
|
Account
Value (1)
|
Account
Value at
Guarantee (1)
|
|||||
|
(In millions)
|
|||||||
|
Greater than 0% but less than 2%
|
$
|
5,003
|
|
$
|
4,877
|
|
|
|
Equal to 2% but less than 4%
|
$
|
1,866
|
|
$
|
1,866
|
|
|
|
Equal to or greater than 4%
|
$
|
724
|
|
$
|
697
|
|
|
__________________
(1)
These amounts are not adjusted for policy loans.
132
Retirement and Income Solutions
Policyholder account balances in this business are comprised of funding agreements. Interest crediting rates vary by type of contract, and can be fixed or variable. Variable interest crediting rates are generally tied to an external index, most commonly (1-month or 3-month) LIBOR. We are exposed to interest rate risks, as well as foreign currency exchange rate risk, when guaranteeing payment of interest and return of principal at the contractual maturity date. We may invest in floating rate assets or enter into receive-floating interest rate swaps, also tied to external indices, as well as caps, to mitigate the impact of changes in market interest rates. We also mitigate our risks by applying various ALM strategies and seek to hedge all foreign currency exchange rate risk through the use of foreign currency hedges, including cross currency swaps.
Asia
Policyholder account balances in this segment are held largely for fixed income retirement and savings plans, fixed deferred annuities, interest sensitive whole life products, universal life and, to a lesser degree, liability amounts for unit-linked-type funds that do not meet the GAAP definition of separate accounts. Also included are certain liabilities for retirement and savings products sold in certain countries in Asia that generally are sold with minimum credited rate guarantees. Liabilities for guarantees on certain variable annuities in Asia are accounted for as embedded derivatives and recorded at estimated fair value and are also included within policyholder account balances. These liabilities are generally impacted by sustained periods of low interest rates, where there are interest rate guarantees. We mitigate our risks by applying various ALM strategies and with reinsurance. Liabilities for unit-linked-type funds are impacted by changes in the fair value of the associated underlying investments, as the return on assets is generally passed directly to the policyholder.
The table below presents the breakdown of account value subject to minimum guaranteed crediting rates for Asia:
|
March 31, 2017
|
|||||||
|
Guaranteed Minimum Crediting Rate (1)
|
Account
Value (2)
|
Account
Value at
Guarantee (2)
|
|||||
|
(In millions)
|
|||||||
|
Annuities
|
|||||||
|
Greater than 0% but less than 2%
|
$
|
20,877
|
|
$
|
2,911
|
|
|
|
Equal to 2% but less than 4%
|
$
|
1,166
|
|
$
|
423
|
|
|
|
Equal to or greater than 4%
|
$
|
1
|
|
$
|
1
|
|
|
|
Life & Other
|
|||||||
|
Greater than 0% but less than 2%
|
$
|
8,338
|
|
$
|
8,014
|
|
|
|
Equal to 2% but less than 4%
|
$
|
20,463
|
|
$
|
8,856
|
|
|
|
Equal to or greater than 4%
|
$
|
273
|
|
$
|
273
|
|
|
__________________
|
(1)
|
Excludes negative VOBA liabilities of $0.9 billion at
March 31, 2017
, primarily held in Japan. These liabilities were established in instances where the estimated fair value of contract obligations exceeded the book value of assumed insurance policy liabilities associated with the acquisition of American Life Insurance Company and Delaware American Life Insurance Company (collectively, “ALICO”). These negative liabilities were established primarily for decreased market interest rates subsequent to the issuance of the policy contracts.
|
|
(2)
|
These amounts are not adjusted for policy loans.
|
Latin America
Policyholder account balances in this segment are held largely for investment-type products and universal life products in Mexico and Chile, and deferred annuities in Brazil. Some of the deferred annuities in Brazil are unit-linked-type funds that do not meet the GAAP definition of separate accounts. The rest of the deferred annuities have minimum credited rate guarantees, and these liabilities and the universal life liabilities are generally impacted by sustained periods of low interest rates. Liabilities for unit-linked-type funds are impacted by changes in the fair value of the associated investments, as the return on assets is generally passed directly to the policyholder.
133
EMEA
Policyholder account balances in this segment are held mostly for universal life, deferred annuity, pension products, and unit-linked-type funds that do not meet the GAAP definition of separate accounts. They are also held for endowment products without significant mortality risk. Where there are interest rate guarantees, these liabilities are generally impacted by sustained periods of low interest rates. We mitigate our risks by applying various ALM strategies. Liabilities for unit-linked-type funds are impacted by changes in the fair value of the associated investments, as the return on assets is generally passed directly to the policyholder.
MetLife Holdings
Life policyholder account balances are held for retained asset accounts, universal life policies, the fixed account of variable life insurance policies, embedded derivatives related to the reinsurance of our former Japan joint venture, and funding agreements. For annuities, policyholder account balances are held for fixed deferred annuities, the fixed account portion of variable annuities, and non-life contingent income annuities. Interest is credited to the policyholder’s account at interest rates we determine which are influenced by current market rates, subject to specified minimums. A sustained low interest rate environment could negatively impact earnings as a result of the minimum credited rate guarantees present in most of these policyholder account balances. We have various interest rate derivative positions to partially mitigate the risks associated with such a scenario. Additionally, for our other products, policyholder account balances are held for variable annuity guaranteed minimum living benefits that are accounted for as embedded derivatives.
The table below presents the breakdown of account value subject to minimum guaranteed crediting rates for the MetLife Holdings segment:
|
March 31, 2017
|
|||||||
|
Guaranteed Minimum Crediting Rate
|
Account
Value (1)
|
Account
Value at
Guarantee (1)
|
|||||
|
(In millions)
|
|||||||
|
Greater than 0% but less than 2%
|
$
|
1,867
|
|
$
|
1,766
|
|
|
|
Equal to 2% but less than 4%
|
$
|
20,181
|
|
$
|
17,092
|
|
|
|
Equal to or greater than 4%
|
$
|
9,322
|
|
$
|
6,290
|
|
|
__________________
|
(1)
|
These amounts are not adjusted for policy loans.
|
Brighthouse Financial
Life policyholder account balances are held for universal life policies and the fixed account of variable life insurance policies. For annuities, policyholder account balances are held for fixed deferred annuities, the fixed account portion of variable annuities, and non-life contingent income annuities. For our other products, policyholder account balances are comprised of funding agreements. Interest is credited to the policyholder’s account at interest rates we determine which are influenced by current market rates, subject to specified minimums. Interest crediting rates vary by type of contract, and can be fixed or variable. Variable interest crediting rates are generally tied to an external index, most commonly (1-month or 3-month) LIBOR. We are exposed to interest rate risks, as well as foreign currency exchange rate risk, when guaranteeing payment of interest and return of principal at the contractual maturity date. We may invest in floating rate assets or enter into receive-floating interest rate swaps, also tied to external indices, as well as caps, to mitigate the impact of changes in market interest rates. We also mitigate our risks by applying various ALM strategies and seek to hedge all foreign currency exchange rate risk through the use of foreign currency hedges, including cross currency swaps. A sustained low interest rate environment could negatively impact earnings as a result of the minimum credited rate guarantees present in most of these policyholder account balances. We have various interest rate derivative positions to partially mitigate the risks associated with such a scenario. Additionally, for our other products policyholder account balances are held for variable annuity guaranteed minimum living benefits that are accounted for as embedded derivatives.
134
The table below presents the breakdown of account value subject to minimum guaranteed crediting rates for the Brighthouse Financial segment:
|
March 31, 2017
|
|||||||
|
Guaranteed Minimum Crediting Rate
|
Account
Value (1)
|
Account
Value at
Guarantee (1)
|
|||||
|
(In millions)
|
|||||||
|
Greater than 0% but less than 2%
|
$
|
1,686
|
|
$
|
1,175
|
|
|
|
Equal to 2% but less than 4%
|
$
|
22,591
|
|
$
|
15,092
|
|
|
|
Equal to or greater than 4%
|
$
|
3,230
|
|
$
|
2,331
|
|
|
__________________
|
(1)
|
These amounts are not adjusted for policy loans.
|
As a result of acquisitions, we establish additional liabilities known as excess interest reserves for policies with credited rates in excess of market rates as of the applicable acquisition dates. At March 31, 2017, excess interest reserves were $412 million for the Brighthouse Financial segment.
Variable Annuity Guarantees
We issue, directly and through assumed business, certain variable annuity products with guaranteed minimum benefits that provide the policyholder a minimum return based on their initial deposit (i.e., the benefit base) less withdrawals. In some cases, the benefit base may be increased by additional deposits, bonus amounts, accruals or optional market value resets. See Notes 1 and 4 of the Notes to the Consolidated Financial Statements included in the 2016 Annual Report, as well as Note
3
of the Notes to the Interim Condensed Consolidated Financial Statements, for additional information.
Certain guarantees, including portions thereof, have insurance liabilities established that are included in future policy benefits. Guarantees accounted for in this manner include GMDBs, the life-contingent portion of certain guaranteed minimum withdrawal benefit (“GMWBs”), and the non-life contingent portions of both GMWBs and GMIBs that require annuitization. These liabilities are accrued over the life of the contract in proportion to actual and future expected policy assessments based on the level of guaranteed minimum benefits generated using multiple scenarios of separate account returns. The scenarios are based on best estimate assumptions consistent with those used to amortize DAC. When current estimates of future benefits exceed those previously projected or when current estimates of future assessments are lower than those previously projected, liabilities will increase, resulting in a current period charge to net income. The opposite result occurs when the current estimates of future benefits are lower than those previously projected or when current estimates of future assessments exceed those previously projected. At each reporting period, we update the actual amount of business remaining in-force, which impacts expected future assessments and the projection of estimated future benefits resulting in a current period charge or increase to earnings.
Certain guarantees, including portions thereof, accounted for as embedded derivatives, are recorded at estimated fair value and included in policyholder account balances. Guarantees accounted for as embedded derivatives include guaranteed minimum accumulation benefits (“GMABs”), and the non-life contingent portions of both GMWBs and GMIBs that do not require annuitization. The estimated fair values of guarantees accounted for as embedded derivatives are determined based on the present value of projected future benefits minus the present value of projected future fees. The projections of future benefits and future fees require capital market and actuarial assumptions including expectations concerning policyholder behavior. A risk neutral valuation methodology is used to project the cash flows from the guarantees under multiple capital market scenarios to determine an economic liability. The reported estimated fair value is then determined by taking the present value of these risk-free generated cash flows using a discount rate that incorporates a spread over the risk-free rate to reflect our nonperformance risk and adding a risk margin. For more information on the determination of estimated fair value, see Note
7
of the Notes to the Interim Condensed Consolidated Financial Statements.
135
The table below contains the carrying value for guarantees at:
|
Future Policy
Benefits
|
Policyholder
Account Balances
|
||||||||||||||
|
March 31, 2017
|
December 31, 2016
|
March 31, 2017
|
December 31, 2016
|
||||||||||||
|
(In millions)
|
|||||||||||||||
|
Asia
|
|||||||||||||||
|
GMDB
|
$
|
30
|
|
$
|
29
|
|
$
|
—
|
|
$
|
—
|
|
|||
|
GMAB
|
—
|
|
—
|
|
31
|
|
36
|
|
|||||||
|
GMWB
|
108
|
|
98
|
|
192
|
|
189
|
|
|||||||
|
EMEA
|
|||||||||||||||
|
GMDB
|
1
|
|
1
|
|
—
|
|
—
|
|
|||||||
|
GMAB
|
—
|
|
—
|
|
16
|
|
17
|
|
|||||||
|
GMWB
|
29
|
|
30
|
|
(66
|
)
|
(50
|
)
|
|||||||
|
MetLife Holdings
|
|||||||||||||||
|
GMDB
|
266
|
|
257
|
|
—
|
|
—
|
|
|||||||
|
GMIB
|
482
|
|
471
|
|
7
|
|
93
|
|
|||||||
|
GMAB
|
—
|
|
—
|
|
10
|
|
13
|
|
|||||||
|
GMWB
|
175
|
|
161
|
|
1,338
|
|
1,268
|
|
|||||||
|
Brighthouse Financial
|
|||||||||||||||
|
GMDB
|
1,011
|
|
987
|
|
—
|
|
—
|
|
|||||||
|
GMIB
|
2,386
|
|
2,335
|
|
1,731
|
|
2,024
|
|
|||||||
|
GMAB
|
—
|
|
—
|
|
(6
|
)
|
1
|
|
|||||||
|
GMWB
|
145
|
|
138
|
|
217
|
|
334
|
|
|||||||
|
Total
|
$
|
4,633
|
|
$
|
4,507
|
|
$
|
3,470
|
|
$
|
3,925
|
|
|||
The carrying amounts for guarantees included in policyholder account balances above include nonperformance risk adjustments of $939 million and $982 million at
March 31, 2017
and
December 31, 2016
, respectively. These nonperformance risk adjustments represent the impact of including a credit spread when discounting the underlying risk neutral cash flows to determine the estimated fair values. The nonperformance risk adjustment does not have an economic impact on us as it cannot be monetized given the nature of these policyholder liabilities. The change in valuation arising from the nonperformance risk adjustment is not hedged.
The carrying values of these guarantees can change significantly during periods of sizable and sustained shifts in equity market performance, equity volatility, interest rates or foreign currency exchange rates. Carrying values are also impacted by our assumptions around mortality, separate account returns and policyholder behavior, including lapse rates.
As discussed below, we use a combination of product design, hedging strategies, reinsurance, and other risk management actions to mitigate the risks related to these benefits. Within each type of guarantee, there is a range of product offerings reflecting the changing nature of these products over time. Changes in product features and terms are in part driven by customer demand but, more importantly, reflect our risk management practices of continuously evaluating the guaranteed benefits and their associated asset-liability matching. Recently, we have been diversifying the concentration of income benefits in the portfolio of the Company’s annuities business by focusing on withdrawal benefits, variable annuities without living benefits and index-linked annuities. To this end, the GMIBs were no longer available for new purchases after February 19, 2016.
The sections below provide further detail by total account value for certain of our most popular guarantees. Total account values include amounts not reported on the consolidated balance sheets from assumed business, contractholder-directed investments which do not qualify for presentation as separate account assets, and amounts included in our general account. The total account values and the net amounts at risk include direct and assumed business, but exclude offsets from hedging or ceded reinsurance, if any.
136
GMDBs
We offer a range of GMDBs to our contractholders. The table below presents GMDBs, by benefit type, at
March 31, 2017
:
|
Total Account Value (1)
|
|||||||||||
|
Asia & EMEA
|
MetLife Holdings
|
Brighthouse Financial
|
|||||||||
|
(In millions)
|
|||||||||||
|
Return of premium or five to seven year step-up
|
$
|
8,330
|
|
$
|
54,923
|
|
$
|
56,758
|
|
||
|
Annual step-up
|
—
|
|
3,724
|
|
23,984
|
|
|||||
|
Roll-up and step-up combination
|
—
|
|
6,503
|
|
30,062
|
|
|||||
|
Total
|
$
|
8,330
|
|
$
|
65,150
|
|
$
|
110,804
|
|
||
__________________
|
(1)
|
Total account value excludes $2.2 billion for contracts with no GMDBs. Further, many of our annuity contracts offer more than one type of guarantee such that GMDB amounts listed above are not mutually exclusive to the amounts in the living benefit guarantees table below.
|
Based on total account value, less than 39% of our GMDBs included enhanced death benefits such as the annual step-up or roll-up and step-up combination products. We expect the above GMDB risk profile to be relatively consistent for the foreseeable future.
Living Benefit Guarantees
The table below presents our living benefit guarantees based on total account values at
March 31, 2017
:
|
Total Account Value (1)
|
|||||||||||
|
Asia & EMEA
|
MetLife Holdings
|
Brighthouse Financial
|
|||||||||
|
(In millions)
|
|||||||||||
|
GMIB
|
$
|
—
|
|
$
|
24,779
|
|
$
|
65,686
|
|
||
|
GMWB - non-life contingent (2)
|
2,432
|
|
3,618
|
|
3,405
|
|
|||||
|
GMWB - life-contingent
|
3,819
|
|
11,320
|
|
19,704
|
|
|||||
|
GMAB
|
1,279
|
|
770
|
|
669
|
|
|||||
|
$
|
7,530
|
|
$
|
40,487
|
|
$
|
89,464
|
|
|||
__________________
|
(1)
|
Total account value excludes $48.2 billion for contracts with no living benefit guarantees. Further, many of our annuity contracts offer more than one type of guarantee such that living benefit guarantee amounts listed above are not mutually exclusive of the amounts in the GMDBs table above.
|
|
(2)
|
The Asia and EMEA segments include the non-life contingent portion of the GMWB total account value of $996 million with a guarantee at annuitization.
|
In terms of total account value, GMIBs are our most significant living benefit guarantee. Our primary risk management strategy for our GMIB products is our derivatives hedging program as discussed below. Additionally, we have engaged in certain reinsurance agreements covering some of our GMIB business. As part of our overall risk management approach for living benefit guarantees, we continually monitor the reinsurance markets for the right opportunity to purchase additional coverage for our GMIB business.
137
The table below presents our GMIB associated total account values, by their guaranteed payout basis, at
March 31, 2017
:
|
Total Account Value
|
|||
|
(In millions)
|
|||
|
7-year setback, 2.5% interest rate
|
$
|
32,533
|
|
|
7-year setback, 1.5% interest rate
|
5,491
|
|
|
|
10-year setback, 1.5% interest rate
|
18,040
|
|
|
|
10-year mortality projection, 10-year setback, 1.0% interest rate
|
30,196
|
|
|
|
10-year mortality projection, 10-year setback, 0.5% interest rate
|
4,205
|
|
|
|
$
|
90,465
|
|
|
The annuitization interest rates on GMIBs have been decreased from 2.5% to 0.5% over time, partially in response to the low interest rate environment, accompanied by an increase in the setback period from seven years to 10 years and the introduction of a 10-year mortality projection.
Additionally, 33% of the $90.5 billion of GMIB total account value has been invested in managed volatility funds as of
March 31, 2017
. These funds seek to manage volatility by adjusting the fund holdings within certain guidelines based on capital market movements. Such activity reduces the overall risk of the underlying funds while maintaining their growth opportunities. These risk mitigation techniques translate to a reduction or elimination of the need for us to manage the funds’ volatility through hedging or reinsurance.
Our GMIB products typically have a waiting period of 10 years to be eligible for annuitization. As of
March 31, 2017
, only 19% of our contracts with GMIBs were eligible for annuitization. The remaining contracts are not eligible for annuitization for an average of five years.
Once eligible for annuitization, contractholders would only be expected to annuitize if their contracts were in-the-money. We calculate in-the-moneyness with respect to GMIBs consistent with net amount at risk as discussed in Note
3
of the Notes to the Interim Condensed Consolidated Financial Statements, by comparing the contractholders’ income benefits based on total account values and current annuity rates versus the guaranteed income benefits. The net amount at risk was $3,647 million at
March 31, 2017
, of which $3,446 million was related to GMIB guarantees. For those contracts with GMIB, the table below presents details of contracts that are in-the-money and out-of-the-money at
March 31, 2017
:
|
In-the-
Moneyness
|
Total
Account Value
|
% of Total
|
|
|||||
|
(Dollars in millions)
|
||||||||
|
In-the-money
|
30% +
|
$
|
3,391
|
|
4
|
%
|
||
|
20% to 30%
|
2,442
|
|
3
|
%
|
||||
|
10% to 20%
|
4,311
|
|
5
|
%
|
||||
|
0% to 10%
|
7,359
|
|
8
|
%
|
||||
|
17,503
|
|
|||||||
|
Out-of-the-money
|
-10% to 0%
|
14,158
|
|
16
|
%
|
|||
|
-20% to -10%
|
9,227
|
|
10
|
%
|
||||
|
-20% +
|
49,577
|
|
55
|
%
|
||||
|
72,962
|
|
|||||||
|
Total GMIBs
|
$
|
90,465
|
|
|||||
138
Derivatives Hedging Variable Annuity Guarantees
Our risk mitigating hedging strategy uses various over-the-counter and exchange traded derivatives. The table below presents the gross notional amount, estimated fair value and primary underlying risk exposure of the derivatives hedging our variable annuity guarantees:
|
Instrument Type
|
March 31, 2017
|
December 31, 2016
|
||||||||||||||||||||||||
|
Primary Underlying
Risk Exposure
|
Gross Notional
Amount
|
Estimated Fair Value
|
Gross Notional
Amount
|
Estimated Fair Value
|
||||||||||||||||||||||
|
Assets
|
Liabilities
|
Assets
|
Liabilities
|
|||||||||||||||||||||||
|
(In millions)
|
||||||||||||||||||||||||||
|
Interest rate
|
Interest rate swaps
|
$
|
31,048
|
|
$
|
1,414
|
|
$
|
381
|
|
$
|
36,266
|
|
$
|
2,770
|
|
$
|
1,711
|
|
|||||||
|
Interest rate futures
|
3,272
|
|
4
|
|
6
|
|
3,959
|
|
11
|
|
11
|
|
||||||||||||||
|
Interest rate options
|
44,728
|
|
544
|
|
36
|
|
18,943
|
|
585
|
|
1
|
|
||||||||||||||
|
Foreign currency exchange rate
|
Foreign currency forwards
|
3,097
|
|
10
|
|
109
|
|
3,086
|
|
10
|
|
222
|
|
|||||||||||||
|
Currency futures
|
—
|
|
—
|
|
—
|
|
85
|
|
—
|
|
—
|
|
||||||||||||||
|
Equity market
|
Equity futures
|
8,977
|
|
21
|
|
9
|
|
12,320
|
|
67
|
|
3
|
|
|||||||||||||
|
Equity index options
|
51,709
|
|
1,283
|
|
1,735
|
|
51,190
|
|
1,298
|
|
1,458
|
|
||||||||||||||
|
Equity variance swaps
|
23,231
|
|
253
|
|
834
|
|
23,157
|
|
223
|
|
756
|
|
||||||||||||||
|
Equity total return swaps
|
3,265
|
|
1
|
|
140
|
|
3,901
|
|
2
|
|
160
|
|
||||||||||||||
|
Total
|
$
|
169,327
|
|
$
|
3,530
|
|
$
|
3,250
|
|
$
|
152,907
|
|
$
|
4,966
|
|
$
|
4,322
|
|
||||||||
The change in estimated fair values of our derivatives is recorded in policyholder benefits and claims if such derivatives are hedging guarantees included in future policy benefits, and in net derivative gains (losses) if such derivatives are hedging guarantees included in policyholder account balances.
Our hedging strategy involves the significant use of static longer-term derivative instruments to avoid the need to execute transactions during periods of market disruption or higher volatility. We continually monitor the capital markets for opportunities to adjust our liability coverage, as appropriate. Futures are also used to dynamically adjust the daily coverage levels as markets and liability exposures fluctuate.
We remain liable for the guaranteed benefits in the event that reinsurers or derivative counterparties are unable or unwilling to pay. Certain of our reinsurance agreements and most derivative positions are collateralized and derivatives positions are subject to master netting agreements, both of which significantly reduce the exposure to counterparty risk. In addition, we are subject to the risk that hedging and other risk management actions prove ineffective or that unanticipated policyholder behavior or mortality, combined with adverse market events, produces economic losses beyond the scope of the risk management techniques employed.
Liquidity and Capital Resources
Overview
Our business and results of operations are materially affected by conditions in the global capital markets and the economy generally. Stressed conditions, volatility and disruptions in global capital markets, particular markets, or financial asset classes can have an adverse effect on us, in part because we have a large investment portfolio and our insurance liabilities and derivatives are sensitive to changing market factors. The global markets and economy continue to experience volatility that may affect our financing costs and market interest for our debt or equity securities. For further information regarding market factors that could affect our ability to meet liquidity and capital needs, see “— Industry Trends” and “— Investments — Current Environment.”
Liquidity Management
Based upon the strength of our franchise, diversification of our businesses, strong financial fundamentals and the substantial funding sources available to us as described herein, we continue to believe we have access to ample liquidity to meet business requirements under current market conditions and reasonably possible stress scenarios. We continuously monitor and adjust our liquidity and capital plans for MetLife, Inc. and its subsidiaries in light of market conditions, as well as changing needs and opportunities.
139
Short-term Liquidity
We maintain a substantial short-term liquidity position, which was $14.3 billion and $14.2 billion at
March 31, 2017
and
December 31, 2016
, respectively. Short-term liquidity includes cash and cash equivalents and short-term investments, excluding assets that are pledged or otherwise committed, including amounts received in connection with securities lending, repurchase agreements, derivatives, and secured borrowings, as well as amounts held in the closed block.
Liquid Assets
An integral part of our liquidity management includes managing our level of liquid assets, which was $234.4 billion and $230.7 billion at
March 31, 2017
and
December 31, 2016
, respectively. Liquid assets include cash and cash equivalents, short-term investments and publicly-traded securities, excluding assets that are pledged or otherwise committed. Assets pledged or otherwise committed include amounts received in connection with securities lending, repurchase agreements, derivatives, regulatory deposits and custodial accounts, collateral financing arrangements, funding agreements and secured borrowings, as well as amounts held in the closed block.
Capital Management
We have established several senior management committees as part of our capital management process. These committees, including the Capital Management Committee and the Enterprise Risk Committee (“ERC”), regularly review actual and projected capital levels (under a variety of scenarios including stress scenarios) and our annual capital plan in accordance with our capital policy. The Capital Management Committee is comprised of members of senior management, including MetLife, Inc.’s Chief Financial Officer (“CFO”), Treasurer and Chief Risk Officer (“CRO”). The ERC is also comprised of members of senior management, including MetLife, Inc.’s CFO, CRO and Chief Investment Officer.
Our Board of Directors and senior management are directly involved in the development and maintenance of our capital policy. The capital policy sets forth, among other things, minimum and target capital levels and the governance of the capital management process. All capital actions, including proposed changes to the annual capital plan, capital targets or capital policy, are reviewed by the Finance and Risk Committee of the Board prior to obtaining full Board approval. The Board approves the capital policy and the annual capital plan and authorizes capital actions, as required.
See “Risk Factors — Capital-Related Risks — Legal and Regulatory Restrictions and Uncertainty and Restrictions Under the Terms of Certain of Our Securities May Prevent Us from Repurchasing Our Stock and Paying Dividends at the Level We Wish” included in the
2016
Annual Report and Note 16 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report for information regarding restrictions on payment of dividends and stock repurchases. See also “— The Company — Liquidity and Capital Uses — Common Stock Repurchases” for information regarding MetLife, Inc.’s common stock repurchase authorization.
The Company
Liquidity
Liquidity refers to the ability to generate adequate amounts of cash to meet our needs. In the event of significant cash requirements beyond anticipated liquidity needs, we have various alternatives available depending on market conditions and the amount and timing of the liquidity need. These available alternatives include cash flows from operations, sales of liquid assets, global funding sources including commercial paper and various credit and committed facilities.
Capital
We manage our capital position to maintain our financial strength and credit ratings. Our capital position is supported by our ability to generate strong cash flows within our operating companies and borrow funds at competitive rates, as well as by our demonstrated ability to raise additional capital to meet operating and growth needs despite adverse market and economic conditions.
140
Summary of the Company’s Primary Sources and Uses of Liquidity and Capital
Our primary sources and uses of liquidity and capital are summarized as follows:
|
Three Months
Ended March 31, |
|||||||
|
2017
|
2016
|
||||||
|
(In millions)
|
|||||||
|
Sources:
|
|||||||
|
Operating activities, net
|
$
|
2,098
|
|
$
|
1,913
|
|
|
|
Changes in policyholder account balances, net
|
2,171
|
|
615
|
|
|||
|
Changes in payables for collateral under securities loaned and other transactions, net
|
391
|
|
4,161
|
|
|||
|
Net change in short-term debt
|
18
|
|
—
|
|
|||
|
Financing element on certain derivative instruments and other derivative related transactions, net
|
188
|
|
—
|
|
|||
|
Other, net
|
48
|
|
34
|
|
|||
|
Effect of change in foreign currency exchange rates on cash and cash equivalents
|
213
|
|
73
|
|
|||
|
Total sources
|
5,127
|
|
6,796
|
|
|||
|
Uses:
|
|||||||
|
Investing activities, net
|
4,276
|
|
5,739
|
|
|||
|
Long-term debt repaid
|
4
|
|
5
|
|
|||
|
Collateral financing arrangements repaid
|
12
|
|
12
|
|
|||
|
Financing element on certain derivative instruments and other derivative related transactions, net
|
—
|
|
13
|
|
|||
|
Treasury stock acquired in connection with share repurchases
|
858
|
|
70
|
|
|||
|
Dividends on preferred stock
|
6
|
|
6
|
|
|||
|
Dividends on common stock
|
437
|
|
413
|
|
|||
|
Total uses
|
5,593
|
|
6,258
|
|
|||
|
Net increase (decrease) in cash and cash equivalents
|
$
|
(466
|
)
|
$
|
538
|
|
|
Cash Flows from Operations
The principal cash inflows from our insurance activities come from insurance premiums, net investment income, annuity considerations and deposit funds. The principal cash outflows are the result of various life insurance, property & casualty, annuity and pension products, operating expenses and income tax, as well as interest expense. A primary liquidity concern with respect to these cash flows is the risk of early contractholder and policyholder withdrawal.
Cash Flows from Investments
The principal cash inflows from our investment activities come from repayments of principal, proceeds from maturities and sales of investments and settlements of freestanding derivatives. The principal cash outflows relate to purchases of investments, issuances of policy loans and settlements of freestanding derivatives. Additional cash outflows relate to purchases of businesses. We typically have a net cash outflow from investing activities because cash inflows from insurance operations are reinvested in accordance with our ALM discipline to fund insurance liabilities. We closely monitor and manage these risks through our comprehensive investment risk management process. The primary liquidity concerns with respect to these cash flows are the risk of default by debtors and market disruption.
Cash Flows from Financing
The principal cash inflows from our financing activities come from issuances of debt and other securities, deposits of funds associated with policyholder account balances and lending of securities. The principal cash outflows come from repayments of debt, payments of dividends on and repurchases of MetLife, Inc.’s securities, withdrawals associated with policyholder account balances and the return of securities on loan. The primary liquidity concerns with respect to these cash flows are market disruption and the risk of early contractholder and policyholder withdrawal.
141
Liquidity and Capital Sources
In addition to the general description of liquidity and capital sources in “— Summary of the Company’s Primary Sources and Uses of Liquidity and Capital,” the following additional information is provided regarding our primary sources of liquidity and capital:
Global Funding Sources
Liquidity is provided by a variety of global funding sources, including funding agreements, credit facilities and commercial paper. Capital is provided by a variety of global funding sources, including short-term and long-term debt, collateral financing arrangements, junior subordinated debt securities, preferred securities, equity securities and equity-linked securities. The diversity of our global funding sources enhances our funding flexibility, limits dependence on any one market or source of funds and generally lowers the cost of funds. Our primary global funding sources include:
Common Stock
During the
three months ended
March 31, 2017
and
2016
, MetLife, Inc. issued
1,840,900
and
1,943,866
new shares of its common stock for
$66 million
and
$78 million
, respectively, to satisfy various stock option exercises and other stock-based awards.
Commercial Paper, Reported in Short-term Debt
MetLife, Inc. and MetLife Funding, Inc. (“MetLife Funding”) each have a commercial paper program that is supported by our general corporate credit facility (see “— Credit and Committed Facilities”). MetLife Funding raises cash from its commercial paper program and uses the proceeds to extend loans through MetLife Credit Corp., another subsidiary of MLIC, to affiliates in order to enhance the financial flexibility and liquidity of these companies.
Federal Home Loan Bank Funding Agreements, Reported in Policyholder Account Balances
Certain of our domestic insurance subsidiaries are members of a regional Federal Home Loan Bank (“FHLB”). During the
three months ended
March 31, 2017
and
2016
, we issued $4.4 billion and $2.5 billion, respectively, and repaid $4.4 billion and $2.5 billion, respectively, under funding agreements with certain regional FHLBs. At both
March 31, 2017
and
December 31, 2016
, total obligations outstanding under these funding agreements were $16.0 billion. See Note 4 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report.
Special Purpose Entity Funding Agreements, Reported in Policyholder Account Balances
We issue fixed and floating rate funding agreements, which are denominated in either U.S. dollars or foreign currencies, to certain special purpose entities (“SPEs”) that have issued either debt securities or commercial paper for which payment of interest and principal is secured by such funding agreements. During the
three months ended
March 31, 2017
and
2016
, we issued $10.3 billion and $10.3 billion, respectively, and repaid $9.5 billion and $11.2 billion, respectively, under such funding agreements. At
March 31, 2017
and
December 31, 2016
, total obligations outstanding under these funding agreements were $32.1 billion and $30.9 billion, respectively. See Note 4 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report.
Federal Agricultural Mortgage Corporation Funding Agreements, Reported in Policyholder Account Balances
We have issued funding agreements to a subsidiary of the Federal Agricultural Mortgage Corporation (“Farmer Mac”), as well as to certain SPEs that have issued debt securities for which payment of interest and principal is secured by such funding agreements, and such debt securities are also guaranteed as to payment of interest and principal by Farmer Mac. The obligations under all such funding agreements are secured by a pledge of certain eligible agricultural mortgage loans. During the
three months ended
March 31, 2017
and
2016
, we issued $0 and $500 million, respectively, and repaid $0 and $500 million, respectively, under such funding agreements. At both
March 31, 2017
and
December 31, 2016
, total obligations outstanding under these funding agreements were $2.6 billion. See Note 4 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report.
Credit and Committed Facilities
At
March 31, 2017
, we maintained a $4.0 billion unsecured revolving credit facility and certain committed facilities aggregating $11.5 billion. When drawn upon, these facilities bear interest at varying rates in accordance with the respective agreements.
The unsecured revolving credit facility is used for general corporate purposes, to support the borrowers’ commercial paper programs and for the issuance of letters of credit. At
March 31, 2017
, we had outstanding $690 million in letters of credit and no drawdowns against this facility. Remaining availability was $3.3 billion at
March 31, 2017
.
142
The committed facilities are used for collateral for certain of our affiliated reinsurance liabilities. At
March 31, 2017
, $6.1 billion in letters of credit and $2.8 billion in aggregate drawdowns under collateral financing arrangements were outstanding. Remaining availability was $2.6 billion at
March 31, 2017
. See
Note 14
of the Notes to the Interim Condensed Consolidated Financial Statement for discussion of reductions in the committed facilities totaling $7.8 billion in April 2017.
In December 2016, MetLife, Inc. and MetLife Funding entered into an agreement to amend their existing $4.0 billion unsecured revolving credit facility, which provides, among other things, that the facility will be amended and restated upon the completion of the proposed Separation and the satisfaction of certain other conditions. As amended and restated, the unsecured revolving credit facility will provide for borrowings and the issuance of letters of credit in an aggregate amount of up to $3.0 billion. All borrowings under this amended revolving credit facility must be repaid by December 20, 2021, except that letters of credit outstanding upon termination may remain outstanding until December 20, 2022.
In December 2016, Brighthouse Financial, Inc. entered into a $3.0 billion three-year senior unsecured delayed draw term loan agreement with a bank syndicate. Borrowings under the term loan agreement may be used for general corporate purposes, including payment of a portion of the dividends to be paid by Brighthouse Financial, Inc. to MetLife, Inc. in connection with the Separation. The term loan agreement provides that borrowings may be made during the period prior to the Separation. There were no outstanding borrowings at
March 31, 2017
. In December 2016, Brighthouse Financial, Inc. also entered into a $2.0 billion five-year senior unsecured revolving credit facility with a bank syndicate. Borrowings and letters of credit under the revolving credit agreement may be used for general corporate purposes, including payment of a portion of the dividends to be paid by Brighthouse Financial, Inc. to MetLife, Inc. in connection with the Separation (the three-year and the five-year Brighthouse credit facilities, collectively, the “Brighthouse Credit Facilities”). The Brighthouse Credit Facilities contain certain administrative, reporting, legal and financial covenants, including requirements by Brighthouse Financial, Inc. to maintain a specified minimum consolidated net worth and to maintain a maximum ratio of indebtedness to total capitalization, and limitations on the dollar amount of indebtedness that may be incurred by Brighthouse Financial, Inc., which could restrict Brighthouse Financial, Inc. operations and use of funds.
See Note 12 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report for further information about these facilities, including the circumstances under which Brighthouse may draw upon such facilities in connection with and after the Separation.
We have no reason to believe that our lending counterparties will be unable to fulfill their respective contractual obligations under these facilities. As commitments associated with letters of credit and financing arrangements may expire unused, these amounts do not necessarily reflect our actual future cash funding requirements.
Outstanding Debt Under Global Funding Sources
The following table summarizes our outstanding debt at:
|
March 31, 2017
|
December 31, 2016
|
||||||
|
(In millions)
|
|||||||
|
Short-term debt
|
$
|
260
|
|
$
|
242
|
|
|
|
Long-term debt (1)
|
$
|
16,479
|
|
$
|
16,467
|
|
|
|
Collateral financing arrangements (2)
|
$
|
4,059
|
|
$
|
4,071
|
|
|
|
Junior subordinated debt securities
|
$
|
3,169
|
|
$
|
3,169
|
|
|
__________________
|
(1)
|
Includes $403 million and $402 million of non-recourse debt at
March 31, 2017
and
December 31, 2016
, respectively, for which creditors have no access, subject to customary exceptions, to the general assets of the Company other than recourse to certain investment subsidiaries.
|
|
(2)
|
See
Note 14
of the Notes to the Interim Condensed Consolidated Financial Statements for discussion of a $2.8 billion repayment on the collateral financing agreement liability in April 2017, utilizing assets held in trust, which had been repositioned into short-term investments and cash equivalents.
|
Debt and Facility Covenants
Certain of our debt instruments and committed facilities, as well as our unsecured credit facility, contain various administrative, reporting, legal and financial covenants. We believe we were in compliance with all applicable covenants at
March 31, 2017
.
143
Dispositions
There were no cash proceeds from dispositions during either of the
three months ended
March 31, 2017
or
2016
.
Liquidity and Capital Uses
In addition to the general description of liquidity and capital uses in “— Summary of the Company’s Primary Sources and Uses of Liquidity and Capital,” the following additional information is provided regarding our primary uses of liquidity and capital:
Common Stock Repurchases
Utilizing an authorization from the MetLife, Inc. Board of Directors, MetLife, Inc. may purchase its common stock from the MetLife Policyholder Trust, in the open market (including pursuant to the terms of a pre-set trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934 (“Exchange Act”)) and in privately negotiated transactions. See “Unregistered Sales of Equity Securities and Use of Proceeds — Issuer Purchases of Equity Securities.”
During the
three months ended
March 31, 2017
and
2016
, MetLife, Inc. repurchased
16,038,791
shares and
1,445,864
shares of common stock in the open market purchases for
$858 million
and
$70 million
, respectively.
At
March 31, 2017
, MetLife, Inc. had
$1.8 billion
remaining under the common stock repurchase authorization. Common stock repurchases are dependent upon several factors, including our capital position, liquidity, financial strength and credit ratings, general market conditions, the market price of MetLife, Inc.’s common stock compared to management’s assessment of the stock’s underlying value and applicable regulatory approvals, as well as other legal and accounting factors. See “— Industry Trends — Regulatory Developments — International Regulation — Global Systemically Important Insurers.” See also “Business — Regulation — U.S. Regulation — Potential Regulation as a Non-Bank SIFI” and “Risk Factors — Capital-Related Risks — Legal and Regulatory Restrictions and Uncertainty and Restrictions Under the Terms of Certain of Our Securities May Prevent Us from Repurchasing Our Stock and Paying Dividends at the Level We Wish” included in the
2016
Annual Report and Note 16 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report.
Preferred Stock Dividends
Information on the declaration, record and payment dates, as well as per share and aggregate dividend amounts, for MetLife, Inc.’s preferred stock was as follows for the
three months ended
March 31, 2017
and
2016
:
|
Declaration Date
|
Record Date
|
Payment Date
|
Preferred Stock Dividend
|
|||||||||||||||
|
Series A
Per
Share
|
Series A
Aggregate
|
Series C
Per Share |
Series C
Aggregate |
|||||||||||||||
|
(In millions, except per share data)
|
||||||||||||||||||
|
March 6, 2017
|
February 28, 2017
|
March 15, 2017
|
$
|
0.250
|
|
6
|
|
$
|
—
|
|
—
|
|
||||||
|
March 7, 2016
|
February 29, 2016
|
March 15, 2016
|
$
|
0.253
|
|
6
|
|
$
|
—
|
|
—
|
|
||||||
Preferred stock dividends are paid quarterly in accordance with the terms of MetLife, Inc.’s Floating Rate Non-Cumulative Preferred Stock, Series A. Dividends are paid semi-annually on MetLife, Inc.’s 5.25% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series C commencing December 15, 2015 and ending on June 15, 2020 and, thereafter, will be paid quarterly.
144
Common Stock Dividends
Information on the declaration, record and payment dates, as well as per share and aggregate dividend amounts, for MetLife, Inc.’s common stock was as follows for the
three months ended
March 31, 2017
and
2016
:
|
Declaration Date
|
Record Date
|
Payment Date
|
Common Stock Dividend
|
|||||||||
|
Per Share
|
Aggregate
|
|||||||||||
|
(In millions, except per share data)
|
||||||||||||
|
January 6, 2017
|
February 6, 2017
|
March 13, 2017
|
$
|
0.400
|
|
$
|
437
|
|
||||
|
January 6, 2016
|
February 5, 2016
|
March 14, 2016
|
$
|
0.375
|
|
$
|
413
|
|
||||
The declaration and payment of common stock dividends is subject to the discretion of our Board of Directors, and will depend on MetLife, Inc.’s financial condition, results of operations, cash requirements, future prospects, regulatory restrictions on the payment of dividends by MetLife, Inc.’s insurance subsidiaries and other factors deemed relevant by the Board. See Note
14
of the Notes to the Interim Condensed Consolidated Financial Statements for information regarding a common stock dividend declared subsequent to
March 31, 2017
.
Dividend Restrictions
If MetLife, Inc. were re-designated as a non-bank SIFI, the payment of dividends and other distributions by MetLife, Inc. to its security holders may be subject to regulation by the Federal Reserve. See “Business — Regulation — U.S. Regulation — Potential Regulation as a Non-Bank SIFI” included in the
2016
Annual Report. In addition, if additional capital requirements are imposed on MetLife, Inc. as a G-SII, its ability to pay dividends could be reduced by any such additional capital requirements that might be imposed. See “— Industry Trends — Regulatory Developments — International Regulation — Global Systemically Important Insurers.” The payment of dividends is also subject to restrictions under the terms of our preferred stock and junior subordinated debentures in situations where we may be experiencing financial stress. See “Risk Factors — Capital-Related Risks — Legal and Regulatory Restrictions and Uncertainty and Restrictions Under the Terms of Certain of Our Securities May Prevent Us from Repurchasing Our Stock and Paying Dividends at the Level We Wish” included in the
2016
Annual Report and Note 16 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report.
Debt Repayments
During both the three months ended
March 31, 2017
and
2016
, following regulatory approval, MetLife Reinsurance Company of Charleston, a wholly-owned subsidiary of MetLife, Inc., repurchased and canceled $12 million in aggregate principal amount of its surplus notes, which were reported in collateral financing arrangements on the consolidated balance sheets.
Debt Repurchases
We may from time to time seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for other securities, in open market purchases, privately negotiated transactions or otherwise. Any such repurchases or exchanges will be dependent upon several factors, including our liquidity requirements, contractual restrictions, general market conditions, and applicable regulatory, legal and accounting factors. Whether or not to repurchase any debt and the size and timing of any such repurchases will be determined at our discretion.
Support Agreements
MetLife, Inc. and several of its subsidiaries (each, an “Obligor”) are parties to various capital support commitments and guarantees with subsidiaries. Under these arrangements, each Obligor, with respect to the applicable entity, has agreed to cause such entity to meet specified capital and surplus levels or has guaranteed certain contractual obligations. We anticipate that in the event that these arrangements place demands upon us, there will be sufficient liquidity and capital to enable us to meet anticipated demands. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — MetLife, Inc. — Liquidity and Capital Uses — Support Agreements” included in the
2016
Annual Report. See also “ — Subsequent Events.”
145
Insurance Liabilities
Liabilities arising from our insurance activities primarily relate to benefit payments under various life insurance, property & casualty, annuity and group pension products, as well as payments for policy surrenders, withdrawals and loans. For annuity or deposit type products, surrender or lapse behavior differs somewhat by segment. In the MetLife Holdings and Brighthouse Financial segments, which include individual annuities, lapses and surrenders tend to occur in the normal course of business. During the
three months ended
March 31, 2017
and
2016
, general account surrenders and withdrawals from annuity products were $772 million and $1.0 billion, respectively. In the Retirement and Income Solutions business within the U.S. segment, which includes pension risk transfers, bank-owned life insurance and other fixed annuity contracts, as well as funding agreements and other capital market products, most of the products offered have fixed maturities or fairly predictable surrenders or withdrawals. With regard to the Retirement and Income Solutions business products that provide customers with limited rights to accelerate payments, at
March 31, 2017
there were no funding agreements or other capital market products that could be put back to the Company.
Pledged Collateral
We pledge collateral to, and have collateral pledged to us by, counterparties in connection with our derivatives. At
March 31, 2017
and
December 31, 2016
, we had received pledged cash collateral from counterparties of
$5.1 billion
and
$6.5 billion
, respectively. At
March 31, 2017
and
December 31, 2016
, we had pledged cash collateral to counterparties of
$584 million
and
$1.6 billion
, respectively. With respect to bilateral contracts between two counterparties derivatives in a net liability position that have credit contingent provisions, a one-notch downgrade in the Company’s credit or financial strength rating, as applicable, would have required
$10 million
of additional collateral be provided to our counterparties as of
March 31, 2017
. See Note
6
of the Notes to the Interim Condensed Consolidated Financial Statements for additional information about collateral pledged to us, collateral we pledge and derivatives subject to credit contingent provisions.
We pledge collateral and have had collateral pledged to us, and may be required from time to time to pledge additional collateral or be entitled to have additional collateral pledged to us, in connection with collateral financing arrangements related to the reinsurance of closed block and universal life secondary guarantee liabilities.
We pledge collateral from time to time in connection with funding agreements. See Note 4 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report.
Securities Lending
We participate in a securities lending program whereby securities are loaned to third parties, primarily brokerage firms and commercial banks. We obtain collateral, usually cash, from the borrower, which must be returned to the borrower when the loaned securities are returned to us. Under our securities lending program, we were liable for cash collateral under our control of
$26.5 billion
and $26.8 billion at
March 31, 2017
and
December 31, 2016
, respectively. Of these amounts,
$6.2 billion
and $6.6 billion at
March 31, 2017
and
December 31, 2016
, respectively, were on open, meaning that the related loaned security could be returned to us on the next business day requiring the immediate return of cash collateral we hold. The estimated fair value of the securities on loan related to the cash collateral on open at
March 31, 2017
was
$6.1 billion
, over
99%
of which were U.S. government and agency securities which, if put to us, could be immediately sold to satisfy the cash requirements to immediately return the cash collateral. See
Note 5
of the Notes to the Interim Condensed Consolidated Financial Statements.
Repurchase Agreements
We participate in short-term repurchase agreements whereby securities are loaned to unaffiliated financial institutions. We obtain collateral, usually cash, from the borrower, which must be returned to the borrower when the loaned securities are returned to us. Under these repurchase agreements, we were liable for cash collateral under our control of
$1.4 billion
and
$102 million
at
March 31, 2017
and
December 31, 2016
, respectively. The estimated fair value of the securities on loan at
March 31, 2017
was
$1.4 billion
which were primarily U.S. government and agency securities which, if put to us, could be immediately sold to satisfy the cash requirements to immediately return the cash collateral. See
Note 5
of the Notes to the Interim Condensed Consolidated Financial Statements.
146
Litigation
Putative or certified class action litigation and other litigation, and claims and assessments against us, in addition to those discussed elsewhere herein and those otherwise provided for in the consolidated financial statements, have arisen in the course of our business, including, but not limited to, in connection with our activities as an insurer, employer, investor, investment advisor, taxpayer and, formerly, a mortgage lending bank. Further, state insurance regulatory authorities and other federal and state authorities regularly make inquiries and conduct investigations concerning our compliance with applicable insurance and other laws and regulations. See Note
13
of the Notes to the Interim Condensed Consolidated Financial Statements.
We establish liabilities for litigation and regulatory loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. For material matters where a loss is believed to be reasonably possible but not probable, no accrual is made but we disclose the nature of the contingency and an aggregate estimate of the reasonably possible range of loss in excess of amounts accrued, when such an estimate can be made. It is not possible to predict or determine the ultimate outcome of all pending investigations and legal proceedings. In some of the matters referred to herein, very large and/or indeterminate amounts, including punitive and treble damages, are sought. Although in light of these considerations, it is possible that an adverse outcome in certain cases could have a material adverse effect upon our financial position, based on information currently known by us, in our opinion, the outcome of such pending investigations and legal proceedings are not likely to have such an effect. However, given the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation, it is possible that an adverse outcome in certain matters could, from time to time, have a material adverse effect on our consolidated net income or cash flows in particular quarterly or annual periods.
Acquisitions
There were no acquisitions during either of the
three months ended
March 31, 2017
or
2016
.
Contractual Obligations
See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — The Company — Contractual Obligations” included in the
2016
Annual Report for additional information regarding the Company’s contractual obligations.
MetLife, Inc.
Liquidity and Capital Management
Liquidity and capital are managed to preserve stable, reliable and cost-effective sources of cash to meet all current and future financial obligations and are provided by a variety of sources, including a portfolio of liquid assets, a diversified mix of short- and long-term funding sources from the wholesale financial markets and the ability to borrow through credit and committed facilities. Liquidity is monitored through the use of internal liquidity risk metrics, including the composition and level of the liquid asset portfolio, timing differences in short-term cash flow obligations, access to the financial markets for capital and debt transactions and exposure to contingent draws on MetLife, Inc.’s liquidity. MetLife, Inc. is an active participant in the global financial markets through which it obtains a significant amount of funding. These markets, which serve as cost-effective sources of funds, are critical components of MetLife, Inc.’s liquidity and capital management. Decisions to access these markets are based upon relative costs, prospective views of balance sheet growth and a targeted liquidity profile and capital structure. A disruption in the financial markets could limit MetLife, Inc.’s access to liquidity.
MetLife, Inc.’s ability to maintain regular access to competitively priced wholesale funds is fostered by its current credit ratings from the major credit rating agencies. We view our capital ratios, credit quality, stable and diverse earnings streams, diversity of liquidity sources and our liquidity monitoring procedures as critical to retaining such credit ratings.
See “— Executive Summary — Consolidated Company Outlook” for a discussion of expected impacts to liquidity and capital resources in connection with the Separation including incremental sources of liquidity and capital from subsidiary dividends that we expect to receive from Brighthouse (expected to be partially funded from the issuance of debt by Brighthouse ) and a MetLife-affiliated reinsurance subsidiary, and proceeds over time from the disposition of our retained shares of Brighthouse common stock, as well as incremental uses of liquidity and capital from foregone subsidiary dividends and foregone incremental debt issuances and ongoing uses of liquidity and capital from the repayment of debt maturities and Separation-related costs.
Liquidity
For a summary of MetLife, Inc.’s liquidity, see “— The Company — Liquidity.”
147
Capital
For a summary of MetLife, Inc.’s capital, see “— The Company — Capital.” For further information regarding potential capital restrictions and limitations on MetLife, Inc. as a non-bank SIFI and G-SII, see “Business — Regulation — U.S. Regulation — Potential Regulation as a Non-Bank SIFI” included in the
2016
Annual Report and “Business — Regulation — International Regulation — Global Systemically Important Insurers.” See also “— The Company — Liquidity and Capital Uses — Common Stock Repurchases” for information regarding MetLife, Inc.’s common stock repurchases.
Liquid Assets
At
March 31, 2017
and
December 31, 2016
, MetLife, Inc. and other MetLife holding companies had $3.8 billion and $5.8 billion, respectively, in liquid assets. Of these amounts, $1.9 billion and $3.7 billion were held by MetLife, Inc. and $1.9 billion and $2.1 billion were held by other MetLife holding companies, at
March 31, 2017
and
December 31, 2016
, respectively. Liquid assets include cash and cash equivalents, short-term investments and publicly-traded securities excluding assets that are pledged or otherwise committed. Assets pledged or otherwise committed include amounts received in connection with derivatives and collateral financing arrangements.
Liquid assets held in non-U.S. holding companies are generated in part through dividends from non-U.S. insurance operations. Such dividends are subject to local insurance regulatory requirements, as discussed in “— Liquidity and Capital Sources — Dividends from Subsidiaries.” The cumulative earnings of certain active non-U.S. operations have been reinvested indefinitely in such non-U.S. operations, as described in Note 19 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report. Under current tax laws, should we repatriate such earnings, we may be subject to additional U.S. income taxes and foreign withholding taxes.
See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — MetLife, Inc. — Liquid Assets” included in the
2016
Annual Report for additional information on the sources and uses of liquid assets for MetLife, Inc. and other MetLife holding companies. See also “— Executive Summary — Consolidated Company Outlook” for the targeted level of liquid assets at the holding companies following the Separation.
Liquidity and Capital Sources
In addition to the description of liquidity and capital sources in “— The Company — Summary of the Company’s Primary Sources and Uses of Liquidity and Capital” and “— The Company — Liquidity and Capital Sources,” the following additional information is provided regarding MetLife, Inc.’s primary sources of liquidity and capital:
Dividends from Subsidiaries
MetLife, Inc. relies, in part, on dividends from its subsidiaries to meet its cash requirements. MetLife, Inc.’s insurance subsidiaries are subject to regulatory restrictions on the payment of dividends imposed by the regulators of their respective domiciles. The dividend limitation for U.S. insurance subsidiaries is generally based on the surplus to policyholders at the end of the immediately preceding calendar year and statutory net gain from operations for the immediately preceding calendar year. Statutory accounting practices, as prescribed by insurance regulators of various states in which we conduct business, differ in certain respects from accounting principles used in financial statements prepared in conformity with GAAP. The significant differences relate to the treatment of DAC, certain deferred income tax, required investment liabilities, statutory reserve calculation assumptions, goodwill and surplus notes.
148
The table below sets forth the dividends permitted to be paid in
2017
by MetLife, Inc.’s primary insurance subsidiaries without insurance regulatory approval and the respective dividends paid during the
three months ended
March 31, 2017
:
|
Company
|
Paid
|
Permitted w/o
Approval (1)
|
|||||||
|
(In millions)
|
|||||||||
|
Metropolitan Life Insurance Company
|
$
|
—
|
|
$
|
2,723
|
|
|||
|
Brighthouse Life Insurance Company
|
$
|
—
|
|
$
|
473
|
|
|||
|
New England Life Insurance Company
|
$
|
—
|
|
$
|
106
|
|
|||
|
Metropolitan Property and Casualty Insurance Company
|
$
|
—
|
|
$
|
98
|
|
|||
|
General American Life Insurance Company
|
$
|
—
|
|
$
|
91
|
|
|||
|
Metropolitan Tower Life Insurance Company
|
$
|
—
|
|
$
|
66
|
|
|||
|
American Life Insurance Company
|
$
|
—
|
|
$
|
—
|
|
|||
__________________
|
(1)
|
Reflects dividend amounts that may be paid during
2017
without prior regulatory approval. However, because dividend tests may be based on dividends previously paid over rolling 12-month periods, if paid before a specified date during 2016, some or all of such dividends may require regulatory approval.
|
In addition to the amounts presented in the table above, for the
three months ended
March 31, 2017
, MetLife, Inc. received cash of $20 million from certain of its other subsidiaries, representing a return of capital from a subsidiary.
The dividend capacity of our non-U.S. operations is subject to similar restrictions established by the local regulators. The non-U.S. regulatory regimes also commonly limit the dividend payments to the parent to a portion of the prior year’s statutory income, as determined by the local accounting principles. The regulators of our non-U.S. operations, including Japan’s Financial Services Agency, may also limit or not permit profit repatriations or other transfers of funds to the U.S. if such transfers are deemed to be detrimental to the solvency or financial strength of the non-U.S. operations, or for other reasons. Most of the non-U.S. subsidiaries are second tier subsidiaries which are owned by various non-U.S. holding companies. The capital and rating considerations applicable to the first tier subsidiaries may also impact the dividend flow into MetLife, Inc.
We actively manage target and excess capital levels and dividend flows on a proactive basis and forecast local capital positions as part of the financial planning cycle. The dividend capacity of certain U.S. and non-U.S. subsidiaries is also subject to business targets in excess of the minimum capital necessary to maintain the desired rating or level of financial strength in the relevant market. See “Risk Factors — Capital-Related Risks — As a Holding Company, MetLife, Inc. Depends on the Ability of Its Subsidiaries to Pay Dividends, a Major Component of Holding Company Free Cash Flow” included in the
2016
Annual Report and Note 16 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report.
Short-term Debt
MetLife, Inc. maintains a commercial paper program, the proceeds of which can be used to finance the general liquidity needs of MetLife, Inc. and its subsidiaries. MetLife, Inc. had no short-term debt outstanding at either
March 31, 2017
or
December 31, 2016
.
Credit and Committed Facilities
See “— The Company — Liquidity and Capital Sources — Global Funding Sources — Credit and Committed Facilities” for information about MetLife, Inc.’s unsecured credit facility.
MetLife, Inc. maintains a committed facility with a capacity of $425 million. At
March 31, 2017
, MetLife, Inc. had outstanding $425 million in letters of credit, no drawdowns outstanding and no remaining availability. In addition, MetLife, Inc. is a party and/or guarantor to committed facilities of certain of its subsidiaries, which aggregated $11.0 billion at
March 31, 2017
. The committed facilities are used as collateral for certain of the Company’s affiliated reinsurance liabilities. See
Note 14
of the Notes to the Interim Condensed Consolidated Financial Statements for discussion of reductions in the committed facilities totaling $7.8 billion in April 2017.
See “— The Company — Liquidity and Capital Sources — Global Funding Sources — Credit and Committed Facilities” for further information regarding these facilities.
149
Long-term Debt Outstanding
The following table summarizes the outstanding long-term debt of MetLife, Inc. at:
|
March 31, 2017
|
December 31, 2016
|
||||||
|
(In millions)
|
|||||||
|
Long-term debt — unaffiliated
|
$
|
15,517
|
|
$
|
15,505
|
|
|
|
Long-term debt — affiliated (1)
|
$
|
3,100
|
|
$
|
3,100
|
|
|
|
Collateral financing arrangements (2)
|
$
|
2,797
|
|
$
|
2,797
|
|
|
|
Junior subordinated debt securities
|
$
|
2,479
|
|
$
|
1,734
|
|
|
__________________
|
(1)
|
On April 28, 2017, in connection with the Separation, MetLife, Inc. repaid $750 million and $350 million senior notes to MetLife Reinsurance Company of Delaware (“MRD”) due September 2032 and December 2033, respectively. The $750 million senior note bore interest at a fixed rate of 4.21% and the $350 million senior note bore interest at a fixed rate 5.10%. Simultaneously, MRD repaid $750 million and $350 million surplus notes to MetLife, Inc. See “— Liquidity and Capital Uses — Affiliated Capital and Debt Transactions.
|
|
(2)
|
See
Note 14
of the Notes to the Interim Condensed Consolidated Financial Statements for discussion of a $2.8 billion repayment on the collateral financing agreement liability in April 2017, utilizing assets held in trust, which had been repositioned into short-term investments and cash equivalents.
|
Debt and Facility Covenants
Certain of MetLife, Inc.’s debt instruments and committed facilities, as well as its credit facility, contain various administrative, reporting, legal and financial covenants. MetLife, Inc. believes it was in compliance with all applicable covenants at
March 31, 2017
.
Dispositions
There were no cash proceeds from dispositions during either of the
three months ended
March 31, 2017
or
2016
.
Liquidity and Capital Uses
The primary uses of liquidity of MetLife, Inc. include debt service, cash dividends on common and preferred stock, capital contributions to subsidiaries, common and preferred stock repurchases, payment of general operating expenses and acquisitions. Based on our analysis and comparison of our current and future cash inflows from the dividends we receive from subsidiaries that are permitted to be paid without prior insurance regulatory approval, our investment portfolio and other cash flows and anticipated access to the capital markets, we believe there will be sufficient liquidity and capital to enable MetLife, Inc. to make payments on debt, pay cash dividends on its common and preferred stock, contribute capital to its subsidiaries, repurchase its common and preferred stock, pay all general operating expenses and meet its cash needs.
In addition to the description of liquidity and capital uses in “— The Company — Liquidity and Capital Uses,” the following additional information is provided regarding MetLife, Inc.’s primary uses of liquidity and capital:
Affiliated Capital and Debt Transactions
During the
three months ended
March 31, 2017
and
2016
, MetLife, Inc. invested a net amount of $31 million and $1.5 billion, respectively, in various subsidiaries. The investment in the first quarter of 2016 included a cash capital contribution of $1.5 billion to Brighthouse Insurance in connection with the Separation.
MetLife, Inc. lends funds, as necessary, to its subsidiaries and affiliates, some of which are regulated, to meet their capital requirements. MetLife, Inc. had loans to subsidiaries outstanding of $1.9 billion and $1.2 billion at
March 31, 2017
and
December 31, 2016
, respectively.
On February 10, 2017, MetLife, Inc. exchanged $750 million aggregate principal amount of its 9.250% Fixed-to-Floating Rate Junior Subordinated Debentures due 2068 for $750 million aggregate liquidation preference of the 9.250% Fixed-to- Floating Rate Exchangeable Surplus Trust Securities of MetLife Capital Trust X (the “Trust”). As a result of the exchange, MetLife, Inc. became the sole beneficial owner of the Trust, a special purpose entity which issued the exchangeable surplus trust securities to third-party investors.
150
On March 23, 2017, MetLife, Inc. dissolved the Trust and became the direct holder of $750 million 8.595% surplus notes previously held by the Trust that were issued by Brighthouse Insurance. MetLife, Inc. has stated that, prior to the Separation, it intends to forgive Brighthouse Insurance’s obligation to pay the principal amount of such surplus notes.
On April 28, 2017, in connection with the Separation, MRD repaid $750 million and $350 million surplus notes to MetLife, Inc. due September 2032 and December 2033. The $750 million surplus note bore interest at a fixed rate of 5.13% and the $350 million surplus note bore interest at a fixed rate of 6.00%, both payable semi-annually. Simultaneously, MetLife, Inc. repaid $750 million and $350 million senior notes to MRD.
Support Agreements
MetLife, Inc. is party to various capital support commitments and guarantees with certain of its subsidiaries. Under these arrangements, MetLife, Inc. has agreed to cause each such entity to meet specified capital and surplus levels or has guaranteed certain contractual obligations. See “— The Company — Liquidity and Capital Uses — Support Agreements.” See also “ — Subsequent Events.”
Acquisitions
There were no acquisitions by MetLife, Inc. during either of the
three months ended
March 31, 2017
or
2016
.
Adoption of New Accounting Pronouncements
See Note
1
of the Notes to the Interim Condensed Consolidated Financial Statements.
Future Adoption of New Accounting Pronouncements
See Note
1
of the Notes to the Interim Condensed Consolidated Financial Statements.
Non-GAAP and Other Financial Disclosures
In this report, the Company presents certain measures of its performance that are not calculated in accordance with GAAP. We believe that these non-GAAP financial measures enhance the understanding of our performance by highlighting the results of operations and the underlying profitability drivers of our business.
The following non-GAAP financial measures should not be viewed as substitutes for the most directly comparable financial measures calculated in accordance with GAAP:
|
Non-GAAP financial measures:
|
Comparable GAAP financial measures:
|
||
|
(i)
|
operating revenues
|
(i)
|
revenues
|
|
(ii)
|
operating expenses
|
(ii)
|
expenses
|
|
(iii)
|
operating earnings
|
(iii)
|
net income (loss)
|
|
(iv)
|
operating earnings available to common shareholders
|
(iv)
|
net income (loss) available to MetLife, Inc.’s common shareholders
|
Reconciliations of
these non-GAAP measures to the most directly comparable historical GAAP measures
are included in this section and the results of operations, see “— Results of Operations.” R
econciliations of these non-GAAP measures to the most directly comparable GAAP measures is not accessible on a forward-looking basis because we believe it is not possible without unreasonable efforts to provide other than a range of net investment gains and losses and net derivative gains and losses, which can fluctuate significantly within or outside the range and from period to period and may have a material impact on net income.
Our definitions of the various non-GAAP and other financial measures discussed in this report may differ from those used by other companies:
Operating earnings and related measures:
|
•
|
operating earnings; and
|
|
•
|
operating earnings available to common shareholders.
|
151
These measures are used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, operating earnings is also our GAAP measure of segment performance. Operating earnings and other financial measures based on operating earnings are also the measures by which senior management’s and many other employees’ performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Operating earnings and other financial measures based on operating earnings allow analysis of our performance relative to our business plan and facilitate comparisons to industry results.
Operating earnings is defined as operating revenues less operating expenses, both net of income tax. Operating earnings available to common shareholders is defined as operating earnings less preferred stock dividends.
Operating revenues and operating expenses
These financial measures focus on our primary businesses principally by excluding the impact of market volatility, which could distort trends, and revenues and costs related to non-core products and divested businesses and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations and other businesses that have been or will be sold or exited by MetLife and are referred to as divested businesses. In addition, for the three months ended March 31, 2016, operating revenues and operating expenses exclude the financial impact of converting the Company’s Japan operations to calendar year-end reporting without retrospective application of this change to prior periods and is referred to as lag elimination. Operating revenues also excludes net investment gains (losses) and net derivative gains (losses). Operating expenses also excludes goodwill impairments.
The following additional adjustments are made to revenues, in the line items indicated, in calculating operating revenues:
|
•
|
Universal life and investment-type product policy fees excludes the amortization of unearned revenue related to net investment gains (losses) and net derivative gains (losses) and certain variable annuity GMIB fees (“GMIB Fees”);
|
|
•
|
Net investment income: (i) includes investment hedge adjustments, (ii) excludes post-tax operating earnings adjustments relating to insurance joint ventures accounted for under the equity method, (iii) excludes certain amounts related to contractholder-directed unit-linked investments, and (iv) excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and
|
|
•
|
Other revenues are adjusted for settlements of foreign currency earnings hedges.
|
The following additional adjustments are made to expenses, in the line items indicated, in calculating operating expenses:
|
•
|
Policyholder benefits and claims and policyholder dividends excludes: (i) changes in the policyholder dividend obligation related to net investment gains (losses) and net derivative gains (losses), (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments and amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass through adjustments, (iii) benefits and hedging costs related to GMIBs (“GMIB Costs”), and (iv) market value adjustments associated with surrenders or terminations of contracts (“Market Value Adjustments”);
|
|
•
|
Interest credited to policyholder account balances includes adjustments for earned income on derivatives and amortization of premium on derivatives that are hedges of policyholder account balances but do not qualify for hedge accounting treatment and excludes amounts related to net investment income earned on contractholder-directed unit-linked investments;
|
|
•
|
Amortization of DAC and VOBA excludes amounts related to: (i) net investment gains (losses) and net derivative gains (losses), (ii) GMIB Fees and GMIB Costs, and (iii) Market Value Adjustments;
|
|
•
|
Amortization of negative VOBA excludes amounts related to Market Value Adjustments;
|
|
•
|
Interest expense on debt excludes certain amounts related to securitization entities that are VIEs consolidated under GAAP; and
|
|
•
|
Other expenses excludes costs related to: (i) noncontrolling interests, (ii) implementation of new insurance regulatory requirements, and (iii) acquisition, integration and other costs.
|
Operating earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.
The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from the Company’s effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.
152
Return on equity, allocated equity and related measures:
|
•
|
MetLife, Inc.’s common stockholders’ equity, excluding accumulated other comprehensive income (loss) (“AOCI”) other than foreign currency translation adjustments (“FCTA”), is defined as MetLife, Inc.’s common stockholders’ equity, excluding the net unrealized investment gains (losses) and defined benefit plans adjustment components of AOCI, net of income tax.
|
|
•
|
Operating ROE is defined as operating earnings available to common shareholders, divided by average GAAP common stockholders’ equity.
|
|
•
|
Operating ROE, excluding AOCI other than FCTA, is defined as operating earnings available to common shareholders divided by average GAAP common stockholders’ equity, excluding AOCI other than FCTA.
|
|
•
|
Allocated equity is the portion of MetLife, Inc.’s common stockholders’ equity that management allocates to each of its segments and sub-segments based on local capital requirements and economic capital. See “— Economic Capital.” Allocated equity excludes the impact of AOCI other than FCTA.
|
The above measures represent a level of equity consistent with the view that, in the ordinary course of business, we do not plan to sell most investments for the sole purpose of realizing gains or losses. Also refer to the utilization of operating earnings and other financial measures based on operating earnings mentioned above.
The following additional information is relevant to an understanding of our performance results:
|
•
|
The impact of changes in our foreign currency exchange rates is calculated using the average foreign currency exchange rates for the current period and is applied to each of the comparable periods (“Constant Currency Basis”).
|
|
•
|
We sometimes refer to sales activity for various products. These sales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity. Further, sales statistics for our Latin America, Asia and EMEA segments are on a Constant Currency Basis.
|
|
•
|
Asymmetrical and non-economic accounting refers to: (i) the portion of net derivative gains (losses) on embedded derivatives attributable to the inclusion of our credit spreads in the liability valuations, (ii) hedging activity that generates net derivative gains (losses) and creates fluctuations in net income because hedge accounting cannot be achieved and the item being hedged does not a have an offsetting gain or loss recognized in earnings, (iii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments and amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass through adjustments, and (iv) impact of changes in foreign currency exchange rates on the re-measurement of foreign denominated unhedged funding agreements and financing transactions to the U.S. dollar and the re-measurement of certain liabilities from non-functional currencies to functional currencies.
|
|
•
|
The Company uses a measure of free cash flow to facilitate an understanding of its ability to generate cash for reinvestment into its businesses or use in non-mandatory capital actions. The Company defines free cash flow as the sum of cash available at MetLife’s holding companies from dividends from operating subsidiaries, expenses and other net flows of the holding companies (including capital contributions to subsidiaries), and net contributions from debt to be at or below target leverage ratios. This measure of free cash flow is prior to capital actions, such as common stock dividends and repurchases, debt reduction and mergers and acquisitions. Free cash flow should not be viewed as a substitute for net cash provided by (used in) operating activities calculated in accordance with GAAP. The free cash flow ratio is typically expressed as a percentage of annual operating earnings available to common shareholders.
|
Subsequent Events
See Note
14
of the Notes to the Interim Condensed Consolidated Financial Statements.
153
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We regularly analyze our exposure to interest rate, equity market price and foreign currency exchange rate risks. As a result of that analysis, we have determined that the estimated fair values of certain assets and liabilities are materially exposed to changes in interest rates, foreign currency exchange rates and changes in the equity markets. We have exposure to market risk through our insurance operations and investment activities. We use a variety of strategies to manage interest rate, foreign currency exchange rate and equity market risk, including the use of derivatives. A description of our market risk exposures may be found under “Quantitative and Qualitative Disclosures About Market Risk” in Part II, Item 7A, of the
2016
Annual Report. There have been no material changes to our market risk exposures from the market risk exposures previously disclosed in the
2016
Annual Report.
154
Item 4. Controls and Procedures
Management, with the participation of the Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as defined in Exchange Act Rule 13a-15(e) as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures are effective.
There were no changes to the Company’s internal control over financial reporting as defined in Exchange Act Rule 13a-15(f) during the quarter ended
March 31, 2017
that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
155
Part II — Other Information
Item 1. Legal Proceedings
The following should be read in conjunction with (i) Part I, Item 3, of the 2016 Annual Report; and (ii)
Note 13
of the Notes to the Interim Condensed Consolidated Financial Statements in Part I of this report.
Asbestos-Related Claims
MLIC is and has been a defendant in a large number of asbestos-related suits filed primarily in state courts. These suits principally allege that the plaintiff or plaintiffs suffered personal injury resulting from exposure to asbestos and seek both actual and punitive damages.
As reported in the 2016 Annual Report, MLIC received approximately 4,146 asbestos-related claims in 2016. During the three months ended March 31, 2017 and 2016, MLIC received approximately 1,104 and 1,386 new asbestos-related claims, respectively. See Note 21 of the Notes to the Consolidated Financial Statements included in the 2016 Annual Report for historical information concerning asbestos claims and MLIC’s increase in its recorded liability at December 31, 2014. The number of asbestos cases that may be brought, the aggregate amount of any liability that MLIC may incur, and the total amount paid in settlements in any given year are uncertain and may vary significantly from year to year.
MLIC reevaluates on a quarterly and annual basis its exposure from asbestos litigation, including studying its claims experience, reviewing external literature regarding asbestos claims experience in the United States, assessing relevant trends impacting asbestos liability and considering numerous variables that can affect its asbestos liability exposure on an overall or per claim basis. These variables include bankruptcies of other companies involved in asbestos litigation, legislative and judicial developments, the number of pending claims involving serious disease, the number of new claims filed against it and other defendants and the jurisdictions in which claims are pending. Based upon its regular reevaluation of its exposure from asbestos litigation, MLIC has updated its liability analysis for asbestos-related claims through March 31, 2017.
Unclaimed Property Litigation
City of Birmingham Retirement and Relief System v. MetLife, Inc., et al. (Circuit Court of Jefferson County, Alabama, filed July 5, 2012)
Seeking to represent a class of persons who purchased MetLife, Inc. common equity units in or traceable to a public offering in March 2011, the plaintiff filed an action alleging that MetLife, Inc., certain current and former directors and executive officers of MetLife, Inc., and various underwriters violated several provisions of the Securities Act of 1933 related to the filing of the registration statement by issuing, or causing MetLife, Inc. to issue, materially false and misleading statements and/or omissions concerning MetLife, Inc.’s potential liability for millions of dollars in insurance benefits that should have been paid to beneficiaries or escheated to the states. Plaintiff seeks unspecified compensatory damages and other relief. In August 2016, the parties reached a mediated settlement under which MetLife, Inc. agreed to a certified class and to pay $9.75 million. On March 9, 2017, the court approved the settlement and dismissed the case with prejudice.
Diversified Lending Group Litigations
Hartshorne v. MetLife Inc., et al. (Los Angeles County Superior Court, filed March 25, 2015)
Plaintiffs named MetLife, Inc., MSI, and NELICO in 12 related lawsuits in California state court alleging various causes of action including multiple negligence and statutory claims relating to a Ponzi scheme involving the Diversified Lending Group. In August 2016, a trial of claims by one of the plaintiffs, Christine Ramirez, resulted in a verdict against MetLife, Inc., MSI, and NELICO for approximately $200 thousand in compensatory damages and $15 million in punitive damages. On November 30, 2016, Ramirez consented to the court’s reduction of punitive damages to approximately $7 million. These companies have filed a notice appealing this judgment to the Second Appellate District of the State of California. On May 2, 2017, the court awarded the plaintiff approximately $6.5 million in attorneys’ fees and costs. The Company intends to appeal this decision.
156
Other Litigation
Newman v. Metropolitan Life Insurance Company (N.D. Ill., filed March 23, 2016)
Plaintiff filed this putative class action alleging causes of action for breach of contract, fraud, and violations of the Illinois Consumer Fraud and Deceptive Business Practices Act, based on MLIC’s class-wide increase in premiums charged for long-term care insurance policies. Plaintiff alleges a class consisting of herself and all persons over age 65 who selected a Reduced Pay at Age 65 payment feature and whose premium rates were increased after age 65. Plaintiff asserts that premiums could not be increased for these class members and/or that marketing material was misleading as to MLIC’s right to increase premiums. Plaintiff seeks unspecified compensatory, statutory and punitive damages as well as recessionary and injunctive relief. On April 12, 2017 the court granted MLIC’s motion, dismissing the action with prejudice. On April 21, 2017, plaintiff appealed this ruling.
Miller, et al. v. MetLife Inc., et al. (C.D. Cal., filed April 7, 2017)
Plaintiff filed this putative class action against MetLife, Inc. and MLIC purporting to assert claims on behalf of all persons who replaced their MetLife Optional Term Life or Group Universal Life policy for a Group Variable Universal Life (GVUL) policy wherein MetLife allegedly charged smoker rates for certain non-smokers. Plaintiff seeks unspecified compensatory and punitive damages, as well as other relief. The Company intends to defend this action vigorously.
Summary
Putative or certified class action litigation and other litigation and claims and assessments against the Company, in addition to those discussed previously and those otherwise provided for in the Company’s consolidated financial statements, have arisen in the course of the Company’s business, including, but not limited to, in connection with its activities as an insurer, mortgage lending bank, employer, investor, investment advisor and taxpayer. Further, state insurance regulatory authorities and other federal and state authorities regularly make inquiries and conduct investigations concerning the Company’s compliance with applicable insurance and other laws and regulations.
It is not possible to predict the ultimate outcome of all pending investigations and legal proceedings. In some of the matters referred to previously, very large and/or indeterminate amounts, including punitive and treble damages, are sought. Although in light of these considerations it is possible that an adverse outcome in certain cases could have a material effect upon the Company’s financial position, based on information currently known by the Company’s management, in its opinion, the outcomes of such pending investigations and legal proceedings are not likely to have such an effect. However, given the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation, it is possible that an adverse outcome in certain matters could, from time to time, have a material effect on the Company’s consolidated net income or cash flows in particular quarterly or annual periods.
157
Item 1A. Risk Factors
The following should be read in conjunction with, and supplements and amends, the factors that may affect the Company’s business or operations described under “Risk Factors” in Part I, Item 1A, of the 2016 Annual Report. Other than as described in this Item 1A, there have been no material changes to our risk factors from the risk factors previously disclosed in the 2016 Annual Report.
Regulatory and Legal Risks
The following updates and replaces the similar paragraphs of similarly named sections of the risk factor entitled “Our Insurance and Brokerage Businesses Are Highly Regulated, and Changes in Regulation and in Supervisory and Enforcement Policies May Reduce Our Profitability and Limit Our Growth” included in the 2016 Annual Report.
Our Insurance and Brokerage Businesses Are Highly Regulated, and Changes in Regulation and in Supervisory and Enforcement Policies May Reduce Our Profitability and Limit Our Growth
* * *
U.S. Regulation
* * *
ERISA Considerations
* * *
The DOL issued new regulations on April 6, 2016, which, in accordance with an April 4, 2017 DOL final rule which delayed the original applicable date by 60 days, will for the most part become applicable on June 9, 2017. These rules, when they become applicable, substantially expand the definition of “investment advice” and require that an impartial or “best interests” standard be met in providing such advice, thereby broadening the circumstances under which MetLife or its representatives, in providing investment advice with respect to ERISA plans, plan participants or IRAs, could be deemed a fiduciary under ERISA or the Code. Pursuant to the final regulations, certain communications with plans, plan participants and IRA holders, including the sales of products, and investment management or advisory services, could be deemed fiduciary investment advice, thus causing increased exposure to fiduciary liability if the distributor does not recommend what is in the client’s best interests. While the final regulations also provide that, to a limited extent, contracts sold and advice provided prior to the applicable date do not have to be modified to comply with the new investment advice regulations, there is lack of clarity surrounding some of the conditions for qualifying for this limited exception. There can be no assurance that the DOL will agree with our interpretation of the provisions of the new regulations, in which case the DOL and IRS could assess significant penalties against a portion of products sold prior to the applicable date. The assessment of such penalties could also trigger substantial litigation risk. Any such penalties and related litigation could adversely affect our results of operations and financial condition.
The DOL also issued amendments to certain of its prohibited transaction exemptions, and issued a new exemption that applies more onerous disclosure and contract requirements to, and increases fiduciary requirements and fiduciary liability exposure in respect of, certain transactions involving ERISA plans, plan participants and IRAs. In general, the changes the rule made to existing prohibited transaction exemptions and contract and disclosure requirements of the new exemption (other than the impartial interest standard) were delayed until January 1, 2018.
On February 3, 2017 President Trump, in a memorandum to the Secretary of Labor, requested that the DOL prepare an updated economic and legal analysis concerning the likely impact of the new rules, and possible revisions to the rules. The applicable date for the new rules could be further extended to provide the DOL with additional time to address the requests in the President’s memorandum.
158
While we continue to analyze the impact of the final regulations on our business as we plan for their implementation, we believe they could have an adverse effect on sales of annuity products to ERISA qualified plans such as IRAs through our independent distribution partners. The new regulations deem advisors, including independent distributors, who sell fixed index-linked annuities to IRAs, IRA rollovers or 401(k) plans, fiduciaries and prohibit them from receiving compensation unless they comply with a prohibited transaction exemption. The exemption requires advisors to comply with impartial conduct standards and may require us to exercise additional oversight of the sales process. Compliance with the prohibited transaction exemption will likely result in increased regulatory burdens on us and our independent distribution partners, changes to our compensation practices and product offerings and increased litigation risk, which could adversely affect our results of operations and financial condition. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Industry Trends — Regulatory Developments — U.S. Regulation — ERISA Considerations,” as well as “Business — Regulation — U.S. Regulation — ERISA Considerations” included in the 2016 Annual Report.
The change of administration and DOL officials leaves uncertainty over whether the regulations will be substantially modified or repealed. Application of the rules on June 9, 2017, in light of the overall reconsideration of the rules requested by President Trump, could create confusion among our distribution partners which could negatively impact product sales. We cannot predict what other proposals may be made, what legislation may be introduced or enacted, or what impact any such legislation may have on our business, results of operations and financial condition.
* * *
Risks Related to Our Business
The following updates and replaces the similar paragraphs in the risk factor entitled “Our International Operations Face Political, Legal, Operational and Other Risks, Including Exposure to Local and Regional Economic Conditions, That Could Negatively Affect Those Operations or Our Profitability” included in the 2016 Annual Report.
Our International Operations Face Political, Legal, Operational and Other Risks, Including Exposure to Local and Regional Economic Conditions, That Could Negatively Affect Those Operations or Our Profitability
* * *
The Trump Administration has discussed potentially putting in place a tax on goods and services imported into the United States, including from countries in which we have international operations, such as Mexico. President Trump has indicated an interest in renegotiating NAFTA, which had eliminated most trade tariffs between the United States, Canada and Mexico. While our current business in Mexico is not directly dependent upon any specific trade agreement provision, and is tied to the general economy and the growth of the market, if the current rules on government procurement under NAFTA were modified or eliminated, it could have a material impact on our business in Mexico, given our business model. We cannot predict with certainty what proposals may be made in connection with international trade agreements or what legislation or regulations may be introduced or enacted, or what impact any such legislation or regulations may have on our business, results of operations and financial condition.
* * *
On June 23, 2016, the U.K. held a referendum regarding its membership in the EU, resulting in a vote in favor of leaving the EU. The U.K. government triggered the withdrawal process by notifying the EU on March 29, 2017 of the U.K.’s intention to withdraw from the EU. The member withdrawal provisions in the applicable EU treaty have not been used before so it is unclear how the provisions will work in practice. This treaty provides that the U.K. and the EU will negotiate a withdrawal agreement during a maximum two-year period (unless such period is extended by unanimous vote of the EU member states). It is possible that the withdrawal agreement would deal with the details of the immediate exit but would not set out final trade arrangements or deal comprehensively with other potentially significant matters. The U.K. Parliament approved Prime Minister Theresa May's plan to hold an early general election on June 8, 2017, the results of which may affect the U.K. strategy for its withdrawal from the EU. With effectiveness of the withdrawal agreement, or, if no agreement is concluded in the two-year period, at the end of the period on March 29, 2019, the U.K. will no longer be a member of the EU. It is likely, however, that a transitional period or implementation phase will be discussed during the negotiations. In the meantime, the U.K. remains a member of the EU with unchanged rights to access the single EU market in goods and services. Our U.K. business model utilizes certain rights to operate cross-border insurance and investment operations which may be modified or eliminated as a result of the U.K. exiting the EU. Operating expenses within our businesses could increase as a result of uncertainties during the negotiation period and upon the U.K.’s withdrawal.
* * *
159
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
Purchases of common stock made by or on behalf of MetLife, Inc. or its affiliates during the quarter ended
March 31, 2017
are set forth below:
|
Period
|
(a) Total Number
of Shares Purchased (1)
|
(b) Average Price Paid per Share
|
(c) Total Number
of Shares
Purchased as Part
of Publicly
Announced Plans
or Programs
|
(d) Maximum Number
(or Approximate
Dollar Value) of
Shares that May Yet
Be Purchased Under the
Plans or Programs (2)
|
||||||||||
|
January 1 — January 31, 2017
|
4,593,403
|
|
$
|
54.22
|
|
4,593,403
|
|
$
|
2,448,521,779
|
|
||||
|
February 1 — February 28, 2017
|
4,966,024
|
|
$
|
53.09
|
|
4,966,024
|
|
$
|
2,184,881,983
|
|
||||
|
March 1 — March 31, 2017
|
6,479,398
|
|
$
|
53.23
|
|
6,479,364
|
|
$
|
1,839,993,044
|
|
||||
__________________
|
(1)
|
Except for the foregoing, there were no shares of common stock which were repurchased by MetLife, Inc. During the periods
January 1 through January 31, 2017
,
February 1 through February 28, 2017
and
March 1 through March 31, 2017
, separate account index funds purchased
0
shares,
0
shares and
34
shares, respectively, of common stock on the open market in nondiscretionary transactions.
|
|
(2)
|
At
March 31, 2017
, MetLife, Inc. had
$1.8 billion
of common stock repurchases remaining under the authorization approved by its Board of Directors. for more information on common stock repurchases, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Liquidity and Capital Resources — The Company — Liquidity and Capital Uses — Common Stock Repurchases,” “Risk Factors — Capital-Related Risks — Legal and Regulatory Restrictions and Uncertainty and Restrictions Under the Terms of Certain of Our Securities May Prevent Us from Repurchasing Our Stock and Paying Dividends at the Level We Wish” included in the
2016
Annual Report and Note 16 of the Notes to the Consolidated Financial Statements included in the
2016
Annual Report.
|
160
Item 6. Exhibits
(Note Regarding Reliance on Statements in Our Contracts:
In reviewing the agreements included as exhibits to this Quarterly Report on Form 10-Q, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about MetLife, Inc., its subsidiaries or affiliates, or the other parties to the agreements. The agreements contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the other parties to the applicable agreement and (i) should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; (ii) have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement; (iii) may apply standards of materiality in a way that is different from what may be viewed as material to investors; and (iv) were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments. Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about MetLife, Inc., its subsidiaries and affiliates may be found elsewhere in this Quarterly Report on Form 10-Q and MetLife, Inc.’s other public filings, which are available without charge through the U.S. Securities and Exchange Commission website at www.sec.gov.)
|
Exhibit
No.
|
|
Description
|
|
31.1
|
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
31.2
|
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
32.1
|
|
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
32.2
|
|
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
101.INS
|
|
XBRL Instance Document.
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document.
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document.
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
161
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
METLIFE, INC.
|
||
|
By:
|
/s/ Peter M. Carlson
|
|
|
Name: Peter M. Carlson
Title: Executive Vice President
and Chief Accounting Officer
(Authorized Signatory and Principal
Accounting Officer)
|
||
Date: May 4, 2017
162
Exhibit Index
(Note Regarding Reliance on Statements in Our Contracts:
In reviewing the agreements included as exhibits to this Quarterly Report on Form 10-Q, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about MetLife, Inc., its subsidiaries or affiliates, or the other parties to the agreements. The agreements contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the other parties to the applicable agreement and (i) should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; (ii) have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement; (iii) may apply standards of materiality in a way that is different from what may be viewed as material to investors; and (iv) were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments. Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about MetLife, Inc., its subsidiaries and affiliates may be found elsewhere in this Quarterly Report on Form 10-Q and MetLife, Inc.’s other public filings, which are available without charge through the U.S. Securities and Exchange Commission website at www.sec.gov.)
|
Exhibit
No. |
|
Description
|
|
31.1
|
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
31.2
|
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
32.1
|
|
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
32.2
|
|
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
101.INS
|
|
XBRL Instance Document.
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document.
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document.
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
E - 1
TABLE OF CONTENTS
Part I Financial InformationprintItem 1. Financial StatementsprintItem 2. Management S Discussion and Analysis Of Financial Condition and Results Of OperationsprintItem 3. Quantitative and Qualitative Disclosures About Market RiskprintItem 4. Controls and ProceduresprintPart II Other InformationprintItem 1. Legal ProceedingsprintItem 1A. Risk FactorsprintItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsprintItem 6. Exhibitsprint